---
document_datetime: 2023-09-21 19:48:40
document_pages: 126
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/xospata-epar-public-assessment-report_en.pdf
document_name: xospata-epar-public-assessment-report_en.pdf
version: success
processing_time: 170.5136451
conversion_datetime: 2025-12-30 07:43:59.781068
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

19 September 2019 EMA/545585/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## XOSPATA

International non-proprietary name: gilteritinib

Procedure No. EMEA/H/C/004752/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................8                                                                                                                           |                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................8                                                                                                |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................9                                                                                                         |                                                                                                          |
| 2. Scientific discussion                                                                                                                                                                                             | ..............................................................................10                         |
| 2.1. Problem statement                                                                                                                                                                                               | .............................................................................................10          |
| 2.1.1. Disease or condition.........................................................................................10                                                                                               |                                                                                                          |
| 2.1.2. Epidemiology and risk factors, screening tools/prevention                                                                                                                                                     | ....................................10                                                                   |
| 2.1.3. Biologic features..............................................................................................11                                                                                             |                                                                                                          |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                                                                                                          | ............................................11                                                           |
| 2.1.5. Management...................................................................................................11                                                                                               |                                                                                                          |
| 2.2. Quality aspects                                                                                                                                                                                                 | ..................................................................................................13     |
| 2.2.1. Introduction....................................................................................................13                                                                                            |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................13                                                                                               |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                                                                                                                    | ................................................................................16                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................20                                                                                                                 |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                                                                                                            | ......................20                                                                                 |
| 2.3. Non-clinical aspects                                                                                                                                                                                            | ............................................................................................21           |
| 2.3.1. Introduction....................................................................................................21                                                                                            |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                                                                                                                  | .................................................................................................21      |
| 2.3.3. Pharmacokinetics.............................................................................................26                                                                                               |                                                                                                          |
| 2.3.4. Toxicology                                                                                                                                                                                                    | ......................................................................................................28 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                                                                                                                     | .........................................................34                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................34                                                                                                    |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................37 ..................................................................................................37 |                                                                                                          |
| 2.4. Clinical aspects                                                                                                                                                                                                |                                                                                                          |
| 2.4.1. Introduction....................................................................................................37                                                                                            |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................39                                                                                               |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................48                                                                                                  |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................50                                                                                                      |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology                                                                                                                                                                          | .................................................................52                                      |
| 2.5. Clinical efficacy                                                                                                                                                                                               | ..................................................................................................52     |
| 2.5.1. Dose response study........................................................................................52                                                                                                 |                                                                                                          |
| 2.5.2. Main study......................................................................................................59                                                                                            |                                                                                                          |
| 2.5.3. Discussion on clinical efficacy............................................................................93                                                                                                 |                                                                                                          |
| 2.5.4. Conclusions on the clinical efficacy.....................................................................97                                                                                                   |                                                                                                          |
| 2.6. Clinical safety                                                                                                                                                                                                 | ....................................................................................................97   |
| 2.6.1. Discussion on clinical safety ............................................................................                                                                                                    | 113                                                                                                      |
| 2.6.2. Conclusions on the clinical safety.....................................................................                                                                                                       | 116                                                                                                      |
| 2.7. Risk Management Plan ......................................................................................                                                                                                     | 117                                                                                                      |
| 2.8. Pharmacovigilance............................................................................................                                                                                                   | 119                                                                                                      |
| 2.9. New Active Substance.......................................................................................                                                                                                     | 119                                                                                                      |
| 2.9.1. Additional monitoring.....................................................................................                                                                                                    | 119                                                                                                      |

<div style=\"page-break-after: always\"></div>

3. Benefit-Risk Balance............................................................................  119

3.1. Therapeutic Context .........................................................................................  119

3.1.1. Disease or condition  .......................................................................................  119

3.1.2. Available therapies and unmet medical need  ..................................................... 119

3.1.3. Main clinical studies .......................................................................................  120

3.2. Favourable effects ............................................................................................  120

3.3. Uncertainties and limitations about favourable effects  ........................................... 120

3.4. Unfavourable effects  .........................................................................................  121

3.5. Uncertainties and limitations about unfavourable effects ....................................... 121

3.6. Effects Table  ....................................................................................................  122

3.7. Benefit-risk assessment and discussion  ............................................................... 123

3.7.1. Importance of favourable and unfavourable effects  ............................................ 123

3.7.2. Balance of benefits and risks  ...........................................................................  123

3.7.3. Additional considerations on the benefit-risk balance ......................................... 123

3.8. Conclusions .....................................................................................................  123

4. Recommendations ...............................................................................  123

5. Appendix ..........................................................

Error! Bookmark not defined.

6. References ..........................................................................................  126

<div style=\"page-break-after: always\"></div>

## List of abbreviations

CPP

Critical process parameter

CQA

Critical Quality Attribute

DIPEA              diisopropylamine

DMF                 Dimethyl formamide

DSC

Differential Scanning Calorimetry

FMEA

Failure mode effects analysis

GC

Gas Chromatography

HDPE

High Density Polyethylene

HPC                 Hydroxypropylcellulose

HPLC

High performance liquid chromatography

ICH

International Conference on Harmonisation of Technical Requirements for Registration

of Pharmaceuticals for Human Use

IR

Infrared

KF

Karl Fischer titration

LDPE

Low density polyethylene

L-HPC              low-substituted hydroxypropylcellulose

LDPE

Low Density Polyethylene

NDEA               N-diethylnitrosamine

NDMA              N-dimethylntrosamine

NIR

Near Infrared Spectroscopy

NLT

Not less than

NMP                N-Methyl-2-pyrrolidone

NMT

Not more than

NOR

Normal Operating Range

OPA                 Oriented polyamide

Ph. Eur.

European Pharmacopoeia

PVC

Polyvinyl chloride

QTPP

Quality target product profile

RH

Relative Humidity

RTRT                Real Time Release Testing

SmPC

Summary of Product Characteristics

TAMC

Total Aerobic Microbial Count

tmax

Time to achieve Cmax

TG

Thermo-Gravimetry

TLC

Thin layer chromatography

TYMC

Total Combined Yeasts/Moulds Count

UV

Ultraviolet

XR(P)D

X-Ray (Powder) Diffraction

A/G

Albumin/Globulin

AE

adverse event

AKT

Protein Kinase B

ALK

anaplastic lymphoma kinase

ALB

albumin

allo-HSC

allogenic haematopoitic stem cell transplant

ALP

Alkaline phosphatase

ALT

alanine aminotransferase

AML

acute myeloid leukemia

ANC

absolute neutrophil count

aPTT

activated partial thromboplastin time

AST

aspartate aminotransferase

ATP

adenosine triphosphate

AUC

area under the concentration-time curve

AUC24

area under the concentration-time curve over the 24-hour dosing interval

AUC24,ss

AUC at steady state over the 24-hour dosing interval

AUCinf

AUC from the time of dosing extrapolated to time infinity

AUCinf,u

AUC from the time of dosing extrapolated to time infinity for unbound concentration

AUClast

AUC from the time of dosing to the last measurable concentration

AXL

AXL receptor tyrosine kinase

BA

Bioavailability

BCRP

Breast cancer resistance protein

BFI

Brief Fatigue Inventory

B/R Benefit-risk BSEP bile salt export pump BW body weight CaV1.2 CaV1.2 calcium channel Cb/Cp blood to plasma radioactivity concentration ratio CHO Chinese hamster ovary CHMP Committee for Medicinal Products for Human Use CI confidence interval Cmax maximum concentration CNS Central nervous system CR complete remission CR/CRh complete remission and complete remission with partial hematological recovery CRc composite complete remission CRh complete remission with partial hematological recovery Cri complete remission with incomplete hematologic recovery CRp complete remission with incomplete platelet recovery CV coefficient of variation CYP Cytochrome P450 DDI drug-drug interaction DFS disease-free survival DLT dose-limiting toxicity DMSO Dimethyl sulfoxide ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EFS event-free survival EGFR Epidermal growth factor receptor EMA European Medicines Agency Emax maximal effective concentration EML4 echinoderm microtubule-associated protein-like 4 ER Exposure response ERK extracellular signal-regulated kinase EQ-5D-5L EuroQol Group-5 Dimension-5 Level EURD European Union reference dates FACT-Leu Functional Assessment of Cancer Therapy-Leukemia FACIT-Dys-SF Functional Assessment of Chronic Illness Therapy-Dyspnea- Short Forms FAS full analysis set FLAG-IDA fludarabine; cytarabine; idarubicin; G-CSF FLT3 FMS-like tyrosine kinase 3 FLZ Fluconazole Fpen market penetration factor Fu fraction of parent or metabolite available systemically unbound (= free fraction) fu,gut fractions of unbound drug in enterocytes fu,p fractions of unbound drug in plasma GCP Good Clinical Practice GI Gastrointestinal GLP Good Laboratory Practice GMR Geometric LS mean ratio Gp glycoprotein GVHD Graft versus host disease HEK293 Human embryonic kidney 293 hERG Human ether-a-go-go-related gene HR hazard ratio HSCT hematopoietic stem cell transplantation IBD international birth date IC50 Half maximal inhibitory concentration ICH International Conference on Harmonisation IDAC intermediate dose cytarabine Imax maximum inhibitory effect IRB Institutional Review Board IRT interactive response technology ITD internal tandem duplication ITT intention to treat ITZ itraconazole iv intravenous

<div style=\"page-break-after: always\"></div>

IWG

international working group

Ka

absorption rate

Kd

equilibrium dissociation constant

KM

Kaplan-Meier

KV7.1/minK

KV7.1/minK potassium channel

LC-MS/MS

liquid chromatography with tandem mass spectrometry

LFS

leukemia-free survival

LoDAC

low dose cytarabine

LS

least squares

LTK

leukocyte tyrosine kinase

MAA

Marketing authorisation application

MAD

multiple ascending dose

MAH

marketing authorisation holder

MATE

multidrug and toxin extrusion

MCH

Mean corpuscular haemoglobin

MCV

Mean corpuscular volume

MDS

Myelodysplastic Syndromes

MEC

mitoxantrone; etoposide; cytarabine

MRAS

modified response analysis set

MRD

minimal residual disease

MRI

magnetic resonance imaging

MTD

maximum tolerated dose

N/A

not applicable/not available

NCI-CTCAE

National Cancer Institute-Common terminology Criteria for Adverse Events

NCI-ODWG

National Cancer Institute Organ Dysfunction Working Group

NE

Not evaluable

NMT

no more than

NOAEL

No Observed Adverse Effect Level

NPM1

nucleophosmin 1

NR

Not reached

NSCLC

non-small-cell lung cancer

NYHA

New York heart association

OAT

organic anion transporter

OATP

organic anion transporting polypeptide

OCT

organic cation transporter

OECD

Organisation for Economic Cooperation and Development

OS

overall survival

PAR

Proven acceptable range

PBT

Persistent Bioaccumulative Toxic

PD

pharmacodynamic

PDGFR

platelet-derived growth factor receptor

PEC

Predicted Environmental Concentration

P-gp (PGP)

P-glycoprotein

PGx

Pharmacogenomics

PhV

pharmacovigilance

PI

Product information

PIA

plasma inhibitory activity

PIF

peak inspiratory flow

PIP

Paediatric Investigation Plan

PK

pharmacokinetics

PKAS

Pharmacokinetic Analysis Set

PND

postnatal day

PopPK

population pharmacokinetic

PPS

per protocol set

PR

partial remission

PRES

Posterior Reversible Encephalopathy Syndrome

PRO

Patient reported outcome

PS

performance status

PSUR

Periodic Safety Update Report

PT

Preferred Term

Q

Interdepartmental clearance

QD

once daily

QTcF

Fridericia-corrected QT interval

Rac

accumulation index

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| RAS   | Response Analysis Set                              |
|-------|----------------------------------------------------|
| RET   | rearranged                                         |
| RIF   | rifampin                                           |
| RMP   | Risk management plan                               |
| RMST  | Restricted Mean Survival Time                      |
| R/R   | relapsed or refractory                             |
| sc    | subcutaneous                                       |
| SAE   | serious adverse event                              |
| SD    | Sprague Dawley                                     |
| SmPC  | Summary of Product Characteristics                 |
| SOC   | System organ class                                 |
| STAT5 | Signal transducer and activator of transcription 5 |
| t1/2  | terminal elimination half-life                     |
| TEAE  | treatment-emergent adverse event                   |
| TKD   | tyrosine kinase domain                             |
| TKI   | Tyrosine kinase inhibitor                          |
| TRKA  | Tropomyosin receptor kinase A                      |
| t max | time to observed C max                             |
| ULN   | upper limit of normal                              |
| UV-A  | ultraviolet A                                      |
| Vc    | Central volume of distribution                     |
| Vp    | Peripheral volume of distribution                  |
| WHO   | World Health Organization                          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Astellas Pharma Europe B.V. submitted on 7 February 2019 an application for marketing authorisation to the European Medicines Agency (EMA) for XOSPATA, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 28 February 2019.

XOSPATA was designated as an orphan medicinal product EU/3/17/1961 on 17 January 2018 in the following condition: treatment of acute myeloid leukaemia.

The applicant applied for the following indication:

Xospata is indicated for the treatment of adult patients who have relapsed or refractory (R/R) acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical da ta based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Xospata as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/Xospata.

## Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/006/2018 on the agreement of a paediatric investigation plan (PIP) and on the granting of a (productspecific) waiver.

At the time of submission of the application, the PIP was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

## Accelerated assessment

The applicant requested accelerated assessment in accordance to Article 14 (9) of Regulation (EC) No 726/2004.

<div style=\"page-break-after: always\"></div>

## New active Substance status

The applicant requested the active substance gilteritinib contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## Protocol assistance

The applicant received Scientific Advice/Protocol Assistance on the development relevant for the approved indication from the CHMP on 25 June 2015 (EMEA/H/SAH/043/1/2015/III), 14 September 2017 (EMEA/H/SAH/043/1/FU/3/2017/II CORRIGENDUM), and 31 May 2018

(EMEA/H/SA/3789/1/FU/4/2018/PA/II). The Scientific Advice pertained to the following quality, nonclinical and clinical aspects of the dossier:

- The regulatory approach to the proposed definition of starting materials
- Completeness of the overall non-clinical programme
- Adequacy of the clinical pharmacology programme
- A randomised, open label, multicentre pivotal phase 3 study with salvage chemotherapy therapy as comparator: the dose regimens and approach to concomitant medications; the target population and eligibility criteria; the method for identification and selection of FLT3mutation positive patients; the overall study design to serve as a single pivotal study for Marketing Authorisation Application (MAA); the statistical approach; the suitability of the Patient Reported Outcome (PRO) instruments and their measurement; the adequacy of proposed interim analyses of composite complete remission rates (complete remission (CR)/complete remission with incomplete platelet recovery (CRp)/complete remission with incomplete hematologic recovery (Cri) and CR/complete remission with partial hematological recovery (CRh)) to support conditional or full MAA

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Bjorg Bolstad

Co-Rapporteur:   Natalja Karpova

| The application was received by the EMA on                                          | 7 February 2019   |
|-------------------------------------------------------------------------------------|-------------------|
| Accelerated Assessment procedure was agreed-upon by CHMP on                         | 31 January 2019   |
| The procedure started on                                                            | 27 February 2019  |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on      | 30 April 2019     |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on   | 3 May 2019        |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on | 6 May 2019        |
| In accordance with Article 6(3) of Regulation (EC) No 726/2004, the                 |                   |

<div style=\"page-break-after: always\"></div>

| Rapporteur and Co-Rapporteur declared that they had completed their assessment report in less than 80 days                                                                              |                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                 | 27 May 2019       |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                     | 20 June 2019      |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                 | 19 July 2019      |
| The CHMP agreed on a list of outstanding issues to be sent to the applicant on                                                                                                          | 23 July 2019      |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 20 August 2019    |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                        | 4 September 2019  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to XOSPATA on | 19 September 2019 |
| The CHMP adopted a report on similarity of XOSPATA with Dacogen, Mylotarg, Rydapt, Vyxeos on (Appendix 1)>                                                                              | 19 September 2019 |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory (R/R) acute myeloid leukaemia (AML) with a FLT3 mutation.

## 2.1.2. Epidemiology and risk factors, screening tools/prevention

Acute  myeloid  leukaemia  (AML)  accounts  for  approximately  80%  of  acute  leukaemias  diagnosed  in adults. It has been estimated that 19,950 people were diagnosed with AML in the US, with a similar incidence in the EU.

Approximately 30% of adult AML patients are refractory to induction therapy. Furthermore, of those who achieve CR, approximately 75% will relapse. The, 5-year survival after first relapse is approximately 10% (1). Patients who are in second relapse or are refractory to first salvage have an extremely poor prognosis, with survival measured in weeks.

In  general,  the  incidence  of  AML  increases  with  advancing  age,  with  a  median  age  of  66  years. Environmental  factors  that  have  long  been  established  to  increase  the  risks  of  Myelodysplastic Syndromes (MDS) and AML include prolonged exposure to petrochemicals; solvents such as benzene; pesticides and ionizing radiation.

<div style=\"page-break-after: always\"></div>

## 2.1.3. Biologic features

AML is generally characterized by aberrant differentiation and proliferation of malignantly transformed myeloid progenitor cells but can be considered a heterogeneous disease state with various molecular and genetic aetiologies that result in variable clinical outcomes. When untreated or refractory to available treatments,  AML  results  in  the  accumulation  of  these  transformed  cells  within  the  bone  marrow, suppression  of the production  of normal  blood  cells (resulting in  severe  neutropenia  and/or thrombocytopenia), as well as infiltration of these cells into other organs and tissues, and can be rapidly fatal.

Sub-classifications of AML are commonly described using the World Health Organization (WHO) system, which establishes prognostic subgroups (good, intermediate, poor) based on cytogenetics and evidence of dysplasia. Among the molecular abnormalities, FLT3 mutations are the most common. Two of these mutations are well described in the literature: an ITD in the juxtamembrane domain of FLT3 that is present in 28% to 34% of AML cases and a tyrosine kinase domain (TKD) mutation at around D835 in the activation loop of FLT3, which is present in 11% to 14% of AML cases. Each of these activated mutations in FLT3 is oncogenic and shows transforming activity in cells.

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

Epidemiological and genetic data have shown that the majority of AML present more than one recurrent alteration, including point mutations, gene rearrangements and chromosomal translocations. Furthermore, it has been suggested that point mutations in transcription factors are sufficient to confer a proliferative and survival advantage to the leukemic clone.

Certain genetic factors appear to predispose patients to poorer outcomes. Mutational status of FLT3, a member of the class III receptor tyrosine kinase, is now well recognized as delineating a subtype of leukaemia with poor prognosis, with a higher relapse rate, a shorter duration of remission from initial therapy (6 months vs 11.5 months for those without FLT3- internal tandem duplication (ITD) mutations), as well as reduced disease-free survival (DFS) (16% to 27% vs 41% at 5 years) and overall survival (OS) (15% to 31% vs 42% at 5 years).

Mutations within the FLT3 gene represent one of the most frequently identified genetic alterations that disturb intracellular signaling networks with a role in leukaemia pathogenesis. FLT3 is a member of the class  III  receptor  tyrosine  kinase  family  that  also  includes  platelet-derived  growth  factor  receptor (PDGFR), macrophage colony-stimulating factor receptor (FMS) and stem cell factor receptor (c-KIT), with which it shares the same structure. Activating mutations in the FLT3 gene, including ITDs and missense point mutations in the TKD, are the molecular abnormalities most frequently observed in the blood cells of AML patients. These mutations lead to the overexpression or constitutive activation of the tyrosine kinase receptor. Many studies indicate that patients with FLT3 mutations have a worse prognosis than patients without FLT3 alterations. In particular, the presence of an FLT3-ITD correlates with an increased risk of relapse and impaired OS. The effect on AML prognosis of the FLT3-TKD mutation has not yet been clearly defined; in several studies, the FLT3-TKD mutation did not seem to affect outcome while other investigations showed opposite results. In addition to cytogenetic abnormalities detected at diagnosis, which are the most important prognostic factor, FLT3 mutations are a significant independent prognostic factor that can influence outcome in terms of survival and duration of CR.

## 2.1.5. Management

There is no universally accepted standard of care for patients with R/R AML with FLT3 mutations and enrolment in a clinical trial should be prioritised whenever possible.  Possible salvage regimens are IDAC (intermediate dose cytarabine) with or without anthracycline, MEC  (mitoxantrone; etoposide;

<div style=\"page-break-after: always\"></div>

cytarabine) or FLAG-IDA (fludarabine; cytarabine; idarubicin; G-CSF). For unfit patients or patients not suitable for intensive chemotherapy, hypomethylating agents (azacytidine or decitabine frequently used in combination with sorafenib, in AML with FLT3-ITD mutation although sorafenib has not been approved for this indication) or low dose cytarabine (LoDAC) are possible alternatives.

The choice of specific regimen is based on factors such as prior treatment, eligibility for allogeneic HSCT and institutional  preference.  The  aim  of  treatment  is  to  achieve  remission  and  proceed  to  allogenic haematopoietic stem cell transplant (allo-HSCT) which offers the best chance of long-term relapse free survival.

## About the product

Gilteritinib  inhibits  FLT3  receptor  signalling  and  proliferation  in  cells  exogenously  expressing  FLT3 including  FLT3  ITD,  FLT3  D835Y,  and  FLT3  ITD  D835Y,  and  it  induced  apoptosis  in  leukaemic  cells expressing FLT3 ITD.

In patients with relapsed or refractory AML receiving gilteritinib 120 mg, substantial (&gt; 90%) inhibition of FLT3 phosphorylation was rapid (within 24 hours after first dose) and sustained, as characterised by an ex vivo plasma inhibitory activity (PIA) assay (SmPC, section 5.1).

The applicant requested the approval for the following indication:

Xospata is indicated for the treatment of adult patients who have R/R AML with a FLT3 mutation.

The final indications following CHMP review of this application is:

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation (sections 4.2 and 5.1).

The recommended starting dose of Xospata is 120 mg gilteritinib (three 40 mg tablets) once daily (SmPC, section 4.2).

Treatment  should  continue  until  the  patient  is  no  longer  clinically  benefiting  from  Xospata  or  until unacceptable toxicity occurs. Response may be delayed; therefore, continuation of treatment at the prescribed dose for up to 6 months should be considered to allow time for a clinical response.

In the absence of a response (patient did not achieve a CRc) after 4 weeks of treatment, the dose can be increased to 200 mg (five 40 mg tablets) once daily, if tolerated or clinically warranted (SmPC, section 4.2).

## Type of Application and aspects on development

The CHMP agreed to the applicant's request for an accelerated assessment as the product was considered to be of major public health interest. This was based on the fact that giltertinib had the potential to be effective in the R/R AML subpopulation with FLT-3 mutations. This subgroup of patients has a very poor prognosis and there are currently no approved standard treatments available in the EU.  Gilteritinib is an  inhibitor  of  the  FLT-3  tyrosin  kinase  receptor  and  based  on  the  biological  rationale  behind  this substance, it can potentially address the unmet medical need. The clinical efficacy data for gilteritinib based on the pivotal phase 3 study (demonstrating statistically and clinically meaningful effects on OS) seemed to support that gilteritinib can be an important new therapeutic treatment option.

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as film-coated tablet containing 40 mg of gilteritinib (corresponding to 44.2 mg gilteritinib fumarate) as active substance.

Other ingredients are: mannitol (E421), hydroxypropylcellulose, low-substituted hydroxypropylcellulose, magnesium stearate and film-coating composed of hypromellose, talc, macrogol 8000, titanium dioxide and iron oxide yellow (E172).

The product is available in OPA/aluminium/PVC/aluminium blisters as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance

## General information

The chemical name of gilteritinib fumarate is ( E )-but-2-enedioic acid;6-ethyl-3-[3-methoxy-4-[4-(4methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide corresponding to the molecular formula (C29H44N8O3)2 Â· C 4H4O4. It has a relative molecular mass of 1221.50 g/mol and the following structure:

Figure 1: active substance structure

<!-- image -->

The chemical structure of gilteritinib fumarate was elucidated by a combination of elemental analysis, infrared absorption spectroscopy,  1 H and  13 C nuclear magnetic resonance spectroscopy, mass spectrometry and ultraviolet-visible absorption spectrophotometry. The solid state properties of the active substance were measured by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and thermogravimetry (TG).

The active substance appears as yellow non-hygroscopic crystals. It is freely soluble in aqueous solution at pH 1-3, soluble at pH 5 and practically insoluble at pH 7 -11. Gilteritinib fumarate has no optical isomers. Polymorphism has not been observed for the active substance. XPRD studies showed that gilteritinib fumarate is crystalline.

It has been shown that the commercial drug substance synthesis method is designed to consistently deliver only one form of gilteritinib fumarate that showed no change during stability studies.

<div style=\"page-break-after: always\"></div>

The Applicant has submitted full details of chemistry, manufacturing process, and quality controls of the active substance.

## Manufacture, characterisation and process controls

The active substance is manufactured in several convergent steps from 5 starting materials, followed by salt formation and crystallisation. The manufacturing is carried out by three manufacturers in total. An acceptable QP declaration, based on on-sites audit of all active substance manufacturers has been submitted.

Overall, the manufacturing process contains eight processing steps including the salt formation and the active substance crystallisation step. Seven solid intermediates are isolated, characterized and controlled. Specifications and batch data have been provided for all isolated intermediates. The controls and proposed limits have been adequately discussed by the applicant.

A detailed narrative description of each step, including quantities of starting materials, intermediates, reagents, catalysts and solvents as well as set points and ranges for all process parameters (temperatures, reaction times) and in-process controls have been provided.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

The selection of regulatory starting materials was discussed in connection with a CHMP Scientific Advice in 2015. The definition of the starting materials is considered justified and acceptable in line with ICH Q11 principles. For all starting materials their chemical name, structural formula, names and full addresses of manufacturers, their synthetic routes and their specifications have been provided and justified. The carry-over of raw materials, impurities and solvents has been addressed.

A control strategy based on the critical quality attributes (CQAs) of the active substance has been developed. Risk assessment and risk control were performed to identify the CQAs, critical process parameters (CPPs), or critical in-process tests of the active substance. The CQAs are: assay, related substances, mutagenic impurities, residual solvents and elemental impurities. The medicine is intended for oral administration and bioburden is controlled by the active substance manufacturing process. No trends in microbial limit test have been seen in stability data. No crystal polymorphism has been observed. The particle size of the active substance is controlled as part of finished product manufacture.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. These included related substances, residual solvents and elemental impurities. The proposed control strategies for these impurities have been provided.

The applicant was requested to perform a risk assessment for the gilteritinib fumarate manufacturing process in order to evaluate the risk of N-nitrosamines formation and contamination. These results indicate that there is no risk to residue on sodium nitrite/potassium nitrite and N-nitrosamines.

Acceptable information and discussion regarding potential/actual impurities and the proposed control strategies for these impurities have been provided. The active substance gilteritinib fumarate is intended for advanced cancer therapy, and therefore it is outside the scope of ICH M7. Nevertheless, the applicant has described the strategy of the control of mutagenic impurities.

The provided information on the manufacturing process development is considered acceptable. The development of each part of the manufacturing process is discussed in detail. Several manufacturing sites and scales have been employed in the manufacture of intermediates since the start of

<div style=\"page-break-after: always\"></div>

development; however, the changes of the sites and scales had no adverse effect on the quality of the drug substance.

Changes made to the route of synthesis during development were described and justified. The quality of the active substance used in the various phases of the development is considered to be comparable with that produced by the proposed commercial process. Gilteritinib fumarate is packed in double polyethylene bags, closed by cable-ties and then packed in polyethylene tube, which is placed in a steel drum. The information provided regarding the active substance packaging materials is considered acceptable. The material is recognized as safe for use as a food contact material, in compliance with Commission Directive 2002/72/EC and Ph.Eur. 3.1.5 Polyethylene with additives for containers.

## Specification

The active substance specification includes tests for description, identification (UV-Vis, IR, fumaric acid by TLC), assay (HPLC), assay (HPLC), related substances (HPLC), residual solvents (GC), water content (KF) and sulphated ash (Ph. Eur.).

The specifications proposed for gilteritinib fumarate are acceptable. They have been established based on the requirements of the ICH guidelines Q3A, Q3C and Q6A and on the results from stability studies. A synthesis related impurity is controlled with a limit above the qualification threshold of ICH Q3A. The limit has been qualified by toxicological studies (see non-clinical section).

Adequate justifications have been provided for the omission of heavy metals, physical form, microbial limit and particle size tests from the specification.

Heavy metals were tested on development batches and the levels observed were always under the limit of detection. The safety assessment for the elemental impurities was also performed based on ICH Q3D (see finished product section). Based on the justification presented, the heavy metals test is not included in the proposed specification.

A test for determination of physical form (polymorphs) is not included. Data from XRPD analyses indicated the presence of only one form of gilteritinib fumarate and showed no change in the polymorphic form during stability studies.

An acceptance criterion for microbial limit test is not proposed for gilteritinib fumarate in line with ICH Q6A decision tree. No trends in microbial limit test have been seen in stability data.

Omission of particle size in the proposed specification has been adequately justified.

Satisfactory description has been provided for the in-house analytical methods and water determination according to Japanese pharmacopoeia. These methods (assay, related substances, determination of residual solvents, water content) in gilteritinib fumarate have been adequately validated in accordance with ICH Q2 (R1) guideline. Stability indicating properties of the HPLC methods used for determination of related substances have been demonstrated by forced degradation studies.

Information from primary and secondary reference standard of gilteritinib fumarate and other reference materials used for the related substances test has been provided.

Batch analysis data of gilteritinib fumarate have been provided. All batches were manufactured by the currently proposed manufacturers using the manufacturing process described in the dossier. All batches were tested according to the proposed specifications and the results demonstrate that the proposed manufacturing process is capable of producing active substance of consistent quality.

<div style=\"page-break-after: always\"></div>

## Stability

Results from ICH stability studies performed on three pilot scale gilteritinib fumarate batches from the proposed manufacturers stored in the intended commercial package have been provided. Up to 24 months long-term (25Â°C/60% RH) and 6 months accelerated data (40Â°C/75% RH) are available. All stability indicating specification parameters were tested. These included: description, Identification (IR), physical form (XRPD), related substances, water and assay. Microbial purity was also evaluated on samples stored under long term conditions (microbial limit test). The analytical methods used in these studies are the same as those for release, except for those for XPRD and microbial limit test, as these are not part of the active substance release specification.

Supportive stability data from three pilot scale batches stored at long term conditions for 36 months and accelerated conditions for 6 months were also provided. Gilteritinib fumarate showed no change in any of the parameters monitored under the long-term condition for 24 months and under the accelerated condition for 6 months for all three batches. No changes were observed in the supportive stability batches either.

Stress testing was performed on one primary pilot scale batch. Samples were stored at 60Â°C and 40Â°C/75% RH for 3 months and to light (in accordance with ICH Q1B) for 2 months. Gilteritinib fumarate showed no change under the temperature and humidity conditions. In the photostability condition, slight decomposition was observed in the related substances test, but all results conformed to the specification.

Forced degradation studies were conducted on one of the supportive pilot scale batches. Samples in solid state were exposed to temperature and light . Active substance in liquid form was exposed to acid , oxidation , base , temperature and light.

The presented results from these studies include assay and chromatographic purity results, mass balance calculations and peak purity results. Based on these results, it has been concluded that gilteritinib fumarate is stable, but relatively sensitive to acid condition and oxidation.

The stability results indicate that the active substance manufactured by the proposed suppliers is sufficiently stable. The stability results justify the proposed retest period in the proposed container. The proposed storage conditions 'This drug substance does not require any special temperature storage conditions. Store in the original package to protect from light\" are acceptable.

## 2.2.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

Gilteritinib 40 mg tablets are round light yellow filmcoated tablets, debossed with the 'Astellas' logo and '235' on the same side. Gilteritinib tablets 40 mg contain 40 mg of gilteritinib (corresponding to 44.2 mg gilteritinib fumarate).

Other ingredients are: mannitol (E421), hydroxypropylcellulose, low-substituted hydroxypropylcellulose, magnesium stearate and film-coating composed of hypromellose, talc, macrogol 8000, titanium dioxide and iron oxide yellow (E172).

The core tablet is composed of mannitol as a filler, hydroxypropylcellulose as a binder, hydoroxypropylcellulose, low-substituted as a disintegrant, and magnesium stearate as a lubricant. The film-coating is composed of hypromellose, talc, macrogol 8000, titanium dioxide, and iron oxide yellow. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards, where available. Iron oxide yellow (E172) is not described in Ph. Eur. but it complies

<div style=\"page-break-after: always\"></div>

with Commission Regulation (EU) No. 231/2012. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC.

The compatibility of gilteritinib fumarate with the excipients included in the tablets was investigated,using binary powder mixtures of the active substance with each excipient . Based on these results, it was concluded that the excipients do not influence the product stability at the proposed formulation ratio, condition of storage and use.

The physicochemical properties of the active substance have been described in the active substance section. Briefly, gilteritinib fumarate is non-hygroscopic, crystalline solid that  is produced as only one crystalline form.Gilteritinib fumarate is classified a BCS class IV compound, having both low solubility and low permeability. In addition, the data from a mass balance study (2215-CL-0105) in humans indicated that gilteritinib fumarate can be classified as a compound with incomplete absorption. In order to ensure rapid drug dissolution in vivo , it was decided to formulate it into immediate release film-coated tablets.

To proceed with the pharmaceutical development systematically, the quality target product profile (QTPP) for gilteritinib tablets 40 mg was defined as inmmedidate release film-coated tablets for oral administration containing 40 mg of gilteritinib, stable for at least 2 years at room temperature and with sufficient physical strength for handling and transportation. Using this profile, the CQAs necessary to ensure the performance of the finished product were identified: dissolution, assay, uniformity of dosage units, related substances, hardness and friability. These CQAs were then further used to set the acceptance criteria of commercial product applied during both the formulation and the manufacturing process development programs.

The robustness of the formulation (composition) was investigated. Based on the analysis using an Ishikawa diagram (representing the relationship between raw material and commercial finished product quality) and prior knowledge from formulation development trials, a risk assessment on material attributes was performed using Failure Mode Effects Analysis (FMEA) to identify the component attributes of gilteritinib 40 mg tablets. The effects of the inert tablet components and film coating amounts on the CQAs of gilteritinib 40 mg tablets were found to be negligible, indicating that they had no significant impact on the quality of the product.

In addition to the formulation that is intended for marketing, three formulations have been subject to clinical trials.

For phase-1/2 clinical trial [2215-CL-0101] and phase-1 clinical trial [2215-CL-0102], tablets in three strengths, namely 10 mg, 40 mg, and 100 mg, were developed as film coated immediate release tablets For phase 3 clinical trials [2215-CL-0301], and commercialisation, a new 40 mg tablet named as gilteritinib 40 mg tablets was developed as a film coated immediate release tablet.

Comparison of dissolution between the 40 mg tablets used in phase 1/2 and phase 3/commercial gilteritinib 40 mg tablets in 0.1 mol/L hydrochloric acid, acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water have been submitted. Rapid and comparable dissolution from both tablets in all media was confirmed. In addition, a relative bioavailability study [2215-CL-0110] between those formulations showed a comparable PK profile. The proposed compositions and manufacturing processes for commercial product are the same as used in Phase 3 clinical studies as well used for the primary stability batches.

The dissolution method development has been adequately described. Gilteritinib active substance is adequately soluble for dissolution testing in neutral to acidic pH range as described in the active substance section of this report. The selection of the dissolution media has been justified. To evaluate the discriminatory nature of the method, engineered tablets prepared making slight modifications of the excipient amounts and tablets prepared with a different compression force were prepared. The

<div style=\"page-break-after: always\"></div>

dissolution profiles of the engineering tablets which have the changed formulation along with the control tablets obtained by using the proposed quality control (QC) method were presented. The engineering tablets showed slower dissolution than the control tablets in both test conditions. The proposed dissolution method showed discriminability to the formulation change and to the variation of main compression force Thus, the discriminatory power of the dissolution method has been demonstrated.

The manufacturing process is standard. For optimisation of the manufacturing process, risk assessment by FMEA was carried out on manufacturing parameters that might have an impact on the CQAs, based on knowledge obtained during examination of the formulation of the final product and experience from the production of the product used for clinical studies.

The applicant has applied QbD principles in the development of the finished product and their manufacturing process. However, no design spaces were claimed for the manufacturing process of the finished product. Commercial scale manufacturing conditions were selected based on risk assessment of the manufacturing process and the results of the optimisation studies on lab scale. Risk reassessment of the manufacturing process was carried out after the examination of optimisation of the manufacturing method and scale-up study for commercial scale.

The tablets are packed in aluminium blisters. The blister consists of a unit dose cavity formed from polyamide/aluminum foil/polyvinyl chloride laminated forming foil sealed with an aluminum foil/heatseal coated lidding foil. The blisters are packed in paperboard cartons.

The PVC film that comes into contact with the drug product complies with EU 10/2011 and its subsequent amendments, including EU 1183/2012, and applicable sections of EC 1935/2004 and EC 2023/2006. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

The packaging for commercial bulk holding and transportation has been described. The packaging material complies with the additive requirements listed in European Pharmacopoeia 3.1.5 'Polyethylene with Additives for Containers for Parenteral Preparations and for Ophthalmic Preparations and Commission Regulation 10/2011. To confirm the suitability of this packaging system for gilteritinib 40 mg tablets, bulk stability studies were performed (see stability section).

## Manufacture of the product and process controls

The manufacturing process for gilteritinib 40 mg tablets consists of milling of the active substance, wet granulation, blending with disintegrant and lubricant, tablet compression, film-coating with a nonfunctional coating and packaging. The process is considered to be a standard manufacturing process.

Manufacturing of the bulk product and packaging (primary and secondary) is performed at different sites.  The proposed hold time is supported by stability data and justified. Process validation has been performed on three consecutive commercial scale batches at the proposed manufacturing site. All the analytical results are well within acceptance criteria. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this type of manufacturing process.

## Product specification

The  finished  product  release  specifications  include  appropriate  tests  for  this  kind  of  dosage  form: description (visual), identification (UV, HPLC), related substances (HPLC), uniformity of dosage units (NIR, HPLC) dissolution (Ph. Eur.), microbial limits (Ph. Eur.) and assay (NIR, HPLC).

<div style=\"page-break-after: always\"></div>

For uniformity of dosage units and assay, real time release testing by NIR using the core tablets is applied for routine release. Since the film-coating process is not expected to affect assay, this is acceptable.

The applicant has described their procedure for alternative, traditional end-product testing by HPLC (on film-coated tables) in case the NIR result is not available (e.g. equipment failure). The HPLC method using the film-coated tablets is applied for assay in the stability studies. Comparative test results (parallel testing) supporting the relationship between the end-product and the RTRT have been provided.

The potential presence of elemental impurities in the finished product has been assessed on a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on batches of gilteritinib tablets were provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls in the finished product specification. The information on the control of elemental impurities is satisfactory.

The absence of control for water content has been justified. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analyses have been presented for several batches including the three primary stability batches. All the commercial formulation batches comply with the specification that applied at the time. The results indicate consistency and uniformity of the product, and that the process is under control.

## Stability of the product

Stability data from three pilot scale batches of finished product stored for up to 36 months under long term conditions (25 ÂºC / 60% RH) and for up to 6 months under accelerated conditions (40 ÂºC / 75% RH)  according  to  the  ICH  guidelines  were  provided.  The  batches  of  Xospata  are  identical  to  those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples were tested for description, assay, related substances, dissolution and water content. Microbial quality (microbial limit test) was also tested on samples stored under long term conditions. The analytical procedures used were the same as those proposed for release, except for water content which is not part of the release specification.

No significant change was observed in any of the parameters tested at the long term or the accelerated storage  conditions.  The  proposed  extrapolation  of  shelf-life  period  (48  months)  beyond  the  period covered by long-term data (36 months) is therefore accepted.

One of the three primary stability batches was also tested in the stress testing and the photostability testing.

For the stress testing samples were exposed to high temperature and high temperature and humidity in open bottles. Data from 3 and 6 months are available, respectively. No significant changes were observed in the results of description, assay and dissolution at any of the tested conditions. A slight increase in a related substance was observed, but the levels were still within the proposed shelf life specification. There were no other degradation products which increased during the storage. At high temperature a slight decrease in the water content was observed during the storage, whereas a slight increase was observed at high temperature and humidity but all results were within the proposed specification limits.

The  photostability  testing  was  conducted  according  to  ICH  Q1B  guideline.  An  increase  in  a  related substance was observed above the shelf-life specification (0.2%) when the samples were exposed under D65 lamp.

<div style=\"page-break-after: always\"></div>

Since D65 lamp is the one that demonstrates the outdoor daylight, xenon lamp with an optical filter to eliminate radiation below 320 nm was used as the next assessment step to simulate indoor indirect daylight. When the tablets were exposed under this light, no degradation and no changes were observed. Therefore, the tablets do not require protection from indoor light.

When the tablets packed in the commercial packaging configuration, aluminum blisters, were exposed under D65 lamp, all the data met the acceptance criteria and no changes were observed after the light exposure.

Although the tablets were demonstrated to not be affected by indoor light, the storage condition 'store in the original package in order to protect from light' applies due to the results observed under standard photostability conditions.

A stability study to support the holding time of the bulk tablets after manufacture and prior to finished product  packaging  was  performed.  No  significant  changes  were  observed  in  any  of  the  parameters tested. All the data met the acceptance criteria. Based on the results of this study, and the justification of the relevance of the data from batches packed in the preliminary bulk package, it was concluded that the proposed bulk packaging and holding time under controlled storage conditions not exceeding the conditions evaluated in the bulk stability studies are acceptable.

Nonetheless, the applicant has committed to continue the bulk stability study with the commercial bulk package up to the claimed holding period

Based on available stability data, the proposed shelf-life of 48 months and the storage condition 'store in the original package in order to protect from light', as stated in the SmPC (section 6.3), are acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The applicant has presented sufficient evidence that the drug substance and the drug product are manufactured under current EU GMP.

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The applicant has applied QbD principles in the development of the active substance and/or finished product and their manufacturing process. However, no design spaces were claimed for the manufacturing process of the active substance, nor for the finished product. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

To clarify characteristics of absorption, distribution, metabolism, and excretion of gilteritinib fumarate, a  series  of in  vitro and in  vivo studies  in  mice,  rats,  rabbits,  dogs,  and  cynomolgus  monkeys  were conducted  using  14C-labeled  gilteritinib  fumarate  (14C-gilteritinib  fumarate)  and  non-radiolabeled gilteritinib fumarate. The animal species used in these studies include those used in the pharmacology and toxicity studies. Oral administration was used in most in vivo studies as in toxicity studies, which is the  same  dosing  route  with  that  used  in  clinical  studies.  In  some  studies,  the  different  route  of administration or dose was used to achieve the aim of the pharmacokinetic investigation. Pharmacokinetics (PK) of gilteritinib-derived components was clarified by investigating tissue distribution of radioactivity after a single and repeated administration of 14C gilteritinib fumarate to rats, plasma protein binding of gilteritinib in animal species, and excretion of radioactivity to urine, bile, and faeces after oral administration to rats and dogs. In addition, in vitro metabolism studies using animal and human biomaterials, and in vivo metabolic profiling studies in rats, dogs, and humans were conducted. Nonclinical safety of gilteritinib fumarate was evaluated in the following studies: a single-dose toxicity study in rats; repeat-dose toxicity studies in rats and dogs (13-week administration in rats, 4- and 13week administrations in dogs); genotoxicity studies using bacteria, cultured mammalian cells, and mice; a reproductive and developmental toxicity study in rats; a juvenile animal toxicity study in rats; and other toxicity studies (a repeat-dose toxicity study of an impurity in rats; genotoxicity studies of an impurity  using  bacteria  and  cultured  mammalian  cells;  and  a  phototoxicity  study  using  cultured mammalian cells).

All pivotal toxicology studies and studies on safety pharmacology are Good Laboratory Practice (GLP) compliant.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

## Â· In vitro

Inhibitory effect of gilteritinib on FLT3 and other tyrosine kinases

Gilteritinib fumarate inhibited activities of FLT3, nucleophosmin 1 (NPM1)-anaplastic lymphoma kinase (ALK), leukocyte tyrosine kinase (LTK), ALK and AXL kinases by over 50% at 1 nmol/L in a mobility shift assay.  At  a  concentration  of  5  nmol/L,  more  than  50%  inhibition  of  the  tyrosine  kinase  activity  of tropomyosin receptor kinase A (TRKA), ROS, RET and MER was also detected (

## Table 1 ).

Table 1: Inhibitory effect of gilteritinib fumarate on tyrosine kinase activity (2215-PH-0006)

<div style=\"page-break-after: always\"></div>

| Kinase   | 9% inhibition                  | 9% inhibition                  |
|----------|--------------------------------|--------------------------------|
|          | Gilteritinib fumarate (mmol/L) | Gilteritinib fumarate (mmol/L) |
|          | 1                              | 5                              |
| FLT3     | 86.8                           | 96.4                           |
| NPM1-ALK | 82.2                           | 99.5                           |
| LTK      | 81.8                           | 97.5                           |
| ALK      | 76.1                           | 97.6                           |
| AXL      | 54.3                           | 85.5                           |
| TRKA     | 38.3                           | 74.9                           |
| ROS      | 35.0                           | 71.7                           |
| RET      | 26.0                           | 65.5                           |
| MER      | 21.5                           | 55.7                           |

Gilteritinib  fumarate  half  maximal  inhibitory  concentration  (IC50)  for  inhibition  of  FLT3,  LTK,  AXL, echinoderm microtubule-associated protein-like 4 (EML4)-ALK variant 1 and KIT tyrosine kinase (KIT) kinase activities were determined to 0.291, 0.350, 0.726, 1.2 and 229 nmol/L, respectively (2215-PH0006, 2215-PH-0017, 2215-PH-0001).

## Effects of gilteritinib in cells expressing FLT3 mutants

Gilteritinib fumarate inhibited the proliferation of Ba/F3 cells expressing FLT3-wt, FLT3-ITD, FLT3- D835Y and FLT3-ITD-D835Y with IC50 values of 0.92, 1.8, 1.6 and 2.1 nmol/L, respectively (2215-PH-0009). In Ba/F3 cells expressing FLT3-ITD, the ratios of phosphorylated FLT3 after treatment with gilteritinib fumarate at 0.1, 1 and 10 nmol/L were 78%, 34% and 3%, respectively, compared to the vehicle control. Similarly, the ratios of phosphorylated FLT3 were 74%, 45% and 1% in Ba/F3 cells expressing FLT3D835Y, and 75%, 42% and 4% in Ba/F3 cells expressing FLT3-ITD-D835Y, respectively. Phosphorylation of STAT5, AKT and extracellular signal-regulated kinase (ERK) was also inhibited by gilteritinib fumarate in these cells (2215-PH-0015).

## Effects of gilteritinib in a human AML cell line (MV4-11) expressing FLT3-ITD

Gilteritinib fumarate inhibited the growth of MV4- 11 cells with an IC50 value of 0.92 nmol/L (2215-PH0008). Treatment of the same cell line with gilteritinib fumarate at 0.1, 1 and 10 nmol/L resulted in FLT3 phosphorylation ratios of 57%, 8% and 1%, respectively, compared to the control (2215-PH- 0010). Downstream molecules of FLT3 such as STAT5, AKT, and ERK phosphorylation were also inhibited by treatment  of  gilteritinib  fumarate.  Gilteritinib  fumarate  at  0.1,  1  and  10  nmol/L  showed  STAT5 phosphorylation ratios of 114%, 23% and 0%, respectively; AKT phosphorylation of 65%, 48% and 9%, respectively; and ERK phosphorylation of 54%, 22% and 1%, respectively, compared to the vehicletreated control (2215-PH-0014). The effect of gilteritinib fumarate (1, 3, 10 and 30 nmol/L) on cell cycle distribution was also investigated. Gilteritinib fumarate at 3 and 10 nmol/L increased the population of MV4-11 cells in G1 phase compared to the 0 nmol/L-treated group (2215-PH-9004). Gilteritinib fumarate at  3,  10  and 30 nmol/L increased the annexin-V-positive population in MV4-11 cells, indicating that gilteritinib fumarate induced apoptosis in this cell line (2215-PH-9005).

## Â· In vivo

## Effects of gilteritinib in mice subcutaneously xenografted with MV4-11 cells

The antitumour effect of gilteritinib fumarate, given by oral administration at 1, 3, 6 and 10 mg/kg per day,  once-daily  for  28  days  in  mice  xenografted  with  MV4-11  cells  was  examined  (2215-PH-0011). Gilteritinib  fumarate  inhibited  the  growth  or  induced  the  regression  of  MV4-11  tumours.  Gilteritinib fumarate  at  6  and  10  mg/kg  per  day  induced  complete  tumour  regression  in  4/6  and  6/6  mice, respectively. The body weights (BWs) of the mice treated with gilteritinib fumarate were not affected at any doses tested.

<div style=\"page-break-after: always\"></div>

The  effect  of  a  single  oral  administration  of  gilteritinib  fumarate  at  1,  3,  6  or  10  mg/kg  on  the phosphorylation of FLT3 and STAT5 was investigated in tumours from mice xenografted subcutaneously (sc) with MV4-11 cells. Tumours were collected 1, 2, 4, 8, 24 h after the administration. Phosphorylation of FLT3 and STAT5, as detected by immunoprecipitation or electrophoresis + immunodetection of lysates from MV4-11 tumours, was decreased by administration of gilteritinib (2215-PH-9006).

Effects of gilteritinib in mice xenografted with MV4-11 cells into tibia

The effect of once-daily oral administration of gilteritinib fumarate at 30 mg/kg per day on tumour growth (monitored  by  bioluminescence)  and  survival  were  examined  in  mice  inoculated  with  MV4-11  cells expressing luciferase (MV4-11-luc cells) into the tibia. Either vehicle or gilteritinib fumarate was orally administered once daily for 56 days starting at 15 days after tumour cell inoculation on day 0. Gilteritinib fumarate  induced  decrease  in  the  tumour  growth  compared  to  the  control  group  on  day  42. Improvement in survival was observed in the gilteritinib fumarate group compared to the control group. Median  survival  time  of  the  control  group  was  61.5  days,  whereas  no  death  was  observed  in  the gilteritinib fumarate group until day 168, the final day of observation (2215-PH-0021).

Plasma and intratumoural gilteritinib concentrations in mice subcutaneous (sc) xenografted with MV411cells

Plasma and intratumoural concentrations of gilteritinib after a single oral administration of gilteritinib fumarate (1, 6 and 10 mg/kg) in mice sc xenografted with MV4-11 cells were measured (2215-PH-0016). Results for plasma and tumour are shown in Table 2 and Table 3, respectively.

Table 2: Pharmacokinetic parameters of gilteritinib in plasma after a single oral administration of gilteritinib fumarate in mice subcutaneously xenografted with MV4-11 cells (2215-PH-0016)

| Gilteritinib fumal'ate (mg/kg)   |   Cmax(ng/mL) |   tmax (h) |   AUC (ngh/mL) |   t1/2(h) |
|----------------------------------|---------------|------------|----------------|-----------|
| 1*                               |         6.558 |          2 |           25.2 |      2.47 |
| 6*                               |        45.9   |          2 |          269   |      3.56 |
| 10                               |        83.01  |          2 |          492.8 |      3.14 |

Table 3: Pharmacokinetic parameters of gilteritinib in tumour after a single oral administration of gilteritinib fumarate in mice subcutaneously xenografted with MV4-11 cells (2215-PH-0016)

|   Gilteritinibfumarate (mg/kg) |   Cmax (ng/g) |   tmax (h) |   AUCt (ngÂ·h/g) |
|--------------------------------|---------------|------------|-----------------|
|                              1 |         90.61 |          4 |            1186 |
|                              6 |        772.1  |          8 |           12880 |
|                             10 |       1125    |          8 |           17330 |

## Secondary pharmacodynamic studies

Effect of gilteritinib fumarate in 3T3 Cells and NCI-H2228 cells expressing EML4-ALK mutants

Gilteritinib fumarate inhibited the proliferation of 3T3 cells expressing EML4-ALK variant 1, 2 and 3 with IC50 values of 0.42, 0.50 and 0.95 nmol/L, respectively (2215-PH-0003). Gilteritinib fumarate inhibited the  anchorage-independent  growth  of  NCI-H2228,  human  non-small-cell  lung  cancer  (NSCLC)  cells

<div style=\"page-break-after: always\"></div>

endogenously expressing EML4-ALK variant 3, with an IC50 value of 0.74 nmol/L (2215-PH-0002). In NCI-H2228  cells,  treatment  of  gilteritinib  fumarate  at  0.1,  1  and  10  nmol/L  resulted  in  ALK phosphorylation of 69%, 18% and 2%, respectively, compared to the vehicle-treated control (2215-PH0004).

## Affinity of gilteritinib fumarate to receptors, ion channels, transporters and inhibitory effect of gilteritinib fumarate on enzyme activities

Gilteritinib fumarate at 10 Î¼mol/L showed more than 50% inhibition against specific radio -ligand binding to  serotonin  5HT2B  (human)  receptor,  sigma  (nonselective,  guinea  pig)  receptor,  serotonin  5HT1 (nonselective,  rat)  receptor  and  adenosine  A1  (rat)  receptor,  with  respective  IC50  values  of  0.190, 0.615,  4.90  and  4.57  Î¼mol/L.  Specific  radioligand  bindings  to  all  other  receptors,  ion  channels, transporters and tested enzyme activities were not inhibited (less than 50% inhibition) by gilteritinib fumarate at 10 Î¼mol/L (2215 -PH-0007). The agonistic and antagonistic effects of gilteritinib fumarate on human serotonin 5HT2B receptor function was examined by measuring intracellular calcium levels in cells expressing human serotonin 5HT2B receptor. Gilteritinib fumarate did not show agonistic activity on  human serotonin  5HT2B  receptor  up  to  10  Î¼mol/L.  Gilteritinib  fumarate  inhibited  human  5HT2B receptor function with an IC50 value of 5.82 Î¼mol/L (2215 -TX-0007).

## Safety pharmacology programme

## Effects of gilteritinib on the hERG current in HEK293 cells (study 2215-PT-0001, GLP)

Potential effects of gilteritinib (1Ã10 -6 , 3Ã10 -6 , 1Ã10 -5 , and 3Ã10 -5  mol/L in 0.1% dimethyl sulfoxide (DMSO)) and positive control E-4031 (1Ã10 -7  mol/L) on the human ether-a-go-go-related gene (hERG)current was tested using the whole-cell patch-clamp technique. The peak amplitude of tail currents was measured in 5 separate cells in each experimental group, and the change rates (suppression rates) of the  amplitude  13  minutes  after  beginning  the  application  were  calculated.  Subsequently,  the hERGcurrent-suppression rate in each cell was compensated for by the mean suppression rate of the negative control (DMSO group).

The positive control, inhibited hERG tail current, and the compensated suppression rate 13 minutes after beginning the application was 88.4% (statistically significant from the control group).

The compensated suppression rates of gilteritinib at the concentrations of 1Ã10 -6 , 3Ã10 -6 , 1Ã10 -5 , and 3Ã10 -5  mol/L were 1.0%, 18.1%, 32.8%, and 70.7%, respectively; statistically significant differences were noted at the three highest doses, when compared to the rate in the negative control group.

The results  indicated  that  gilteritinib  suppresses  the  hERG  current  in  human  embryonic  kidney  293 (HEK293) cells in a concentration-dependent manner with an IC50 of 1.6Ã10 -5  mol/L (16 Âµmol/L, = 8.84 Î¼ g/mL).

Effects of gilteritinib on the cardiac ion channels (NaV1.5, CaV1.2 calcium channel (CaV1.2), KV7.1/minK potassium channel (KV7.1/minK), KV4.3, and Kir2.1) in Stably Expressing Cell Lines (study 2215-PT0006, GLP)

The effects of gilteritinib fumarate (0.09, 1, and 10 Î¼mol/L in 0.1% DMSO) on the cardiac ion channels were investigated using HEK293 cells transfected with NaV1.5 and KV7.1/minK, or chinese hamster ovary (CHO) cells transfected with CaV1.2, KV4.3, and Kir2.1. After 15-min (NaV1.5, KV7.1/minK, KV4.3, and Kir2.1) or 13-min (CaV1.2) exposure, change in each channel current was measured using a patchclamp technique.

Table 4 Effects of gilteritinib on the cardiac ion channels in Stably Expressing Cell Lines (study 2215-PT-0006, GLP)

<div style=\"page-break-after: always\"></div>

| ConcentrationasASP22l5Hemifumarate (umol/L)t   | 0 (Vehicle Control)t   | 0.1 (0.0882-0.0887)   | 1           | 10            |
|------------------------------------------------|------------------------|-----------------------|-------------|---------------|
| Number of Cells                                |                        | 5                     | 5           | 5             |
| Nay1.5 (%)                                     | 0.0 Â± 6.1              | 1.1 Â± 6.9             | 2.2Â±3.0     | 1.0Â±9.4       |
| Cay1.2 (%)                                     | 0.0 Â± 7.7              | 2.0Â±9.2               | -4.3 Â± 28.3 | -12.3Â±21.2    |
| Ky7.1/minK (%)                                 | 0.1 Â± 10.5             | 5.1 Â± 5.1             | -5.1 Â± 20.5 | -59.5Â±10.9**s |
| Ky4.3 (%)                                      | 0.0 Â± 7.1              | -0.2 Â± 7.4            | -2.4Â±6.2    | 3.5 Â± 5.3     |
| K,2.1 (%)                                      | 0.0 Â± 4.7              | -2.7Â±8.3              | -3.0Â±2.8    | -0.4Â± 5.5     |

Numerical data are the values compensated for bythe mean suppression rate in the vehicle-control group, and expressed asmeanÂ± SD unless otherwise specified.

Underlined:Test substance-related change.ForCay1.2,the current increased at 1 and 10 pmol/L in 2 of 5 cells each(compensated individual suppression rate: -33.9% and -34.8% at 1 Î¼mo1/L, -24.8% and -43.8% at 10 Î¼mo1/L).ForKy7.1/minK, the increase was also noted at 1 Î¼mo1/L in 1 of5 cells(compensated individual suppression rate: -38.2%).

**:P&lt;0.01(statisticallysignificantlevel)

â:AtO.1 pmol/L,thenumberin parenthesesrepresents the exposure concentrationestimated based on the recovery rates at the time of completing applicationin the separate stability and adsorption study. At 1 and 10 Î¼mo/L, the concentrations are not compensated because the recovery rates were 93.8%-98.0% in the study.

f:Vehiclecontrol,dimethylsulfoxide at 0.1vol%

:Dunnett's test

Only  the  compensated  suppression  rate  of  KV7.1/minK  at  10  Î¼mol/L  showed  statistically  significant difference from the control group. Furthermore, KV7.1/minK current was higher in 1 of 5 cells at 1 Î¼mol/L (the compensated suppression rate: -38.2%), and CaV1 .2 current was higher in 2 of 5 cells each at 1 and 10 Î¼mol/L (the compensated suppression rate: -33.9% and -34.8% at 1 Î¼mol/L; -24.8% and -43.8% at 10 Î¼mol/L).

## Effects of gilteritinib on hERG trafficking in hERG-transfected HEK293 cells (study 2215-PT-0008, GLP)

The effect of gilteritinib fumarate (0.1, 1, and 10 Î¼mol/L in 0.09% DMSO), negative control (DMSO) and positive control (pentamidine at 30 Î¼mol/L) on hERG trafficking was tested in HEK293 cells. After 24 -h exposure, the peak amplitude of tail currents and membrane capacities were measured in 5 separate cells  for  each  group. In  the  vehicle  control  group, the  current  density  was  159.7  pA/pF. The hERGtrafficking inhibitor pentamidine reduced the current density to 5.4% Â± 1.6% of the negative control. The curr ent densities in the gilteritinib hemifumarate groups at 0.1, 1, and 10 Î¼mol/L, were 74.5%, 75.7%,  and  58.6%,  respectively,  of  that  in  the  negative  control  group,  and  were  not  statistically significantly different from controls, although a trend towards lower density compared to controls were indicated  in  the  high  dose  group.  Gilteritinib  fumarate  did  not  affect  the  hERG  trafficking  at concentrations of up to 10 Î¼mol/L (5.53 Î¼g/mL).

## Effects of gilteritinib on action potential duration in ex-vivo human ventricular purkinje fibers from normal male donors (study 2215-PT-0007, non-GLP)

The effects of gilteritinib on action potentials in isolated human cardiac Purkinje fibers from brain-dead male donors were studied at 0.1, 1.0, and 5.0 Î¼M (presumed concentrations: 0.05570 and 0.5219 Î¼M at 0.1 and 1.0 Î¼M nominal concentrations, respectively, and mean actual concentration: 4.245 Î¼M at 5.0 Î¼M nominal concentration (studies 2215 -PT-0009, 2215-PT-0010, 2215-PT-0012).The positive control prolonged APD30, APD50, APD90, Triangulation, and STV by 11.78%, 43.20%, 105.76%, 227.01%, and 700.12, respectively, at the 1 Hz pacing frequency. Gilteritinib hemifumarate did not affect any of the evaluated parameters at concentrations up to 4.245 ÂµM (2346 ng/mL).

## Effects of gilteritinib hemifumarate on the central nervous system in rats (study 2215-PT-0003, GLP)

Gilteritinib  fumarate  was  suspended  in  0.5  w/v  %  methylcellulose  aqueous  solution  and  orally administered once at 10, 30, and 100 mg/kg to 6 male Sprague Dawley (SD) rats per group to investigate the effects on the central nervous system (CNS) for 24 hours following the modified Irwin's method. A satellite group was added to measure plasma concentration of gilteritinib. No gilteritinib-related effects were observed on general activity or behaviour, including spontaneous activity, motor incoordination, central excitation (tremor, twitches or convulsions), reflexes, muscle tonus, or general behaviour. At 30 mg/kg, a decreased number of animals with urination were noted from 4 to 10 h after dosing. At 100 mg/kg, a decreased number of animals with urination was noted from 4 to 24 h after dosing, and

<div style=\"page-break-after: always\"></div>

decreased number of animals with defecation was noted from 2 to 24 h after dosing.   The time to observed Cmax (tmax) in plasma at 10, 30, and 100 mg/kg was 10, 10, and 8 h, respectively, and the maximum concentration (Cmax) was 109.71, 318.62, and 805.52 ng/mL respectively.

Effects of gilteritinib hemifumarate on the central nervous system in rats (follow up study, study 2215PT-0004, GLP).

An additional study with observations until 168 hours was conducted to investigate the reversibility of the effects observed at 100 mg/kg in the study 2215-PT-0003. At 100 mg/kg, a decreased number of animals with urination were observed from 8 through 48 h after dosing, but not from 72 h after dosing onward. Similarly, a decreased number of animals with defecation were observed from 4 through 24 h after dosing, but not from 48 h after dosing onward. The tmax value was 10.0 h and the Cmax value was 729 ng/mL.

Effects of gilteritinib hemifumarate on the cardiovascular and respiratory system in conscious beagle dogs (study 2215-PT-0002, GLP)

Gilteritinib  fumarate  was  suspended  in  0.5  w/v%  methylcellulose  aqueous  solution  and  orally administered once at escalating dose levels of 0 (vehicle, control), 1, 3, 10, 30, and 100 mg/kg to 4 male beagle dogs (fasted overnight). Parameters evaluated included general activity and behaviour, body temperature, blood pressure, heart rate, electrocardiogram (ECG), respiration rate, blood gas, and blood electrolyte concentrations; and plasma drug concentrations. At 3 mg/kg, retching was noted in 1 animal. At 10 mg/kg, vomiting (2 animals) and a positive faecal occult blood reaction (2 animals) were noted. At 30 mg/kg, vomiting and a positive faecal occult blood reaction were noted in 3 and 1 animals, respectively. Blood calcium concentration was also decreased by 7% of pre-dose value 48 h after dosing. At 100 mg/kg, vomiting in all animals, a positive faecal occult blood reaction in 2 animals, and salivation in 1 animal were noted. An increase (11%) and a decrease (3%) in the blood calcium concentration compared to  pre-dose  value  were  noted  24  and  48  h  post  dose,  respectively.  All  of  these  findings recovered  by  the  end  of  1-  or  2-week  recovery  period.  Gilteritinib  fumarate  did  not  affect  body temperature, blood pressure, heart rate, ECG, respiration rate, or blood gas, at any doses tested. The plasma concentration of gilteritinib at 1, 3, 10, 30, and 100 mg/kg had tmax values of 8.0, 9.0, 9.5, 13.0, and 9.0 h, respectively, and Cmax of 13.85, 46.02, 125.64, 265.76, and 257.44 ng/mL, respectively. Vomiting occurred in all animals of the 100 mg/kg group in 9 to 118 min after dosing.

## Pharmacodynamic drug interactions

No pharmacodynamic (PD) drug interaction studies have been conducted with gilteritinib (see discussion on non-clinical aspects).

## 2.3.3. Pharmacokinetics

The radioactivity level in biological samples obtained after administration of 14C-gilteritinib fumarate was measured using a liquid scintillation counter, or by whole body autoradiography.  Gilteritinib plasma concentrations in mice, rats, rabbits, and dogs were measured using validated liquid chromatographytandem mass spectrometry (LC-MS/MS).

After  a  single  intravenous  (iv)  administration  of  gilteritinib  fumarate  to  rats  and  dogs,  the  plasma concentration of gilteritinib showed two elimination phases and decreased with t1/2 of 6.93 and 25.4 h in  rats  and  dogs,  respectively.  In  patients,  the  reported  half-life  following  repeated  oral  dose administration is reported to be even longer (45 to 159 h, ref, study 2215-CL-0101). CLtot and Vss were 3.89 L/h/kg and 25.7 L/kg in rats, and 1.28 L/h/kg and 38.8 L/kg in dogs, respectively. After a single oral administration of gilteritinib fumarate to rats and dogs, tmax was 4 to 6.5 h.

<div style=\"page-break-after: always\"></div>

Cmax and area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf) increased more than dose-proportionally from 1 to 10 mg/kg in rats, of which tendency was more remarkable from 3 to 10 mg/kg. In dogs, Cmax and AUCinf increased almost dose-proportionally from 0.3 to 1 mg/kg, and slightly more than dose-proportionally from 1 to 3 mg/kg in dogs. Bioavailability (BA) was 26.8%, 35.8%, and 68.6% at 1, 3, and 10 mg/kg in rats and BA was 88.2%, 88.7%, and 118.4% at 0.3, 1, and 3 mg/kg in dogs, respectively.

A tendency to lower exposure in female dogs compared to male dogs was observed, but there was no consistent gender related differences in rats.

After repeated dose administration retention and slow elimination was observed in the following organs: adrenal gland, thoracic aorta, spleen, thyroid, heart, kidney, testis, femoral muscle, brain, white fat, thymus, submandibular lymph node, bone marrow, and stomach. In these tissues, levels &gt; 10% of the maxima were still detectable 14 days after the last dose. Binding to melanin was evident and Cmax s of unchanged gilteritinib in the eyeballs of pigmented rats were approximately 30-fold higher than those of non-pigmented  rats.  The  elimination  half-life  from  eyeballs  was  409  days.  The  retention  time  in pigmented skin was approximately 2-4 weeks, compared to a few days in non-pigmented skin.

After a single oral administration of 14C-gilteritinib fumarate at 1 mg/kg to rats on Day 14 of gestation, radioactivity was detected in the placenta during the whole sample period of 72 hours. In the foetus, the radioactivity concentration was above levels detected in plasma. After a single oral administration of 14C-gilteritinib  fumarate  at  1  mg/kg  to  lactating  rats  on  day  14  postpartum,  the  radioactivity  was detected in milk at a concentration &gt; 30 fold the concentration in plasma. Foetal exposure via milk was confirmed by detection of radioactivity in infant tissues.

The in vitro plasma protein binding ratios of gilteritinib were 85.1% to 89.6% in normal mice, 75.4% to 84.2% in pharmacological model mice, 77.7% to 79.2% in rats, 75.5% to 78.7% in rabbits, 78.0% to 80.7% in dogs, 81.3% to 82.4% in cynomolgus monkeys, and 90.2% to 90.5% in humans.  After a single oral administration of 14C-gilteritinib fumarate at 1 mg/kg to rats and dogs, the blood to plasma radioactivity concentration ratios (Cb/Cp) at 4 and 8 h were 3.42 and 3.09, respectively.

In in vitro metabolic profiling studies of gilteritinib in liver microsomes and cryopreserved hepatocytes in mice, rats, rabbits, dogs, cynomolgus monkeys, and humans, the metabolite peaks detected in human liver microsomes and hepatocytes, except for one minor metabolite, were also detected in at least one other species. After a single oral administration of 14C-gilteritinib fumarate at 1 mg/kg to rats and dogs, the major radioactive component of plasma was gilteritinib. Various metabolites were detected in urine, bile,  and  faeces.  Giteritinib  was  suggested  to  be  metabolized  by  oxidation,  N-dealkylation,  and glutathione conjugation. All metabolites detected in humans, except for two minor metabolites (M4 and M6), were detected in at least either rats or dogs.

The major excretion route in rats and dogs was faeces, which is similar to the excretion pattern in patients. After a single oral administration of 14C-gilteritinib fumarate at 1 mg/kg to rats, the cumulative urinary and faecal excretion of radioactivity within 168 h post-dose was 1.4% and 89.9% of the dose, respectively.  After  a  single  oral  administration  of  14C-gilteritinib  fumarate  at  1  mg/kg  to  dogs,  the cumulative urinary and faecal excretion of radioactivity within 504 h post-dose was 9.5% and 88.1% of the dose, respectively. Enterohepatic circulation of gilteritinib-derived components was also observed in rats.

<div style=\"page-break-after: always\"></div>

## 2.3.4. Toxicology

## Single dose toxicity

Single  dose  toxicity  studies  were  performed  in  rats  and  acute  toxicity  of  gilteritinib  fumarate  was evaluated in a 4-week study in dogs.

## Single dose oral toxicity study in Sprague Dawley rats (report nr 2215-TX-0001, GLP)

A  single  oral  gavage  dose  of  gilteritinib  fumarate  suspended  in  vehicle  (0.5  w/v%  methylcellulose aqueous solution) was administered at a dose of 100 or 300 mg/kg to 5 male and 5 female 7 week old Crl:CD SD strain rats per group after overnight fasting. Male and female rats in the 300 mg/kg group died or were sacrificed moribund from 1 to 2 days after dosing; the approximate lethal dose of gilteritinib fumarate in rats was considered to be 300 mg/kg.  In animals that died or were moribund, decreased BW,  decreased  spontaneous  activity,  hyphema,  sparse  fur  (abdomen),  pale  skin,  decreased  stool volume, black stool (a positive fecal occult blood reaction), and hypothermia, were noted. Histopathology  of  animals  that  died  or  were  sacrificed  moribund  showed  haemorrhage,  epithelial vacuolation, and inflammatory cell infiltration in the duodenum; haemorrhage in the anterior chamber; haemorrhage and erosion in the forestomach, necrosis of the lymphocyte in the ceacal lymphoid follicle; and necrosis of the lymphocyte and haemorrhage in the thymus.

## Repeat dose toxicity

An overview of repeat dose toxicity studies conducted with gilteritinib is displayed in Table 5.

Table 5: Pivotal repeat dose toxicity studies (GLP)

| Species / strain/ Study ID      | Dose (mg/kg/day) Route        | n/sex /group Duration                                                                                                                | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | NOAEL mg/kg/ day   |
|---------------------------------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| SD rats Study no. 2215-TX- 0002 | 0, 2.5, 5, 10, 20 Oral gavage | Main groups: 15 (0, 10 and 20 mg/kg/day) 10 (2.5 and 5 mg/kg/day) Satellite groups: 9 3 in control group 13 weeks + 4 weeks recovery | â¥ 2.5 mg/kg/day: â BW and BW gain (M) and â lymphocyte/leukocyte count, â Î³ -globulin fraction and spleen weight (F). â¥ 5 mg/kg/day: dilatation of the sinusoid in the spleen and lymphocyte necrosis in the Peyer's patch (Males+Females). â food consumption, Î³ -globulin fraction, and spleen weight (M). â erythrocyte count, â mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH), â Î² -globulin fraction, â albumin (ALB) /globulin (A/G) ratio, â pituitary weight, and microgranuloma in the mesenteric lymph nodes (F). â¥ 10 mg/kg/day: â thymus weight (Males+Females) Male only: â total urinary electrolyte, â MCV and MCH, decreased lymphocyte and leukocyte count, â in aspartate aminotransferase (AST), alanine transaminase (ALT), and relative lung weight, atrophy of the thymus, microgranuloma in the mesenteric lymph node, accumulation of foam cells in the lung (phospholipidosis), microvacuolation in the ileum and cecum. Female only: â BW and BW gain, food consumption, and ALB fraction. 20 mg/kg/day: 2 animals died. Death was likely caused by bacterial infection, with bacterial findings and inflammation in the renal tubule, kidney; cecum and heart (left auricle). Surviving animals: Urinary effects, bone marrow effects (hypocellularity), thymus (necrosis, atrophy), lymp node (atrophy), spleen (atrophy, microgran), kidney (renal lesions, phospholipidosis), lungs (macrophage changes, foam | < 2.5              |

<div style=\"page-break-after: always\"></div>

|                         |                                                                                                              |                                                                                                                        | cells, increased weight in F), ileum/cecum (microvacuolation in F), eye (inflammatory, histopat), â spontaneous activity (F). gastrointestinal (GI) ( â stool (F), liver . Recovery: Full or partial recovery was obtained after                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |    |
|-------------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Beagle dogs             | 0, 1, 10, 100, 1000                                                                                          | 4 M (0, 1, 10 mg/kg/day)                                                                                               | the 4 week recovery period. â¥ 2.5 mg/kg/day: â BW (1M), positive fecal occult blood reaction, â alkaline phosphatase (ALP), â bilirubin, â AST, â ALB + A/G ratio, â globulin , â ALB fraction, â Î±2 - globulin and Î³ -globulin fractions, and â inorganic phosphorus and calcium (M) and â platelet (1F), atrophy of thymus, necrosis in lymph node â¥ 5 mg/kg/day: diarrhea (3M), reddish stool (pos. occult blood reaction, 1M), vomiting (1M.), â BW (2M). Eye changes in tapetal area and corresponding zones in both eyes, urine effects (M+ 1F) â phospholipidosis and total cholesterol, effects on organ weight and/or histopathology in thymus (M), submandibular and/or mesenteric lymph node, Peyer's patch, ileum, colon, rectum and duodenal mucosal epithelia. â¥ 10 mg/kg/day: 1 animal was sacrificed moribund on day 12 of dosing, and the remaining 3 animals were necropsied after 12 days of dosing due to â food consumption and severe toxicity affecting many organs and tissues. Histopathological findings in testis (degeneration/necrosis, germ cell spermatid giant cell formation), epididymis (necrosis), eyeball. â¥ 100 mg/kg/day: Some animals died or were moribund, resulting in dosing discontinuation after 4 days. Severe toxicity findings in numerous tissues and organs. Histopathological findings (thymus, lymph nodes, oral mucosa), haemorrhage (GI, gallbladder, mucosa, eye) were noted. 1000 mg/kg/day Some animals died or were moribund, resulting in dosing discontinuation after 2 days. 1 animal survived the 4-week recovery period after 2 days of dosing, the remaining 13 animals died or were sacrificed by 6 days after dosing discontinuation. Findings were clinical observations, haematological findings, gross pathology (red discolouration and dark contents in many organs) histopathology (esophageal erosion and increased foam cells in the Peyer's patch). Recovery: Full or partial recovery was obtained after the 4 week recovery period. Since necropsy was | 1  |
| Study no. 2215-TX- 0003 | 2.5, 5 (additional groups, started after discontinuation of administration of 10-1000 mg/kg/day) Oral gavage | 4 F (0 and 1 mg/kg/day) 7 M (100 and 1000 mg/kg/day) 6 M + 7 F (2,5 and 5 mg/kg/day groups) 4 weeks + 4 weeks recovery | performed at the end of the dosing period in animals showing changes in phospholipids, total cholesterol, and urine sediment, reversibility of these findings could not be evaluated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |    |
| Beagle dogs             | 0, 1, 2.5, 5                                                                                                 | 4 (0 and 1 mg/kg/day)                                                                                                  | â¥2.5 mg/kg/day: in the foot pad, pos. fecal occult blood reaction, â neutrophile count and platelet, prolonged activated partial thromboplastin time (aPTT), â AST/ALP , â ALB concentration, â in globulin/total protein, â A/G ratio and ALB fraction, and â Î² -globulin and Î³ -globulin fractions. Organ changes were noted in lungs (oedema (M), focal interstitial fibrosis (1F),                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1  |
| Study no. 2215-TX- 0009 | Oral gavage                                                                                                  | 7 (2.5 and 5 mg/kg/day) 13 weeks + 4 weeks recovery                                                                    | haemorrhage and inflammatory changes in both sexes) and gingiva (inflammation, 1F). â¥ 5 mg/kg/day: 1 male found dead (d42). I male sacrificed moribund day 77 of dosing. In the dead/sacrificed animal: clinical findings. Ophthalmology-findings, urinalysis, haematology, blood chemistry. Gross pathology findings, organ weight changes, histopathology observations (e.g. alveoli, lung, bronchus, thymus, spleen, lymph node, PeyerÂ´s patch, bone marrow, oral mucosa, liver, kidney, pancreas, lacrimal gland, etc). In surviving animals: clinical signs â BW, â food consumption, funduscopy findings, urinalysis changes, haematology findings, gross                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |    |

<div style=\"page-break-after: always\"></div>

| pathology findings (lungs, oral mucosa, crust, malar ulcers), organ weight changes. Histopathology changes in many organs electron microscopy findings (liver, kidney, eye/retina). Recovery: Full or partial recovery was obtained. The animals showing increased urinary glucose and large unstained cell count and decreased lymphocyte count and serum glucose were necropsied at the end of the dosing period, therefore, reversibility of these findings could not be evaluated.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Genotoxicity

An overview of the genotoxicity studies conducted with gilteritinib is displayed in Table 6.

Table 6: Genotoxicity testing of gilteritinib

| Type of test (study ID)                | Test Substance                                                                                         | Test system (strain)                                              | S9   | Concentration/Dose                                                                                                                              | Results                                                              | GLP   |
|----------------------------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-------|
|                                        | Non-pivotal (screening) studies                                                                        |                                                                   |      |                                                                                                                                                 |                                                                      |       |
| In vitro                               |                                                                                                        |                                                                   |      |                                                                                                                                                 |                                                                      |       |
| Ames test (2215-TX- 3008)              | Gilteritinib hemifumarate Test article precipitation: â¥2500 Î¼g/plate without S9; 5000 Î¼g/plate with S9 | S. typhimurium (TA1535, TA1537) and E. coli (WP2uvrA)             | Â±    | 0, 156-5000 Âµg/plate Cytotoxicity: TA1535: 5000 Î¼g/plate without S9 TA1537: â¥ 2500 Âµg g/plate without S9, and 5000 Âµg /plate with S9            | Positive                                                             | No    |
| Ames test (2215-TX- 3011)              | Gilteritinib hemifumarate Test article precipitation: â¥2500 Âµg/plate, with and without S9              | S. typhimurium (TA100, TA98)                                      | Â±    | 0, 156-5000 Âµg/plate Cytotoxicity: TA100: 5000 Î¼g/plate, with and without S9                                                                    | Negative                                                             | No    |
| Micronucle us (2215-TX- 3009)          | Gilteritinib hemifumarate                                                                              | Chinese hamster lung fibroblasts                                  | Â±    | Without S9: 0, 0.0391- 0.156 Î¼g/mL With S9:0, 1.25- 5 Î¼g/mL                                                                                     | Positive                                                             | No    |
| In vivo Micronucle us (2215-TX- 3010   | Gilteritinib (free)                                                                                    | Mice(male)/ICR                                                    |      | 0, 31.3, 62.5, 125, 250 mg/kg (No examination of 31.3 mg/kg group)â                                                                              | Positive                                                             | No    |
|                                        | Pivotal studies                                                                                        |                                                                   |      |                                                                                                                                                 |                                                                      |       |
| In vitro                               |                                                                                                        |                                                                   |      |                                                                                                                                                 |                                                                      |       |
| Ames test (2215-TX- 0004)              | Gilteritinib hemifumarate No test article precipitation                                                | S. typhimurium TA98, TA100, TA1535, TA1537) and E. coli (WP2uvrA) | Â±    | 0, 156-5000 Âµg/plate Cytotoxicity: 2500 Âµg/plate TA1537, without metabolic activation)                                                          | Negative                                                             | Yes   |
| Chromoso me aberration (2215-TX- 0005) | Gilteritinib fumarate                                                                                  | Chinese hamster lung fibroblaster                                 | Â±    | 6 h: (Â±S9) 0.781-50 Î¼ g/mL; 24 h (-S9) : 0.0313-2 Î¼ g/mL Dose-dependent decrease in the cell proliferation ratio under all treatment conditions | Negative                                                             | Yes   |
| In vivo                                | In vivo                                                                                                |                                                                   |      |                                                                                                                                                 |                                                                      |       |
| Mouse micronucl eus (2215-TX- 0008)    | Gilteritinib hemifumarate                                                                              | Mouse/Crlj:CD1 (ICR)                                              |      | Micronucleus test: 0, 20, 65, 200 mg/kg                                                                                                         | Positive (males and females in the 65 and 200 mg/kg/day dose groups) | Yes   |

<div style=\"page-break-after: always\"></div>

## Carcinogenicity

No carcinogenicity studies have been conducted with gilteritinib (see discussion on non-clinical aspects).

## Reproduction Toxicity

- Dose-range finding study of gilteritinib  hemifumarate on embryo-foetal development by oral gavage administration in SD rats (study report no 2215-TX-0010, non-GLP)

Gilteritinib hemifumarate was administered orally to pregnant rats (12 weeks old when administration started) at dose levels of 0, 5, 20, or 30 mg/kg/day during the period from implantation to closure of the hard palate (from Day 7 to Day 17 of gestation). In the 20 and 30 mg/kg groups, decreases in BW and food consumption were noted from the initiation of dosing in dams. From 20 mg/kg, postimplantation loss rate, low foetal BW, and low numbers of ossified sternebrae and sacral and caudal vertebrae were observed. Visceral and skeletal variations were observed at high frequencies in these groups. In the 30 mg/kg group, anasarca, limb hyperextension, membranous ventricular septum defect, absent kidney, malpositioned  kidney,  small  kidney,  malpositioned  adrenal,  absent  uterine  horn,  fused  rib,  and hemicentric thoracic centrum were observed as abnormalities. In the 20 mg/kg group, membranous ventricular septum defect was observed as a visceral abnormality in 1 foetus.

- Embryo-foetal development study of gilteritinib fumarate by oral gavage in SD rats ( study report no 2215-TX-0011, GLP)

Gilteritinib fumarate was administered once daily by oral gavage to 19 to 20 pregnant (SD) rats (12 to 15 weeks of age at the initiation of dosing). The dose levels were 0.3, 3, 10, and 30 mg/kg per day during the period from implantation to closure of the hard palate (from day 7 through 17 of gestation). In dams at the highest dose of 30 mg/kg /day, decrease in BW was noted from the initiation of dosing until necropsy, and a decrease in food consumption was noted from the initiation of dosing until the completion of dosing. In the same dose group of 30 mg/kg/day changes related to gilteritinib was noted. High  postimplantation  loss  rate,  low  foetal  BW,  low  placental  weight,  and  low  numbers  of  ossified sternebrae and sacral and caudal vertebrae were observed. Anasarca, local oedema, exencephaly, cleft lip, cleft palate, short tail, and umbilical hernia as external abnormalities (frequency of each abnormality were 0.41% to 6.74% and frequency of total abnormalities were 13.53%). Microphthalmia, enlarged atrial chamber, enlarged ventricular chamber, membranous ventricular septum defect, hypoplastic right ventricle, absent kidney, fused kidney, abnormal revolution of kidney, malpositioned kidney, misshapen kidney,  small  kidney,  malpositioned  adrenal,  and  malpositioned  ovary  as  visceral  abnormalities (frequency of each finding were 0.75% to 12.21% and frequency of total abnormalities were 32.74%) were observed. Sternoschisis, absent rib, fused rib, fused cervical arch, misaligned cervical vertebra, and absent thoracic vertebra were seen as skeletal abnormalities. The frequency of each abnormality was 0.88% to 1.05%, with a frequency of total abnormalities of 3.69%. Visceral and skeletal variations were also observed at high frequencies.

Based on these results, the maternal and developmental no observed adverse effect level (NOAEL) was considered 10 mg/kg /day. At the NOAEL of 10 mg/kg/day, the gilteritinib exposure (AUC over the 24hour dosing interval (AUC24) on day 17) was 1930 ngÂ·h/mL which was approximately 0.06 times the exposure at maximum clinical dose (31428 ngÂ·h/mL at 200 mg/kg/day)

Toxicokinetic analysis of plasma exposures to gilteritinib is displayed in Table 7.

Table 7: Mean TK parameters in an embryo-foetal development study of gilteritinib fumarate in pregnant rats, GD 7 and 17

| Day of gestation   | Dose level (mg/kg) C max (ng/mL)   | t max (h)   | AUC24 (ngÂ·h/mL)   |
|--------------------|------------------------------------|-------------|-------------------|

<div style=\"page-break-after: always\"></div>

|   7 |   0.3 |   0.821 |   10.0 |   11.3 |
|-----|-------|---------|--------|--------|
|   7 |   3   |  25.8   |      8 |  266   |
|   7 |  10   | 119     |      6 | 1610   |
|   7 |  30   | 432     |     10 | 6750   |
|  17 |   0.3 |   0.847 |      4 |   11.7 |
|  17 |   3   |  32.1   |      8 |  307   |
|  17 |  10   | 148     |      6 | 1930   |
|  17 |  30   | 394     |      8 | 5880   |

## Dose range finding toxicity study of gilteritinib fumarate in SD rats (study report no 2215-TX-0015, nonGLP)

Gilteritinib was suspended in 0.5 w/v% methylcellulose solution and orally administered once daily for 18 days from postnatal days (PNDs) 4 to 21. The dose levels of 0 (vehicle control), 5, and 10 mg/kg/day gilteritinib were administered to 6 male and 6 female (SD) juvenile rats per group in order to select dose levels of gilteritinib hemifumarate for a definitive GLP study where juvenile animals would be dose from PND 4 to 42.

A satellite group (12 males and 12 females in the control group, and 39 males and 39 females at 5, 10, and  20  mg/kg/day)  was  added  to  assess  systemic  exposure  to  gilteritinib,  and  this  satellite  group included some toxicity evaluation. From 10 mg/kg per day, some animals died or were euthanized due to  moribundity,  and  abnormal  stool  color  (dark  red)  and/or  abdominal  distention  were  observed  in moribund or surviving animals.

## Juvenile toxicity study of gilteritinib hemifumarate in SD rats (study report no 2215-TX-0016, GLP)

Gilteritinib hemifumarate was suspended in 0.5 w/v% methylcellulose solution and orally administered once daily for 39 days from PND 4 to 42 at dose levels of 0 (vehicle control), 1, 2.5, and 5 mg/kg/day to male and  female (SD) juvenile rats (n=12). 6 male and 6 female rats were added to the control and 2.5 and 5 mg/kg/day groups to assess the reversibility of toxicity during a subsequent 28-day recovery period. A satellite group (15 males and 15 females in the control group, and 48 males and 48 females in each test article group) was added to assess systemic exposure.

One male rat in the 2.5 mg/kg per day satellite group showed prone position and hypothermia before dosing on day 9 of dosing, and this animal was then euthanized due to moribundity. Congestion/haemorrhage were observed in the lamina propria of the ileum and in the mucosa of the cecum, and necrosis of the lymphocytes was observed in the thymus cortex. Necrosis of the lymphocytes in  the  thymus  cortex  was  considered to  be  a  secondary  change  due  to  deterioration  of  the  general condition. In the surviving animals, decreased BW and BW gain were noted in males at 5 mg/kg per day and in females at 2.5 mg/kg per day and higher, and decreased food consumption was noted from2.5 mg/kg per day (both sexes).The changes in BW and food consumption noted during the dosing period showed reversibility.

The NOAEL was determined to 1 mg/kg/day, based on the findings in the 2.5 mg/kg/day dose group. Toxicokinetic parameters of gilteritinib are displayed in Table 8.

Table 8: Toxicokinetic parameters of gilteritinib in a juvenile toxicity study in rats, report no 2215-TX-0016

| Dose Level (mg/kg/day)   | 1     | 1      | 2.5   | 2.5    | 5     | 5      |
|--------------------------|-------|--------|-------|--------|-------|--------|
|                          | Males | Female | Males | Female | Males | Female |

s

s

s

<div style=\"page-break-after: always\"></div>

| Mean      | Day 1 (PND 4)     |      8 |      6 |    24 |     6 |      8 |      8 |
|-----------|-------------------|--------|--------|-------|-------|--------|--------|
| tmax      | Day 17 (PND       |   4    |   8    |   8   |   4   |    8   |   10   |
| (h)       | 20) Day 39 (PND   |   6    |   6    |   4   |   6   |    6   |    6   |
| Mean      | 42) Day 1 (PND 4) |  11    |   9.11 |  39.5 |  35   |   84.7 |   81.2 |
| Cmax      | Day 17 (PND       |   9.95 |   7.68 |  29.9 |  30.5 |   87.6 |   53.8 |
| (ng/mL)   | 20) Day 39 (PND   |   4.24 |   3.18 |  12.8 |  12.4 |   25.1 |   29.9 |
| Mean      | 42) Day 1 (PND 4) | 187    | 164    | 746   | 641   | 1540   | 1490   |
| AUC24     | Day 17 (PND       |  77.8  |  71.8  | 312   | 315   | 1090   |  854   |
| (ngÂ·h/mL) | 20) Day 39 (PND   |  39.3  |  20.8  | 141   |  91.3 |  322   |  279   |

42)

## Toxicokinetic data

Data presented under '' Reproduction Toxicity '' section.

## Local tolerance

Dedicated studies of local tolerance have not been submitted (see discussion on non-clinical aspects).

## Other toxicity studies

In 4-Week Repeated Oral Dose Toxicity Study evaluating the synthesis related impurity in Rats (Impurity Toxicity  Study,  2215-TX-0012,  GLP) the  following  observations  and  examinations  were  performed: clinical  signs,  BW,  food  consumption, ophthalmology, hematology, blood chemistry, urinalysis, gross pathology,  organ  weight,  and  histopathology.  There  were  no  dead  or  moribund  animals.  No toxicologically significant changes were noted in any observations, measurements, or examinations in any groups.

Bacterial reverse mutation test was performed with 5 test strains of bacteria ( S. typhimurium TA100, TA1535, TA98, and TA1537, and E. coli WP2 uvrA ) using the preincubation method, in the presence or absence of rat liver S9 (Bacterial Reverse Mutation Test of the related impurity, 2215-TX-0013, GLP). As compared with the negative control, no 2-fold or greater increases or dose-dependent increases in the number of revertant colonies were observed in any test strain, with or without S9, in either the dose range-finding test or the main test. It was concluded that the related impurity did not induce gene mutation in S. typhimurium or E. coli under the conditions of this study.

A Chromosomal Aberration Test of the synthesis related impurity in Cultured Mammalian Cells (2215TX-0014, GLP) was performed with CHL cells in short-term treatment for 6 h in the presence of absence of rat liver S9, and in continuous treatment for 24 h without S9. Chromosomal aberrations were analyzed at the following concentrations:2.5, 3, 3.5 and 4 Î¼g/mL in short -term treatment without S9 (the cell proliferation ratio at the highest concentration was 51.4% that of the negative control); 2.5, 3, 3.5, and 4 Î¼g/mL in short -term treatment with S9 (the cell proliferation ratio at the highest concentration was 58.6% that of the negative contr ol); and 2, 2.5, 3, and 3.5 Î¼g/mL in continuous treatment for 24 h without S9 (the cell proliferation ratio at the highest concentration was 52.6% that of the negative control). The number and incidence of cells with structural and numerical chromosomal aberrations were counted  and  calculated. As  compared  with  the  negative  control  group,  no  statistically  significant increases in the number of cells with structural or numerical chromosomal aberrations were noted in any treatment group. It was concluded that, under the conditions of this study, the related impurity did not induce chromosomal aberrations in CHL cells, regardless of treatment time with or without S9.

As a result, the high dose level in the 4-week toxicity study was the NOAEL for rats, and the synthesis related impurity did not show mutagenicity or clastogenicity. A human equivalent dose calculated based

<div style=\"page-break-after: always\"></div>

on the NOAEL in rats multiplied by purity of used test substance, the rat body surface area conversion factor (0.162), and a human BW of 60 kg is higher than the possible maximum intake of this impurity at the maximum clinical dose (200 mg per day), which is calculated based on the acceptance criterion for this impurity in the specification.

A phototoxicity study (report no 2215-TX-0006) was performed with cultured mammalian cells (Balb/c 3T3 cells) at 9.49, 13.3, 18.6, 26.0, 36.4, 51.0, 71.4 and 100 Î¼g/mL, with and without ultraviolet A (UVA) irradiation. The IC50 was calculated in both the presence and absence of irradiation, and the peak inspiratory  flow  (PIF) (actual  value:  1.018)  was  less  than  2.  A  PIF  value  below  2  indicates  'no phototoxicity' (according to Organisation for Economic Cooperation and Development (OECD) guideline 432 regarding in vitro 3T3 NRU phototoxicity test).

## 2.3.5. Ecotoxicity/environmental risk assessment

## Table 9.Summary of main study results

| Substance (INN/Invented Name): Gilteritinib fumarate; Gilteritinib                                                                 | Substance (INN/Invented Name): Gilteritinib fumarate; Gilteritinib                          | Substance (INN/Invented Name): Gilteritinib fumarate; Gilteritinib                          | Substance (INN/Invented Name): Gilteritinib fumarate; Gilteritinib                          |
|------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| CAS-number (if available): 1254053-84-3 (gilteritinib fumarate) 1254053-43-4 (gilteritinib)                                        | CAS-number (if available): 1254053-84-3 (gilteritinib fumarate) 1254053-43-4 (gilteritinib) | CAS-number (if available): 1254053-84-3 (gilteritinib fumarate) 1254053-43-4 (gilteritinib) | CAS-number (if available): 1254053-84-3 (gilteritinib fumarate) 1254053-43-4 (gilteritinib) |
| Persistent Bioaccumulative Toxic (PBT) screening                                                                                   |                                                                                             | Result                                                                                      | Conclusion                                                                                  |
| Bioaccumulation potential- log D ow (at pH 7)                                                                                      | OECD107                                                                                     | 2.32                                                                                        | Potential PBT (N)                                                                           |
| Phase I                                                                                                                            |                                                                                             |                                                                                             |                                                                                             |
| Calculation                                                                                                                        | Value                                                                                       | Unit                                                                                        | Conclusion                                                                                  |
| Predicted environmental concentration of surfacewater (PEC surfacewater ), based on the refined market penetration factor (F pen ) | 0.0048                                                                                      | ï­ g/L                                                                                       | > 0.01 threshold (N)                                                                        |

## 2.3.6. Discussion on non-clinical aspects

The non-clinical pharmacology data that have been submitted, they confirmed a role of FLT3 inhibition in the observed anti-proliferative effect induced by gilteritinib fumarate in vitro and in animal xenograft models. Kd-values have not been presented, but gilteritinib appears to display comparable inhibitory potency on both wild-type FLT3, FLT3-IDT and FLT3-D835Y. In view of the known role of FLT3, and overexpression of FLT3 and oncogenic FLT3 mutants occurring in AML cells, a therapeutic rationale is justified. The presented in vitro and xenograft model results are based on FLT3 forms assumed to be of human origin. Inhibition of EML4-ALK or LTK is not expected to contribute to the effect of gilteritinib in AML, since these kinases have not been reported to play a role in FLT3 mutated AML. In contrast, inhibition of AXL by gilteritinib may translate into antiproliferative effect in AML. In addition, activated AXL is reported to be responsible for resistance to FLT3 inhibitors such as quizartinib and midostaurin in FLT3-ITD positive AML cells.

An IC50 = 5.82 Âµmol/L for inhibition of 5HT2B function was established (2215-TX-0007). At a daily dose of 120 mg and 200 mg gilteritinib in the phase 1/2 dose escalation/dose expansion study 2215-CL-0101, the median unbound Cmax at day 15 was 22.1-146.2 ng/mL (40.0-264.4 nmol/L). This is approximately 22-145 fold lower than the IC50 for functional inhibition of the serotonin 5HT2B receptor. Taken together, results from non-clinical pharmacology studies suggest low probability of secondary effects of gilteritinib related to targets that are not tyrosine kinases.

Based  on in  vitro data,  gilteritinib  may  reduce  the  effects  of  medicinal  products  that  target  5HT2B receptor or sigma nonspecific receptor (e.g., escitalopram, fluoxetine, sertraline). The concomitant use of these medicinal products with Xospata should be avoided unless use is considered essential for the

<div style=\"page-break-after: always\"></div>

care of the patient (SmPC section 4.5). Due to in vitro binding to 5HT2B (there is a potential impact on cardiac development in patients less than 6 months of age (SmPC section 4.2).

Specific PD interaction studies have not been conducted which is acceptable. The probability of secondary effects of gilteritinib related to targets that are not tyrosine kinases is considered to be low. Concomitant use of other medicinal products targeting FLT3 and/or ALK, is also considered unlikely in view of the approved indications.

In  rats,  decreased  urination  at  30  mg/kg  and  higher  and  decreased  defecation  at  100  mg/kg  were observed. In dogs, positive faecal occult blood at 10 mg/kg and higher, a decrease in the blood calcium concentration at 30 mg/kg, and salivation and an increase followed by a decrease in the blood calcium concentration at 100 mg/kg were observed. These changes were observed at plasma exposure levels similar to or less than clinical exposure levels. A possible clinical relevance of these findings is unknown. (SmPC, section 5.3).

In patients, QT prolongation was observed, similar to other tyrosine kinase inhibitors (TKIs) (Cortes et al, 2018). The results of in vitro and in vivo non-clinical studies did however not provide a clear indication of a strong potential to prolong QT in humans. Based on the literature reporting, in some cases, 10% to 20% inhibition of the hERG current can be related to QT prolongation in vivo (Jonker et al [2005] and Redfern et al [2003]). Taken together there may be multiple factors contributing to gilteritinib induced QT prolongation  seen  in  patients,  such  as  a  weak  hERG  current  suppression  and  increased  CaV1.2 current.

Long  half-lifes  in  dogs  and  patients  support  gilteritinib  administration  once  daily.  The  very  wide distribution of gilteritinib in rats suggests a potential for gilteritinib related adverse effects across all tissues and organs, including the CNS. Long retention in pigmented skin and eyes indicates binding to melanin. Concern for phototoxicity in patients was however resolved by the negative outcome of the in vitro NRU phototoxicity test with Balb/c 3T3 cells.

All metabolites detected in humans, except for two minor metabolites (M4 and M6), were detected in rats and/or dogs (species chosen for toxicity testing). The major excretion route in rats and dogs was faeces, which is similar to the excretion pattern in patients.

In the repeated dose toxicity studies in rats and dogs, target organs of toxicity were the gastrointestinal tract  (heamorrhage in dogs), lymphohaematopoietic system (lymphocyte necrosis and bone marrow hypocellularity with changes in haematological parameters), eye (inflammation and lens opacity in rats, fundus colour change in dogs, retinal vacuolation), lung (interstitial pneumonia in rats and inflammation in dogs), kidney (renal tubule changes with a positive urine occult blood reaction) and liver (hepatocyte vacuolation),  urinary  bladder  (epithelial  vacuolation),  epithelial  tissue  (ulcer  and  inflammation),  and phospholipidosis (lung and kidney in rats). These changes were observed at plasma exposure levels similar to or less than clinical exposure levels. Reversibility of most of the changes was indicated by the end of the 4 week recovery period. A possible clinical relevance of these findings is unknown (SmPC, section 5.3).

GI effects in dogs treated for 4 and 13 weeks showed full or partial recovery except for inflammation in molar and incisor alveoli and gingiva, and were considered by the applicant to be associated with the GI disorder or liver toxicity observed in the 13-week study. The GI tract is a target organ of toxicity and GI-related effects have been observed in patients (some cases of bleeding, perforation and obstruction). Diarrhoea, nausea and constipation are described as very common adverse drug reactions in the SmPC.

The  lung  effects  in  animals  were  noted  at  low  exposure  levels  when  comparing  to  clinical  relevant exposure. Phospholipidosis in rat is however considered to be caused by a common structural feature of gilteritinib as a cationic amphiphilic drug. Oedema, haemorrhage and congestion in the lungs in rats were likely  non-specific  findings  associated  with  a  deteriorated  general  condition  observed  following

<div style=\"page-break-after: always\"></div>

administration of gilteritinib at a lethal dose. Lung findings in dogs were severe and have also observed in  dogs treated with midostaurin. Taken together, the lung findings in dogs are considered clinically relevant as they may predict toxicity mediated by FLT3 inhibition. The concern for lung effects in patients has  not  been  weakened  by  clinical  safety  data,  because  of  lung  toxicity  findings  seen  in  patients. Nevertheless, toxicity is monitorable and the histopathological changes in the lungs of dogs recovered, or tended to recover, during the recovery period.

Recovery (full or partial) were noted regarding changes in the kidney and liver (except for increases in total cholesterol and phospholipids). The liver and kidney/urinary bladder are considered target organs of toxicity and clinical relevance of the findings in these organs cannot be excluded. Effects on the liver and kidneys have been observed in patients (acute kidney injury, increased enzyme levels).

Eye effects were observed in the 13-week dog study and were considered reversible, except for fundus changes that recovered in all except 1 animal. The eye changes observed in rats and dogs were without margin of safety when compared to a therapeutic gilteritinib dose. Distribution of gilteritinib and binding to melanin in eyes of rats was detected in biodistribution studies. The eye is considered a target organ of toxicity in animals. Retina findings have been observed in patients (retinopathy).

Taken together, the adverse findings in the lungs, immune system, bone marrow, hematopoietic system, epithelial tissue, liver, kidney/urinary bladder and GI tract seem to be pharmacologically related and similar to observations from animal studies with the FLT3/KIT inhibitor midostaurin. The mechanism behind the eye toxicity findings in rats and dogs is not fully understood. However, the slight lens opacity noted in rats were without histopathology and the inflammatory changes (conjunctivitis and uveitis) detected in rats could be caused by immunosuppression. The ocular findings in the 4- and 13-week dog studies were reversible and without impairment of visual response test or gait test, indicating no serious impairment in vision. The potential clinical relevance of these findings therefore seems low.

Gilteritinib did not induce gene mutation or chromosomal aberrations in vitro. The in vivo micronucleus test showed that gilteritinib has a potential to induce micronuclei in mice (SmPC, section 5.3). This is acceptable under the conditions of an indication covering treatment of adult patients who have R/R AML.

No carcinogenicity studies were performed for gilteritinib. This is in line with recommendations in the International Conference on Harmonisation (ICH) S9, and these studies are not essential to support a marketing application for the proposed patient population.

Since embryo-fetal development toxicities were observed in rat, a confirmatory reproductive toxicity study in a second species is not warranted (Ref. ICH S9).

Gilteritinib showed suppressed foetal growth, and induced embryo foetal deaths and teratogenicity in the embryo foetal development studies in rats at exposure levels similar to clinical exposure levels. Placental transfer of gilteritinib was shown in the rat resulting in transfer of radioactivity to the foetus similar to that observed in maternal plasma (SmPC, section 5.3).

Gilteritinib was excreted into the milk of lactating rats with milk concentrations being higher than in maternal plasma. Gilteritinib was distributed through the breast milk to different tissues, except for the brain, of suckling rats (SmPC, section 5.3).

It is unknown whether gilteritinib or its metabolites are excreted in human milk. Available animal data have shown excretion of gilteritinib and its metabolites in the animal milk of lactating rats and distribution to the tissues in infant rats via the milk. A risk to the breast fed children cannot be excluded. Breast feeding should be discontinued during treatment with Xospata and for at least two months after the last dose (see section 4.6).

<div style=\"page-break-after: always\"></div>

In the juvenile toxicity study in rats, the minimum lethal dose level (2.5 mg/kg/day) was much lower than that of adult rats (20 mg/kg/day). The gastrointestinal tract was identified as one of the target organs similar as in adult rats (SmPC, section 5.3).

The  embryo-foetal  toxicity  effects  were  noted  at  low  exposures  compared  to  the  relevant  clinical exposure and are considered clinical relevant.

Pregnancy testing is recommended for females of reproductive potential seven days prior to initiating Xospata treatment. Women of childbearing potential are recommended to use effective contraception (methods that result in less than 1% pregnancy rates) during and up to 6 months after treatment. It is unknown whether gilteritinib may reduce the effectiveness of hormonal contraceptives, and therefore women  using  hormonal  contraceptives  should  add  a  barrier  method  of  contraception.    Males  of reproductive potential should be advised to use effective contraception during treatment and for at least 4 months after the last dose of Xospata (SmPC, sections 4.4 and 4.6). Embryo-fetal lethality, suppressed fetal growth, and teratogenicity has been categorized as a potential risk in the Risk Management Plan (RMP) (see RMP).

The proposed specification for the related impurity is considered adequately qualified from a non-clinical point of view.

Gilteritinib was not phototoxic in the in vitro NRU phototoxicity test with Balb/c 3T3 cells.

Gilteritinib PECsurfacewater value is below the action limit of 0.01 Âµg/L and is not a PBT substance as log Kow does not exceed 4.5. Therefore, gilteritinib is not expected to pose a risk to the environment.

## 2.3.7. Conclusion on the non-clinical aspects

Overall, the non-clinical documentation submitted was considered adequate. The relevant information has been included in the SmPC (sections 4.4, 4.5, 4.6, 5.1, 5.3).

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with Good Clinical Practice (GCP) as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 10 Summary of main clinical studies in R/R AML

| Study Name     | Study Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Study Design                                          | Dosage Regime n                                                                                                                                                                                                                                                                                           | Duration of Treatment                                                                                     | Number of Patients Enrolled   | Study Status                                   | Efficacy Endpoints                                                                                                                                                                                                                                                                                        |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2215- CL- 0301 | Primary: Determine the clinical benefit of gilteritinib therapy in patients with FLT3- mutated AML who are refractory to or have relapsed after first-line AML therapy as shown with OS compared to salvage chemotherapy. Determine the efficacy of gilteritinib therapy as assessed by the rate of CR/CRh in patients with FLT3-mutated AML who are refractory to or have relapsed after first- line AML therapy. Key Secondary: Determine the overall efficacy in EFS of gilteritinib compared to salvage chemotherapy. Determine the overall efficacy in CR rate of gilteritinib compared to salvage chemotherapy. | Phase 3, open- label, multicent er, randomiz ed study | Gilteritini b starting dose of 120 mg/ day, which could have been titrated accordin g to protocol direction s, or compara tive drugs administ ered as 28-day cycles and per institutio nal guideline s (LoDAC, azacitidi ne, MEC induction chemo- therapy, or FLAG- idarubici n induction chemo- therapy) | For gilteritinib, treatment will continue until the patient meets a treatment discontin- uation criterion | 371 patients were randomiz ed | Ongoing (IA1, IA2 and final analysis complete) | Co-Primary Efficacy Endpointsâ  : OS CR/CRh rate Key Secondary Efficacy Endpoints: EFS CR rate Other Secondary Efficacy Endpoints: leukemia- free survival (LFS) Duration of remission CRh, CRc (CR, CRi, or CRp) rate Transfusion conversion rate and transfusion maintenanc e rate Transplantat ion rate |

<div style=\"page-break-after: always\"></div>

| Study Name     | Study Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Study Design                                                     | Dosage Regime n                                        | Duration of Treatment   | Number of Patients Enrolled                                                             | Study Status   | Efficacy Endpoints                                                                                           |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|--------------------------------------------------------|-------------------------|-----------------------------------------------------------------------------------------|----------------|--------------------------------------------------------------------------------------------------------------|
| 2215- CL- 0101 | Primary: to assess the safety and tolerability, including determination of the maximum tolerated dose (MTD) of oral gilteritinib in patients with relapsed or treatment-refractory AML and to determine the pharmacokinetic parameters of gilteritinib. Secondary: to investigate the anti- leukemic activity of various doses of gilteritinib in patients with AML, evaluate the effect of strong or moderate CYP3A4 inhibitors on the PK of gilteritinib, evaluate the potential induction of CYP3A4 by gilteritinib by assessment of midazolam PK and evaluate the effect of gilteritinib on MATE1 substrates by assessment of | Phase 1/2, open- label, dose escalatio n, first- in- human study | Gilteritini b 20, 40, 80, 120, 200, 300 or 450 mg/ day | 28-day cycles           | 347 patients consente d; 252 uniq ue patients received at least 1 dose of gilteritini b | Completed      | Best response including CRc rate and response rate Duration of remission Time to remission OS EFS LFS CR/CRh |
| 2215- CL- 0102 | Primary: to assess the safety and tolerability of gilteritinib, determine the MTD based on the onset of dose-limiting toxicity (DLT) and/or determine the RD of gilteritinib for the next phase. Secondary: to assess the antileukemic activity of various doses of gilteritinib and determine the pharmacokinetic parameters of gilteritinib.                                                                                                                                                                                                                                                                                    | Phase 1, un- controlle d, open- label, dose- escalatio n study   | Gilteritini b 20, 40, 80, 120, 200 or 300 mg/ day      | 28-day cycles           | 27 patients enrolled; 24 patients received gilteritini b                                | Completed      | Best response including CRc rate and response rate Duration of remission                                     |

## 2.4.2. Pharmacokinetics

The gilteritinib (ASP2215) hemifumarate clinical pharmacology program consisted of two biopharmaceutic (relative BA and food effect) studies and six clinical pharmacology phase I studies. A population pharmacokinetic (popPK) approach was used to characterise the gilteritinib PK, including the impact of various extrinsic and intrinsic factors. The popPK dataset was comprised of sparse and intensive PK data from healthy volunteers and AML patients in five phase I studies, 1 phase I/II study and 1 phase III study. An overview of clinical studies used to characterize the clinical pharmacology of gilteritinib is

<div style=\"page-break-after: always\"></div>

given in Table 11. In addition in vitro studies using human biomaterials to investigate plasma protein binding, metabolism and drug-drug interaction (DDI) potential (CYP450, transporters) were conducted.

Table 11. Overview of clinical studies to characterize the clinical pharmacology

|   Study identifier* | Objectives                                                                                                              | Study design                                                      | Test product**                                                            | Subjects                                                                              | Number                                                                                                                    | PK data                         |
|---------------------|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------|
|                0110 | Bioavailability                                                                                                         | Phase I                                                           | Formulation 2 vs. 4                                                       | Healthy                                                                               | 42 dosed                                                                                                                  | Intensive                       |
|                0113 | Food effect                                                                                                             | Phase I                                                           | Gilteritinib 40 mg Formulation 4                                          | Healthy                                                                               | 32 dosed                                                                                                                  | Intensive                       |
|                0106 | Hepatic impairment                                                                                                      | Phase I                                                           | Gilteritinib: 10 mg                                                       | Normal hep. function, Child- Pugh A and B                                             | 24 dosed                                                                                                                  | Intensive                       |
|                0108 | DDI                                                                                                                     | Phase I                                                           | Formulation 1                                                             | Healthy                                                                               | 81 dosed                                                                                                                  | Intensive                       |
|                0101 | Primary: safety, tolerability, MTD, and PK of gilteritinib Secondary: antileukemic act., CYP3A4 inhib/ind. impact on PK | Phase I/II, uncontrolled, open-label multicenter, dose escalation | Gilteritinib: 20, 40, 80, 120, 200, 300, 450 mg qd Formulation 1, 2 and 3 | R/R AML                                                                               | 265 enrolled (252 dosed): 25 multiple ascending dose (MAD) (23 dosed), 240 expansion (229 dosed, 5 re- enrolled and dosed | Intensive and sparse            |
|                0102 | Primary: safety, tolerability, MTD Secondary: PK, antileukemic act.                                                     | Phase I, uncontrolled, open-label multicenter, dose escalation    | Gilteritinib: 20, 40, 80, 120, 200, 300 mg qd Formulation 1 and 3         | Japanese R/R AML                                                                      | 27 enrolled (24 dosed)                                                                                                    | Intensive Plasma, urine         |
|                0301 | Efficacy, safety (pivotal study)                                                                                        | Phase III open-label, multicenter, randomised                     | Gilteritinib 120 mg qd or comparative chemotherapy Formulation 4          | FLT3+ R/R AML                                                                         | Of 371 enrolled, gilteritinib 247 (246 dosed)                                                                             | Sparse                          |
|                5101 | Safety, RP2D, efficacy, PK of gilteritinib and erlotinib in comb.                                                       | Phase Ib/II                                                       | Gilteritinib 80 or 120 mg, erlotinib 150 mg Formulation 2                 | Epidermal growth factor receptor m+ (EGFRm+) NSCLC w/ acquired resistance to EGFR TKI | 10 dosed                                                                                                                  | Intensive                       |
|                0105 | Mass balance                                                                                                            | Phase I                                                           | Gilteritinib 120 mg qd Formulation 2                                      | Patients with solid tumours                                                           | Patients with advanced solid tumors, 6 dosed                                                                              | Intensive Plasma, urine, faeces |

* Study codes are given by the prefix 2215-CL- followed by a four-digit identification number.

** Different gilteritinib formulations were used throughout the clinical pharmacology programme: Formulation 1: 10 mg tablets (A2215-002C); Formulation 2: 40 mg tablets (A2215-004C); Formulation 3: 100 mg tablets (A2215-

<div style=\"page-break-after: always\"></div>

003C); Formulation 4: 40 mg tablets identical to the formulation intended for marketing (A2215-005C, gilteritinib tablets 40 mg).

## Absorption

Following oral administration of gilteritinib, peak plasma concentrations are observed at a median tmax approximately  between 4  and  6  hours  in  healthy  volunteers  and  patients  with  R/R  AML.  Gilteritinib undergoes first order absorption with an estimated absorption rate (ka) of 0.43 h 1 with a lag time of 0.34 hours based on population PK modelling. Median steady state Cmax is 282.0 ng/mL (coefficient of variation (CV)% = 50.8), and area under the plasma concentration curve during 24 hour dosing interval (AUC0-24) is 6180 ngÂ·h/mL (CV% = 46.4) after once daily dosing of 120 mg gilteritinib. Steady state plasma levels are reached within 15 days of once daily dosing with an approximate 10 fold accumulation (SmPC, section 5.2).

In  healthy  adults,  gilteritinib  Cmax  and  AUC  decreased  by  approximately  26%  and  less  than  10%, respectively, when a single 40 mg dose of gilteritinib was co-administered with a high fat meal compared to  gilteritinib  exposure  in  fasted  state.  Median  tmax  was  delayed  2  hours  when  gilteritinib  was administered with a high-fat meal (SmPC, section 5.2).

In  healthy  adults,  gilteritinib  Cmax  and  AUC  decreased  by  approximately  26%  and  less  than  10%, respectively, when a single 40 mg dose of gilteritinib was co administered with a high fat meal compared to  gilteritinib  exposure  in  fasted  state.  Median  tmax  was  delayed  2  hours  when  gilteritinib  was administered with a high fat meal.

## Distribution

In the popPK analysis, the apparent central and peripheral volume of distribution were estimated to be 1092 L and 1100 L, respectively. Apparent volume of distribution ranged from 3340 L in healthy subjects with normal hepatic function to 5090 L in subjects with moderate hepatic impairment.

The plasma protein binding of gilteritinib in humans was 90.5% and concentration independent within the concentration range investigated in vitro (0.1-10 Âµg/mL). The major binding protein appears to be human serum ALB. Mean unbound fraction in healthy individuals with normal hepatic function was 0.057, and  an  increase  in  the  unbound  fraction  was  observed  in  patients  with  mild  or  moderate  hepatic impairment.

In the mass balance study (120-240 mg single dose), the blood-to-plasma ratios ranged from 0.85 to 1.36, indicating limited penetration of gilteritinib into red blood cells. A concentration dependency is indicated by the higher ratio observed at the 240 mg dose.

Tissue distribution has not been investigated in humans. Animal data indicate a wide distribution to and retention in different organs, including the brain and bone marrow.

## Elimination

In the popPK analysis gilteritinib plasma concentrations declined in a bi-exponential manner with a halflife of 113 hours. The estimated apparent clearance (CL/F) was 14.85 L/h. Gilteritinib clearance is 46% greater in healthy volunteers compared to patients with AML based on the final covariate model. The main elimination route was hepatic metabolism via CYP3A4 enzyme and excretion of metabolites and unchanged substance in both urine and faeces.

In vitro studies investigating metabolite formation in various species (mice, rats, rabbits, dogs, humans) indicated  that  no  major  human-specific  gilteritinib  metabolites  were  formed  by  liver  microsomes  or hepatocytes.

<div style=\"page-break-after: always\"></div>

In vitro , gilteritinib is metabolised by CYP3A4 with one metabolite accounting for approximately 1/3 of CYP3A4 metabolism, while other metabolites each accounted for less than 4.8% of metabolism. The identity of the metabolites has not been specified. Metabolism by other CYP enzymes (1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A5) was negligible.

In vivo , gilteritinib was extensively metabolised with 14 metabolites (M1, M4, M7-17) detected in plasma in the mass balance study. Several metabolites (M1-17, one unknown) were also detected both in urine and in faeces. No single metabolite in urine or faeces accounted for &gt;2% or &gt;10%, respectively, of administered dose. Up to ~16% (6.3-15.8%) and 24% (11.7-23.8%) of administered dose was found as unchanged substance in urine and faeces, respectively, after 336h.

The postulated metabolic pathways involve at least oxidation, N-dealkylation, glutathione conjugation and glucuronidation. No major inter-individual differences in metabolites were observed in humans. The three metabolites in plasma that were quantified are formed by N-dealkylation (M10 [AS2651096] and M16 [AS3322943]) and N-dealkylation and oxidation (M17 [AS3397391]).

The PK of gilteritinib and the routes of excretion and the extent of metabolism following administration of a single oral dose of [ 14 C]-gilteritinib after repeated doses of gilteritinib tablets was investigated in four evaluable patients with advanced solid tumours.

The  overall  mean  recovery  of  radioactivity  in  urine,  faeces  and  toilet  tissue  samples  was  80.9% (interpolated to 91.3%) over the 768-hour collection period. A mean of 64.5% (interpolated to 73.4%) and 16.4% (interpolated to 17.9%) were recovered in faeces and urine, respectively. Up to ~13% of the administered dose was excreted in urine as unchanged gilteritinib. Three (M10, M16, M17) of the fourteen identified metabolites in plasma were quantified. Mean exposure (AUC24) of these metabolites at steady state was less than 10% that of parent substance. Total radioactivity half-life in plasma was comparable to gilteritinib half-life. Clinical data on metabolite PK were obtained only in the mass balance study.

In healthy adults, mean Cmax (%CV) were 21.6 ng/mL (21.4) and 30.4 ng/mL (38.1) and AUCinf (%CV)

were 1800 ng*h/mL (17.3) and 1970 ng*h/mL (30.8) in the fed and fasted group, respectively. Absorption was delayed (2-hour increase in median tmax) when gilteritinib was administered with a high-fat meal relative to fasted conditions. Gilteritinib t1/2, CL/F and VZ/F were comparable in the fasted and fed treatment groups.

## Dose proportionality and time dependencies

A slightly more-than dose proportional increase in exposure (Cmax and AUC24) at multiple dosing in R/R AML  patients  were  observed,  with  a  slope  estimate  of  1.21  (1.02,  1.41)  and  1.22  (1.00,  1.43), respectively when all data in the dose range 20-450 mg was considered (study 2215-CL-0101). Similar findings were observed in Japanese R/R AML patients over the 20 to mg 200 mg dose interval.

<div style=\"page-break-after: always\"></div>

Figure 2. Mean gilteritinib plasma concentration-time profiles after multiple-dose (Cycle 1 Day 15) administration in patients with R/R AML (PK Analysis, study 2215-CL-0101)

<!-- image -->

Table 12. Statistical assessment of gilteritinib dose proportionality in patients with relapsed or refractory AML -PK Analysis Set, study 2215-CL-0101

| Visit                         | Parameter       |   SlopeEstimate | I0 %06         |
|-------------------------------|-----------------|-----------------|----------------|
| Day -2                        | AUC24(ngÂ°h/mL)  |           0.99  | (0.788, 1.19)  |
| (single dose)                 | Cmax (ng/mL)    |           0.808 | (0.629, 0.988) |
| Cycle1 Day 15 (multiple dose) | AUC24 (ng-h/mL) |           1.22  | (1.00, 1.43)   |
|                               | Cmax (ng/mL)    |           1.21  | (1.02, 1.41)   |

Allpatientswhoreceived atleast1doseofstudydrugforwhomsufficientplasmaconcentrationdatawere available tofacilitatederivationof atleast 1pharmacokineticparameter andfor whom the time of dosing on the dayofsamplingwasknown.

Extensive accumulation of gilteritinib up to ~10-fold (range 3.29-9.64) was observed in R/R AML patients following repeated doses once daily (QD) of gilteritinib compared to single dose administration (C1D1 vs C1D15, study 2215-CL-0101). Up to 8-fold accumulation was observed in Japanese R/R AMPL patients (C1D1 vs. C1D28, study 2215-CL-0102). Steady state was reached after 15 days of once daily dosing.

## Special populations

A  popPK  analysis  was  performed  to  evaluate  the  impact  of  intrinsic  and  extrinsic  covariates  on  the predicted exposure of gilteritinib in patients with R/R AML (SmPC, section 5.2).

<div style=\"page-break-after: always\"></div>

The effect of hepatic impairment on gilteritinib PK was studied in subjects with mild (Child-Pugh Class A) and moderate (Child-Pugh Class B) hepatic impairment. Gilteritinib has not been studied in patients with severe hepatic impairment (Child Pugh Class C) (SmPC, section 5.2).

Table 13. Statistical analysis of hepatic impairment on total and unbound gilteritinib PK -PK Analysis Set, study 2215-CL-0106

<!-- image -->

|                  | Hepatic Function   |    | Geometric LS Mean*   | Geometric LS Mean*   | Ratio (%) Impaired/Normal*   | Ratio (%) Impaired/Normal*   | 90% CIof Ratio   | 90% CIof Ratio   |
|------------------|--------------------|----|----------------------|----------------------|------------------------------|------------------------------|------------------|------------------|
| Parameter        | Group              | 11 | Total                | Unbound              | Total                        | Unbound                      | Total            | Unbound          |
| AUCinf (h-ng/mL) | Mild (Group 1)     |  8 | 433.3                | 27.53                | 78.88                        | 88.42                        | (61.10, 101.83)  | (65.92, 118.61)  |
| AUCinf (h-ng/mL) | Moderate (Group 2) |  8 | 337.4                | 27.54                | 61.43                        | 88.48                        | (47.59, 79.30)   | (65.97, 118.69)  |
| AUCinf (h-ng/mL) | Normal (Group 3)   |  8 | 549.3                | 31.13                | NA                           | NA                           | NA               | NA               |
| AUC4s0 (h-ng/mL) | Mild (Group 1)     |  8 | 408.4                | 25.95                | 78.13                        | 87.59                        | (60.78, 100.44)  | (65.89,116.43)   |
| AUC4s0 (h-ng/mL) | Moderate (Group 2) |  8 | 316.5                | 25.84                | 60.55                        | 87.21                        | (47.10, 77.84)   | (65.61, 115.93)  |
| AUC4s0 (h-ng/mL) | Normal (Group 3)   |  8 | 522.7                | 29.62                | NA                           | NA                           | NA               | NA               |
| Cmx (ng/mL)      | Mild (Group 1)     |  8 | 8.140                | 0.5171               | 106.59                       | 119.49                       | (82.09, 138.39)  | (91.25, 156.46)  |
| Cmx (ng/mL)      | Moderate (Group 2) |  8 | 6.242                | 0.5095               | 81.73                        | 117.72                       | (62.95, 106.12)  | (89.90, 154.15)  |
| Cmx (ng/mL)      | Nomal (Group 3)    |  8 | 7.637                | 0.4328               | NA                           | NA                           | NA               | NA               |

A dedicated renal impairment study has not been conducted to assess of the effect of renal impairment on gilteritinib PK (SmPC, section 5.2). The popPK model included serum creatinine, a marker of renal function, as a statistically significant covariate, but the impact on gilteritinib exposure was less than 2fold and less than 1.5-fold different in non-Japanese and Japanese patients with R/R AML, respectively. The effect of severe renal impairment on gilteritinib exposure has not been investigated (SmpC section 4.2).

A population PK analysis was performed to evaluate the impact of intrinsic and extrinsic covariates on the predicted exposure of gilteritinib in patients with R/R AML. In the population PK analysis age and body weight were identified as statistically significant covariates. An overview of studies in the elderly population is displayed in Table 14.

Table 14 Studies in elderly population

|                      | Age 65-74 (Older patients number /total number)   | Age 65-74 (Older patients number /total number)   | Age 75-84 (Older patients number /total number)   | Age 75-84 (Older patients number /total number)   | Age 85+ (Older patients number /total number)   | Age 85+ (Older patients number /total number)   |
|----------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Controlled Trial     | Gilteritinib 78/247 (31.6%)                       | Chemotherapy 34/124 (27.4%)                       | Gilteritinib 28/247 (11.3%)                       | Chemotherapy 14/124 (11.3%)                       | Gilteritinib 0                                  | Chemotherapy 1/124 (0.3%)                       |
|                      | Gilteritinib                                      | Gilteritinib                                      | Gilteritinib                                      | Gilteritinib                                      | Gilteritinib                                    | Gilteritinib                                    |
| Non Controlled Trial | Escalation Phase 0/2                              | Expansion Phase 10/54 (18.5%)                     | Escalation Phase 0/2                              | Expansion Phase 7/54 (13.0%)                      | Escalation Phase 0/2                            | Expansion Phase 1/54 (1.9%)                     |

## Pharmacokinetic interaction studies

In vitro

A number of in vitro studies have been performed. The in vitro results are presented below:

<div style=\"page-break-after: always\"></div>

Table 15 Overview of the in vitro studies results conducted with gilteritinib

| Enzyme*   | Substrate   | Induction   | Inhibitor   | IC50 (ÂµM)              | Clinical relevance   |
|-----------|-------------|-------------|-------------|------------------------|----------------------|
| CYP1A2    | No          | No          | No          | >100                   | -                    |
| CYP2B6    | No          | Yes         | No          | >100                   | -                    |
| CYP2C8    | No          | Yes         | No          | >100                   | -                    |
| CYP2C9    | No          | Yes         | No          | >100                   | -                    |
| CYP2C19   | No          | Yes         | Yes         | 61.7                   | No**                 |
| CYP2D6    | No          | Not invest. | No          | >100                   | -                    |
| CYP3A4    | Yes         | Yes         | Yes         | 62.9 (MDZ) 70.9 (TEST) | Yes: intestine       |

| Transporter         | Substrate           | Inhibitor           | IC50 (ÂµM)           | Clinical relevance   |
|---------------------|---------------------|---------------------|---------------------|----------------------|
| Efflux transporters | Efflux transporters | Efflux transporters | Efflux transporters | Efflux transporters  |
| P-gp                | Yes                 | Yes                 | >30                 | Yes - intestine*     |
| BCRP                | No?                 | Yes                 | 1.41                | Yes                  |
| MATE1               | NA                  | Yes                 | 0.0543              | Yes                  |
| MATE2               | NA                  | Yes                 | 47.7                | No                   |
| Uptake transporters | Uptake transporters | Uptake transporters | Uptake transporters | Uptake transporters  |
| OATP1B1             | ?                   | Yes                 | 29.4                | No                   |
| OATP1B3             | ?                   | No                  | >50                 | -                    |
| OAT1                | NA                  | No                  | >50                 | -                    |
| OAT3                | NA                  | No                  | >50                 | -                    |
| OCT1                | Not invest.         | Yes                 | 2.92                | Yes                  |
| OCT2                | NA                  | Yes                 | 34.9                | No                   |

Abbreviations: MDZ=midazolam; TEST=testosterone; not invest.=not investigated; NA=not applicable

* Metabolism by other CYP enzymes ( i.e. 1B1, 2A6, 2E1, 3A5) was negligible (2215-ME-0001).

** Minor intestinal CYP enzyme.

* Cytotoxicity at concentrations (50 and 100 ÂµM) prevented further determination of IC50.

## In vivo

In Study 2215-CL-0101 the effect of strong or moderate CYP3A4 inhibitors on the PK of gilteritinib has been  evaluated.  This  study  also  evaluated  the  potential  induction  of  CYP3A4  by  gilteritinib  through assessment of midazolam PK and the effect of gilteritinib on MATE1 substrates through assessment of cephalexin PK.

An exploratory analysis of the effect of strong and moderate CYP3A4 inhibitors on gilteritinib exposure was performed. Approximately 70% of enrolled patients in the current study required co-administration of strong (voriconazole or posaconazole) or moderate fluconazole FLZ CYP3A4 inhibitors.

<div style=\"page-break-after: always\"></div>

Figure  3.Dose-normalised  gilteritinib  trough  plasma  concentration-time  profiles  (Day  -2 through Cycle 2 Day 1) by use of CYP3A inhibitor -PK Analysis Set, study 2215-CL-0101

<!-- image -->

Patients also received gilteritinib 300 mg QD starting on C1D1 and a single oral dose of 2 mg midazolam on day -1 and C1D15. The geometric LS mean ratios (GMRs) were 111.64% and 123.47% (Cmax) and 109.46% and 149.90% (AUC24) for midazolam and its metabolite, respectively (Table 16).

Table 16. Statistical comparison of midazolam exposure after administration of midazolam alone or co-administered with gilteritinib -PK Analysis Set, study 2215-CL-0101

| Analyte            | Parameter       |   N |   Geometric LS Mean for Referencet |   Geometric LS Mean for Testt |   Geometric LS Mean Ratio (%)s (Test/Reference) | 90% CI of Mean Ratio (%)s   |
|--------------------|-----------------|-----|------------------------------------|-------------------------------|-------------------------------------------------|-----------------------------|
|                    | AUC24 (ngh/mL)  |   8 |                             54.28  |                        59.42  |                                          109.46 | (49.82, 240.48)             |
| Midazolam          | Cmax (ng/mL)    |   9 |                             14.33  |                        16     |                                          111.64 | (69.54, 179.25)             |
|                    | AUC24 (ng:h/mL) |   8 |                             11.31  |                        16.95  |                                          149.9  | (74.88, 300.06)             |
| 1-hydroxymidazolam | Cmax (ng/mL)    |   9 |                              3.489 |                         4.308 |                                          123.47 | (72.41, 210.52)             |

All patients who received at least 1 dose of study drug for whom sufficient plasma concentration data were availabletofacilitatederivationofatleast1pharmacokineticparameterandforwhomthetimeofdosingonthe dayofsamplingwasknown.

Reference Treatment = Single dose of 2 mg midazolam syrup.

Test Treatment = Single dose of 2 mg midazolam syrup + 300 mg gilteritinib once daily.

N' refers to number of DDI evaluable patients which is defined as the patients who have both day -1 and cycle 1 day15pharmacokineticparameterresultsinexpansion2Dcohort.

CI: confidence interval; DDI: drug-druginteraction; LS least squares.

âCorresponds to\"GeometricLSMeanfortheNumerator\"asreflectedintheStudy2215-CL-0101CSR.

Correspondsto\"GeometricLSMeanfortheDenominator\"asreflectedintheStudy2215-CL-0101CSR

sThedifferenceofLSmeansoflog-transformedpharmacokineticparametersbetween

1-hydroxymidazolam/midazolam aloneand1-hydroxymidazolam/midazolam+gilteritinibandits90%CIare backtransformed to the raw scale and are expressed as percent.

Patients received gilteritinib 200 mg starting on C1D1 and a single dose of 500 mg cephalexin on day 1  and  C1D15.  Relative  to  administration  of  cephalexin  alone,  cephalexin  systemic  exposure  was comparable when gilteritinib was coadministered with cephalexin as reflected by an approximate minimal decrease (3% to 9%) in Cmax, AUC from the time of dosing to the last measurable concentration (AUClast) and AUCinf (Table 17).

<div style=\"page-break-after: always\"></div>

Table  17.  Statistical  assessment  of  the  effect  of  gilteritinib  on  cephalexin  PK  after administration  of  cephalexin  alone  or  co-administered  with  gilteritinib -PK  Analysis  Set, study 2215-CL-0101

| Parameter        |   N |   GeometricLSMean forReference |   Geometric LS MeanforTest |   Geometric LS MeanRatio(%) (Iest/Reference) | 90%CIofMean Ratio (%)   |
|------------------|-----|--------------------------------|----------------------------|----------------------------------------------|-------------------------|
| AUClast (ngh/mL) |  16 |                       50808    |                  49647     |                                        97.71 | (74.19, 128.70)         |
| AUCinf (ng-h/mL) |  12 |                       54066    |                  50802     |                                        93.96 | (75.29, 117.26)         |
| Cmax (ng/mL)     |  16 |                       16946    |                  15498     |                                        91.46 | (74.60, 112.12)         |
| Ae (mg)          |  10 |                         436.9  |                    366.7   |                                        83.93 | (46.53, 151.39)         |
| CLr (L/h)        |   6 |                          10.67 |                      8.842 |                                        82.84 | (40.25, 170.48)         |

Allpatientswhoreceivedatleast1doseofstudydrugforwhomsufficientplasmaconcentrationdatawere availabletofacilitatederivationofatleast1pharmacokineticparameterandforwhomthetimeofdosingonthe dayofsamplingwasknown.

Reference Treatment =Single dose of 5o0 mg cephalexin.

N'referstonumberof DDIevaluablepatientswhichisdefinedasthepatientswhohavebothday-1and cycle 1 day 15 pharmacokinetic parameter results in Expansion 2E cohort. CI: confidence interval; DDI: dose-dose interaction; LS: least squares.

âThedifferenceof LSmeansoflog-transformed pharmacokineticparametersbetweencephalexin alone and cephalexin + gilteritinib and its 9o%CI are backtransformed to the raw scale and are expressed as percent.

In  Study  0108 the  effect  of  the  strong  CYP3A4  and  P-gp  inhibitor  itraconazole  (ITZ),  the  moderate CYP3A4 inhibitor FLZ and the strong CYP3A4 inducer rifampicin (RIF) on the single-dose PK of gilteritinib, a CYP3A4 and P-gp substrate, was evaluated in 81 healthy adult subjects. The results are summarised in Table 18.

Table  18.  Statistical  assessment  of  the  interaction  effect  of  itraconazole,  fluconazole  and rifampin on the PK of gilteritinib -PK Analysis Set, study 2215-CL-0108

| Comparison                            | Dose Normalized Parameter   |   Geometric LS Mean for Referencet |   GeometricLS MIeanforTest |   GeometricLS MeanRatio(%) | 90%CIofthe Ratio (%)   |
|---------------------------------------|-----------------------------|------------------------------------|----------------------------|----------------------------|------------------------|
| ITZ+Gilteritinib/ Gilteritinibalones  | AUCinf (ngh/mL)             |                             67.7   |                     30.6   |                     221.39 | (188.26,260.36)        |
| ITZ+Gilteritinib/ Gilteritinibalones  | AUCiast (ng-h/mL)           |                             61.5   |                     28.8   |                     213.51 | (180.58,252.44)        |
| ITZ+Gilteritinib/ Gilteritinibalones  | (ng/mL)                     |                              0.593 |                      0.495 |                     119.8  | (100.09, 143.39)       |
| FLZ+Gilteritinib/ Gilteritinibalone   | AUCimf (ng-h/mL)            |                             43.9   |                     30.6   |                     143.46 | (121.99, 168.71)       |
| FLZ+Gilteritinib/ Gilteritinibalone   | (ng-h/mL) AUCiast           |                             41.5   |                     28.8   |                     144.02 | (121.81, 170.28)       |
| FLZ+Gilteritinib/ Gilteritinibalone   | (ng/mL)                     |                              0.573 |                      0.495 |                     115.73 | (96.69, 138.52)        |
| RIF+Gilteritinib/ Gilteritinibalonett | AUCimf (ng-h/mL)            |                              8.71  |                     30.6   |                      28.47 | (24.21, 33.48)         |
| RIF+Gilteritinib/ Gilteritinibalonett | AUCiast (ng:h/mL)           |                              8.42  |                     28.8   |                      29.21 | (24.71, 34.54)         |
| RIF+Gilteritinib/ Gilteritinibalonett | Cmax (ng/mL)                |                              0.364 |                      0.495 |                      73.44 | (61.36, 87.91)         |

Thepharmacokineticanalysissetconsistedofthesubsetofthesafetyanalysissetforwhichconcentrationdata wereavailabletofacilitatederivationofatleast1primarypharmacokineticparameterandforwhomthetimeof dosingonthedayofsamplingwasknown.

Theanalysiswasperformedonlog-transformedpharmacokineticparametersusingamixedmodelwith treatment asafixedeffectandsubjectasarandomeffect.ThedifferenceofLSmeansoflog-transformed pharmacokineticparametersbetweentreatmentsandits9o%CIareback-transformedtotherawscaleandare expressed as a ratio.Dose-normalized gilteritinibpharmacokinetic parameters were used in the RIF +gilteritinib treatment.Referencegroup is gilteritinib alone treatment.

CI:confidence interval;CSR:clinicalstudy report;FLZ:fluconazole;ITZ:itraconazole;LS:least squares; RIF:rifampin.

âCorrespondsto\"GeometricLSMeanfortheNumerator\"asreflectedintheStudy2215-CL-0108CSR Correspondsto\"GeometricLSMeanfortheDenominator\"asreflectedintheStudy2215-CL-0108CSR

s200mgITZtwicedailyonday1,200-mgoncedailyondays2to28and10mggilteritinibonday6.

[400mgFLZonday1,200mgoncedailyondays2to28and10-mggilteritinibonday6.

tt600mgRlFoncedailyondays1to21and20mggilteritinibonday8.

## Pharmacokinetics using human biomaterials

The in vitro studies using human biomaterials were conducted to investigate plasma protein binding, metabolism and DDI potential (CYP450, transporters) and are described in respective sections.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Pharmacodynamics

## Mechanism of action

Gilteritinib  inhibits  FLT3  receptor  signalling  and  proliferation  in  cells  exogenously  expressing  FLT3 including  FLT3  ITD,  FLT3  D835Y,  and  FLT3  ITD  D835Y,  and  it  induced  apoptosis  in  leukemic  cells expressing FLT3 ITD (SmPC, section 5.1).

## Primary and Secondary pharmacology

Relationship between gilteritinib exposure and FLT3 phosphorylation in relapsed or refractory (R/R) AML patients

The effect of gilteritinib fumarate on FLT3 phosphorylation was assessed using an ex-vivo PIA assay described by Levis et al. (5). In this PIA assay plasma samples were incubated with Ba/F3 or TF-1 cells transfected with an expression vector containing the ITD-mutated FLT3 coding sequence. Cell lysates were analyzed for FLT3 using immunoprecipitation and antiphophotyrosine immunoblotting was used to detect tyrosine kinase substrates. Densitometry was performed on the immunoblot bands. Inhibition of FLT3 phosphorylation for plasma samples at each time point was calculated by expressing the density of the corresponding band as a percent decrease from the density of the baseline (pretreatment plasma sample) band, which was arbitrarily set at 100%. A total of 233 patients were included in the PD analysis set. Assessment  of the relationship between  gilteritinib concentration and  inhibition of FLT3 phosphorylation  showed  a  good  correlation.  The  time-matched  data  were  characterized  using  a maximum inhibitory effect (Imax) model. Final model parameters are summarized in Table 19.

Table 19. Final model parameter estimates characterizing inhibitory effect of gilteritinib on phosphorylation of FLT3 (2215-CL-0101)

| Parameter'           | Unit   |   Estimates | RSE (%CV)   |
|----------------------|--------|-------------|-------------|
| Baseline             | %      |       98.9  | 0.34        |
|                      | %      |      100    |             |
| IC50                 | ng/mL  |        7.55 | 8.1         |
| IIV on IC50          | %      |       69.2  | 13.87       |
| Residual variability | %      |        5.11 | 12.9        |

Source:PharmacokineticModeling and SimulationReport, Table 18

A dose-related increase in inhibition of FLT3 phosphorylation was observed across doses ranging from 20 to 450 mg. More than 90% inhibition of FLT3 phosphorylation was observed by cycle 1 day 8 predose at gilteritinib doses of â¥ 80 mg.

## Minimal residual disease (MRD) evaluation

The MRD analysis  was performed retrospectively  on  patients  at  any  dose  level  who  were  FLT3-ITD positive by central testing at screening/baseline, and had a bone marrow aspirate sample available at baseline/screening and at least one post-baseline time point. Presence or absence of MRD was measured by a FLT3-ITD signal ratio defined as the ratio of FLT3-ITD to total FLT3. A molecular response was defined as an FLT3-ITD signal ratio of  â¤  0. 01 at any post baseline time point, and deep molecular response was defined as an FLTITD signal ratio â¤ 0. 0001.

Overall, 108 patients were eligible for MRD analysis; 95 patients at doses of â¥ 80 mg and 13 patients at doses &lt; 80 mg. 21 patients had a molecular response (ratio FLT3ITD:total FLT3 â¤ 0.1 at any post baseline time point), all at doses of â¥ 80 mg. In patients who received doses of â¥ 80 mg, 58.3% (14/24)

<div style=\"page-break-after: always\"></div>

of patients who achieved CR/CRh had a molecular response, while 9.9% (7/71) of patients who did not achieve CR/CRh had a molecular response. The CR/CRh rate was 66.7% in patients with a molecular response compared to 13.5% in patients without a molecular response.  In patients who received doses of â¥ 80 mg, 41.7% (10/24) of patients who achieved CR/CRh had a deep molecular response, while 4.2% (3/71) of patients who did not achieve CR/CRh had a deep molecular response. The CR/CRh rate was 76.9% in patients with deep molecular response, compared to 17.1% in patients without deep molecular response.

## AXL, c-CBL and FLT3 Mutational Analysis

All exons of AXL, E3 ubiquitin-protein ligase C-CBL (c-CBL) and FLT3 were sequenced using a capture based NGS assay (data not shown). Due to small number of patients, results from AXL, c-CBL and FLT3 (other than D835) mutational analysis does not allow any conclusion on response to gilteritinib.

## Exposure response (ER) analysis -efficacy (2215-PK-0008)

The objective of the study was to  explore PK/PD relationships between estimated gilteritinib exposure (AUC24,ss,  Cmin,ss  and  Cmax,ss)  and  clinical  response  (CR/CRh)  in  those  patients  that  were  considered clinically evaluable in studies 0301 and 0101, and to explore PK/PD relationships between estimated gilteritinib exposure (AUC24,ss and Cmin,ss, Cmax,ss) and OS in those patients that were considered clinically evaluable in study 0301. No exposure-efficacy relationship could be characterised at the exposure range studied.

In the multiple dose study 0101, mean (SD) AUC24 was 31428 (21412) ng*h/mL and mean Cmax was 1462 (815.1) ng/mL at the maximum clinical dose of 200 mg QD for 15 days (N=2). Mean (SD) AUC24 and mean (SD) Cmax for the 120 mg dose QD for 15 days were 6943 (3221) ng*h/mL and 374.2 (190.1) ng/mL, respectively (N=3).

In the multiple dose study 0102, mean (SD) AUC24 was 21573.86 (6230.86) ng*h/mL and mean Cmax was 1016.28 (295.23) ng/mL at the maximum clinical dose of 200 mg QD for 28 days (N=5). Mean (SD) AUC24 and mean (SD) Cmax for the 120 mg dose QD for 28 days were 13463.35 (NA) ng*h/mL and 680.23 (NA) ng/mL, respectively (N=2).

## Concentration-safety analysis based on integrated data

A merged gilteritinib concentration - dCK, dAST, dALT, dALB and dQTcF data set was prepared based on the data from studies 0101 (Data cut off 07.03.2018), 0102 and 0301 (Data cut off 17.09.2018).

The dataset for hematological and QTc analysis consisted of 497 and 487 subjects, respectively. Although large  variability  was  observed,  the  box  plot  showed  the  dependency  of  safety  data  on  gilteritinib concentration. Statistical significant trends towards increasing levels of ALT, AST, creatinine kinase (CK) and QTc and decreasing levels of ALB with increasing gilteritinib concentrations were shown.

The prediction (upper 1-sided 95%CI) at the 120-mg dose (median Cmax 282 ng/mL) was 107 U/L (116 U/L) in ÎCK, 15.2 U/L (16.6 U/L) in ÎAST and 18.9 U/L (21.1 U/L) in ÎALT. The prediction of ÎALB was -0.327 g/L (lower 1-sided 95% CI: -0.634 g/L).

The  QTc  relationship  was  described  by  an  maximal  effective  concentration  (Emax)vmodel.  The prolongation at the 120 mg dose (median Cmax 282 ng/mL) was 4.96 msec (upper 1-sided 95%CI: 6.20 msec), which did not reach the 10-msec threshold for regulatory significance. The predicted change in the fridericia-corrected QT interval (QTcF) from baseline at the median Cmax,ss associated with once-daily doses of 200 mg gilteritinib is 9.93 msec with an upper 95% confidence limit of 12.5 msec. Covariate models on QTc were developed (covariates race, CYP3A4 inhibitors, baseline QTc) revealing only impact of baseline QTc. Patients who had longer baseline QTcF intervals showed smaller Î QTcF with increasing gilteritinib concentration.

<div style=\"page-break-after: always\"></div>

No secondary pharmacology studies have been contucted with gilteritinib.

## 2.4.4. Discussion on clinical pharmacology

The  population  estimate  of  central  and  peripheral  volume  of  distribution  was  1092  L  and  1100  L, respectively. These data indicate gilteritinib distributes extensively outside of plasma, which may indicate extensive  tissue  distribution. In  vivo plasma  protein  binding  in  humans  is  approximately  90%  and gilteritinib is primarily bound to ALB (SmPC, section 5.2).

Based on in  vitro data,  gilteritinib  is  primarily  metabolised  via  CYP3A4.  The  primary  metabolites  in humans include M17 (formed via N  -dealkylation and oxidation),  M16  and M10  (both  formed  via  N dealkylation) and were observed in animals. None of these three metabolites exceeded 10% of overall parent exposure. The pharmacological activity of the metabolites against FLT3 and AXL receptors is unknown (SmPC, section 5.2).

Absolute bioavailability is not known.  After a single dose of [14C] gilteritinib, gilteritinib is primarily excreted in faeces with 64.5% of the total administered dose recovered in faeces. Approximately 16.4% of  the  total  dose  was  excreted  in  urine  as  unchanged  drug  and  metabolites.  Gilteritinib  plasma concentrations declined in a bi exponential manner with a population mean estimated half-life of 113 hours. The estimated CL/F based on the population PK model is 14.85 L/h (SmPC, section 5.2).

In  healthy  adults,  gilteritinib  Cmax  and  AUC  decreased  by  approximately  26%  and  less  than  10%, respectively, when a single 40 mg dose of gilteritinib was co administered with a high fat meal compared to  gilteritinib  exposure  in  fasted  state.  Median  tmax  was  delayed  2  hours  when  gilteritinib  was administered with a high fat meal (SmPC, section 5.2).The tablets can be taken with or without food (SmPC, section 4.2).

In general, gilteritinib exhibited linear,  dose -proportional PK  after single and  multiple  dose administration at doses ranging from 20 to 450 mg in patients with R/R AML (SmPC, section 5.2).

The effect of hepatic impairment on gilteritinib PK was studied in subjects with mild (Child-Pugh Class A) and moderate (Child-Pugh Class B) hepatic impairment.

Following  a  10  mg  single  oral  dose  of  gilteritinib  in  the  dedicated  hepatic  impairment  study  AUCinf decreased by 22% and 35% in the mild and moderate group, respectively, and mean Cmax decreased by 14% in the moderate group compared to the normal group. Both CL/F and the apparent volume of distribution during the terminal elimination phase (Vz/F) increased with increasing severity of hepatic impairment, while t1/2 was comparable across groups. Unbound gilteritinib exposure in subjects in the mild or moderate hepatic impairment groups was comparable to that observed in subjects in the normal hepatic function group.

Results indicate unbound gilteritinib exposure in subjects with mild or moderate hepatic impairment is comparable  to  that  observed  in  subjects  with  normal  hepatic  function.  The  effect  of  mild  hepatic impairment [as defined by the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG)] on gilteritinib exposure was also assessed using the population PK model and the results demonstrate little difference in predicted steady-state gilteritinib exposure relative to a typical patient with R/R AML and normal liver function (SmPC, section 5.2).

The effect of mild or moderate renal impairment was evaluated using  a popPK model. Serum creatinine, a marker of renal function, was identified as a statistically significant covariate. However, the predicted increase on gilteritinib exposure was less than 2 fold Impaired renal function is thus not expected to significantly affect gilteritinib exposure, indicating dose adjustment is not warranted in patients with mild or moderate renal impairment. The CHMP recommended the applicant to conduct a phase I study to

<div style=\"page-break-after: always\"></div>

investigate the effect of renal impairment on the pharmacokinetics, safety and tolerability of gilteritinib compared to subjects with normal renal function (see RMP).

In vitro investigations indicated that gilteritinib was not a substrate of hepatic transporters OATP1B1, OATP1B3 or OCT1, however the data are not conclusive as only one, relatively high concentration of gilteritinib was used. According to the EMA DDI guideline, hepatic uptake transporters OATP1B1 and OATP1B3 should be investigated for substances where hepatic metabolism accounts for â¥25% of total elimination. Additionally, gilteritinib was not found to be a substrate of breast cancer resistance protein (BCRP), however the study should be repeated using four concentrations 0.01-1-fold the therapeutic dose/250  mL  in  accordance  with  the  EMA  DDI  guideline.  The  CHMP  recommended  the  applicant  to conduct an in vitro study post-approval, designed to investigate gilteritinib as a substrate of BCRP and hepatic uptake transporters OATP1B1, OATP1B3 and OCT1.

Concomitant use of Xospata with strong CYP3A/P glycoprotein (gp) inducers (e.g., phenytoin, rifampin and St. John's Wort) should be avoided because they can decrease gilteritinib plasma concentrations. In healthy subjects, co administration of RIF (600 mg), a strong CYP3A/P gp inducer, to steady state with a single 20 mg dose of gilteritinib decreased gilteritinib mean Cmax by 27% and mean AUCinf by 70%, respectively, compared to subjects administered a single dose of gilteritinib alone (SmPC sections 4.4, 4.5).

Strong  inhibitors  of  CYP3A  and/or  P  gp  (e.g.,  voriconazole,  ITZ,  posaconazole,  clarithromycin, erythromycin, captopril, carvedilol, ritonavir, azithromycin) can increase gilteritinib plasma concentrations. A single, 10 mg dose of gilteritinib co administered with ITZ (200 mg once daily for 28 days), a strong CYP3A and/or P gp inhibitor, to healthy subjects resulted in an approximate 20% increase in mean Cmax and 2.2 fold increase in mean AUCinf relative to subjects administered a single dose of gilteritinib alone. Gilteritinib exposure increased approximately 1.5 fold in patients with R/R AML when co administered with a strong CYP3A and/or P gp inhibitor (SmpC sections 4.4, 4.5).

Gilteritinib is not an inhibitor or inducer of CYP3A4 or and inhibitor of MATE1 in vivo. The PK of midazolam (a  sensitive  CYP3A4  substrate)  were  not  significantly  (Cmax  and  AUC  increased  approximately  10%) affected after once daily administration of gilteritinib (300 mg) for 15 days in patients with FLT3 mutated R/R AML. Additionally, the PK of cephalexin (a sensitive MATE1 substrate) were not significantly (Cmax and AUC decreased by less than 10%) affected after once daily administration of gilteritinib (200 mg) for 15 days in patients with FLT3 mutated R/R AML (SmPC section 4.5).

There is no data available on the concomitant use of contraceptive steroids. Gilteritinib is considered a potential human teratogen and the proposed indication could include females of childbearing potential. Appropriate recommendations have been included in the SmPC section 4.6 (See discussion on nonclinical aspects).

Two separate experimental systems should have been used to investigate P-gp inhibition due to the high inter-laboratory variability in the inhibition parameter estimation for P-gp, and an additional study is required. The CHMP recommended the applicant to perform a post-authorization study to investigate the potential of gilteritinib to inhibit P-gp and the bile salt export pump (BSEP).

No exposure-efficacy relationship could be characterised at the exposure range studied. Considering that ER analysis conducted on phase III data mainly can be used to identify major deviations in the adequacy of the selected dosing regimen either in the target or in subpopulations, this is to be expected. No phase II  dose-finding  study  has been conducted, and the ER analysis  has not been prospectively planned. Overall, the ER efficacy analysis is exploratory only, and is insufficient to draw any conclusions on the ER relationship or to support the proposed dose regimen.

There  was  a  tendency  for  increasing  QTc  prolongation  with  increasing  gilteritinib  exposures.  At  the median Cmax,ss associated with the proposed dose of 200 mg QD, the upper bound of the predicted change

<div style=\"page-break-after: always\"></div>

in QTcF was 12.5 msec. Thus an increased risk of QTc prolongation at the 200 mg dose of gilteritinib cannot be ruled out (see discussion on clinical safety).

## 2.4.5. Conclusions on clinical pharmacology

The PK and PD of gilteritinib have been reasonably well investigated.

## 2.5. Clinical efficacy

## 2.5.1. Dose response study

## Study 2215-CL-0101

No formal dose-finding study was conducted.

The dose-escalating study 2215-CL-0101, was a phase 1/2 open-label, first-in-human study in patients with R/R AML, with concomitant expansion cohort for multiple doses.

The primary objectives of this phase 1/2 study were to assess the safety and tolerability, including determination of the MTD of oral gilteritinib in patients with relapsed or treatment-refractory AML, and to determine the pharmacokinetic parameters of gilteritinib.

The secondary objectives of the study were to investigate the antileukemic activity of various doses of gilteritinib in patients with AML and to evaluate the effect of strong or moderate CYP3A4 inhibitors on the PK of gilteritinib ( see section ''Pharmacokinetic interaction studies'').

The study consisted of two cohorts:

- Cohort 1 - the initial dose escalation cohort, with up to 10 dose levels. Dose levels were set at around 50% increments. Cohort 1 was designed to determine the MTD based on assessment of DLTs at each dose level;
- Cohort 2 -the dose expansion cohort. Cohort 2 was conducted to further explore expanded dose levels.

Twenty-five patients were allocated to treatment for the dose escalation phase and an additional 240 randomized to the dose expansion phase, which includes 5 patients who were re-enrolled into the study. The doses assessed 20, 40, 80, 120, 200, 300 and 450 mg/day.  The starting dose level of gilteritinib was 20 mg daily, and the decision to dose escalate to the next dose level was made based on the assessment of safety variables, including occurrence of grade 2 adverse events (AEs) or DLTs. The DLT observation period was 30 days starting with the first dose taken on day -2 and including the first 28day treatment cycle.

Efficacy  endpoints  included  best  response  including  CR  rate,  CRc  rate  and  response  (CRc  +  partial remission [PR]) rate, CRh; duration of remission; OS; EFS and LFS.

The study initiation date (Date of First Enrolment) was 9 October 2013 and the study completion date (Date of Last Evaluation) was 7 March 2018.

Median age was 62.0 years. Overall, the duration of AML ranged from less than 1 month to 132.7 months, with a median duration of 9.07 months.  Overall, 70.6% (178/252) of patients in the SAF were FTL3ITD mutation positive and 13.1% (33/252) were FLT3-TKD positive by local testing, with 23.0% of patients (58/252) testing as FLT3 mutation negative. Previous line of AML therapies were 1-3 where 44% (111/252) had received &gt;3 lines, 26.2% (66/252) 2 lines and 29.8% (75/252) 1 line. The most common recurrent genetic abnormalities (WHO Classification) were AML with mutated NPM1 (27.0%, 68/252), AML with myelodysplasia-related changes (17.1%, 43/252), acute myelomonocytic leukaemia

<div style=\"page-break-after: always\"></div>

(11.1%, 28/252), AML without maturation (9.1%, 23/252), AML with maturation (7.5%, 19/252) and AML  minimally  differentiated  (6.3%,  16/252);  no  other  classification  occurred  in  more  than  5%  of patients.        A  majority  of  patients  were  characterized  with  intermediate  cytogenetic  risk  (56.7%, 143/252),  with  intermediate:  normal  being  the  single  most  common  characterization  (122  patients, 48.4%); 22.2% of patients were characterized with unfavorable cytogenetic risk (56/252) and 2.8% were characterized with favorable cytogenetic risk (7/252).

The MTD established in Study 2215-CL-0101, based on DLTs was 300 mg daily. PD analyses showed that  gilteritinib  exhibited  rapid  and  sustained  inhibition  of  FLT3 phosphorylation  at  doses  â¥  80  mg. Similarly, in FLT3 mutation positive patients, the CRc rates at end of treatment were generally low for patients randomized to the 20-mg and 40-mg dose groups (&lt; 10%) and generally similar for patients randomized to the 80 mg (41.7%), 120 mg (46.4%) and 200 mg (40.4%) dose groups.

Response was assessed based on central assessment supplemented by local assessment (i.e., derived response) and investigator-reported response.  Patients are included in the dose group of the initial dose received prior to any dose increase or decrease, unless otherwise noted.  Based on the derived response at end of treatment in the FLT3 mutation positive patients (local FLT3 testing, full analysis set (FAS)) including all doses, 71 patients achieved CRc for a CRc rate of 37.2%, and the best overall response rate (i.e., CRc + PR) was 48.7%.

The CR, CRh, and CR/CRh rates were also assessed per dose group.  The dose expansions for the 20 and 40 mg dose levels were closed early due to insufficient efficacy; as a result, efficacy evaluations were focused on the 80, 120, 200 and 300 mg dose groups. When analyzed by original planned doses, the derived CRc rate in the 80-, 120-, 200- and 300-mg dose groups was 41.7%, 46.4%, 40.4% and 30.0%,  respectively,  and  the  best  overall    response  rate  was  66.7%,  53.6%,  48.3%  and  60.0%, respectively.

The CR rate for FLT3 mutation positive patients receiving 120 mg was 12.5%.  The derived CRh rate for FLT3 mutation positive patients receiving 120 mg was 10.7% and the CR/CRh rate was 23.2%.The median duration of CRc in FLT3 mutation positive patients in â¥ 80-mg dose groups was 147.0 days (95% CI: 97.0, 307.0).  Median time to best response was 56.0 days, ranging from 26 to 364 days.

For the population of FLT3 mutation positive patients, the median OS from Kaplan-Meier (KM) estimates for dose groups â¥ 80 mg gilteritinib was 218.0 days.  The survival probability was 85.7% at 8 weeks, 56.2% at 26 weeks, and 24.9% at 1 year.

<div style=\"page-break-after: always\"></div>

Table 20 Overall Survival for Locally Evaluated FLT3 Mutated Patients in the â¥ 80-mg Dose Groups -Full Analysis (Set 2215-CL-0101)

| Parameter Category/ Statistics   | 80 mg (N = 12)                 | 120 mg (N = 56)      | 200 mg (N = 89)      | 300 mg (N = 10)      | 450 mg (N = 2)      | Total (N = 169)      |
|----------------------------------|--------------------------------|----------------------|----------------------|----------------------|---------------------|----------------------|
| Patient status, n (%)            |                                |                      |                      |                      |                     |                      |
| n                                | 12                             | 56                   | 89                   | 10                   | 2                   | 169                  |
| Events                           | 12 (100)                       | 43 (76.8)            | 70 (78.7)            | 9 (90.0)             | 2 (100)             | 136 (80.5)           |
| Censored                         | 0                              | 13 (23.2)            | 19 (21.3)            | 1 (10.0)             | 0                   | 33 (19.5)            |
| Kaplan-Meier quartiles (days)    | Kaplan-Meier quartiles (days)  |                      |                      |                      |                     |                      |
| Minimum                          | 18.0                           | 12.0                 | 12.0                 | 20.0                 | 51.0                | 12.0                 |
| Q1 (95% CI)                      | 112.5 [18.0, 194.0]            | 99.0 [57.0, 190.0]   | 91.0 [57.0, 121.0]   | 65.0 [20.0, 157.0]   | 51.0 [51.0, 357.0]  | 99.0 [73.0, 118.0]   |
| Median (95% CI)                  | 197.5 [61.0, 329.0]            | 246.0 [190.0, 309.0] | 214.0 [126.0, 264.0] | 157.0 [20.0, 218.0]  | 204.0 [51.0, 357.0] | 218.0 [161.0, 253.0] |
| Q3 (95% CI)                      | 317.0 [194.0, 1181.0]          | 559.0 [309.0, NE]    | 354.0 [291.0, 510.0] | 185.0 [157.0, 491.0] | 357.0 [51.0, 357.0] | 362.0 [323.0, 510.0] |
| Maximum                          | 1181.0                         | 694.0                | 658.0                | 419.0                | 357.0               | 1181.0               |
| Survival probability %[95% CI]   | Survival probability %[95% CI] |                      |                      |                      |                     |                      |
| 8 weeks                          | 91.7 [53.9, 98.8]              | 87.5 [75.6, 93.8]    | 85.2 [75.9, 91.1]    | 80.0 [40.9, 94.6]    | 50.0 [0.6, 91.0]    | 85.7 [79.4, 90.2]    |
| 12 weeks                         | 83.3 [48.2, 95.6]              | 82.1 [69.4, 90.0]    | 77.1 [66.7, 84.6]    | 70.0 [32.9, 89.2]    | 50.0 [0.6, 91.0]    | 78.5 [71.4, 84.0]    |
| 26 weeks                         | 58.3 [27.0, 80.1]              | 65.7 [51.6, 76.6]    | 51.8 40.6, 61.8]     | 36.0 [9.0, 64.8]     | 50.0 [0.6, 91.0]    | 56.2 [48.2, 63.4]    |
| 52 weeks                         | 16.7 [2.7, 41.3]               | 31.0 [19.1, 43.6]    | 24.2 [15.4, 34.1]    | 12.0 [0.7, 40.8]     | 0 NE                | 24.9 [18.4, 32.0]    |

CI: confidence interval; FLT3: FMS-like tyrosine kinase; NE: not estimated; Q1: first quartile; Q3: third quartile.

The supportive Phase 1/2 dose-escalation study 2215 CL 0101 included 157 patients with FLT3 mutated AML treated with either 1 (N=49) or &gt;1 prior lines of treatment (N=108) in the combined dose group (i.e. 80 mg, 120 mg or 200 mg);  31.2% received 1 prior line of treatment and 68.8% received &gt;1 prior lines of treatment.

Table 21 CR/CRh Rate by Prior Lines of Therapy - Local FLT3 Mutated Subjects Treated with Gilteritinib 80 mg, 120 mg or 200 mg, Full Analysis Set (Study 2215-CL-0101)

| Parameter n (%), (95% CI) â    | 2215-CL-0101                     | 2215-CL-0101                               | 2215-CL-0101                     | 2215-CL-0101                                |
|-------------------------------|----------------------------------|--------------------------------------------|----------------------------------|---------------------------------------------|
| Parameter n (%), (95% CI) â    | 1 Line of Therapy                | 1 Line of Therapy                          | > 1 Line of Therapy              | > 1 Line of Therapy                         |
| Parameter n (%), (95% CI) â    | Gilteritinib 120 mg/day (N = 14) | Gilteritinib Combined Dose Levels (N = 49) | Gilteritinib 120 mg/day (N = 42) | Gilteritinib Combined Dose Levels (N = 108) |
| CR/CRh Rateâ¡                  | 4 (28.6), (8.4, 58.1)            | 16 (32.7), (19.9, 47.5)                    | 9 (21.4), (10.3, 36.8)           | 17 (15.7), (9.4, 24.0)                      |
| CRh Rateâ¡                     | 1 (7.1), (0.2, 33.9)             | 6 (12.2), (4.6, 24.8)                      | 5 (11.9), (4.0, 25.6)            | 8 (7.4), (3.3, 14.1)                        |
| CR Rateâ¡                      | 3 (21.4), (4.7, 50.8)            | 10 (20.4), (10.2, 34.3)                    | 4 (9.5), (2.7, 22.6)             | 9 (8.3), (3.9, 15.2)                        |

Combined dose levels include 80 mg, 120 mg, and 200 mg dose levels.

â Exact 95% confidence interval was estimated using the binomial distribution.

â¡CR/CRh rate is defined as the number of subjects who achieve either CR or CRh at any postbaseline visit divided by the number of subjects in the analysis population.CI: confidence interval; CR: complete remission; CRh: complete remission with partial hematological recovery; FLT3: FMS-like tyrosine kinase 3.Sources: Adhoc

<div style=\"page-break-after: always\"></div>

Table 22 Overall Survival by Prior Lines of Therapy - Local FLT3 Mutated Patients Treated with Gilteritinib 80 mg, 120 mg or 200 mg, Full Analysis Set

| Parameter               | 2215-CL-0101                     | 2215-CL-0101                               | 2215-CL-0101                     | 2215-CL-0101                                | 2215-CL-0301                      | 2215-CL-0301            |
|-------------------------|----------------------------------|--------------------------------------------|----------------------------------|---------------------------------------------|-----------------------------------|-------------------------|
| Parameter               | 1 Prior Line of Therapy          | 1 Prior Line of Therapy                    | > 1 Prior Line of Therapy        | > 1 Prior Line of Therapy                   | 1 Prior Line of Therapy           | 1 Prior Line of Therapy |
| Parameter               | Gilteritinib 120 mg/day (N = 14) | Gilteritinib Combined Dose Levels (N = 49) | Gilteritinib 120 mg/day (N = 42) | Gilteritinib Combined Dose Levels (N = 108) | Gilteritinib 120 mg/day (N = 247) | Chemotherapy (N = 124)  |
| Deaths, n (%)           | 12 (85.7)                        | 41 (83.7)                                  | 31 (73.8)                        | 84 (77.8)                                   | 171 (69.2)                        | 90 (72.6)               |
| Censored, n (%)         | 2 (14.3)                         | 8 (16.3)                                   | 11 (26.2)                        | 24 (22.2)                                   | 76 (30.8)                         | 34 (27.4)               |
| Duration of OS, monthsâ  | Duration of OS, monthsâ           | Duration of OS, monthsâ                     | Duration of OS, monthsâ           | Duration of OS, monthsâ                      | Duration of OS, monthsâ            | Duration of OS, monthsâ  |
| 1 st quartile (95% CI)  | 7.7 (2.4, 9.8)                   | 3.9 (2.4, 4.8)                             | 3.3 (1.5, 5.6)                   | 3.1 (1.9, 3.8)                              | 4.4 (3.8, 5.1)                    | 3.0 (1.9, 3.5)          |
| Median (95% CI)         | 10.3 (3.1, 17.5)                 | 8.6 (4.7, 12.8)                            | 7.2 (4.3, 9.4)                   | 7.1 (5.0, 8.3)                              | 9.3 (7.7, 10.7)                   | 5.6 (4.7, 7.3)          |
| 3 rd quartile (95% CI)  | 17.5 (9.8, NE)                   | 17.5 (10.8, 38.8)                          | 18.4 (8.1, NE)                   | 11.1 (9.8, 16.8)                            | 18.7 (14.9, 24.1)                 | 10.0 (8.0, 15.7)        |
| Rangeâ¡                  | 2.4, 38.1+                       | 0.4, 38.8                                  | 0.4, 43.4+                       | 0.4, 43.4+                                  | 0.2, 31.9+                        | < 0.1+, 33.0            |
| OS Rate, %(95% CI)Â§     | OS Rate, %(95% CI)Â§              | OS Rate, %(95% CI)Â§                        | OS Rate, %(95% CI)Â§              | OS Rate, %(95% CI)Â§                         | OS Rate, %(95% CI)Â§               | OS Rate, %(95% CI)Â§     |
| At 6 months             | 78.6 (47.2, 92.5)                | 59.2 (44.2, 71.4)                          | 61.3 (44.7, 74.2)                | 56.6 (46.4, 65.5)                           | 65.5 (59.2, 71.1)                 | 48.9 (39.3, 57.8)       |
| At 12 months            | 42.9 (17.7, 66.0)                | 38.0 (24.6, 51.4)                          | 26.8 (14.1, 41.2)                | 19.9 (12.5, 28.5)                           | 37.1 (30.7, 43.6)                 | 16.7 (9.9, 25.0)        |
| At 24 months            | 14.3 (2.3, 36.6)                 | 16.9 (7.9, 28.7)                           | 21.4 (10.1, 35.4)                | 14.0 (7.8, 22.0)                            | 19.0 (12.8, 26.0)                 | 13.8 (7.5, 22.0)        |
| At 36 months            | 14.3 (2.3, 36.6)                 | 16.9 (7.9, 28.7)                           | 21.4 (10.1, 35.4)                | 14.0 (7.8, 22.0)                            | NE (NE, NE)                       | 0.0 (NE, NE)            |

Combined dose levels include 80 mg, 120 mg, and 200 mg dose levels.

â Based on Kaplan-Meier estimates; â¡+ indicates censoring; Â§Survival rate and 95% CI were estimated using Kaplan-Meier method and Greenwood formula.

## Study 2215 -CL-0102

This was a phase 1 one open-label dose-escalation study in Japanese patients with R/R AML. 27 patients were randomised and 24 received study medication with gilteritinib in doses from 20 to 300 mg. The starting dose level was 20 mg daily. Gilteritinib was to be administered in at least 1 patient at the 20mg dose level and at least 3 patients at the subsequent dose levels (40, 80, 120, 200 and 300 mg). Patients who had received gilteritinib in a certain dose level were not assigned to another dose level. The DLT observation period was 30 days starting with the first dose in cycle 0 (day -2) and including cycle 1 (the first 28-day treatment cycle).

The best overall response was stratified by central FLT3 mutation status.  At end of treatment, in the 5 FLT3 mutation-positive patients, 3 patients achieved CRc with a CRc rate of 60.0% (95% CI: 14.7%, 94.7%) and the response rate was 80.0% (95% CI: 28.4%, 99.5%).  In the FLT3 mutation-negative patients, the CRc rate and the response rate were 27.3% (95% CI: 6.0%, 61.0%) and 36.4% (95% CI: 10.9%, 69.2%), respectively (data not shown).

## Dose escalation to 200mg

## Efficacy

A comparison of response rates during cycle 1 compared to best overall response for patients in Study 2215-CL-0301 who did not escalate to gilteritinib 200 mg per day showed that composite complete remission (CRc) and complete remission (CR) rates were higher in the best overall response compared to the cycle 1 best response (overall CRc rate was 58.9% versus 33.3% for the CRc rate following 1 cycle of treatment; overall CR rate was 24.4% versus 5.4% for the CR rate following 1 cycle of treatment), suggesting that patients benefit from a prolonged exposure to gilteritinib and not all patients who will respond to gilteritinib will reach CR or CRc during the first treatment cycle.

<div style=\"page-break-after: always\"></div>

Table 23 Response before Cd2D1 compared to best overall response-study 2215-CL-0301 IIT-Patients who did not increase to 200mg gilteritinib

| Parameter, n (%)       | Cycle l Best Response (n =168)   | Best Overall Response (n=168)   |
|------------------------|----------------------------------|---------------------------------|
| Best Overall Responses |                                  |                                 |
| CR.                    | 9 (5.4)                          | 41 (24.4)                       |
| CRp                    | 7 (4.2)                          | 15 (8.9)                        |
| CRi                    | 40 (23.8)                        | 43 (25.6)                       |
| PR                     | 21 (12.5)                        | 17 (10.1)                       |
| NR                     | 71 (42.3)                        | 39 (23.2)                       |
| NE                     | 20 (11.9)                        | 13 (7.7)                        |
| CRc                    | 56 (33.3)                        | 99 (58.9)                       |
| Response Ratett        | 77 (45.8)                        | 116 (69.0)                      |

CR: complete remission; CRc: composite complete remission; CRi: complete remission with incomplete hematologic recovery; CRp: complete remission with incomplete platelet recovery; NE: not evaluable; NR: no response; PR: partial remission

â Includes patients who remained on 120 mg gilteritinib and patients who had a dose reduction to 80 mg gilteritinib.

â Defined as the best response up to cycle 2 day 1.

Â§ Categories were mutually exclusive.

- CRc = CR + CRp + CRi
- ât Response = CRc + PR

When analysing best overall response in the group of patients who did not respond after cycle 1, the difference in CRc rates between patients who were not escalated to gilteritinib 200 mg per day and those who were escalated to gilteritinib 200 mg per day was small (38.4% vs 40.3%).

Table 24 Best overall response- study 2215-CL-0301 IIT-Patients not responding after cycle 1

| Parameter, n (%)      | Did Not Escalate to 200 mg Gilteritinibt (n =112)   | Escalated to 200 mg Gilteritinib (n = 72)   |
|-----------------------|-----------------------------------------------------|---------------------------------------------|
| Best Overall Response |                                                     |                                             |
| CR                    | 18 (16.1)                                           | 7 (9.7)                                     |
| CRp                   | 8 (7.1)                                             | 4 (5.6)                                     |
| CRi                   | 17 (15.2)                                           | 18 (25.0)                                   |
| PR                    | 17 (15.2)                                           | 16 (22.2)                                   |
| NR                    | 39 (34.8)                                           | 27 (37.5)                                   |
| NE                    | 13 (11.6)                                           | 0                                           |
| CRcS                  | 43 (38.4)                                           | 29 (40.3)                                   |
| Response Rate         | 60 (53.6)                                           | 45 (62.5)                                   |

CR: complete remission; CRc: composite complete remission; CRi: complete remission with incomplete hematologic recovery; CRp: complete remission with incomplete platelet recovery; NE: not evaluable; NR: no response; PR: partial remission

â Includes patients who remained on 120 mg gilteritinib and patients who had a dose reduction to 80 mg gilteritinib.

<!-- formula-not-decoded -->

Response = CRc + PR

A summary of OS by dose adjustment in the gilteritinib arm is presented in table below.

<div style=\"page-break-after: always\"></div>

Table 25 Summary of OS by Dose Adjustment in the Gilteritinib Arm (ITT) (Study 2215-CL0301)

| Parameter Category/ Statistics     | (n = 78)          | GilteritinibIncreaseGilteritinibDecrease (n = 58)   | Gilteritinib No Change (n = 110)   |
|------------------------------------|-------------------|-----------------------------------------------------|------------------------------------|
| Patient status,n (%o)              |                   |                                                     |                                    |
| Death events                       | 59 (75.6)         | 37 (63.8)                                           | 74 (67.3)                          |
| Censored events                    | 19 (24.4)         | 21 (36.2)                                           | 36 (32.7)                          |
| Durationof OverallSurvival,Monthst |                   |                                                     |                                    |
| Q1 (95% CI)                        | 4.8 (4.0, 6.6)    | 5.3 (4.0, 8.3)                                      | 3.1 (2.4, 4.2)                     |
| Median (95% CI)                    | 8.9 (6.8, 10.8)   | 10.8 (8.3, 14.3)                                    | 8.9 (6.1, 11.0)                    |
| Q3 (95% CI)                        | 14.7 (11.0, 16.5) | 19.8 (14.3, NE)                                     | 19.9 (14.1, NE)                    |
| Ranget                             | 1.9, 29.5         | 0.7,25.7+                                           | 0.2,31.9+                          |
| Overall Survival Rate % (95% C1)s  |                   |                                                     |                                    |
| 6 months                           | 69.9 (58.2, 78.9) | 69.0 (55.4, 79.2)                                   | 61.3 (51.4, 69.7)                  |
| 12 months                          | 33.3 (22.2,44.8)  | 44.4 (30.5, 57.4)                                   | 36.2 (26.8, 45.6)                  |
| 24 months                          | 8.4 (2.6, 18.8)   | 23.2 (10.1,39.5)                                    | 23.6 (13.9, 34.8)                  |
| 36 months                          | 0 (NE, NE)        | NE (NE, NE)                                         | NE (NE, NE)                        |

## Safety

Comparison of the safety p rofile (SAEs, â¥ Grade 3 TEAEs and Grade 5 TEAEs) between patients who dose escalated to gilteritinib 200 mg and patients who did not dose escalate is presented in the table below.

<div style=\"page-break-after: always\"></div>

Table 26 TEAEs leading to dose interruption of treatment discontinuation in â¥1% of patients who dose escalated to gilteritinib 200mg

| SOC Preferred Term MedDRA V19.1 n (%)          | Did Not Escalate to 200 mg Gilteritinibi (n=168)   | Did Not Escalate to 200 mg Gilteritinibi (n=168)   | Escalated to Gilteritinib 200 mg (N = 78)   | Escalated to Gilteritinib 200 mg (N = 78)   |
|------------------------------------------------|----------------------------------------------------|----------------------------------------------------|---------------------------------------------|---------------------------------------------|
| SOC Preferred Term MedDRA V19.1 n (%)          | Interruption                                       | Discontinuation                                    | Interruption                                | Discontinuation                             |
| Overall                                        | 78 (46.4)                                          | 41 (24.4)                                          | 34 (43.6)                                   | 17 (21.8)                                   |
| Blood and Lymphatic System Disorder's          | 21 (12.5)                                          | 3 (1.8)                                            | 9 (11.5)                                    | 0                                           |
| Anaemia                                        | 1 (0.6)                                            | 1 (0.6)                                            | 1 (1.3)                                     | 0                                           |
| Disseminated intravascular coagulation         | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Febrile neutropenia                            | 13 (7.7)                                           | 1 (0.0)                                            | 6 (7.7)                                     | 0                                           |
| Pancytopenia                                   | 0                                                  | 1 (0.6)                                            | 2 (2.6)                                     | 0                                           |
| Thrombcytopenia                                | 4 (2.4)                                            | 0                                                  | 2 (2.6)                                     | 0                                           |
| Cardiac Disorder's                             | 4 (2.4)                                            | 4 (2.4)                                            | 1 (1.3)                                     | 0                                           |
| Cardiac failure                                | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Eye Disorders                                  | 3 (1.8)                                            | 1 (0.0)                                            | 0                                           | 1 (1.3)                                     |
| Retinopathy                                    | 1 (0.0)                                            | 1 (0.0)                                            | 0                                           | 1 (1.3)                                     |
| Gastrointestinal Disorder's                    | 7 (4.2)                                            | 2 (1.2)                                            | 6 (7.7)                                     | 0                                           |
| Abdominal pain                                 | 1 (0.0)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Colitis                                        | 1 (0.0)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Diarrhoea                                      | 2 (1.2)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Enterocolitis                                  | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Haematemesis                                   | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Nausea                                         | 1 (0.6)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Stomatitis necrotising                         | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| General Disorders and Administration Site      | 13 (7.7)                                           | 1 (0.0)                                            | 5 (6.4)                                     | 0                                           |
| Conditions                                     |                                                    |                                                    |                                             |                                             |
| Asthenia                                       | 1 (0.6)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Generalised oedema                             | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Malaise                                        | 1 (0.6)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Pyrexia                                        | 7 (4.2)                                            | 0                                                  | 2 (2.6)                                     | 0                                           |
| Hepatobiliary Disorders                        | 3 (1.8)                                            | 0                                                  | 1 (1.3)                                     | 1 (1.3)                                     |
| Hepatic function abnormal                      | 1 (0.6)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Cholecystitis                                  | 0                                                  | 0                                                  | 0                                           | 1 (1.3)                                     |
| Immune System Disorder's                       | 3 (1.8)                                            | 0                                                  | 2 (2.0)                                     | 1 (1.3)                                     |
| Acute graft versus host disease in intestine   | 0                                                  | 0                                                  | 1 (1.3)                                     | 1 (1.3)                                     |
| Drug hypersensitivity                          | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Infections and Infestations                    | 18 (10.7)                                          | 13 (7.7)                                           | 8 (10.3)                                    | 5 (6.4)                                     |
| Endocarditis                                   | 0                                                  | 0                                                  | 0                                           | 1 (1.3)                                     |
| Device related infection                       | 1 (0.0)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Influenza                                      | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Lung infection                                 | 2 (1.2)                                            | 4 (2.4)                                            | 0                                           | 1 (1.3)                                     |
| Pneumonia                                      | 3 (1.8)                                            | 1 (0.6)                                            | 1 (1.3)                                     | 2 (2.6)                                     |
| Pneumonia viral                                | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Septic shock                                   | 2 (1.2)                                            | 2 (1.2)                                            | 1 (1.3)                                     | 2 (2.0)                                     |
| Sinusitis fungal                               | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Skin infection                                 | 0                                                  | 0                                                  | 3 (3.8)                                     | 0                                           |
| Urinary tract infection                        | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |
| Injury, Poisoning and Procedural Complications | 3 (1.8)                                            | 0                                                  | 1 (1.3)                                     | 0                                           |
| Toxicty to various agents                      | 0                                                  | 0                                                  | 1 (1.3)                                     | 0                                           |

<div style=\"page-break-after: always\"></div>

| SOC Preferred Term MedDRA V19.1                                     | Did Not Escalate to 200 mg Gilteritinib (n =168)   | Did Not Escalate to 200 mg Gilteritinib (n =168)   | Escalated to Gilteritinib 200 mg (N =78)   | Escalated to Gilteritinib 200 mg (N =78)   |
|---------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|--------------------------------------------|--------------------------------------------|
| n (%)                                                               | Interruption                                       | Discontinuation                                    | Interruption                               | Discontinuation                            |
| Investigations                                                      | 30 (17.9)                                          | 7 (4.2)                                            | 9 (11.5)                                   | 3 (3.8)                                    |
| ALT increased                                                       | 16 (9.5)                                           | 3 (1.8)                                            | 3 (3.8)                                    | 1 (1.3)                                    |
| AST increased                                                       | 14 (8.3)                                           | 3 (1.8)                                            | 4 (5.1)                                    | 2 (2.0)                                    |
| Blood AP increased                                                  | 2 (1.2)                                            | 1 (0.6)                                            | 0                                          | 1 (1.3)                                    |
| Blood bilirubin increased                                           | 3 (1.8)                                            | 1 (0.6)                                            | 1 (1.3)                                    | 0                                          |
| Blood LDH increased                                                 | 1 (0.0)                                            | 0                                                  | 1 (1.3)                                    | 0                                          |
| ECG QT prolonged                                                    | 2 (1.2)                                            | 0                                                  | 1 (1.3)                                    | 0                                          |
| Fibrin D dimer increased                                            | 0                                                  | 0                                                  | 1 (1.3)                                    | 0                                          |
| GGT increased                                                       | 1 (0.0)                                            | 0                                                  | 1 (1.3)                                    | 0                                          |
| Weight decreased                                                    | 0                                                  | 0                                                  | 1 (1.3)                                    | 0                                          |
| Metabolism and Nutrition Disorder's                                 | 3 (1.8)                                            | 1 (0.0)                                            | 3 (3.8)                                    | 0                                          |
| Decreased appetite                                                  | 0                                                  | 0                                                  | 1 (1.3)                                    | 0                                          |
| Dehydration                                                         | 0                                                  | 0                                                  | 2 (2.0)                                    | 0                                          |
| Hyperglycemia                                                       | 0                                                  | 1 (0.6)                                            | 1 (1.3)                                    | 0                                          |
| Hypophosphataemia                                                   | 2 (1.2)                                            | 0                                                  | 1 (1.3)                                    | 0                                          |
| Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) | 0                                                  | 6 (3.0)                                            | 1 (1.3)                                    | 6 (7.7)                                    |
| AML                                                                 | 0                                                  | 2 (1.2)                                            | 1 (1.3)                                    | 6 (7.7)                                    |
| NervousSystemDisorders                                              | 3 (1.8)                                            | 2 (1.2)                                            | 3 (3.8)                                    | 1 (1.3)                                    |
| Carpal tumnel syndrome                                              | 0                                                  | 0                                                  | 1 (1.3)                                    | 0                                          |
| Cerebral haemorrhage                                                | 0                                                  | 1 (0.6)                                            | 0                                          | 1 (1.3)                                    |
| Headache                                                            | 1 (0.6)                                            | 0                                                  | 1 (1.3)                                    | 0                                          |
| Syncope                                                             | 1 (0.0)                                            | 0                                                  | 1 (1.3)                                    | 0                                          |
| Renal and Urinary Disorders                                         | 1 (0.0)                                            | 2 (1.2)                                            | 1 (1.3)                                    | 0                                          |
| Haematuria                                                          | 0                                                  | 0                                                  | 1 (1.3)                                    | 0                                          |
| Respiratory, Thoracic and Mediastinal Disorder's                    | 6 (3.0)                                            | 6 (3.0)                                            | 0                                          | 1 (1.3)                                    |
| Respiratory failure                                                 | 2 (1.2)                                            | 1 (0.6)                                            | 0                                          | 1 (1.3)                                    |
| Skin and subcutaneous tissue disorders                              | 5 (3.0)                                            | 1 (0.6)                                            | 2 (2.6)                                    | 0                                          |
| Drug enuption                                                       | 1 (0.6)                                            | 0                                                  | 1 (1.3)                                    | 0                                          |
| Rash erythematous                                                   | 0                                                  | 0                                                  | 1 (1.3)                                    | 0                                          |
| Vascular Disorder's                                                 | 6 (3.0)                                            | 1 (0.0)                                            | 2 (2.0)                                    | 0                                          |
| Haematoma                                                           | 0                                                  | 0                                                  | 1 (1.3)                                    | 0                                          |
| Orthostatis hypotension                                             | 0                                                  | 0                                                  | 1 (1.3)                                    | 0                                          |

## 2.5.2. Main study

## Â· ADMIRAL Study (2215-CL-0301)

## Methods

This was a phase 3 open-label, multicenter, randomized study of ASP2215 versus salvage chemotherapy in patients with R/R AML with FLT3 mutation.

<div style=\"page-break-after: always\"></div>

## Study Participants

## Inclusion Criteria

1.  Provision  of  written  informed  consent  approved  by  the  Institutional  Review  Board  (IRB)  or Independent  Ethics  Committee  and  privacy  language  as  per  national  regulations  (e.g.,  HIPAA Authorization for US sites) was obtained from the patient or legally authorized representative prior to any study-related procedures including withdrawal of prohibited medication, if applicable.

2. Patient was considered an adult according to local regulation at the time of signing informed consent.

3. Patient had a diagnosis of primary AML or AML secondary to MDS according to WHO classification (6) as determined by pathology review at the treating institution.

4. Patient was refractory to or relapsed after first-line AML therapy (with or without HSCT)
- Refractory to first-line AML therapy was defined as:

(a) Patient did not achieve CR/CRi/CRp under initial therapy. A patient eligible for standard therapy must have received at least 1 cycle of an anthracycline containing induction block in standard dose for the selected induction regimen. A patient not eligible for standard therapy must have received at least 1 complete block of induction therapy seen as the optimum choice of therapy to induce remission for this patient as per investigator's assessment.

- Untreated first hematologic relapse was defined as:

(b) Patient must have achieved a CR/CRi/CRp  as defined by Cheson et al. (7), with first-line treatment and had hematologic relapse.

5. Patient was positive for the FLT3 mutation in bone marrow or whole blood as determined by central testing by FLT3 CDx. In the investigator's opinion, a patient with rapidly proliferative disease and unable to wait for central testing by FLT3 CDx results could have been enrolled based on a local test performed after completion of the last interventional treatment. Patients could have been enrolled from a local test result if they had any of the following FLT3 mutations: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

6. Patient had an ECOG performance status (PS) â¤ 2.
7. Patient was eligible for preselected salvage chemotherapy according to investigator assessment.
8. Patient must have met the following criteria as indicated on the clinical laboratory tests:
- Serum AST and alanine aminotransferase (ALT) â¤ 2.5 x upper limit of normal (ULN)
- Serum total bilirubin (TBL) â¤ 1.5 x ULN
- Serum creatinine â¤ 1.5  x  ULN  or  an  estimated  glomerular  filtration  rate  of  &gt;  50  mL/min  as calculated by the Modification of Diet in Renal Disease equation.

9. Patient was suitable for oral administration of study drug.

10. Female patient must have been either:

-Of non-childbearing potential: Postmenopausal (defined as at least 1 year without any menses) prior to screening, or documented as surgically sterile (at least 1 month prior to screening)

-Or, if of childbearing potential: Agreed not to try to become pregnant during the study and for 180 days after the final study drug administration.

<div style=\"page-break-after: always\"></div>

And had a negative urine pregnancy test at screening, and if heterosexually active, agreed to consistently use highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and throughout the study period and for 180 days after the final study drug administration.

11. Female patient must have agreed not to breastfeed at screening and throughout the study period and for 60 days after the final study drug administration.

12. Female patient must not have donated ova starting at screening and throughout the study period and for 180 days after the final study drug administration.

13. Male patient and their female partners who were of childbearing potential must have been using highly effective contraception per locally accepted standards in addition to a barrier method starting at screening  and  continue  throughout  the  study  period  and  for  120  days  after  the  final  study  drug administration.

14. Male patient must not have donated sperm starting at screening and throughout the study period and 120 days after the final study drug administration

15. Patient agreed not to participate in another interventional study while on treatment.

## Exclusion Criteria

Patients were excluded from participation if any of the following applied:

1. Patient was diagnosed as having acute promyelocytic leukaemia.
2. Patient had BCR-ABL-positive leukaemia (chronic myelogenous leukaemia in blast crisis).
3. Patient had AML secondary to prior chemotherapy for other neoplasms (except for MDS).

4. Patient was in second or later hematologic relapse or had received salvage therapy for refractory disease.

5. Patient had clinically active CNS leukaemia.

6. Patient had been diagnosed with another malignancy, unless disease-free for at least 5 years. Patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, were eligible for this study if definitive treatment for the condition had been completed. Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease  were  eligible  if  hormonal  therapy  had  been  initiated  or  the  malignancy  had  been  surgically removed or treated with definitive radiotherapy.

7. Patient had received prior treatment with gilteritinib or other FLT3 inhibitors (with the exception of sorafenib and midostaurin used in first-line therapy regimen as part of induction, consolidation and/or maintenance).

8. Patient had clinically significant abnormality of coagulation profile, such as disseminated intravascular coagulation.

9. Patient had major surgery within 4 weeks prior to the first study dose.
10. Patient had radiation therapy within 4 weeks prior to the first study dose.

11. Patient had congestive heart failure New York Heart Association (NYHA) class 3 or 4 or patient with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram performed within 1 month prior to study entry resulted in a left ventricular ejection fraction that was â¥ 45%.

12. Patient had a mean of triplicate QTcF &gt; 450 msec at screening based on central reading.

<div style=\"page-break-after: always\"></div>

13. Patient had Long QT Syndrome at screening.
14. Patient had hypokalemia and hypomagnesemia at screening (defined as values below the LLN).
15. Patient required treatment with concomitant drugs that are strong inducers of CYP3A.
16. Patient required treatment with concomitant drugs that are strong inhibitors or inducers of P-gp with the exception of drugs that were considered absolutely essential for the care of the patient.
17.  Patient  required  treatment  with  concomitant  drugs  that  target  serotonin  5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that were considered absolutely essential for the care of the patient.
18. Patient had an active uncontrolled infection.
19. Patient was known to have human immunodeficiency virus infection.
20. Patient had active hepatitis B or C or other active hepatic disorder.
21. Patient had any condition which, in the investigator's opinion, made the patient unsuitable for study participation.
22. Patient had active clinically significant graft versus host disease (GVHD) or was on treatment with systemic corticosteroids for GVHD.
23. Patient had an FLT3 mutation other than the following: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

## Treatments

Subjects were randomized to receive either gilteritinib (staring dose 120 mg administered orally once daily) or salvage chemotherapy administered sc [LoDAC] or azacitidine or iv [MEC and FLAG-IDA]). A study flow chart is provided in Figure 4.

Figure 4 Study Design 2215-CL-0301

<!-- image -->

1Âº: primary; AML: acute myeloid leukemia; FLT3: FMS-like tyrosine kinase 3; FLAG-IDA: fludarabine, cytarabine and granulocyte colony-stimulating factor with idarubicin; MEC: mitoxantrone, etoposide and intermediate-dose cytarabine; NR: no response; PD: progressive disease.

<div style=\"page-break-after: always\"></div>

Gilteritinib tablets were administered orally once daily in continuous 28-day cycles.  The starting dose was 120 mg per day (3 tablets of 40 mg), which could be titrated per protocol instructions. Subjects receiving gilteritinib treatment should continue until there was no longer clinical benefit from therapy, until unacceptable toxicity occurred or another discontinuation criterion was met.

## Interruption, reduction or escalation in dose of gilteritinib

Dose reductions/interruptions were based on the following criteria: QTcF prolongation, retinopathy, nonhematologic  toxicity  (Grade  3  or  4),  or  myelosuppression.  Additionally,  dosing  may  have  been interrupted  or  reduced  at  the  investigators  discretion  if  deemed  necessary  for  safety  reasons.  The gilteritinib dose may be initially reduced to 80 mg per day, and could be further reduced to 40 mg per day if the patient had already experienced clinical benefit. No further dose reductions were allowed (i.e., if a patient was receiving gilteritinib 40 mg and further dose reduction was required, study treatment was discontinued). If the gilteritinib dose was reduced, it was not re-escalated.

Any patients that were off treatment for more than 14 days, other than for HSCT, could only resume treatment after discussion with the medical monitor.  Dose escalations to 200 mg per day were allowed in patients on a dose of 120 mg per day who did not achieve a CRc (CR, CRp or CRi) during or after cycle 1, based on bone marrow and hematology results. No further dose escalation was allowed.

## Resumption of Treatment After Hematopoietic Stem Cell Transplantation

## Gilteritinib could be resumed after HSCT if the following conditions were met:

Subject was between 30 - 90 days post HSCT; Subject had successful engraftment as demonstrated by ANC â¥ 500/mm3 and plate lets â¥ 20000/mm3 without transfusions ; Subject did not have â¥ grade 2 acute GVHD; Subject was in CRc.

## Salvage Chemotherapy:

The investigator pre-selected the specific salvage chemotherapy regimen before randomization of each subject.  All  regimens  were  administered  as  28-day  cycles  and  per  institutional  guidelines  for chemotherapy product preparation/administration 1 .  Options  for  comparative  salvage  chemotherapies were limited to the following (all dose levels as defined below must have been followed):

## Low intensity chemotherapy

LoDAC (Burnett et al. (8)):  20 mg cytarabine was administered twice daily by sc or intravenous (iv) injection for 10 days.

Azacitidine (Itzykson et al. (9)):  75 mg/m 2  azacitidine was administered daily by sc or iv injection for 7 days.

Institutional guidelines were followed if dose reduction was needed after cycle 1.

Patients who received LoDAC or azacitidine treatment should have continued until meeting a treatment discontinuation criterion.

## High intensity chemotherapy

## MEC Induction Chemotherapy (Levis et al. (10)):

- Mitoxantrone 8 mg/m 2  per day was administered by iv for 5 days (days 1 through 5).
- Etoposide 100 mg/m 2  per day was administered by iv for 5 days (days 1 through 5).
- Cytarabine 1000 mg/m 2  per day was administered by iv for 5 days (days 1 through 5).

<div style=\"page-break-after: always\"></div>

FLAG-IDA Induction Chemotherapy (Parker et al., Pallis et al. (11, 12)) :

Â· G-CSF 300 Âµg/m 2  per day was administered by sc/iv for 5 days (days 1 through 5).  Additional G-CSF by sc/iv was recommended 7 days after completing chemotherapy until absolute neutrophil count (ANC) &gt; 0.5 X 10 9 /L.

- Fludarabine 30 mg/m 2  per day was administered by iv for 5 days (days 2 through 6).
- Cytarabine 2000 mg/m 2  per day was administered by iv for 5 days (days 2 through 6).
- Idarubicin 10 mg/m 2  per day was administered by iv for 3 days (days 2 through 4).

Patients who received MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15, per institutional guidelines.  If the bone marrow cellularity was 20% or greater with at least a 50% reduction in blasts, the patient may have received a second cycle of the same chemotherapy. If bone marrow cellularity was between 5% and 20%, the investigator made the decision whether the patient should have received another treatment cycle or should have been observed for recovery.  If bone marrow cellularity was 5% or less, the patient was observed for recovery.  Patients achieving CR, CRi or CRp may have received a second cycle of chemotherapy at the investigator's discretion.

## Objectives

## Primary Objectives

- Determine the clinical benefit of gilteritinib in subjects with FLT3-mutated AML who are refractory to  or  have  relapsed  after  first-line  AML  therapy  as  shown  with  OS  compared  to  salvage chemotherapy.
- Determine the efficacy of gilteritinib as assessed by the rate of CR and CRh in subjects with FLT3-mutated AML who are refractory to or have relapsed after first-line AML therapy  (first interim analysis).

## Secondary Objectives

The key secondary objectives were to determine the overall efficacy in event-free survival (EFS) of gilteritinib  compared  to  salvage  chemotherapy  and  to  determine  the  overall  efficacy  in  CR  rate  of gilteritinib compared to salvage chemotherapy.

Other secondary objectives are to evaluate the efficacy of gilteritinib versus salvage chemotherapy in terms of:  LFS;  Duration  of  remission;  CRh  rate;  CRc  rate;  Transfusion  conversion  rate;  transfusion maintenance rate; Transplantation rate; Patient reported fatigue (Brief Fatigue Inventory [BFI]); AEs, safety  labs,  vital  signs,  ophthalmologic  exams,  ECGs;  Eastern  Cooperative  Oncology  Group  (ECOG) performance scores; Evaluation of gilteritinib (and metabolites as appropriate) plasma concentration and popPK.

## Exploratory Objectives

Exploratory objectives included the e valuation of the safety and efficacy of gilteritinib versus salvage chemotherapy  in  terms  of  pharmacogenomics  (PGx),  FLT3  gene  mutation  status,  biomarkers  of gilteritinib activity, resource utilization and PROs.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

## Primary endpoint

OS was the primary endpoint for the second interim analysis and in the final analysis. OS was defined as the time from the date of randomization until the date of death from any cause. For a subject who is not known to have died by the end of study follow-up, OS is censored at the date of last contact.

In addition, for the first interim analysis, CR/CRh rate was a co-primary endpoint. CR/CRh was defined as the number of patients who achieved either CR or CRh at any of the post baseline visits divided by the number of patients in the analysis population.

## Key secondary endpoints

EFS defined as the time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death, within 30 days after the last dose of study drug, whichever occurs first.

Treatment failure includes those pa tients who discontinued the treatment due to ''progressive disease'' or ''lack of efficacy''.

CR rate defined as the number of subjects who achieve the best response of CR divided by the number of subjects in the analysis population.

Relapse after CR, CRh, CRp or CRi is defined as a reappearance of leukemic blasts in the peripheral blood or â¥ 5% blasts in the bone marrow aspirate not attributable to any other cause or reappearance or new appearance of extramedullary leukaemia.

Relapse after PR is similarly defined with reappearance of significant numbers of peripheral blasts and an increase in the percentage of blasts in the bone marrow aspirate to &gt; 25% not attributable to any other cause or reappearance or new appearance of extramedullary leukaemia.

Best response is defined as the best measured response to treatment for all visits (in the order of CR, CRp, CRi, PR, not reached (NR) and not evaluable (NE)) post-baseline.

## Other secondary endpoints

- LFS,  defined  as  the  time  from  the  date  of  first  CRc  until  the  date  of  documented  relapse (excluding relapse from PR) or death.  For a patient who was not known to have relapsed or died, LFS was censored on the date of last relapse-free disease assessment.
- Duration of remission includes duration of CRc, duration of CR/CRh, duration of CRh, duration of CR, duration of CRi, duration of CRp and duration of response (CRc + PR).
- o Duration of CRc is defined as the time from the date of first CRc until the date of documented relapse for subjects who achieve CRc.
- o Duration of CR/CRh, CRh, CR, CRp, CRi is defined similarly as duration of CRc.
- o Duration of response is defined as the time from the date of either first CRc or PR until the date of documented relapse of any type for subjects who achieve CRc or PR.
- CRh rate
- CRc (CR + CRi + CRp) rate
- Transfusion conversion rate; transfusion maintenance rate (gilteritinib arm only):

<div style=\"page-break-after: always\"></div>

o Transfusion  conversion  rate  was  defined  as  the  number  of  patients  who  were  transfusion dependent during the baseline  period  but  become transfusion  independent  during  the  post  baseline period divided by the total number of patients who were transfusion dependent during the baseline period.

o Transfusion  maintenance  rate  was  defined  as  the  number  of  patients  who  were  transfusion independent during the baseline period and still maintained transfusion independence during the post baseline period divided by the total number of patients who were transfusion independent during the baseline period.

- Transplantation rate, defined as the percentage of patients undergoing HSCT post baseline
- BFI developed to assess the severity of fatigue and the impact of fatigue on daily functioning in patients with fatigue due to cancer and cancer treatment.

## Exploratory endpoints

- Functional  Assessment  of  Chronic  Illness  Therapy-Dyspnea-  Short  Forms  [FACIT-Dys-SF]  administered to assess dyspnoea severity and related functional limitations.
- Functional Assessment of Cancer Therapy-Leukemia [FACT-Leu], dizziness and mouth sore.
- EuroQol Group-5 Dimension-5 Level (EQ-5D-5L) Instrument.

## Sample size

The study utilized a group sequential design using the O'Brien -Fleming boundaries (non-binding) as implemented by Lan-DeMets alpha/beta spending Method. The overall 0.025 one-sided type I error rate was allocated by 0.0005 and 0.0245 (corresponding to 0.001 and 0.049 for two-sided type I error rates) for the two co-primary efficacy endpoints of CR/CRh and OS, respectively. In subjects randomized into ASP2215 only, an arbitrarily selected nominal alpha of 0.0005 was spent, which was not recycled in the second interim and final analyses.

Two interim analyses and one final analysis were planned. The first interim analysis was planned when approximately 141 subjects are randomized into ASP2215 arm and at least 112 days (4 treatment cycles) post first dose or randomization (for subjects who received no study drug). The second interim analysis was planned when approximately 129 death events had occurred and the final analysis was planned when approximately 258 death events had occurred.

Approximately  369  subjects  (the  planned  sample  size  with  10%  dropout  rate)  was  planned  to  be randomized in a 2:1 ratio to receive ASP2215 or salvage chemotherapy (246 subjects in the ASP2215 treatment arm and 123 subjects in the salvage chemotherapy arm). The planned 258 death events was calculated to provide about 90% power to detect a difference in OS between the ASP2215 arm with 7.7 months  median  survival  time  and  salvage  chemotherapy  arm  with  5  months  median  survival  time (hazard ratio (HR) = 0.65) at the overall one-sided 0.0245 significance level.

The co-primary endpoint of CR/CRh rate was to be evaluated only at the first interim analysis. A sample size of 141 subjects was calculated to provides 80% power to exclude a CR/CRh rate of 12% using the two-sided 95% exact CI when the CR/CRh rate of ASP2215 is assumed to be 21% (211 subjects in total: 141 in the ASP2215 arm and 70 in the salvage chemotherapy arm). With a minimum follow-up of 4 treatment cycles are considered to achieve a maximum width of 15.78% for the two-sided 95% exact confidence interval (CI) when the CR/CRh is expected to be in the 5% to 30% range as summarized in below table. A sample size of 141 subjects provides 80% power to exclude a CR/CRh rate of 12% using the two-sided 95% exact CI when the CR/CRh rate of ASP2215 is assumed to be 21%.

<div style=\"page-break-after: always\"></div>

The planned sample size with 258 EFS events would provide about 90% power to detect the difference in EFS (6 months median EFS for ASP2215 arm and 3.9 months for salvage chemotherapy arm with HR = 0.65) and &gt; 90% power to detect a difference in CR rate between ASP2215 (with 25% CR rate) and the salvage chemotherapy (with 10% CR rate) at the overall 1-sided 0.0245 significance level.

## Randomisation

Subjects were randomized in a 2:1 ratio via an interactive response technology (IRT) to receive ASP2215 or salvage chemotherapy. Randomization was stratified by response to first-line AML therapy and preselected salvage chemotherapy.

Prior therapy and response:  Primary refractor without HSCT; Relapse within 6 months after CRc and no HSCT ; Relapse within 6 months after allogeneic HSCT; Relapse after 6 months after CRc and no HSCT; Relapse after 6 months after allogeneic HSCT.

Pre-selected chemotherapy (preselected before randomization in both arms): High-intensity chemotherapy (MEC; FLAG-IDA); Low-intensity chemotherapy (LoDAC, Azacitidin).

## Blinding (masking)

This was an open-label study.

## Statistical methods

## Primary Hypothesis

The  primary  efficacy  endpoint  of  comparing  OS  in  the  intention  to  treat  (ITT)  population  between ASP2215 and the selected salvage chemotherapies had the null and alternative hypotheses:

H01: OS in ASP2215 is worse or equal to the OS in salvage chemotherapy

H11: OS in ASP2215 is better than the OS in salvage chemotherapy

This was tested only at the second interim and final analyses, using the stratified log-rank test (primary test) with strata used in randomization to control for response to first-line AML therapy and preselected salvage chemotherapy. The HR of the treatment effect along with 95%  CI was calculated by the stratified Cox proportional hazard model using the same stratification factors.

Sensitivity analyses for OS included the same analysis as primary analysis but on FAS or per protocol set (PPS), or censoring for HSCT or new antileukemia therapy, and stratified Cox proportional hazard models  with  strata  to  control  for  response  to  first  line  AML  therapy  and  preselected  salvage chemotherapy on ITT, and optionally initiation of new antileukemia therapy as a time-dependent binary covariate on ITT. An additional sensitivity analysis, weighted differences of Kaplan -Meier curves with estimation of difference of Restricted Mean Survival Time (RMST) and its 95% CI by a pre-specified cutoff time at 18 months was carried out.

Further sensitivity analyses were conducted to explore the impact of early censoring, predominantly affecting the chemotherapy arm (see section on ancillary analyses). Analyses covering both the first 8 weeks (EC8) (1 vs 10 censorings in the gilteritinib vs chemotherapy arm) and the first 6 months (EC6M) (6  vs  15  censorings  in  the  gilteritinib  vs  chemotherapy  arms)  were  performed,  using  'Bootstrap resampling' and 'Tipping point analysis' (Zhao, et al 2014).

The bootstrap resampling analysis was based on a neutral assumption that the survival risk of eraly censored patients was comparable with the survival risk of patients with non- early censoring (by same treatment and stratum).

<div style=\"page-break-after: always\"></div>

The tipping point analysis covered the same neutral scenario as the bootstrap resampling, assuming equal hazard for imputed and remaining patients ( Ï´ = 1) (by treatment and strata). In addition, several more conservative assumptions were made, i.e. the analysis imputing censoring up to 6 months included a scenario where a 3- fold decrease  in survival risk was assumed for the censored patients in the gilteritinib  ( Ï´ =  3)  arm  combined  with  an  increase  of  survival  risk  in  the  censored  patients  in  the chemotherapy arm ( Ï´ = from 0.1). For this analysis a &gt;85% rejection rate of the null hypothesis with Ï´ â¥ 0.5 for the chemotherapy arm was reported.

For the first interim analysis, CR/CRh was a co-primary efficacy endpoint. The two-sided 95% exact  CI of CR/CRh rate was planned to be calculated for approximately 141 subjects who were randomized into ASP2215 arm and at least 112 days (4 treatment cycles) post first dose, or randomization for subjects who received no study drug, i.e. ASP2215 subjects in the response analysis set (RAS). The lower limit of the 95% CI was compared to the benchmark CR/CRh rate of 12%.

## Handling of missing data

For primary endpoint OS, missing or incomplete death date was imputed as the earliest possible date on or after the date of last contact compatible with the (partial) information available. Partial relapse dates was imputed to the first day of the month of the missing parameter but not earlier than the last disease assessment date. A month and year had to be present or the date was to remain missing.

Missing centrally evaluated bone marrow assessment were imputed with local bone marrow assessment. Non-responder imputation was used for binary response variables.

For  OS  and  EFS  analyses,  if  all  events  were  from  one  treatment  group  in  at  least  one  stratum combination, or the Cox proportional hazard model did not converge due to small event size in some stratum  combinations,  the  stratum  combinations  were  planned  to  be  pooled  as  needed,  first  by successively decreasing the number of levels of response to first-line therapy to three, two and one, and secondly by pooling across preselected chemotherapies.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow (Study 2215-CL-0301)

<!-- image -->

## Recruitment

The study initiation date (date of first evaluation) was 20 October 2015. The final analysis data cut-off date was 17 September 2018.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

Protocol Amendments: The protocol (Original Version) was dated 24 March 2015. As of the final analysis data cut-off date of 17 September 2018, there were 8 substantial amendments (listed below) to the protocol in addition to 3 non-substantial amendments.

## Substantial Amendment 1 dated 22 June 2015

- The entry criteria were modified:

Inclusion Criterion No. 2 was modified to clarify the eligibility age; Inclusion Criterion No. 4 (second bullet) was modified to define 'relapsed after firstline therapy' as untreated relapse patients who had achieved CR/CRi/CRp with first-line treatment and had hematologic relapse; Exclusion Criterion No. 4 was modified to exclude patients who experienced a hematologic relapse after their second or later line of treatment or who received salvage therapy for refractory disease; Exclusion Criterion No. 12 was modified to clarify that patients were excluded if they required treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A; A separate exclusion criterion (Criterion No. 13) was added to exclude patients who required treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) or substrates of multidrug and toxin extrusion protein 1 (MATE1) with the exception of drugs that were considered absolutely essential for the care of the patient; An exclusion criterion (Criterion No. 19) was added to exclude patients with active GVHD or who were on treatment with corticosteroids for GVHD.

- The treatment discontinuation criteria were amended:

A discontinuation criterion was added to define lack of efficacy for a patient who was receiving LoDAC, azacitidine or gilteritinib; A discontinuation criterion was modified to clarify that use of hydroxyurea was not a reason for discontinuation;  Monitoring for the development of hyperuricemia was added; PRO measurements of BFI, FACT-leu, FACIT-Dys-SF and dizziness/mouth sore were removed from the 30day follow-up assessment; Clinical efficacy and safety information were updated; The guidelines for gilteritinib dose interruption or reduction were revised by deleting the requirement for 48 hours duration of Grade 3 AEs to interrupt dosing and state that treatment with gilteritinib was interrupted for any related Grade 3 AE; The definition of transfusion independence was changed from 4 weeks to 1 week without red blood cell transfusion and 1 week without platelet transfusion for the CR criterion; No patients were included at time of implementation of Substantial Amendment 1.

## Substantial Amendment 2 dated 13 August 2015

The exclusion criteria were modified: Exclusion Criterion No.12 was added to exclude patients with mean QTcF &gt; 450 msec at screening based on central reading; Exclusion Criterion No.13 was added to exclude patients with Long QT Syndrome at screening; Exclusion Criterion No.14 was added to exclude patients with hypokalaemia and hypomagnesemia at screening; HSCT was removed from the discontinuation criteria;  12-lead  ECG  and  pharmacokinetic  sampling  was  added  (whole  blood  samples  for  plasma pharmacokinetic) to occur on day 8 Â± 1 pre-dose; A confirmatory ECG that was to be performed on day 9 and an investigator assessment to consider a dose reduction for a patient if the mean QTcF for a patient from day 1 to day 8 had increased &gt; 30 msec with no other known aetiology was added; The mean QTcF of the triplicate ECG tracings based on central reading was clarified to be used for all treatment decisions; The  statement  regarding  relationship  between  QTcF  interval  prolongation  and  gilteritinib  plasma concentrations was updated; A criterion to the dose medication modification category was added to consider reducing the dose of gilteritinib if the mean QTcF from day 1 to day 8 had increased &gt; 30 msec, which was confirmed on day 9 without any other aetiology.

<div style=\"page-break-after: always\"></div>

## Country-specific Substantial Amendment 3 (Korea) dated 8 October 2015

Inclusion criterion No. 5 was modified to describe the FLT3 mutation types as ITD alone or ITD with concurrent TKD.

## Substantial Amendment 4 dated 9 December 2015

Clarification that if bone cellularity was between 5% and 20%, the investigator should have determined whether  a  patient  should  have  received  another  treatment  cycle  was  provided;  The  description  of acceptable contraception methods was changed for females in inclusion Criterion No. 10 and for males and their spouse/partners in inclusion Criterion No. 13; The mean of triplicate QTcF &gt; 450 msec was clarified to be cause for exclusion in Criterion No. 12 and the terminology for Long QT Syndrome in exclusion Criterion No. 13 was modified. A precaution regarding the use of gilteritinib with concomitant medications  that  are  known  to  prolong  QT  or  corrected  QT  interval  (QTc)  was  added  and  further instructions were provi ded to the investigator to check each patient's concomitant drugs for those that might have prolonged QT or QTc interval. A guideline for gilteritinib dose interruption and dose reduction if  a  patient had a mean of triplicate QTcF &gt; 500 msec was added; The discontinuation criterion that patients receiving MEC or FLAG-IDA who had NR or progressive disease should have been discontinued if it occurred following cycle 1 was clarified.

## Country-Specific Substantial Amendment 5 (Korea) dated 31 March 2016

Inclusion Criteria No. 10 and No. 13 were clarified to include all highly effective contraception examples for females and males and their spouse/partners.

## Country-specific Substantial Amendment 6 (France) dated 22 June 2016

Language  clarifying  local  requirements  for  inclusion  and  exclusion  criteria  was  added:  Per  local regulations,  patients  must  have  consented  personally,  patients  too  young  or  incapable  of  personal consent were excluded, and patients must have participated in a national social security scheme.

## Substantial Amendment 7 dated 8 August 2016

The long-term follow-up was clarified to be every 3 months for up to 3 years from the p atient's end of treatment visit; Midostaurin was included as a permitted prior treatment in exclusion Criterion No. 7; Patients with disallowed FLT3 mutation types (exclusion Criterion No. 23) were excluded; patients were included on the basis of local laboratory testing for allowed FLT3 mutation types (inclusion Criterion No. 5). If a subject is enrolled from a local FLT3 test result, the local test must have been performed after the subject's last interventional treatment. A subject's disease's clonal architecture or allelic ratio may have changed because of treatment and may no longer be FLT3 mutation positive. This could result in a negative FLT3 result from the central lab; Exclusion of MATE1 substrates as a concomitant medication restriction was deleted. Donor lymphocyte infusion as an allowed concomitant treatment for AML was included; Discontinuation criteria were clarified to include language stating that patients were eligible to continue  treatment  until  a  discontinuation  criterion  was  met  or  gilteritinib  gained  a  marketing authorization  and  became  commercially  available;  HR  in  the  interim  analysis  was  included;  Disease assessment  from  bone  marrow  samples  was  clarified  to  only  be  required  for  MEC  and  FLAG-IDA treatment per institutional guidelines on cycle 1 day 15 or later; Gilteritinib clinical and pharmacokinetic data from the 02 Feb 2015 cut-off was updated with data from the 31 Oct 2015 cut-off; Instructions to investigators  regarding  gilteritinib  dose  reduction  and  interruptions  were  clarified;  Methodology  for assessment of exposure and compliance were clarified; Laboratory tests administered were updated with the addition of thyroxine, thyroid-stimulating hormone and aPPT. Language to clarify that 2 laboratories were assaying bone marrow samples for different parameters was added; Purposes and conditions of the PGx substudy participation were updated to clarify that genes of relevance to AML patients may be

<div style=\"page-break-after: always\"></div>

analyzed  in  relationship  to  gilteritinib  treatment,  and  that  consenting  patients  may  (instead  of  will) participate.

Early  after  implementation  of  this  amendment,  a  non-substantial  amendment  was  implemented  (27 September 2016).

## Substantial Amendment 8 dated 20 September 2017

A co-primary objective for Interim Analysis 1 and updated response definitions were added. Co-primary objective of CR/CRh was added including a formal interim analysis for the co-primary endpoint; The secondary objectives and endpoints were updated. Two new secondary objectives/endpoints were added to the study. These secondary objectives are to evaluate the efficacy and safety of ASP2215 therapy versus salvage chemotherapy in terms of: (1) complete remission with partial hematologic recovery (CRh) rate and (2) transfusion conversion rate; transfusion maintenance rate; Additional language was added to describe the collection of concomitant medications; Additional language was added to describe the collection of AEs for patients who underwent HSCT; Statistical analyses for key secondary efficacy endpoints, secondary endpoints and exploratory endpoints were updated.

## Protocol Deviations

Overall (for the ITT) as of the final analysis data cut-off date, 11.6 % (43/371) of patients had a protocol deviation.

Table 27 Summary of Protocol Deviations -All Randomized Patients (Study 2215-CL-0301)

| Deviation Code,n(%)                                             | Gilteritinib (n=247)   | Chemotherapy (n=124)   | Total (n=371)   |
|-----------------------------------------------------------------|------------------------|------------------------|-----------------|
| Anydeviationt                                                   | 29 (11.7)              | 14 (11.3)              | 43 (11.6)       |
| Enteredintothestudyeventhough theydidnotsatisfyentrycriteria    | 21(8.5)                | 11 (8.9)               | 32(8.6)         |
| Receivedexcludedconcomitant treatment                           | 6 (2.4)                | 3(2.4)                 | 9 (2.4)         |
| Developedwithdrawalcriteria duringthestudy andwerenot withdrawn | 2(0.8)                 | 0                      | 2 (0.5)         |

Nopatientsmettheprotocoldeviationcriteriaofreceivedwrongtreatmentorincorrectdose.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 28 Demographic and Baseline Characteristics -ITT (Study 2215-CL-0301)

<div style=\"page-break-after: always\"></div>

| Parameter Category/Statistic                               | Gilteritinib 120 mg (n = 247)                              | Chemotherapy (n = 124)                                     | Total (n = 371)                                            |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Sex, n (%)                                                 |                                                            |                                                            |                                                            |
| Female                                                     | 131 (53.0)                                                 | 70 (56.5)                                                  | 201 (54.2)                                                 |
| Male                                                       | 116 (47.0)                                                 | 54 (43.5)                                                  | 170 (45.8)                                                 |
| Ethnicity, n (%)                                           |                                                            |                                                            |                                                            |
| Not Hispanic or Latino                                     | 221 (93.6)                                                 | 116 (96.7)                                                 | 337 (94.7)                                                 |
| Hispanic or Latino                                         | 12 (5.1)                                                   | 2 (1.7)                                                    | 14 (3.9)                                                   |
| Unknown                                                    | 3 (1.3)                                                    | 2 (1.7)                                                    | 5 (1.4)                                                    |
| Missing                                                    | 11                                                         | 4                                                          | 15                                                         |
| Race, n (%)                                                |                                                            |                                                            |                                                            |
| White (Caucasian)                                          | 145 (60.9)                                                 | 75 (62.5)                                                  | 220 (59.3)                                                 |
| Asian                                                      | 69 (29.0)                                                  | 33 (27.5)                                                  | 102 (27.5)                                                 |
| Black or African American                                  | 14 (5.9)                                                   | 7 (5.8)                                                    | 21 (5.7)                                                   |
| Native Hawaiian or Other Pacific Islander                  | 1 (0.4)                                                    | 0                                                          | 1 (0.3)                                                    |
| Unknown                                                    | 4 (1.7)                                                    | 4 (3.3)                                                    | 13 (3.5)                                                   |
| Other                                                      | 5 (2.1)                                                    | 1 (0.8)                                                    | 15 (4)                                                     |
| Missing                                                    | 9                                                          | 4                                                          | 13                                                         |
| Age (Years)                                                |                                                            |                                                            |                                                            |
| Mean (SD)                                                  | 59.0 (14.6)                                                | 57.6 (14.8)                                                | 58.5 (14.7)                                                |
| Median (min, max)                                          | 62.0 (20, 84)                                              | 61.5 (19, 85)                                              | 62.0 (19, 85)                                              |
| Age Group (Years), n (%)                                   |                                                            |                                                            |                                                            |
| < 65                                                       | 141 (57.1)                                                 | 75 (60.5)                                                  | 216 (58.2)                                                 |
| â¥ 65                                                       | 106 (42.9)                                                 | 49 (39.5)                                                  | 155 (41.8)                                                 |
| Region, n (%)                                              |                                                            |                                                            |                                                            |
| North America                                              | 114 (46.2)                                                 | 52 (41.9)                                                  | 166 (44.7)                                                 |
| Europe (Including Turkey, Israel)                          | 68 (27.5)                                                  | 43 (34.7)                                                  | 111 (29.9)                                                 |
| Asia                                                       | 65 (26.3)                                                  | 29 (23.4)                                                  | 94 (25.3)                                                  |
| Baseline ECOG, n (%)                                       |                                                            |                                                            |                                                            |
| 0-1                                                        | 206 (83.4)                                                 | 105 (84.7)                                                 | 311 (83.8)                                                 |
| â¥ 2                                                        | 41 (16.6)                                                  | 19 (15.3)                                                  | 60 (16.2)                                                  |
| Weight (kg)                                                |                                                            |                                                            |                                                            |
| n                                                          | 243                                                        | 124                                                        | 367                                                        |
| Mean                                                       | 72.79 (20.47)                                              | 69.91 (19.73)                                              | 71.82 (20.25)                                              |
| (SD) Median (min, max)                                     | 71.00 (39.0, 157.1)                                        | 67.00 (36.5, 157.9)                                        | 70.00 (36.5, 157.9)                                        |
| Height (cm)                                                |                                                            |                                                            |                                                            |
| n                                                          | 234                                                        | 123                                                        | 357                                                        |
| Mean (SD)                                                  | 167.25 (10.31)                                             | 166.39 (10.63)                                             | 166.95 (10.41)                                             |
| Median (min, max)                                          | 167.00 (140.0, 193.0)                                      | 166.00 (137.5, 191.0)                                      | 166.50 (137.5, 193.0)                                      |
| Table continued on next page                               | Table continued on next page                               | Table continued on next page                               | Table continued on next page                               |
| FLT3 Mutation Status by Central Testing by FLT3 CDx, n (%) | FLT3 Mutation Status by Central Testing by FLT3 CDx, n (%) | FLT3 Mutation Status by Central Testing by FLT3 CDx, n (%) | FLT3 Mutation Status by Central Testing by FLT3 CDx, n (%) |
| FLT3-ITD alone                                             | 215 (87.0)                                                 | 113 (91.1)                                                 | 328 (88.4)                                                 |
| FLT3-TKD alone                                             | 21 (8.5)                                                   | 10 (8.1)                                                   | 31 (8.4)                                                   |
| FLT3-ITD and FLT3-TKD                                      | 7 (2.8)                                                    | 0                                                          | 7 (1.9)                                                    |
| Others (negative)                                          | 4 (1.6)                                                    | 1 (0.8)                                                    | 5 (1.3)                                                    |

<div style=\"page-break-after: always\"></div>

| Parameter Category/Statistic         | Gilteritinib 120 mg (n = 247)        | Chemotherapy (n = 124)               | Total (n = 371)                      |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Prior Use of FLT3 Inhibitor, n (%) â  | Prior Use of FLT3 Inhibitor, n (%) â  | Prior Use of FLT3 Inhibitor, n (%) â  | Prior Use of FLT3 Inhibitor, n (%) â  |
| No                                   | 215 (87.0)                           | 110 (88.7)                           | 325 (87.6)                           |
| Yes                                  | 32 (13.0)                            | 14 (11.3)                            | 46 (12.4)                            |
| Cytogenetic Risk Status, n (%)       | Cytogenetic Risk Status, n (%)       | Cytogenetic Risk Status, n (%)       | Cytogenetic Risk Status, n (%)       |
| Intermediate                         | 182 (73.7)                           | 89 (71.8)                            | 271 (73.0)                           |
| Unfavorable                          | 26 (10.5)                            | 11 (8.9)                             | 37 (10.0)                            |
| Favorable                            | 4 (1.6)                              | 1 (0.8)                              | 5 (1.3)                              |
| Otherâ¡                               | 35 (14.2)                            | 23 (18.5)                            | 58 (15.6)                            |

â  Prior use of FLT3 inhibitor is defined as 'Yes' if patients received prior AML therapy of midostaurin, sorafenib or quizartinib; otherwise, prior use of FLT3 inhibitor is assigned as 'No'; â¡ The category of 'Other' includes those with cytogenetic risk status that cannot be categorized as favorable, intermediate or unfavorable.

<div style=\"page-break-after: always\"></div>

Table 29 Targeted disease history -Intention to Treatment Set (Study 2215-CL-0301)

| Parameter Category/Statistic             | Gilteritinib 120 mg (n = 247)   | Chemotherapy (n = 124)   | Total (n = 371)   |
|------------------------------------------|---------------------------------|--------------------------|-------------------|
| Duration of Disease (months)             |                                 |                          |                   |
| Mean (SD)                                | 7.37 (7.21)                     | 8.07 (9.67)              | 7.60 (8.11)       |
| Median (min, max)                        | 5.80 (0.6, 65.1)                | 5.30 (0.5, 52.0)         | 5.60 (0.5, 65.1)  |
| Antecedent Hematological Disorder, n (%) |                                 |                          |                   |
| No                                       | 206 (83.4)                      | 113 (91.1)               | 319 (86.0)        |
| Yes                                      | 41 (16.6)                       | 11 (8.9)                 | 52 (14.0)         |
| Type of Hematological Disorder, n (%) â   |                                 |                          |                   |
| MDS                                      | 34 (13.8)                       | 8 (6.5)                  | 42 (11.3)         |
| Other                                    | 7 (2.8)                         | 3 (2.4)                  | 10 (2.7)          |
| Central Nervous System Leukemia, n (%)   |                                 |                          |                   |
| No                                       | 244 (98.8)                      | 122 (98.4)               | 366 (98.7)        |
| Yes                                      | 3 (1.2)                         | 2 (1.6)                  | 5 (1.3)           |
| Rapidly Progressing Disease, n (%)       |                                 |                          |                   |
| No                                       | 133 (53.8)                      | 69 (55.6)                | 202 (54.4)        |
| Yes                                      | 113 (45.7)                      | 55 (44.4)                | 168 (45.3)        |
| Other Disease Characteristics, n (%)     |                                 |                          |                   |
| Untreated relapse AML                    | 151 (61.1)                      | 75 (60.5)                | 226 (60.9)        |
| Primary refractory AML                   | 96 (38.9)                       | 49 (39.5)                | 145 (39.1)        |
| Median number of relapses (range)        | 1 (0, 2)                        | 1 (0, 2)                 | 1 (0, 2)          |
| Number of relapses, n (%)                |                                 |                          |                   |
| 0                                        | 96 (38.9)                       | 49 (39.5)                | 145 (39.1)        |
| 1                                        | 147 (59.5)                      | 72 (58.1)                | 219 (59.0)        |
| 2                                        | 4 (1.6)                         | 3 (2.4)                  | 7 (1.9)           |
| > 2                                      | 0                               | 0                        | 0                 |
| WHOClassification, n (%)                 |                                 |                          |                   |
| AML with recurrent genetic abnormalities |                                 |                          |                   |
| AML with mutated NPM1                    | 83 (33.6)                       | 37 (29.8)                | 120 (32.3)        |
| AMLwith myelodysplasia-related changes   | 33 (13.4)                       | 10 (8.1)                 | 43 (11.6)         |

<div style=\"page-break-after: always\"></div>

| AML with t(8;21)(q22;q22), RUNX1-RUNX1T1                  | 5 (2.0)                                               | 5 (4.0)                                               | 10 (2.7)                                              |
|-----------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| AML with t(6;9)(q23;q34); DEK- NUP214                     | 5 (2.0)                                               | 3 (2.4)                                               | 8 (2.2)                                               |
| AML with mutated CEBPA                                    | 4 (1.6)                                               | 1 (0.8)                                               | 5 (1.3)                                               |
| AML with t(9;11)(q22;q23); MLLT3- MLL                     | 2 (0.8)                                               | 2 (1.6)                                               | 4 (1.1)                                               |
| AML with inv(3)(q21q26.2) or t(3;3)q(21;q26.2); RPN1-EVI1 | 1 (0.4)                                               | 0                                                     | 1 (0.3)                                               |
| AML (megakaryoblastic) with t(1;22) (p13;q13); RBM15-MKL1 | 1 (0.4)                                               | 0                                                     | 1 (0.3)                                               |
| AML not otherwise categorized                             | AML not otherwise categorized                         | AML not otherwise categorized                         | AML not otherwise categorized                         |
| AML without maturation                                    | 34 (13.8)                                             | 23 (18.5)                                             | 57 (15.4)                                             |
| AML with maturation                                       | 30 (12.1)                                             | 9 (7.3)                                               | 39 (10.5)                                             |
| Acute myelomonocytic leukemia                             | 20 (8.1)                                              | 10 (8.1)                                              | 30 (8.1)                                              |
| Acute monoblastic/monocytic leukemia                      | 20 (8.1)                                              | 14 (11.3)                                             | 34 (9.2)                                              |
| AML minimally differentiated                              | 16 (6.5)                                              | 10 (8.1)                                              | 26 (7.0)                                              |
| Acute erythroid leukemia                                  | Acute erythroid leukemia                              | Acute erythroid leukemia                              | Acute erythroid leukemia                              |
| Erythroleukemia, erythroid/myeloid                        | 1 (0.4)                                               | 2 (1.6)                                               | 3 (0.8)                                               |
| Myeloid Sarcoma                                           | 0                                                     | 1 (0.8)                                               | 1 (0.3)                                               |
| FAB Classification Subtype, n (%)                         | FAB Classification Subtype, n (%)                     | FAB Classification Subtype, n (%)                     | FAB Classification Subtype, n (%)                     |
| Unknown                                                   | 74 (30.0)                                             | 25 (20.2)                                             | 99 (26.7)                                             |
| M1: Acute myeloblastic leukemia, without maturation       | 45 (18.2)                                             | 35 (28.2)                                             | 80 (21.6)                                             |
| M2: AML with differentiation                              | 51 (20.6)                                             | 17 (13.7)                                             | 68 (18.3)                                             |
| M4: Acute myelomonocytic leukemia                         | 33 (13.4)                                             | 21 (16.9)                                             | 54 (14.6)                                             |
| M5: Acute monoblastic leukemia                            | 27 (10.9)                                             | 14 (11.3)                                             | 41 (11.1)                                             |
| M0: Minimally differentiated acute myeloblastic leukemia  | 15 (6.1)                                              | 9 (7.3)                                               | 24 (6.5)                                              |
| M6: Acute erythroid leukemia                              | 2 (0.8)                                               | 3 (2.4)                                               | 5 (1.3)                                               |
| Risk Status With Specific Cytogenetic Patterns, n (%)     | Risk Status With Specific Cytogenetic Patterns, n (%) | Risk Status With Specific Cytogenetic Patterns, n (%) | Risk Status With Specific Cytogenetic Patterns, n (%) |
| Intermediate: Normal                                      | 163 (66.0)                                            | 78 (62.9)                                             | 241 (65.0)                                            |
| Unknown Risk                                              | 32 (13.0)                                             | 17 (13.7)                                             | 49 (13.2)                                             |
| Unfavorable: Complex                                      | 18 (7.3)                                              | 6 (4.8)                                               | 24 (6.5)                                              |
| Intermediate: + 8                                         | 11 (4.5)                                              | 9 (7.3)                                               | 20 (5.4)                                              |
| Other Risk                                                | 8 (3.2)                                               | 8 6.5)                                                | 16 (4.3)                                              |
| Favorable: t(8;21)                                        | 3 (1.2)                                               | 2 (1.6)                                               | 5 (1.3)                                               |
| Unfavorable: del7q                                        | 4 (1.6)                                               | 0                                                     | 4 (1.1)                                               |
| Unfavorable: - 7                                          | 3 (1.2)                                               | 1 (0.8)                                               | 4 (1.1)                                               |
| Intermediate: - y                                         | 3 (1.2)                                               | 0                                                     | 3 (0.8)                                               |
| Unfavorable: del5q                                        | 2 (0.8)                                               | 1 (0.8)                                               | 3 (0.8)                                               |
| Intermediate: + 6                                         | 1 (0.4)                                               | 1 (0.8)                                               | 2 (0.5)                                               |
| Unfavorable: - 5                                          | 1 (0.4)                                               | 0                                                     | 1 (0.3)                                               |
| Favorable: inv(16)                                        | 1 (0.4)                                               | 0                                                     | 1 (0.3)                                               |
| Favorable: t(16;16)                                       | 0                                                     | 1 (0.8)                                               | 1 (0.3)                                               |

â Only for patients who had antecedent hematological disorder.

<div style=\"page-break-after: always\"></div>

Table 30 Baseline Stratification Factors Based on IRT -Intention to Treatment Set, (Study 2215-CL-0301)

| Parameter Category                                                         | Gilteritinib 120 mg (n = 247) (%) uI                             | Chemotherapy (n = 124) (%) u                                     | Total (n = 371) (%) I                                            |
|----------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Response to First-line Therapy                                             |                                                                  |                                                                  |                                                                  |
| Primary refractory without HSCT                                            | 98 (39.7)                                                        | 48 (38.7)                                                        | 146 (39.4)                                                       |
| Relapse within 6 months after CRc and no HSCT                              | 67 (27.1)                                                        | 34 (27.4)                                                        | 101 (27.2)                                                       |
| Relapse after 6 months after CRc and no HSCT                               | 34 (13.8)                                                        | 17 (13.7)                                                        | 51 (13.7)                                                        |
| Relapse within 6 months after allogeneic HSCT                              | 31 (12.6)                                                        | 17 (13.7)                                                        | 48 (12.9)                                                        |
| Relapse after 6 months after allogeneic HSCT                               | 17 (6.9)                                                         | 8 (6.5)                                                          | 25 (6.7)                                                         |
| Preselected Salvage Chemotherapy                                           |                                                                  |                                                                  |                                                                  |
| High-intensity chemotherapy                                                | 149 (60.3)                                                       | 75 (60.5)                                                        | 224 (60.4)                                                       |
| Low-intensity chemotherapy                                                 | 98 (39.7)                                                        | 49 (39.5)                                                        | 147 (39.6)                                                       |
| Response to First-Line Therapy, Preselected Salvage Chemotherapy           | Response to First-Line Therapy, Preselected Salvage Chemotherapy | Response to First-Line Therapy, Preselected Salvage Chemotherapy | Response to First-Line Therapy, Preselected Salvage Chemotherapy |
| Primary refractory without HSCT, high- intensity chemotherapy              | 57 (23.1)                                                        | 28 (22.6)                                                        | 85 (22.9)                                                        |
| Primary refractory without HSCT, low- intensity chemotherapy               | 41 (16.6)                                                        | 20 (16.1)                                                        | 61 (16.4)                                                        |
| Relapse within 6 months after CRc and no HSCT, high-intensity chemotherapy | 40 (16.2)                                                        | 21 (16.9)                                                        | 61 (16.4)                                                        |
| Relapse within 6 months after CRc and no HSCT, low-intensity chemotherapy  | 27 (10.9)                                                        | 13 (10.5)                                                        | 40 (10.8)                                                        |
| Relapse after 6 months after CRc and no HSCT, high intensity chemotherapy  | 23 (9.3)                                                         | 11 (8.9)                                                         | 34 (9.2)                                                         |
| Relapse within 6 months after allogeneic HSCT, low-intensity chemotherapy  | 16 (6.5)                                                         | (EL) 6                                                           | 25 (6.7)                                                         |
| Relapse within 6 months after allogeneic HSCT, high-intensity chemotherapy | 15 (6.1)                                                         | 8 (6.5)                                                          | 23 (6.2)                                                         |
| Relapse after 6 months after allogeneic HSCT, high-intensity chemotherapy  | 14 (5.7)                                                         | 7 (5.6)                                                          | 21 (5.7)                                                         |
| Relapse after 6 months after CRc and no HSCT, low-intensity chemotherapy   | 11 (4.5)                                                         | 6 (4.8)                                                          | 17 (4.6)                                                         |
| Relapse after 6 months after allogeneic HSCT, low-intensity chemotherapy   | 3 (1.2)                                                          | 1 (0.8)                                                          | 4 (1.1)                                                          |

<div style=\"page-break-after: always\"></div>

## Numbers analysed

The following study populations were used for analysis of efficacy data:

The  ITT  population  consisted  of  all  patients  who  were  randomized  (gilteritinib  N  =  247;  salvage chemotherapy N = 124).

The FAS consisted of all randomized patients with an FLT3 mutation detected by the FLT3 CDx and was used for sensitivity analyses of efficacy data in interim analysis 2 and the final analysis (gilteritinib N = 243; salvage chemotherapy N = 123).

The  RAS  consisted  of  patients  who  were  at  least  112  days  past  the  first  dose  of  gilteritinib  or randomization (for patients who did not receive gilteritinib). It was defined only for interim analysis 1, where it was used for efficacy analyses (gilteritinib N = 142).

The PPS included all patients of the ITT who did not meet any of the protocol defined criteria for exclusion. The  PPS  was  used  for  sensitivity  analyses  of  efficacy  data  (gilteritinib  arm  N  =  217;  salvage chemotherapy arm N = 124).

The mRAS was defined for Interim Analysis 1 only, where it was used for sensitivity analyses. Included all patients of the RAS who did not meet any 1 of the exclusion criteria listed for PPS, with the criteria on FLT3 mutation modification to 'No central FLT3 mutation at baseline' (gilteritinib arm N = 124).

The safety analysis set (SAF) consisted of all subjects who received at least one dose of study treatment (ASP2215 or salvage chemotherapy) and was used for all safety variables (gilteritinib N = 246; salvage chemotherapy N = 109).

The pharmacokinetic analysis set (PKAS) consisted of the subset of the SAF for which at least 1 plasma concentration data is available and for whom the time of dosing on the day of sampling is known.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

- Primary endpoint - Overall survival (OS)

OS analyses for the ITT population are shown in Table 31.

Table 31 Overall Survival ITT (Study 2215-CL-0301) (Data cut 17 September 2018)

| Category/ Statistics                                                 | Gilteritinib 120 mg (n = 247)                                        | Chemotherapy (n = 124)                                               |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Patient Status, n (%)                                                |                                                                      |                                                                      |
| Death events                                                         | 171 (69.2)                                                           | 90 (72.6)                                                            |
| Censored events                                                      | 76 (30.8)                                                            | 34 (27.4)                                                            |
| Duration of Overall Survival, Month â                                 | Duration of Overall Survival, Month â                                 |                                                                      |
| Q1 (95% CI)                                                          | 4.4 (3.8, 5.1)                                                       | 3.0 (1.9, 3.5)                                                       |
| Median (95% CI)                                                      | 9.3 (7.7, 10.7)                                                      | 5.6 (4.7, 7.3)                                                       |
| Q3 (95% CI)                                                          | 18.7 (14.9, 24.1)                                                    | 10.0 (8.0, 15.7)                                                     |
| Rangeâ¡                                                               | 0.2, 31.9+                                                           | < 0.1+, 33.0                                                         |
| Stratified Analysis (Primary) Â§                                      |                                                                      |                                                                      |
| Log-rank test: P-value [1-sided P-value]                             | 0.0007 [1-sided P-value: 0.0004]                                     |                                                                      |
| Wald test: P-valueÂ¶                                                  | 0.0008                                                               |                                                                      |
| Hazard ratio (95% CI)Â¶                                               | 0.637 (0.490, 0.830)                                                 |                                                                      |
| Unstratified Analysis                                                |                                                                      |                                                                      |
| Log-rank test (P-value)                                              | 0.0005                                                               |                                                                      |
| Wald test: P-valueÂ¶                                                  | 0.0006                                                               |                                                                      |
| Hazard ratio (95% CI)Â¶                                               | 0.636 (0.491, 0.823)                                                 |                                                                      |
| Overall Survival Rate %(95% CI) â â                                    | Overall Survival Rate %(95% CI) â â                                    |                                                                      |
| 6 months                                                             | 65.5 (59.2, 71.1)                                                    | 48.9 (39.3, 57.8)                                                    |
| 12 months                                                            | 37.1 (30.7, 43.6)                                                    | 16.7 (9.9, 25.0)                                                     |
| 24 months                                                            | 19.0 (12.8, 26.0)                                                    | 13.8 (7.5, 22.0)                                                     |
| 36 months                                                            | NE (NE, NE)                                                          | 0 (NE, NE)                                                           |
| Overall Survival Sensitivity Analysis With Patients Censored at HSCT | Overall Survival Sensitivity Analysis With Patients Censored at HSCT | Overall Survival Sensitivity Analysis With Patients Censored at HSCT |
| Patient Status, n (%)                                                |                                                                      |                                                                      |
| Death events                                                         | 142 (57.5)                                                           | 84 (67.7)                                                            |
| Censored events                                                      | 105 (42.5)                                                           | 80 (32.3)                                                            |
| Duration of Overall Survival, Months â                                | Duration of Overall Survival, Months â                                |                                                                      |
| Q1 (95% CI)                                                          | 4.1 (3.6, 4.6)                                                       | 3.0 (1.9, 3.5)                                                       |
| Median (95% CI)                                                      | 8.3 (6.7, 10.2)                                                      | 5.3 (4.3, 6.1)                                                       |
| Q3 (95% CI)                                                          | 14.9 (11.1, 18.7)                                                    | 8.9 (7.3, 9.6)                                                       |
| Rangeâ¡                                                               | 0.2, 27.4+                                                           | < 0.1+, 33.0                                                         |
| Stratified Analysis Â§                                                |                                                                      |                                                                      |
| Log-rank test: 1-sided P-value                                       | 0.0001 [1-sided P-value: < 0.0001]                                   |                                                                      |
| Wald Test: P-ValueÂ¶                                                  | 0.0001                                                               |                                                                      |
| Hazard ratio (95% CI)Â¶                                               | 0.575 (0.434, 0.762)                                                 |                                                                      |
| Overall Survival Rate %(95% CI) â â                                    |                                                                      |                                                                      |
| 6 months                                                             | 62.1 (55.1, 68.4)                                                    | 43.5 (33.2, 53.4)                                                    |
| 12 months                                                            | 30.5 (23.2, 38.0)                                                    | 8.7 (3.6, 16.5)                                                      |
| 24 months                                                            | 13.2 (7.3, 20.9)                                                     | 5.4 (1.6, 12.6)                                                      |
| 36 months                                                            | NE (NE, NE)                                                          | 0 (NE, NE)                                                           |

â Based on Kaplan-Meier estimates; â¡A '+' indicates censoring; Â§Stratification factors were response to first-line AML therapy and preselected salvage chemotherapy per IRT;m; Â¶Based on Cox proportional hazards model.  Assuming proportional hazards, an HR of &lt; 1 indicates a reduction in the hazard rate in favor of the gilteritinib arm; â â Survival rate and 95% CI were estimated using the Kaplan-Meier method and the Greenwood formula.

<div style=\"page-break-after: always\"></div>

Figure 5 Kaplan-Meier Plot of Overall Survival by Treatment Arm (ITT) (Study 2215-CL-0301)

<!-- image -->

All patients who were randomized (Intention to Treatment Set).

Note: 1-sided P-value is from stratified log-rank test.

ASP2215: gilteritinib; Chemo: chemotherapy; CI: confidence interval; HR: hazard ratio; N: total number of patients.

Figure 6 Kaplan-Meier Plot of OS by Treatment Arm Censoring at HSCT (ITT) (Study 2215-CL0301)

<!-- image -->

<div style=\"page-break-after: always\"></div>

- Key secondary endpoint: Complete response rates

## Table 32 Summary of CR Rate (Study 2215-CL-0301)

| Parameter Category/Statistics                                                 | Gilteritinib (n = 247)                                                        | Chemotherapy (n = 124)                                                        |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Primary Analysis, ITT                                                         |                                                                               |                                                                               |
| CR Rate , n/N (%) [95% CI]â                                                    | 52/247 (21.1) [16.1, 26.7]                                                    | 13/124 (10.5) [5.7, 17.3]                                                     |
| Adjusted treatment difference %[95% CI]â¡                                      | 10.6 [2.8, 18.4]                                                              |                                                                               |
| Stratified P-value (primary) [1-sided P-value]â¡                               | 0.0106 [1-sided P-value: 0.0053]                                              |                                                                               |
| Unstratified P-value [1-sided P-value]Â§                                       | 0.0134 [1-sided P-value: 0.0067]                                              |                                                                               |
| Sensitivity Analysis, ITT and Received at Least 1 Dose of Study Drug          | Sensitivity Analysis, ITT and Received at Least 1 Dose of Study Drug          |                                                                               |
| CR Rate , n/N (%) [95% CI]â                                                    | 52/246 (21.1) [16.2, 26.8]                                                    | 13/109 (11.9) [6.5, 19.5]                                                     |
| Adjusted treatment difference% [95% CI]â¡                                      | 9.3 [1.0, 17.6]                                                               |                                                                               |
| P-valueâ¡                                                                      | 0.0348                                                                        |                                                                               |
| Sensitivity Analysis, ITT With at Least 1 Postbaseline Bone Marrow Assessment | Sensitivity Analysis, ITT With at Least 1 Postbaseline Bone Marrow Assessment | Sensitivity Analysis, ITT With at Least 1 Postbaseline Bone Marrow Assessment |
| CR Rate , n/N (%) [95% CI]â                                                    | 52/232 (22.4) [17.2, 28.3]                                                    | 13/65 (20.0) [11.1, 31.8]                                                     |
| Adjusted treatment difference %[95% CI]â¡                                      | 3.3 [-8.1, 14.7]                                                              |                                                                               |
| P-valueâ¡                                                                      | 0.5693                                                                        |                                                                               |
| Sensitivity Analysis, FAS                                                     |                                                                               |                                                                               |
| CR Rate , n/N (%) [95% CI]â                                                    | 50/243 (20.6) [15.7, 26.2]                                                    | 13/123 (10.6%) [5.7, 17.4]                                                    |
| Adjusted treatment difference %[95% CI]â¡                                      | 10.0 [2.2, 17.8]                                                              |                                                                               |
| P-valueâ¡                                                                      | 0.0155                                                                        |                                                                               |
| Sensitivity Analysis, PPS                                                     |                                                                               |                                                                               |
| CR Rate , n/N (%) [95% CI]â                                                    | 50/217 (23.0) [17.6, 29.2]                                                    | 13/70 (18.6) [10.3, 29.7]                                                     |
| Adjusted treatment difference %[95% CI]â¡                                      | 5.4 [-5.7, 16.6]                                                              |                                                                               |
| P-valueâ¡                                                                      | 0.3405                                                                        |                                                                               |
| Sensitivity Analysis, ITT, Achieving CR Prior to HSCT Â¶                       | Sensitivity Analysis, ITT, Achieving CR Prior to HSCT Â¶                       |                                                                               |
| CR Rate , n/N (%) [95% CI]â                                                    | 34/247 (13.8) [9.7, 18.7]                                                     | 13/124 (10.5) [5.7, 17.3]                                                     |
| Adjusted treatment difference %[95% CI]â¡                                      | 3.3 [-4.0, 10.5]                                                              |                                                                               |
| P-valueâ¡                                                                      | 0.3639                                                                        |                                                                               |

- Best response rates

## Table 33 Summary of Best Response Rate -ITT (Study 2215-CL-0301)

| Parameter, n (%)                                                                           | Gilteritinib 120 mg (n = 247)   | Chemotherapy (n = 124)   |
|--------------------------------------------------------------------------------------------|---------------------------------|--------------------------|
| Best overall responseâ                                                                      |                                 |                          |
| Complete remission (CR) 95%CI                                                              | 52 (21.1) (16.1, 26.7)          | 13 (10.5) (5.7, 17.3)    |
| Complete remission with incomplete platelet recovery (CRp)                                 | 19 (7.7)                        | 0                        |
| Complete remission with incomplete hematological recovery (CRi)                            | 63 (25.5)                       | 14 (11.3)                |
| Partial remission (PR)                                                                     | 33 (13.4)                       | 5 (4.0)                  |
| No response (NR)                                                                           | 66 (26.7)                       | 43 (34.7)                |
| Not evaluable                                                                              | 14 (5.7)                        | 49 (39.5)                |
| Composite complete remission (CRc)â¡                                                        | 134 (54.3)                      | 27 (21.8)                |
| Complete remission with partial hematologic recovery (CRh) 95%CI                           | 32 (13.0) (9.0, 17.8)           | 6 (4.8) (1.8, 10.2)      |
| Complete remission and complete remission with partial hematologic recovery (CR/CRh) 95%CI | 84 (34.0) (28.1, 40.3)          | 19 (15.3) (9.5, 22.9)    |

<div style=\"page-break-after: always\"></div>

| Parameter, n (%)       | Gilteritinib 120 mg (n = 247)   | Chemotherapy (n = 124)   |
|------------------------|---------------------------------|--------------------------|
| Overall response rateÂ§ | 167 (67.6)                      | 32 (25.8)                |

## Â· Response rates by dose

In the gilteritinib 120 mg arm, 78 patients had a dose increase to 200 mg from 120 mg. Among those patient with a dose increase, 12 patients (15.4%) experienced CR/CRh after the dose adjustment. Fiftyeight patients had a dose decrease from 120 mg to 80 mg. Among the gilteritinib patients with a dose decrease, 24 patients (41.4%) achieved CR/CRh after the dose adjustment.

## Â· Event free survival (EFS) (Key secondary)

## Table 34 Event-free Survival -ITT (Study 2215-CL-0301)

| Parameter Category/Statistics                                         | Gilteritinib 120 mg (n = 247)    | Chemotherapy (n = 124)   |
|-----------------------------------------------------------------------|----------------------------------|--------------------------|
| EFS Events, n (%) â                                                    | 189 (76.5)                       | 62 (50.0)                |
| Relapse                                                               | 75 (30.4)                        | 1 (0.8)                  |
| Treatment failure                                                     | 97 (39.3)                        | 48 (38.7)                |
| Death                                                                 | 17 (6.9)                         | 13 (10.5)                |
| Censored events                                                       | 58 (23.5)                        | 62 (50.0)                |
| Duration of EFS, Months â¡                                             |                                  |                          |
| Q1 (95% CI)                                                           | < 0.1 (NE, NE)                   | < 0.1 (NE, NE)           |
| Median (95% CI)                                                       | 2.8 (1.4, 3.7)                   | 0.7 (0.2, NE)            |
| Q3 (95% CI)                                                           | 8.3 (6.5, 12.1)                  | NE (3.4, NE)             |
| RangeÂ§                                                                | < 0.1, 31.2+                     | < 0.1, 6.6+              |
| Stratified Analysis (Primary) Â¶                                       |                                  |                          |
| Log-rank test (primary) (P-value [1-sided P-value])                   | 0.0830 [1-sided P-value: 0.0415] |                          |
| Wald test: P-value                                                    | 0.1521                           |                          |
| HR (95% CI)â â                                                          | 0.793 (0.577, 1.089)             |                          |
| Table continued on next page                                          |                                  |                          |
| Unstratified Analysis                                                 |                                  |                          |
| Log-rank test (P-value)                                               | 0.1364                           |                          |
| Wald test: P-value                                                    | 0.2287                           |                          |
| HR (95% CI)â â                                                          | 0.825 (0.604, 1.128)             |                          |
| EFS Rate %(95% CI) â¡â¡                                                 |                                  |                          |
| 6 months                                                              | 33.2 (27.2, 39.3)                | 27.1 (8.2, 50.6)         |
| 12 months                                                             | 19.8 (14.6, 25.7)                | NE (NE, NE)              |
| 24 months                                                             | 12.2 (6.7, 19.6)                 | NE (NE, NE)              |
| 36 months                                                             | NE (NE, NE)                      | NE (NE, NE)              |
| EFS Using the Long-term Follow-up Data of Death and New AML Therapies |                                  |                          |
| EFS Events, n (%) Â§Â§                                                  | 207 (83.8)                       | 111 (89.5)               |
| Relapse                                                               | 75 (30.4)                        | 1 (0.8)                  |
| Relapse-off treatment                                                 | 6 (2.4)                          | 8 (6.5)                  |
| New AML therapy                                                       | 3 (1.2)                          | 26 (21.0)                |
| Treatment failure                                                     | 97 (39.3)                        | 48 (38.7)                |
| Death                                                                 | 26 (10.5)                        | 28 (22.6)                |
| Censored events                                                       | 40 (16.2)                        | 13 (10.5)                |
| Duration of EFS, Months â¡                                             |                                  |                          |
| Q1 (95% CI)                                                           | < 0.1 (NE, NE)                   | < 0.1 (NE, NE)           |
| Median (95% CI)                                                       | 2.3 (1.4, 3.6)                   | 0.7 (0.1, 1.3)           |
| Q3 (95% CI)                                                           | 7.4 (5.7, 10.0)                  | 2.0 (1.7, 2.6)           |
| RangeÂ§                                                                | < 0.1, 31.2+                     | < 0.1, 10.0              |

<div style=\"page-break-after: always\"></div>

| Parameter Category/Statistics                       | Gilteritinib 120 mg (n = 247)        | Chemotherapy (n = 124)          |
|-----------------------------------------------------|--------------------------------------|---------------------------------|
| Stratified Analysis (Primary) Â¶                     | Stratified Analysis (Primary) Â¶      | Stratified Analysis (Primary) Â¶ |
| Log-rank test (primary) (P-value [1-sided P-value]) | < 0.0001 (1-sided P-value: < 0.0001) |                                 |
| Wald test: P-valueâ â                                 | < 0.0001                             |                                 |
| HR (95% CI)â â                                        | 0.499 (0.387, 0.643)                 |                                 |
| Unstratified Analysis                               | Unstratified Analysis                | Unstratified Analysis           |
| Log-rank test (P-value)                             | < 0.0001                             |                                 |
| Wald test: P-valueâ â                                 | < 0.0001                             |                                 |
| HR (95% CI)â â                                        | 0.508 (0.397, 0.651)                 |                                 |
| EFS Rate %(95% CI) â¡â¡                               | EFS Rate %(95% CI) â¡â¡                | EFS Rate %(95% CI) â¡â¡           |
| 6 months                                            | 30.5 (24.8, 36.3)                    | 5.8 (2.2, 11.8)                 |
| 12 months                                           | 16.3 (11.7, 21.5)                    | 0 (NE, NE)                      |
| 24 months                                           | 9.4 (5.0, 15.5)                      | 0 (NE, NE)                      |
| 36 months                                           | NE (NE, NE)                          | 0 (NE, NE)                      |

percentages were calculated based on the total number of patients with nonmissing event/censored value.

â Patients were summarized under the categories that occurred first.  If treatment failure and death occurred on the same day, patients were summarized under death; â¡Based on Kaplan-Meier estimates; Â§A '+' indicates censoring; Â¶Stratification factors were response to  first-line  AML  therapy  and  preselected  salvage  chemotherapy  per  interactive  response  technology;  â â Based  on  the  Cox proportional hazards model.  Assuming proportional hazards, an HR of &lt; 1 indicates a reduction in the hazard rate in favor of the gilteritinib arm;â¡â¡EFS rate and 95% CI were estimated using the Kaplan-Meier method and the Greenwood formula; Â§Â§Patients were summarized under the event categories that occurred first.  If treatment failure and death occurred on the same day, patients were summarized under death.

Figure 7 Kaplan-Meier Plot of EFS by Treatment Arm ITT (Study 2215-CL-0301)

<!-- image -->

- Other secondary endpoints: Duration of response

In the ITT population the median (95% CI) duration of CR was 14.8 (11.0, NE) months in the gilteritinib arm and 1.8 (NE, NE) in the salvage chemotherapy arm (Log-Rank test P-value = 0.1189). Results were similar  in  the  analysis  of  duration  of  CR/CRh  (median  of  11  vs  1.8  months,  respectively)  (data  not shown).

- Transplantation rate

<div style=\"page-break-after: always\"></div>

The transplantation rate was 25.5% (63/247) in the gilteritinib arm and 15.3% (19/124) in the salvage chemotherapy arm. The treatment difference in transplantation rate between the gilteritinib and salvage chemotherapy arms was 10.2% (95% CI: 1.2, 19.1, p=0.0333).

Table 35 Summary of transplantation rate post randomization (ITT) (Study 2215-CL-0301)

| Parameter Category/Statistics                                        | Gilteritinib (n = 247)   | Chemotherapy (n = 124)   |
|----------------------------------------------------------------------|--------------------------|--------------------------|
| Transplantation Rate, n (%) [95 % CI]t                               | 63 (25.5) [20.2, 31.4]   | 19 (15.3) [9.5, 22.9]    |
| Treatment difference % [95% Exact CI]t Unstratified 2-sided P-values | 10.2 [1.2, 19.1] 0.0333  | 10.2 [1.2, 19.1] 0.0333  |

Table 36 Best Overall Response Prior to HSCT (Study 2215-CL-0301)

| BOR, n (%)   | Gilteritinib (N = 63)   | Chemotherapy (N = 19)   |
|--------------|-------------------------|-------------------------|
| CRc          | 40 (63.5)               | 11 (57.9)               |
| PR           | 14 (22.2)               | 1 (5.3)                 |
| NR or NE     | 9 (14.3)                | 7 (36.8)                |

BOR: best overall response; CRc: composite complete remission; HSCT: hematopoietic stem cell transplant; NE: not evaluable; NR: no response; PR: partial response. Source: Adhoc Table D60RAPP.OC.36.

## Â· Leukaemia free survival

Leukaemia free survival was only applicable to patients with a best response of CRc (gilteritinib 134/247 vs salvage chemotherapy 27/124). The gilteritinib arm had a median LFS (95%CI) of 4.4 months (3.6, 5.2).

- Transfusion conversion rate; transfusion maintenance rate

Among the 197 patients who were dependent on RBC and/or platelet transfusions at baseline, 68 became independent of RBC and platelet transfusions during any 56-day postbaseline period; the transfusion conversion rate was 34.5% (95% CI: 27.9, 41.6) ].  For the 49 patients who were independent of both RBC and platelet transfusions at baseline, 29  remained transfusion-independent during any 56-day postbaseline period; the transfusion maintenance rate was 59.2% (95% CI: 44.2, 73.0).

Table 37 Shift Table of Transfusion Status (ITT) (Study 2215-CL-0301)

| Baseline Transfusion Status   | Postbaseline Transfusion Status n = 246 n (%)   | Postbaseline Transfusion Status n = 246 n (%)   | Postbaseline Transfusion Status n = 246 n (%)   |
|-------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                               | Independent                                     | Dependent                                       | Not Evaluable                                   |
| Independent (n = 49)          | 29 (59.2)                                       | 12 (24.5)                                       | 8 (16.3)                                        |
| Dependent (n = 197)           | 68 (34.5)                                       | 110 (55.8)                                      | 19 (9.6)                                        |

## Â· Subsequent AML therapies

Overall in the ITT population, 114 (46.2%) subjects in the gilteritinib arm and 76 (61.3%) subjects in the  salvage  chemotherapy arm received subsequent AML therapy during the  follow-up period, after discontinuation of the study drug. For 143 (75.3%) of the patients subsequent AML therapy regimes were not specified but recorded as Â«OtherÂ».

<div style=\"page-break-after: always\"></div>

- Exploratory endpoints: Patient reported outcomes (PRO)

The change from baseline in BFI fatigue score, FACIT-Dys-SF and functional limitations subscales scores, FACT-Leu total score and dizziness and mouth sore subscales scores for cycle 2, day 1 were similar in the gilteritinib arm compared with the salvage chemotherapy arm. The median EQ-5D-5L VAS change from baseline score was 0 for the gilteritinib arm and -3.0 for the salvage chemotherapy arm at cycle 2, day 1. The median utility change from baseline score was 0 for the gilteritinib arm and 0.1 for the salvage chemotherapy arm at cycle 2, day 1. For each of the 5 EQ-5D-5L dimension scores, the majority of patients in both treatment arms reported no problem (score of 1) at baseline and at cycle 2, day 1.

## Ancillary analyses

## Sensitivity analysis of OS

Median OS was also longer in the gilteritinib arm compared with the salvage chemotherapy arm for the sensitivity analyses conducted using the FAS (HR= 0.637; 95% CI:0.488, 0.830, p= 0.0008) and by censoring patients at the time of new antileukemia therapy (HR= 0.447: 95% CI 0.312, 0.639, p&lt; 0.0001). The PPS sensitivity analysis the showed a HR of 0.841 (95% CI: 0.600, 1.180, p=0.1577) with a median OS of 10.3 months for gilteritinib and 7.8 months for salvage chemotherapy.

Resampling and tipping-point analysis for early censored vs non-censored patients

Based on 10,000 resampled datasets, the mean HR estimate was 0.638 (95% CI: 0.605, 0.679) for the analysis covering the first 8 weeks and 0.635 (95% CI: 0.591, 0.687), for the analysis covering the first 6 months. The rejection of the null hypothesis was 100% for both scenarios.

Table 38 Bootstrapping resampling results (based on 10,000 simulation)

|          | Estimated HR      | Estimated HR   | Estimated HR       | Median P-   |                        |
|----------|-------------------|----------------|--------------------|-------------|------------------------|
| Scenario | 2.5 th Percentile | Mean           | 97.5 th Percentile | value       | Rejection Probabilityâ  |
| EC8      | 0.605             | 0.638          | 0.679              | 0.0006      | 100%                   |
| EC6M     | 0.591             | 0.635          | 0.687              | 0.0004      | 100%                   |

## Table 39 Tipping point analysis based on multiple imputation of early censored patients (EC8) - probability of rejecting the null hypothesis

| Ï´ for Chemo Arm   |   Ï´ for Gilteritinib Arm |   Ï´ for Gilteritinib Arm |   Ï´ for Gilteritinib Arm |
|-------------------|--------------------------|--------------------------|--------------------------|
|                   |                        1 |                        2 |                        3 |
| 3                 |                        1 |                        1 |                        1 |
| 2                 |                        1 |                        1 |                        1 |
| 1                 |                        1 |                        1 |                        1 |
| 0.9               |                        1 |                        1 |                        1 |
| 0.8               |                        1 |                        1 |                        1 |
| 0.7               |                        1 |                        1 |                        1 |
| 0.6               |                        1 |                        1 |                        1 |
| 0.5               |                        1 |                        1 |                        1 |
| 0.4               |                        1 |                        1 |                        1 |
| 0.3               |                        1 |                        1 |                        1 |

Note: Ï´ is the hazard ratio of overall survival of EC8 vs non-EC8 (non-early censored) patients, EC8: early censored patients within 8 weeks.

Updated OS analyses including data for previous administrative censoring

An update of the primary OS analysis based on a new data cut off 17 May 2019 was provided. The analysis included no new survival information on the early censored subjects, but several of the

<div style=\"page-break-after: always\"></div>

previous administrative censorings had been updated, including 19 and 3 additional deaths in the gilteritinib and chemotherapy arms respectively. Results of the new OS analysis were consistent with the primary analysis (data cut of 17 Sep 2018). Median OS 9.3 and 5.4 months respectively in the gilteritinib and chemotherapy arms, HR: 0.683, 1-sided p= 0.0016 (data not shown).

OS in patients receiving HSCT

Figure 8  KM Plot of OS in Patients Receiving HSCT During Study 2215-CL-0301 in the Gilteritinib and Chemotherapy Arms -Overall -ITT, data cut-off 17-05-2019 (Study 2215CL-0301)

<!-- image -->

The majority of patients continued gilteritinib post-HSCT (40/63, 63%). A total of 14 patients did not fulfil the criteria for re-initiation of gilteritinib (including the 8 patients receiving HSCT off-study) and in 9 patients the reason for not reintroducing gilteritinib was not known.

<div style=\"page-break-after: always\"></div>

Subgroup analysis OS

Table 40 Subgroup Analysis of Overall Survival -ITT (Study 2215-CL-0301)

| Parameter Category/ Statistics                    | Gilteritinib 120 mg                               | Chemotherapy                                      | Hazard Ratioâ¡                                     | P-valueÂ§                                          |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Overall Survival, events/N (%), [Median Months] â  | Overall Survival, events/N (%), [Median Months] â  | Overall Survival, events/N (%), [Median Months] â  | Overall Survival, events/N (%), [Median Months] â  | Overall Survival, events/N (%), [Median Months] â  |
| Age                                               |                                                   |                                                   |                                                   |                                                   |
| < 65 years                                        | 91/141 (64.5) [10.8]                              | 52/75 (69.3) [6.5]                                | 0.610 (0.432, 0.863)                              | 0.0049                                            |
| â¥ 65 years                                        | 80/106 (75.5) [7.2]                               | 38/49 (77.6) [5.1]                                | 0.643 (0.436, 0.948)                              | 0.0249                                            |
| Sex                                               |                                                   |                                                   |                                                   |                                                   |
| Male                                              | 86/116 (74.1) [8.0]                               | 40/54 (74.1) [6.1]                                | 0.717 (0.491, 1.048)                              | 0.0849                                            |
| Female                                            | 85/131 (64.9) [10.8]                              | 50/70 (71.4) [5.5]                                | 0.573 (0.402, 0.816)                              | 0.0018                                            |
| Race                                              |                                                   |                                                   |                                                   |                                                   |
| White                                             | 102/145 (70.3) [7.9]                              | 56/75 (74.7) [5.5]                                | 0.723 (0.520, 1.005)                              | 0.0526                                            |
| Black or African American                         | 13/14 (92.9) [9.6]                                | 6/7 (85.7) [7.4]                                  | 0.538 (0.178, 1.627)                              | 0.2649                                            |
| Asian                                             | 42/69 (60.9) [11.0]                               | 20/33 (60.6) [6.5]                                | 0.342 (0.195, 0.602)                              | <0.0001                                           |
| Other/Missing                                     | 14/19 (73.7) [8.3]                                | 8/9 (88.9) [5.5]                                  | 0.872 (0.359, 2.121)                              | 0.7631                                            |
| Baseline ECOG                                     |                                                   |                                                   |                                                   |                                                   |
| 0-1                                               | 138/206 (67.0) [9.6]                              | 78/105 (74.3) [5.6]                               | 0.595 (0.449, 0.788)                              | 0.0003                                            |
| â¥ 2                                               | 33/41 (80.5) [6.4]                                | 12/19 (63.2) [6.1]                                | 0.868 (0.446, 1.690)                              | 0.6761                                            |
| Region                                            |                                                   |                                                   |                                                   |                                                   |
| North America                                     | 88/114 (77.2) [8.9]                               | 42/52 (80.8) [6.2]                                | 0.722 (0.497, 1.050)                              | 0.0889                                            |
| Europe (including Turkey and Israel)              | 43/68 (63.2) [7.7]                                | 32/43 (74.4) [5.5]                                | 0.674 (0.426, 1.066)                              | 0.0894                                            |
| Asia                                              | 40/65 (61.5) [10.8]                               | 16/29 (55.2) [5.6]                                | 0.378 (0.206, 0.693)                              | 0.0011                                            |
| FLT3 Mutation Type by Central Testing by FLT3 CDx | FLT3 Mutation Type by Central Testing by FLT3 CDx | FLT3 Mutation Type by Central Testing by FLT3 CDx | FLT3 Mutation Type by Central Testing by FLT3 CDx | FLT3 Mutation Type by Central Testing by FLT3 CDx |
| FLT3-ITD alone                                    | 145/215 (67.4) [9.3]                              | 81/113 (71.7) [5.6]                               | 0.623 (0.473, 0.820)                              | 0.0007                                            |
| FLT3-TKD alone                                    | 16/21 (76.2) [8.0]                                | 8/10 (80.0) [5.7]                                 | 0.693 (0.293, 1.643)                              | 0.4029                                            |
| FLT3-ITD and FLT3-TKD                             | 6/7 (85.7) [10.2]                                 | 0                                                 | NE                                                | NE                                                |
| Others (negative/missing/unknown)                 | 4/4 (100) [10.0]                                  | 1/1 (100) [7.6]                                   | 0.702 (0.062, 7.918)                              | 0.7741                                            |

<div style=\"page-break-after: always\"></div>

| Prior use of FLT3 inhibitor                   | Prior use of FLT3 inhibitor              | Prior use of FLT3 inhibitor              | Prior use of FLT3 inhibitor              | Prior use of FLT3 inhibitor              |
|-----------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Yes                                           | 26/32 (81.3) [6.5]                       | 11/14 (78.6) [4.7]                       | 0.705 (0.346, 1.438)                     | 0.3293                                   |
| No                                            | 145/215 (67.4) [9.6]                     | 79/110 (71.8) [6.0]                      | 0.620 (0.470, 0.818)                     | 0.0007                                   |
| Cytogenetic Risk Status                       | Cytogenetic Risk Status                  | Cytogenetic Risk Status                  | Cytogenetic Risk Status                  | Cytogenetic Risk Status                  |
| Favorable                                     | 3/4 (75.0) [6.9]                         | 1/1 [100) [4.6]                          | 0.702 (0.062, 7.918)                     | 0.7741                                   |
| Intermediate                                  | 119/182 (65.4) [10.2]                    | 63/89 (70.8) [6.1]                       | 0.605 (0.444, 0.824)                     | 0.0013                                   |
| Unfavorable                                   | 22/26 (84.6) [6.7]                       | 7/11 (63.6) [9.4]                        | 1.630 (0.690, 3.848)                     | 0.2585                                   |
| Other                                         | 27/35 (77.1) [8.3]                       | 19/23 (82.6) [3.4]                       | 0.462 (0.254, 0.843)                     | 0.0102                                   |
| Response to First-line Therapy (per IRT)      | Response to First-line Therapy (per IRT) | Response to First-line Therapy (per IRT) | Response to First-line Therapy (per IRT) | Response to First-line Therapy (per IRT) |
| Relapse within 6 months after allogenic HSCT  | 24/31 (77.4) [6.1]                       | 16/17 (94.1) [3.4]                       | 0.382 (0.195, 0.747)                     | 0.0036                                   |
| Relapse after 6 months after allogenic HSCT   | 10/17 (58.8) [10.1]                      | 4/8 (50.0) [11.3]                        | 0.860 (0.264, 2.803)                     | 0.7930                                   |
| Primary refractory without HSCT               | 70/98 (71.4) [10.3]                      | 28/48 (58.3) [6.9]                       | 0.990 (0.632, 1.550)                     | 0.9711                                   |
| Relapse within 6 months after CRc and no HSCT | 47/67 (70.1) [8.6]                       | 28/34 (82.4) [5.2]                       | 0.492 (0.304, 0.795)                     | 0.0031                                   |
| Relapse after 6 months after CRc and no HSCT  | 20/34 (58.8) [10.5]                      | 14/17 (82.4) [6.1]                       | 0.492 (0.247, 0.978)                     | 0.0402                                   |
| Preselected Chemotherapy (per IRT)            | Preselected Chemotherapy (per IRT)       | Preselected Chemotherapy (per IRT)       | Preselected Chemotherapy (per IRT)       | Preselected Chemotherapy (per IRT)       |
| High intensity                                | 96/149 (64.4) [10.5]                     | 52/75 (69.3) [6.9]                       | 0.663 (0.471, 0.932)                     | 0.0177                                   |
| Low intensity                                 | 75/98 (76.5) [6.4]                       | 38/49 (77.6) [4.7]                       | 0.563 (0.378, 0.839)                     | 0.0043                                   |

â Based on Kaplan-Meier estimates; â¡In each subgroup, the HR was estimated using unstratified Cox proportional hazards model. Assuming proportional hazards, an HR &lt;1 indicates a reduction in hazard rate in favor of gilteritinib arm; Â§Based on log-rank test.

## OS in patients with primary refractory disease

Figure 9 Kaplan-Meier Plot of Overall Survival -in Month Scale by Response to First-Line Therapy per IRT- data cut-off 17-05-2019 (Study 2215-CL-0301)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## FLT3 TKD mutations

In the gilteritinib arm, median OS was 8.0 months (95% confidence interval [CI]: 3.5, 11.1) in the FLT3-TKD alone subgroup versus 9.5 months (95% CI: 7.7, 10.7) in the FLT3-ITD subgroup.  Survival probability at 6 months was 56.4% (95% CI: 32.8, 74.5) in the FLT3-TKD alone subgroup and 66.2% (95% CI: 59.5, 72.1) in the FLT3-ITD subgroup.

## FLT3 ITD allelic ratio

Exploratory analysis based on different FLT-3 ITD allelic ratio cut-off levels have been provided, based on 335 patients that tested positive for FLT3 -ITD before inclusion in the study 2215-CL-0301.

Table 41 Overall Survival by FLT3 Signal Ratio Group -Full Analysis Set (Study 2215-CL0301)

| Parameter Category/ Statistics   | N   | Gilteritinib 120 mg (N = 222), n (%)   | MedianDuration of Overall Survival, Monthst   | N   | Chemotherapy (N = 113), n (%)   | Median Duration of OverallSurvival Monthst   | Hazard Ratio(95%Log-RankTest(P- CI)t   | value)   |
|----------------------------------|-----|----------------------------------------|-----------------------------------------------|-----|---------------------------------|----------------------------------------------|----------------------------------------|----------|
| FLT3SignalRatio                  |     |                                        |                                               |     |                                 |                                              |                                        |          |
| ITD (with or without TKD) <0.77  | 113 | 72 (63.7)                              | 10.6                                          | 53  | 35 (66.0)                       | 6.9                                          | 0.795 (0.526, 1.200)                   | 0.2719   |
| ITD (with or without TKD) â¥0.77  | 109 | 79 (72.5)                              | 7.1                                           | 60  | 46 (76.7)                       | 4.3                                          | 0.492 (0.339, 0.714)                   | 0.0001   |

P-values are based on an unstratified, 2-sided log-rank test.

CI: confidence interval; FLT3: FMS-like tyrosine kinase 3; IDT: internal tandem duplication; TKD: tyrosine kinase domain.

Based onKaplan-Meier estimates.

Based on an unstratified Cox proportional hazards model. Assuming proportional hazards, a hazardratio of&lt; 1 indicates a reduction in the hazard rate in favor of the treatment arm.

## Â· Multigene Analysis

The screening samples from FLT3 mutation assessment or disease assessment were evaluated by a multigene AML mutation panel to assess the relationship of efficacy of gilteritinib and mutational status of AML-related genes. Four mutational subgroups were identified where a mutation was detected in at least 10% of patients in the multigene analysis set (MAS). These were DNMT3A (31.9%, 115/361), NPM1 (47.9%, 173/361)), WT1 (18%, 65/361)), co-occurring DNMT3A and NPM1 mutations (23.8% 86/361)) and  AXL  positive  blasts  (16%).  This  was  as  expected  based  on  the  reported  prevalence  of  these mutations in patients with FLT3 mutation positive AML (Garg et al. (13)).

The median (95% CI) OS for patients with DNMT3A mutation in the gilteritinib arm was 9.1 (6.3, 11.1) and 5.5 (3.7, 7.4) in the chemotherapy compared to 9.0 (7.1, 10.7) and 5.6 (4.3, 7.5) respectively, in the population without DNMT3A mutation.

The median (95% CI) OS for patients with NPM1 mutation in the gilteritinib arm was 8.3 (6.1, 11.0) and 5.1 (3.4, 6.1) in the chemotherapy arm compared to 9.6 (7.7, 10.8) and 7.1 (4.7, 10.0) respectively, in the population without NPM1 mutation.

For WT1 mutation positive patients the median OS (95% CI) was 9.1 (6.6, 14.7) in the gilteritinib arm and 3.4 (1.9, 5.2) in the chemotherapy compared to 9.0 (7.1, 10.7) and 6.3 (5.2, 7.6) respectively, in the population without WT1 mutation.

The median AXL positive blasts as a percent of the total blast population was 16%. The median OS (95% CI) of gilteritinib-treated patients with greater than or equal to the median AXL positive blast percent

<div style=\"page-break-after: always\"></div>

(AXL high) was 10.7 (8.7, 12.5) compared to 8.0 (6.1, 10.4) in the gilteritinib- treated with less than the median AXL positive blast percent (AXL low). Median OS in AXL high and AXL low chemotherapytreated patients was 6.3 (3.5, 8.0) and 6.1 (4.3, 8.9) respectively.

## Summary of main study

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy (see later sections).

## Table 42 Summary of Efficacy for trial 2215-CL-0301

| Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation   | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation   | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation                                                                                                                              | Title : A Phase 3 Open-label, multicenter, randomized study of Gilteritinib fumarate (ASP 2215) versus salvage chemotherapy in patients with R/R AML with FLT3 mutation   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2215-CL-0301, EudraCT 2015-000140-42                                                                                                                                      | Hypothesis Superiority                                                                                                                                                    | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                    |
| CR                                                                                                                                                                        | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                        | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                                                                                                                                                   | Number of patients who achieved CR at any of the post baseline visits divided by the number of patients in the analysis population                                        |
| CR                                                                                                                                                                        | Event survival (EFS)                                                                                                                                                      | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] | free The time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] |                                                                                                                                                                           |
| Other secondary Transplanta tion rate Defined as the percentage of patients undergoing HSCT postrandomization                                                             |                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                            | Transplantation rate n/N(%)63 (25.5)                                                                                                                                                                                                                                                                                                                                                                  | Transplantation rate n/N(%)63 (25.5)                                                                                                                                                                                                                                                                                                                                                                  | 19 (15.3)                                                                                                                                                                                                                                                                                                                                                                                             |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                | 20.2, 31.4                                                                                                                                                                                                                                                                                                                                                                                            | 9.5, 22.9                                                                                                                                                                                                                                                                                                                                                                                             |
| Effect estimate comparison | per Primary OS                                                                                                                                                                                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                     | Gilteritinib vs chemotherapy                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate comparison | per Primary OS                                                                                                                                                                                                                                                                                                                                                                                        | HR                                                                                                                                                                                                                                                                                                                                                                                                    | 0.637                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate comparison | per Primary OS                                                                                                                                                                                                                                                                                                                                                                                        | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                | (0.490, 0.830)                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate comparison | per Primary OS                                                                                                                                                                                                                                                                                                                                                                                        | Stratified 1- sided P- value                                                                                                                                                                                                                                                                                                                                                                          | 0.0004                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate comparison | Key secondary CR                                                                                                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                     | Gilteritinib vs chemotherapy                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate comparison | Key secondary CR                                                                                                                                                                                                                                                                                                                                                                                      | Adjusted Treatment Difference%                                                                                                                                                                                                                                                                                                                                                                        | 10.6                                                                                                                                                                                                                                                                                                                                                                                                  |
| Effect estimate comparison | Key secondary CR                                                                                                                                                                                                                                                                                                                                                                                      | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                | (2.8, 18.4)                                                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate comparison | Key secondary EFS                                                                                                                                                                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                     | Gilteritinib vs chemotherapy                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate comparison | Key secondary EFS                                                                                                                                                                                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                                                                                                                                                                                                    | HR 0.793                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate comparison | Key secondary EFS                                                                                                                                                                                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                | (0.577, 1.089)                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate comparison | Key secondary EFS                                                                                                                                                                                                                                                                                                                                                                                     | Stratified 1 sided P- value                                                                                                                                                                                                                                                                                                                                                                           | 0.0415                                                                                                                                                                                                                                                                                                                                                                                                |
|                            | Other secondary Transplantation rate                                                                                                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                     | Gilteritinib vs chemotherapy                                                                                                                                                                                                                                                                                                                                                                          |
|                            | Other secondary Transplantation rate                                                                                                                                                                                                                                                                                                                                                                  | Adjusted treatment difference%                                                                                                                                                                                                                                                                                                                                                                        | 10.2                                                                                                                                                                                                                                                                                                                                                                                                  |
|                            | Other secondary Transplantation rate                                                                                                                                                                                                                                                                                                                                                                  | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                | (1.2, 19.1)                                                                                                                                                                                                                                                                                                                                                                                           |
| Notes                      | Stratification factors were response to first-line AML therapy (relapse within 6 months after allogeneic HSCT vs relapse after 6 months after allogeneic HSCT vs primary refractory without HSCT vs relapse within 6 months after CRc and no HSCT vs relapse after 6 months after CRc and no HSCT) and preselected salvage chemotherapy per IRT -high intensity chemotherapy [FLAG-IDA or MEC] vs low | Stratification factors were response to first-line AML therapy (relapse within 6 months after allogeneic HSCT vs relapse after 6 months after allogeneic HSCT vs primary refractory without HSCT vs relapse within 6 months after CRc and no HSCT vs relapse after 6 months after CRc and no HSCT) and preselected salvage chemotherapy per IRT -high intensity chemotherapy [FLAG-IDA or MEC] vs low | Stratification factors were response to first-line AML therapy (relapse within 6 months after allogeneic HSCT vs relapse after 6 months after allogeneic HSCT vs primary refractory without HSCT vs relapse within 6 months after CRc and no HSCT vs relapse after 6 months after CRc and no HSCT) and preselected salvage chemotherapy per IRT -high intensity chemotherapy [FLAG-IDA or MEC] vs low |

## Clinical studies in special populations

Table 43. Elderly Patients in Study 2215-CL-0301 and Study 2215-CL-0101 -Full Analysis Set

|                      | Age 65-74 (Older patients number /total number)   | Age 65-74 (Older patients number /total number)   | Age 75-84 (Older patients number /total number)   | Age 75-84 (Older patients number /total number)   | Age 85+ (Older patients number /total number)   | Age 85+ (Older patients number /total number)   |
|----------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Controlled Trial     | Gilteritinib 78/247 (31.6%)                       | Chemotherapy 34/124 (27.4%)                       | Gilteritinib 28/247 (11.3%)                       | Chemotherapy 14/124 (11.3%)                       | Gilteritinib 0                                  | Chemotherapy 1/124 (0.3%)                       |
|                      | Gilteritinib                                      | Gilteritinib                                      | Gilteritinib                                      | Gilteritinib                                      | Gilteritinib                                    | Gilteritinib                                    |
| Non Controlled Trial | Escalation Phase 0/2                              | Expansion Phase 10/54 (18.5%)                     | Escalation Phase 0/2                              | Expansion Phase 7/54 (13.0%)                      | Escalation Phase 0/2                            | Expansion Phase 1/54 (1.9%)                     |

## Supportive studies

Studies 2215-CL-0101 and 2215-CL-0102 are described under section ''Dose response study'' .

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The main evidence of efficacy comes from a single pivotal phase III multicenter randomised, open-label study comparing gilteritinib monotherapy (n=247) vs. salvage chemotherapy (n=124) in patients with FLT3 positive AML refractory to or relapsed after first-line treatment with or without HSCT consolidation. The overall design of the study is considered adequate to demonstrate the clinical benefit of gilteritinib 120 mg daily over salvage chemotherapy in R/R AML patients with one prior line of AML therapy.

<div style=\"page-break-after: always\"></div>

The open label design is considered acceptable, due to the differences in the mode of administrations of gilteritinib and the different chemotherapy regimens.

As per study design, patients in the high intensity chemotherapy group (60%, treated for 1-2 cycles) reached the long-term follow-up part (with no protocol required bone marrow or clinical and laboratory assessments) several months earlier than patients in the gilteritinib arm, who were treated until lack of clinical benefit. These differences both in frequency and type of follow-up lead to a lack of systematic documentation of response/relapse status beyond 1-2 months post randomisation in the high intensity chemotherapy group.

The sponsor modified response criteria are less stringent than the 2003 International Working Group (IWG) criteria i.e. the IWG criteria lack the CRp definition and are more stringent in the definition of CRi, allowing for either incomplete neutrophil or platelet recovery (not both) with requirement of platelet and red blood cell transfusion independence. A responder analysis using the IWG (2003) criteria showed a reduction of the CRi rate, and thus a substantial decrease in the CRc rate in both treatment arms (54% to 35% for gilteritinib vs 22% to 13% for chemotherapy). Based on these data, it is not clear that the modified criteria are better suited to capture the efficacy of gilteritinib. Nevertheless, the SmPC includes only the CR and CRh rates, and these have been adequately defined in section 5.1, which is considered acceptable.

The inclusion and exclusion criteria are considered adequate to enrol a heterogeneous population with R/R FLT3-ITD (+) AML. The inclusion of patients with ECOG PS â¤ 2, patients not eligible for standard first-line therapy, and patients with both short and long duration of CRc following 1st line treatment is supported, as it improves the external validity of the results.

Patients could be defined as refractory after receiving only 1 cycle of induction therapy. This deviates from standard of care (ELN guidelines) which recommends 2 cycles. The majority of patients classified as primary refractory (90/146) had only received 1 cycle of high intensity chemotherapy; this is reflected in section 5.1 of the SmPC.

As would be expected, the number of patients with FLT3-TKD alone mutations was limited. There is no clear indication that the efficacy of gilteritinib in these patients would be substantially reduced since the OS benefit of gilteritinib over chemotherapy is comparable to that observed in patients with FLT ITD mutations, and the non-clinical data indicate that gilteritinib would be effective also in patients with TKD mutations.

There is no standard treatment for R/R AML, and the 4 chemotherapy regimens chosen for the active control arm (two high intensity regimens and tow low intensity regimen) are considered appropriate in the current R/R setting. Allocation of high vs low intensity chemotherapy was at the discretion of the investigator.  Despite  the  lack  of  pre-specified  criteria,  it  is  considered  that  the  pre-randomization assignment of patients and the stratification based on high vs low intensity therapy is sufficient to ensure trial validity and the balanced distribution of patients across treatments.

The starting dose of gilteritinib (120 mg) appears reasonably justified, although data are rather limited. Dose-escalation to 200 mg was allowed at the discretion of the investigator, in patients not achieving a response (CRc) following one treatment cycle. There is an uncertainty with regard to the benefit of the proposed dose escalation strategy in non-responding patients, as it cannot be determined whether the observed increased response rates is due to the increase in gilteritinib dose or the longer treatment duration. Never the less, the dose escalation strategy was a central part of the pivotal study design, (i.e. 31% (78/247) of the patients in the gilteritinib arm actually received the 200 mg dose/day), and the ITT analyses on which the B/R is established includes 78 patients that were dose escalated. Furthermore, there are no data that can reliable establish a lack of benefit for the proposed dose escalation strategy. Therefore, the option to dose escalate non-responding patients should be included in the SmPC.

<div style=\"page-break-after: always\"></div>

Supplemental data from the pivotal study confirms that a substantial proportion of patients will only respond after several treatment cycles; therefore, continuation of treatment at the prescribed dose for up to 6 months should be considered to allow time for a clinical response. (SmPC, section 4.2).

The co-primary efficacy endpoint of CR/CRh rate was evaluated at the first interim analysis only. For the second interim analysis and in the final analysis, OS was the primary endpoint and CR and EFS was defined  as  key  secondary  endpoints.  For  the  purpose  of  this  assessment,  the  final  OS  analysis  is considered the primary efficacy outcome measure, in line with the CHMP  scientific advice (EMEA/H/SA/3789/1/FU/4/2018/PA/II). The statistical methods are considered acceptable. The group sequential design with hierarchical testing is adequate to control the Type I error for the OS, EFS and CR rate endpoints. Adequate sensitivity and subgroup analyses has been planned and performed.

There were eight protocol amendments defined as substantial. None of these are expected to have substantively affected the overall interpretation of the results.  The number of protocol deviations was low, and there were no meaningful differences between treatment arms.

## Efficacy data and additional analyses

Patient and disease characteristics, including the stratification factors, were in general well balanced between treatment arms.

The primary endpoint (OS) in the ITT population showed a statistically significant increase in OS, with a HR of 0.637 (95% CI: 0.490- to 0.830, p=0.0004 one-sided log rank test) and a median OS of 9.3 months and 5.6 months in the qilteritinib and salvage chemotherapy arms, respectively.  An increase in median OS of 3.7 months is considered clinically relevant in this patient population with a rather poor prognosis. There was a difference in distribution of censored subjects between treatment arms, with more early censored observations occurring in the salvage chemotherapy (15/124) arm compared to the gilteritinib  arm  (6/247).  Most  of  these  censorings  were  informative. The Bootstrap  resampling'  and 'Tipping point analysis' using multiple imputation (Zhao, et al 2014) analysis confirmed the robustness of the OS results.

The results of the other pre-planned sensitivity analysis (including censoring at HSCT and at time of new antileukemia treatment) are generally consistent with the primary analysis. Patient who had received prior treatment with gilteritinib or other FLT3 inhibitors (with the exception of sorafenib and midostaurin used in first-line  therapy  regimen  as  part  of  induction,  consolidation  and/or maintenance)  were  not eligible. The proportion of patients with prior use of FLT3 inhibitors was small (12%). However, also in this subpopulation results were in favour of gilteritinib in terms of CR rate (18% vs 0%) and the HR for OS  0.705  (95%CI:  0.346,  1.438).  Thus,  exclusion  of  patients  with  prior  FLT3  inhibitors  from  the indication was not considered necessary.

Subgroup analyses showed a beneficial effect of gilteritinib over chemotherapy across several prognostic factors such as age, response category to first line therapy, AML risk score, and for patients eligible for low and high intensity treatment. In primary refractory patients the observed median OS benefit was not supported by the HR. However, this discrepancy could be explained by the crossing of survival curves at 15 months, making the HR estimate unreliable. Furthermore, the median OS benefit was supported by a consistent increase in response rates for gilteritinib vs chemotherapy, thus supporting a positive B/R also in this subpopulation.

The EFS endpoint did not meet the pre-specified criteria for statistical significance (HR= 0.93 95% CI 0.577, 1.089, p=0.0830 two-sided log rank test), although a trend towards an increased duration was observed (median 2.8 months vs 0.7 months for gilteritinib vs chemotherapy). The early steep drop in EFS is due to the definition of treatment failures in the analysis (fails to achieve any of the response of CR, CRp or CRi during the treatment) with the event date assigned to randomization date. Treatment

<div style=\"page-break-after: always\"></div>

failures assigned to randomisation date constitutes a high proportion (38-39%) of the total EFS events, and by month 3 there were only 108 vs 4 patients included in the number at risk for the chemotherapy and gilteritinib arms, respectively. The lack of long-term (beyond 2 months) systematic documentation of response and relapse status in the high intensity chemotherapy group, and the large proportion of patients  with  no  evaluable  post-baseline  response  assessments  in  the  salvage  chemotherapy  arm preclude relevant comparisons of response rates and response related time-to event endpoints between the treatment arms, and the benefit evaluation relies heavily on the OS data.

More patients in the gilteritinib arm compared to the salvage chemotherapy arm achieved a response to treatment, including 21.1% vs 10.5% obtaining a CR. A large proportion of patients in the salvage chemotherapy group had 'No evaluable post -baseline bone marrow assessment ' (39.5% vs 5.7% in the gilteritinib arm) of which the majority were randomized but not treated and patients treated without post baseline assessment. In the ITT population the median (95% CI) duration of CR was 14.8 (11.0, NE) months in the gilteritinib arm and 1.8 (NE, NE) in the salvage chemotherapy arm (Log-Rank test P-value = 0.1189). Results were similar in the analysis of duration of CR/CRh (median of 11 vs 1.8 months, respectively).

Similar to the EFS analysis, the limited follow-up of responses and high censoring rate in the salvage chemotherapy group precludes relevant comparisons of duration of response. In the gilteritinib arm, durable complete responses were achieved.

Transplantation  rate  was  higher  in  the  gilteritinib  arm  compared  to  the  salvage  chemotherapy  arm (25.5%  vs 15.3%,  unstratified p-value 0.033). Post-transplantation outcomes  were  generally comparable between treatment arms, with the majority of patients being in remission  (65% in  the gilteritinib arm vs 68% in the chemotherapy arm).  OS analyses based on the latest data cut off (17 May 2019) are still immature, but based on the KM curves, OS is comparable up to approximately 20 months after which the number of patients at risk is limited.

Due to the lack of re-randomization following HSCT, the benefit-risk profile of post-HSCT gilteritinib cannot be determined. However, as this was the overall treatment strategy for giteritinib and as there are  no  comparative  data  to  substantiate  long-term  benefit  in  patients  not  receiving  post-transplant treatment, the option to re-initiate gilteritinib following HSCT in is included in section 4.2 of the PI. The pivotal study included R/R AML patients previously treated with only 1 prior line of therapy and could therefore  not  support  the  wide  claimed  indication.  Data  from  the  supportive  study  (2215-CL-0101), including a total of 108 patients treated with &gt;1 previous therapy, indicate that responses, (CR and CRc) are achieved also for patients in later treatment lines, and the reported median OS generally exceeds that observed with chemotherapy both in the clinical pivotal study and in a historical dataset provided (Roboz  2014).  Furthermore,  there  is  no  clear  indication  from  the  PD  data  on  potential  resistance mechanisms, to suggest a reduced benefit of gilteritinib vs chemotherapy in later treatment lines. Also the safety data do not indicate any clinically meaningful differences with regards to number of prior treatment lines. Thus, although the magnitude of the clinical benefit of gilteritinib over chemotherapy in later treatment lines cannot be reliably established based on the presented naÃ¯ve, indirect treatment comparisons, taking into account the totality of the data, the B/R ratio of gilteritinib is considered positive also in patients with &gt; 1 prior treatments.

The OS and CR rates in the gilteritinib arm dose groups â¥ 80 mg observed in the dose escalation study are considered supportive for the results obtained in the gilteritinib arm in the pivotal efficacy study.

<div style=\"page-break-after: always\"></div>

## 2.5.4. Conclusions on the clinical efficacy

Study 2215-CL-0301 has provided convincing evidence of clinical efficacy of gilteritinib monotherapy in terms of the primary endpoint OS, compared to salvage chemotherapy, in adult patients who have R/R AML with a FLT3 mutation.   The  statistically  significant  improvement  of  3.7  months  in  the  primary endpoint of OS is considered clinically relevant in the intended target population with a poor prognosis and a high unmet medical need.

## 2.6. Clinical safety

The  safety  profile  for  gilteritinib  is  derived  from  studies  in  healthy  volunteers,  hepatic-impaired volunteers and patients with either NSCLC, solid tumours or AML. As of the data cut-off date of 17 September 2018, a total of 179 healthy subjects and 764 patients have received at least 1 dose of gilteritinib.

The  safety  of  gilteritinib  has  been  evaluated  in  18  clinical  studies  across  different  posology  and indications. The safety data within the R/R AML patient population have been pooled across 3 studies. The overall safety evaluation included the following safety populations:

- Integrated R/R AML Safety Population: This population is the primary focus of safety assessments and includes all patients who received at least 1 dose of study drug in Studies 2215 CL 0101, 2215 CL0102 or 2215 CL-0301 with R/R AML.  The integrated R/R AML safety population included a total of 522 patients who received at least 1 dose of gilteritinib, comprised of 252 patients from Study 2215-CL-0101 (completed study), 24 patients from Study 2215-CL-0102 (completed study) and 246 patients from Study 2215 CL-0301 (data cut-off date: 17 September 2018). Of these 522 patients, 319 received a starting dose of gilteritinib 120 mg (including all 246 patients from Study 2215-CL-0301).
- Integrated R/R FLT3+ AML Safety Population: This population includes all FLT3 mutation positive (FLT3+) patients who received at least 1 dose of study drug in Studies 2215 CL-0101, 2215 CL 0102 or 2215 CL 0301 with R/R AML.  FLT3+ patients are those who were locally assessed as FLT3+ in Studies 2215 CL-0101 and 2215 CL-0102, and those who were centrally assessed as FLT3+ in Study 2215 CL 0301.
- Study 2215-CL-0301 Safety Population: This population includes all patients with R/R AML who received at least 1 dose of study drug in the pivotal Study 2215 CL-0301.  This population was used for subgroup analyses based on the stratification factors unique to this study and for a safety analysis of patients who had a dose escalation to gilteritinib 200 mg.

Table 44 Overview of the main studies for evaluation of safety in the R/R AML population

| StudyID Location    | Study phase   | Studypopulation (Studytype)                     | Study design                         | Treatmentregimen                         | Study status   | SubjectsinSafetyAnalysis Set,totalandbytreatment group (asof04-Jan-2018)   |   SubjectsinSafetyAnalysis Set,totalandbytreatment group (asof04-Jan-2018) |
|---------------------|---------------|-------------------------------------------------|--------------------------------------|------------------------------------------|----------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| 2215-CL-0101 US,EU  | 1/2           | R/RAML ï¼safety,MTD,PK,cacy, DDI)                | Open-label dose escalation/expansion | Gilteritinibï¼20,40 80.120.200,300 450mg) | Ongoing        | 252 Gilteritinib:                                                          |                                                                        252 |
| 2215-CL-0102 Japan  | 1             | R/RAML ï¼safety,MTD,ficacy,PK PD)                | Open-labeldose escalation            | Gilteritinibï¼24,40, 80,120,200,300mg     | Completed      | 24 Gilteritinib:                                                           |                                                                         24 |
| 2215-CL-0301 Global | 3             | R/RFLT3+AML (efficacy,safety, population,PK,PDï¼ | Open-label randomized                | Gilteritinib120mgVs. chemotherapy        | Ongoing        | 355 Gilteritinib: Salvagechemotherapy:109                                  |                                                                        246 |

â   The  data  cutoff  date  for  the ongoing  studies  was  17-Sep-2018; â¡  Non -gilteritinib  salvage  chemotherapy randomization options in Study 2215-CL-0301 consisted of LoDAC, azacitidine, MEC or FLAG-IDA.

<div style=\"page-break-after: always\"></div>

## Patient exposure

Tabular overview of the integrated R/R AML safety population is given in Table 45.

Table 45 Number of Patients by Study Protocol and Treatment Group -Integrated R/R AML Safety Population

| Study        | IntegratedData      | IntegratedData     | Study2215-CL-0301   | Study2215-CL-0301   |
|--------------|---------------------|--------------------|---------------------|---------------------|
|              | Gilteritinib 120 mg | Gilteritinib Total | Gilteritinib 120 mg | Chemo               |
| 2215-CL-0101 | 69                  | 252                | 0                   | 0                   |
| 2215-CL-0102 | 4                   | 24                 | 0                   | 0                   |
| 2215-CL-0301 | 246                 | 246                | 246                 | 109                 |
| Total        | 319                 | 522                | 246                 | 109                 |

â Integrated data includes patients in Studies 2215 -CL-0101, 2215-CL-0102 and 2215-CL-0301 who received at least 1 dose of gilteritinib 120 mg (gilteritinib 120 mg group) or any dose of gilteritinib (gilteritinib total group; doses ranging from gilteritinib 20 to 450 mg). â¡For patients with dose adjustments, dose groups were based on the initial dose.

Table 46 Study Drug Exposure -Integrated R/R AML Safety Population

|                                   | Integrated Datat      | Integrated Datat     | Study 2215-CL-0301    | Study 2215-CL-0301         | Study 2215-CL-0301   |
|-----------------------------------|-----------------------|----------------------|-----------------------|----------------------------|----------------------|
|                                   | Gilterifinib 120 mg   | Gilteritinib Total   | Gilteritinib 120 mg   | Gilteritinib 120 mg        | Chemo                |
|                                   | (N=319)               | (N=522)              | Overall (N=246)       | No Dose Escalation (N=168) | (N=109)              |
| Duration of Exposure Dayst        |                       |                      |                       |                            |                      |
| 1                                 | 319                   | 522                  | 246                   | 168                        | 109                  |
| Mean (SD)                         | 181.2 (199.8)         | 156.1 (190.5)        | 180.7 (168.5)         | 186.2 (183.1)              | 39.9 (37.0)          |
| Median (Min, Max)                 | 111.0 (4, 1320)       | 88.0 (3, 1320)       | 126.0 (4, 885)        | 116.0 (4, 885)             | 28.0 (5, 217)        |
| Duration of Exposure Dayst, n (%) |                       |                      |                       |                            |                      |
| â¤5                                | 1 (0.3)               | 6 (1.1)              | 1(0.4)                | 1 (0.6)                    | 1 (0.9)              |
| â¥6to<28                           | 19 (6.0)              | 60 (11.5)            | 10 (4.1)              | 10 (6.0)                   | 10 (9.2)             |
| â¥28to<84                          | 99 (31.0)             | 179 (34.3)           | 75 (30.5)             | 55 (32.7)                  | 88 (80.7)            |
| â¥84to<168                         | 87 (27.3)             | 131 (25.1)           | 68 (27.6)             | 38 (22.6)                  | 6 (5.5)              |
| â¥168                              | 113 (35.4)            | 146 (28.0)           | 92 (37.4)             | 64 (38.1)                  | 4 (3.7)              |
| Number of Dosing DaysS            |                       |                      |                       |                            |                      |
|                                   | 319                   | 521                  | 246                   | 168                        | 109                  |
| Mean (SD)                         | 173.6 (192.2)         | 146.9 (180.0)        | 172.7 (162.7)         | 177.1 (176.2)              | 9.5 (10.3)           |
| Median (Min, Max)                 | 106.0 (4, 1313)       | 85.0 (3, 1313)       | 114.0 (4, 885)        | 107.5 (4, 885)             | 6.0 (1, 70)          |
| Dosing, n (%)                     |                       |                      |                       |                            |                      |
| Increases                         | 113 (35.4)            | 171 (32.8)           | 78 (31.7)             | 0                          | 8 (7.3)              |
| Decreases                         | 82 (25.7)             | 103 (19.7)           | 75 (30.5)             | 58 (34.5)                  | 9 (8.3)              |
| Intermuptions                     | 151 (47.3)            | 224 (42.9)           | 122 (49.6)            | 84 (50.0)                  | 5 (4.6)              |
| Cumulative Dose (mg)              |                       |                      |                       |                            |                      |
|                                   | 319                   | 521                  | 246                   | 168                        | NA                   |
| Mean (SD)                         | 21911.3 (25954.3)     | 20116.4 (25506.1)    | 20985.2 (19682.6)     | 19138.8 (19572.1)          |                      |
| Median (Min, Max)                 | 13640.0 (480, 259800) | 11880.0 (60, 259800) | 13980.0 (480, 106200) | 11140.0 (480, 106200)      |                      |

<div style=\"page-break-after: always\"></div>

| AverageDailyDose(mg/day)   | AverageDailyDose(mg/day)   | AverageDailyDose(mg/day)   | AverageDailyDose(mg/day)   | AverageDailyDose(mg/day)   | AverageDailyDose(mg/day)   |
|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                            | 319                        | 521                        | 246                        | 168                        | NA                         |
| Mean (SD)                  | 127.2 (28.1)               | 143.6 (61.4)               | 123.9 (25.8)               | 110.6 (15.2)               |                            |
| Median (Min,Max)           | 120.0 ï¼50,290)             | 120.0 (20,402)             | 120.0 (50,192)             | 120.0 (50,120)             | \"-                         |
| DoseIntensityï¼mg/day)tt    | DoseIntensityï¼mg/day)tt    | DoseIntensityï¼mg/day)tt    | DoseIntensityï¼mg/day)tt    | DoseIntensityï¼mg/day)tt    | DoseIntensityï¼mg/day)tt    |
| n                          | 319                        | 521                        | 246                        | 168                        | NA                         |
| Mean (SD)                  | 122.7 (30.1)               | 137.1 (60.4)               | 119.1 (28.2)               | 105.8 (19.3)               | \"**                        |
| Median (Min,Max)           | 120.0 ï¼46,273ï¼             | 120.0 (13,400)             | 120.0 (46.192)             | 120.0 (46.120)             |                            |
| RelativeDoseIntensity(%)   | RelativeDoseIntensity(%)   | RelativeDoseIntensity(%)   | RelativeDoseIntensity(%)   | RelativeDoseIntensity(%)   | RelativeDoseIntensity(%)   |
| n                          | 319                        | 521                        | 246                        | 168                        | 109                        |
| Mean (SD)                  | 102.2 (25.1)               | 102.1 (26.4)               | 99.2 (23.5)                | 88.2 (16.1)                | 98.2 (35.1)                |
| Median (Min,Max)           | 100.0 (39,227)             | 100.0 (23,292)             | 100.0 (39,160)             | 100.0 (39,100)             | 99.6 (10,322)              |

â Integrated data includes patients in Studies 2215 -CL-0101, 2215-CL-0102 and 2215-CL-0301 who received at least 1 dose of gilteritinib 120 mg (gilteritinib 120 mg group) or any dose of gilteritinib (gilteritinib total group; doses ranging from gilteritinib 20 to 450 mg); â¡Defined as (last date of exposure) (first dose date) + 1 -(on-study HSCT period for patients who underwent on-study HSCT);Â§Defined as the number of days with nonzero dosing; Â¶Defined as (cumulative dose) / (number of dosing days); â â Defined as (cumulative dose/ duration of exposure) for gilteritinib ; â¡â¡Defined as (dose intensity/planned dose intensity) *100%

Dose reduction s were experienced by 25.7% (82/319) of patients. In the integrated gilteritinib 120 mg group, 12.9% (41/319) of patients experienced TEAEs leading to dose reduction. Of those patients, 11.0% (35/319) experienced TEAEs leading to dose reduction that were attributed by the Investigator as drug-related.  At least 1 day of dose interruption were experienced by 47.3% (151/319) of patients. TEAEs leading to drug interruption were experienced by 45.1% (144/319) of patients and drug-related TEAEs leading to dose interruption were experienced by 30.4% (97/319) of patients.

All patients randomized to the gilteritinib arm began at a starting dose of 120 mg but had the option of receiving an escalated dose of 200 mg based on lack of efficacy, as assessed by the Investigator. For patients who were administered an escalated dose of gilteritinib 200 mg, the median number of dosing days for patients before dose escalation was 42.0 days, ranging from 26 to 531 days. The median number of dosing days for patients after dose escalation was 48.0 days, ranging from 1 to 756 days. In the integrated gilteritinib 120 mg safety population, dose increase was experienced by 35.4% (113/319) of patients.

## Adverse events

An overview of the AEs observed in the integrated R/R AML safety population is given in Table 47.

<div style=\"page-break-after: always\"></div>

Table  47  Overview  of  Treatment-emergent  Adverse  Events -Integrated  R/R  AML  Safety Population

| Parameter                                           | Integrated Datat    | Integrated Datat    | Integrated Datat   | Integrated Datat   | Study 2215-CL-0301   | Study 2215-CL-0301   | Study 2215-CL-0301   | Study 2215-CL-0301   |
|-----------------------------------------------------|---------------------|---------------------|--------------------|--------------------|----------------------|----------------------|----------------------|----------------------|
| Parameter                                           | Gilteritinib 120 mg | Gilteritinib 120 mg | Gilteriinib Total  | Gilteriinib Total  | Gilteritinib 120 mg  | Gilteritinib 120 mg  | Chemo                | Chemo                |
| Parameter                                           | N=319 n (%)         | PY=158 E (E/PY)     | N=522 n (%)        | PY=223 E (E/PY)    | N=246 n (%)          | PY=122 E (E/PY)      | N=109 n (%)          | PY=12 E (E/PY)       |
| TEAE                                                | 317 (99.4)          | 10302 (65.2)        | 519 (99.4)         | 15044 (67.5)       | 246 (100)            | 8464 (69.4)          | 107 (98.2)           | 1596 (133.0)         |
| Drug-relatedt TEAE                                  | 265 (83.1)          | 2426 (15.4)         | 418 (80.1)         | 3570 (16.0)        | 206 (83.7)           | 2011 (16.5)          | 71 (65.1)            | 562 (46.8)           |
| Serious TEAES                                       | 258 (80.9)          | 1105 (7.0)          | 425 (81.4)         | 1796 (8.1)         | 205 (83.3)           | 865 (7.1)            | 34 (31.2)            | 110 (9.2)            |
| Drug-relatedseriousTEAES                            | 108 (33.9)          | 231 (1.5)           | 170 (32.6)         | 341 (1.5)          | 88 (35.8)            | 193 (1.6)            | 16 (14.7)            | 35 (2.9)             |
| TEAEleading to death                                | 95 (29.8)           | 111 (0.7)           | 181 (34.7)         | 205 (0.9)          | 71 (28.9)            | 87 (0.7)             | 16 (14.7)            | 23 (1.9)             |
| Dnug-relatedi TEAE leading to death                 | 12 (3.8)            | 16 (0.1)            | 18 (3.4)           | 22 (0.1)           | 10 (4.1)             | 14 (0.1)             | 5 (4.6)              | 8 (0.7)              |
| TEAEleading towithdrawal of treatment               | 70 (21.9)           | 95 (0.6)            | 152 (29.1)         | 210 (0.9)          | 58 (23.6)            | 80 (0.7)             | 13 (11.9)            | 18 (1.5)             |
| Drug-relatedi TEAE leading to withdrawaloftreatment | 32(10.0)            | 44 (0.3)            | 58 (11.1)          | 78 (0.3)           | 27 (11.0)            | 37(0.3)              | 5 (4.6)              | 8(0.7)               |
| Grade3or higherTEAE                                 | 298 (93.4)          | 2822 (17.9)         | 482 (92.3)         | 4063 (18.2)        | 236 (95.9)           | 2354 (19.3)          | 94 (86.2)            | 505 (42.1)           |
| Grade3orhigherdrug-relatedt TEAE                    | 192 (60.2)          | 754 (4.8)           | 288 (55.2)         | 1025 (4.6)         | 153 (62.2)           | 638 (5.2)            | 57 (52.3)            | 227 (18.9)           |
| TEAEs leading to dose reduction                     | 41 (12.9)           | 55 (0.3)            | 52 (10.0)          | 70 (0.3)           | 35 (14.2)            | 46 (0.4)             | 1(0.9)               | 7 (0.6)              |
| Drug-relatedi TEAE leading to dose reduction        | 35 (11.0)           | 44 (0.3)            | 44 (8.4)           | 57 (0.3)           | 31 (12.6)            | 40 (0.3)             | 0                    | 0                    |
| TEAEleading to drug interruption                    | 144 (45.1)          | 338 (2.1)           | 224 (42.9)         | 512 (2.3)          | 112 (45.5)           | 269 (2.2)            | 5 (4.6)              | 9 (0.8)              |
| Drug-related TEAE leading to drugintemuption        | 97(30.4)            | 180 (1.1)           | 138 (26.4)         | 254 (1.1)          | 79 (32.1)            | 153 (1.3)            | 3 (2.8)              | 4(0.3)               |
| TEAE during HSCT Period                             | 34 (10.7)           | 272 (1.7)           | 41 (7.9)           | 351 (1.6)          | 31 (12.6)            | 256 (2.1)            | 0                    | 0                    |
| Serious TEAE during HSCT Period                     | 4(1.3)              | 7 (0.0)             | 5 (1.0)            | 10 (0.0)           | 4 (1.6)              | 7 (0.1)              | 0                    | 0                    |
| Death                                               | 226 (70.8)          | 226 (1.4)           | 386 (73.9)         | 386 (1.7)          | 170 (69.1)           | 170 (1.4)            | 81 (74.3)            | 81 (6.8)             |

â Integrated data includes patients in Studies 2215 -CL-0101, 2215-CL-0102 and 2215-CL-0301 who received at least 1 dose of gilteritinib 120 mg (gilteritinib 120 mg group) or any dose of gilteritinib (gilteritinib total group; doses ranging from gilteritinib 20 to 450 mg) ; â¡Possible or probable, as assessed by the Investigator, or records where relationship is missing; Â§Includes SAEs upgraded by the Sponsor based on review of the Sponsor's list of Always Serious terms, if any update was done.

## Â· Treatment-emergent adverse events

An overview of the treatment-emergent adverse events (TEAEs) observed in the integrated R/R AML safety population is given in

Table 48 . TEAEs were defined as an AE observed after starting administration of the study drug.

<div style=\"page-break-after: always\"></div>

Table  48  Treatmentemergent  Adverse  Events  (â¥  10%  of  Integrated  Gilteritinib  120  mg Patients) by System Organ Class, Preferred Term and Severity -Integrated R/R AML Safety Population

| MedDRA (v19.1) SystemOrgan Class Preferred Term    | IntegratedData     | IntegratedData     | IntegratedData    | IntegratedData    | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301          | Study2215-CL-0301          | Study2215-CL-0301   | Study2215-CL-0301   |
|----------------------------------------------------|--------------------|--------------------|-------------------|-------------------|---------------------|---------------------|---------------------|---------------------|----------------------------|----------------------------|---------------------|---------------------|
| MedDRA (v19.1) SystemOrgan Class Preferred Term    | Gilteriinib 120 mg | Gilteriinib 120 mg | Gilteriinib Total | Gilteriinib Total | Giteritinib         | Giteritinib         | Giteritinib         | Giteritinib         | Chemo                      | Chemo                      | Chemo               | Chemo               |
| MedDRA (v19.1) SystemOrgan Class Preferred Term    | AIl 2Grade3 N=319  | AIl 2Grade3 N=319  | All Grade3 N-522  | All Grade3 N-522  | AlI                 | AlI                 | 120mg 2Grade3       | 120mg 2Grade3       | All N=109 PY=11.9 E (E/PY) | All N=109 PY=11.9 E (E/PY) | 2Grade3             | 2Grade3             |
| MedDRA (v19.1) SystemOrgan Class Preferred Term    |                    |                    |                   |                   | N=246               | PY=121.7 E(E/PY)    | N=246               | PY=121.7 E (E/PY)   |                            |                            | N-109               | PY-11.9 E (E/PY)    |
| Overall, n (%)                                     | 317 (99.4)         | 298 (93.4)         | 519 (99.4)        | 482 (92.3)        | 246 (100)           | 8464 (69.55)        | 236 (95.9)          | 2354 (19.34)        | 107 (98.2)                 | 1596 (134.12)              | 94 (86.2)           | 505 (42.44)         |
| General Disorders and AdministrationSiteConditions | 254 (79.0)         | 48 (15.0)          | 398 (76.2)        | 88 (16.9)         | 198 (80.5)          | 616 (5.06)          | 33 (13.4)           | 36 (0.30)           | 61 (56.0)                  | 165 (13.87)                | 10 (9.2)            | 15 (1.26)           |
| Pyrexia                                            | 131 (41.1)         | 13 (4.1)           | 182 (34.9)        | 21 (4.0)          | 105 (42.7)          | 179 (1.47)          | 8 (3.3)             | 9 (0.07)            | 32 (29.4)                  | 59 (4.96)                  | 4 (3.7)             | 6 (0.50)            |
| Fatigue                                            | 97 (30.4)          | 10 (3.1)           | 158 (30.3)        | 21 (4.0)          | 70 (28.5)           | 102 (0.84)          | 6 (2.4)             | 6 (0.05)            | 14 (12.8)                  | 18 (1.51)                  | 2 (1.8)             | 2 (0.17)            |
| Oedema peripheral                                  | 77 (24.1)          | 1 (0.3)            | 125 (23.9)        | 5 (1.0)           | 59 (24.0)           | 77 (0.63)           | 1 (0.4)             | 1 (0.01)            | 13 (11.9)                  | 19 (1.60)                  | 0                   | 0                   |
| Asthenia                                           | 44 (13.8)          | 8 (2.5)            | 71 (13.0)         | 12 (2.3)          | 38 (15.4)           | 53 (0.44)           | 6 (2.4)             | 6 (0.05)            | 10 (9.2)                   | 11 (0.92)                  | 2 (1.8)             | 2 (0.17)            |
| Investigations                                     | 249 (78.1)         | 153 (48.0)         | 383 (73.4)        | 235 (45.0)        | 161 (77.0)          | 1702 (13.99)        | 129 (52.4)          | 614 (5.05)          | 59 (54.1)                  | 252 (21.18)                | 47 (43.1)           | 133 (11.18)         |
| Alanine aminotransferase increased                 | 120 (37.6)         | 37 (11.6)          | 160 (30.7)        | 49 (9.4)          | 103 (41.9)          | 247 (2.03)          | 34 (13.8)           | 42 (0.35)           | 10 (9.2)                   | 20 (1.68)                  | 5 (4.6)             | 5 (0.42)            |
| Aspartate aminotransferase increased               | 120 (37.6)         | 40 (12.5)          | 172 (33.0)        | 55 (10.5)         | 99 (40.2)           | 251 (2.06)          | 36 (14.6)           | 45 (0.37)           | 13 (11.9)                  | 21 (1.76)                  | 2 (1.8)             | 2 (0.17)            |
| Plateletcount decreased                            | 68 (21.3)          | 64 (20.1)          | 102 (19.5)        | 96 (18.4)         | 56 (22.8)           | 256 (2.10)          | 54 (22.0)           | 207 (1.70)          | 28 (25.7)                  | 76 (6.39)                  | 27 (24.8)           | 59 (4.96)           |
| Blood alkaline phosphatase increased               | 22 (20.7)          | 7 (2.2)            | 91 (17.4)         | 8 (1.5)           | 56 (22.8)           | 113 (0.93)          | 7 (2.8)             | 9 (0.07)            | 2 (1.8)                    | 2 (0.17)                   | 0                   | 0                   |
| Neutrophil count decreased                         | 50 (15.7)          | 48 (15.0)          | 70 (13.4)         | 65 (12.5)         | 42 (17.1)           | 167 (1.37)          | 42 (17.1)           | 124 (1.02)          | 12 (11.0)                  | 28 (2.35)                  | 12 (11.0)           | 19 (1.60)           |
| Blood creatinine increased                         | 42 (13.2)          | 4 (1.3)            | 75 (14.4)         | 8 (1.5)           | 29 (11.8)           | 65 (0.53)           | 3 (1.2)             | 4 (0.03)            | 4 (3.7)                    | 4 (0.34)                   | 0                   | 0                   |
| Blood creatine phosphokinase increased             | 40 (12.5)          | 15 (4.7)           | 70 (13.4)         | 28 (5.4)          | 33 (13.4)           | 96 (0.79)           | 13 (5.3)            | 20 (0.16)           | 0                          | 0                          | 0                   | 0                   |
| White blood cell count decreased                   | 38 (11.9)          | 35 (11.0)          | 51 (9.8)          | 47 (9.0)          | 34 (13.8)           | 128 (1.05)          | 32 (13.0)           | 84 (0.69)           | 19 (17.4)                  | 27 (2.27)                  | 19 (17.4)           | 26 (2.18)           |
| GastrointestinalDisorders                          | 246 (77.1)         | 63 (19.7)          | 397 (76.1)        | 106 (20.3)        | 192 (78.0)          | 818 (6.72)          | 48 (19.5)           | 71 (0.58)           | 80 (73.4)                  | 228 (19.16)                | 9 (8.3)             | 11 (0.92)           |
| Diarrhoea                                          | 112 (35.1)         | 13 (14.1)          | 188 (36.0)        | 25 (4.8)          | 81 (32.9)           | 136 (1.12)          | 9 (3.7)             | 10 (0.08)           | 32 (29.4)                  | 37 (3.11)                  | 3 (2.8)             | 3 (0.25)            |
| Nausea                                             | 95 (29.8)          | 6 (1.9)            | 143 (27.4)        | 10 (1.9)          | 79 (32.1)           | 122 (1.00)          | 5 (2.0)             | 5 (0.04)            | 36 (33.0)                  | 41 (3.45)                  | 0                   | 0                   |
| Constipation                                       | 90 (28.2)          | 2 (0.6)            | 141 (27.0)        | 2 (0.4)           | 76 (30.9)           | 94 (0.77)           | 2 (0.8)             | 3 (0.02)            | 16 (14.7)                  | 18 (1.51)                  | 0                   | 0                   |
| Vomiting                                           | 67 (21.0)          | 3 (0.9)            | 106 (20.3)        | 6 (1.1)           | 53 (21.5)           | 80 (0.66)           | 1 (0.4)             | 1 (0.01)            | 15 (13.8)                  | 16 (1.34)                  | 0                   | 0                   |
| Stomatitis                                         | 43 (13.5)          | 7 (2.2)            | 68 (13.0)         | 10 (1.9)          | 34 (13.8)           | 45 (0.37)           | 6 (2.4)             | 6 (0.05)            | 16 (14.7)                  | 20 (1.68)                  | 4 (3.7)             | 4 (0.34)            |
| Abdominal pain                                     | 42 (13.0)          | 6                  | 63                | 8                 | 37                  | 44 (0.36)           | 5                   | 5                   | 56 (51.4)                  | 17                         | 0                   | 0                   |
| Infections and Infestations                        | 243                | (1.9) 165          | (12.1) 381        | (1.5) 267         | (15.0) 199          | 659                 | (2.0) 133           | (0.04) 296          | 16 (14.7)                  | (1.43) 107                 | 25 (22.9)           | 52 (4.37)           |
| Pneumonia                                          | (76.2) 59 (18.5)   | (51.7) 43 (13.5)   | (73.0) 91 (17.4)  | (51.1) 68 (13.0)  | (80.9) 43 (17.5)    | (5.41) 66 (0.54)    | (54.1) 29 (11.8)    | (2.43) 39 (0.32)    | 8 (7.3)                    | (8.99) 11 (0.92)           | 5 (4.6)             | 7 (0.59)            |

<div style=\"page-break-after: always\"></div>

| MedDRA (v19.1) System Organ Class PreferredTerm   | Integrated Data    | Integrated Data    | Integrated Data    | Integrated Data    | Study2215-CL-0301   | Study2215-CL-0301      | Study2215-CL-0301   | Study2215-CL-0301    | Study2215-CL-0301    | Study2215-CL-0301    | Study2215-CL-0301    | Study2215-CL-0301    |
|---------------------------------------------------|--------------------|--------------------|--------------------|--------------------|---------------------|------------------------|---------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| MedDRA (v19.1) System Organ Class PreferredTerm   | Gilteritinib       | Gilteritinib       | Gilteritinib Total | Gilteritinib Total | Gilteritinib 120 mg | Gilteritinib 120 mg    | Gilteritinib 120 mg | Chemo                | Chemo                | Chemo                | Chemo                | Chemo                |
| MedDRA (v19.1) System Organ Class PreferredTerm   | 120mg All â¥Grade 3 | 120mg All â¥Grade 3 | All â¥Grade 3       | All â¥Grade 3       |                     |                        |                     | â¥Grade 3 All â¥Grade3 | â¥Grade 3 All â¥Grade3 | â¥Grade 3 All â¥Grade3 | â¥Grade 3 All â¥Grade3 | â¥Grade 3 All â¥Grade3 |
| MedDRA (v19.1) System Organ Class PreferredTerm   | N=319              | N=319              | N=522              | N=522              | N=246               | All PY =121.7 E (E/PY) | N=246               | PY = 121.7           | N=109                | PY = 11.9            | N= 109               | PY =11.9             |
| Blood and Lynphatic System                        | 241                | 220                | 373                | 338                | 189                 | 1147                   | 176                 | E (E/PY) 768         | 78                   | E (E/PY) 237         | 75                   | E (E/PY) 171         |
| Disorders Anaemia                                 | (75.5) 143 (44.8)  | (69.0) 115 (36.1)  | (71.5) 207         | (64.8) 166         | (76.8) 116 (47.2)   | (9.42) 481 (3.95)      | (71.5) 100 (40.7)   | (6.31) 247 (2.03)    | (71.6) 38 (34.9)     | (19.92) 80 (6.72)    | (68.8) 33            | (14.37) 45           |
| Febrile neutropenia                               | 140 (43.9)         | 137 (42.9)         | (39.7) 220 (42.1)  | (31.8) 216 (41.4)  | 115 (46.7)          | 184 (1.51)             | 113 (45.9)          | 181 (1.49)           | 40 (36.7)            | 52 (4.37)            | (10.3) 40 (36.7)     | (3.78) 52 (4.37)     |
| Thrombocytopenia                                  | 76 (23.8)          | 66 (20.7)          | 102 19.5)          | 89 (17.0)          | 63 (25.6)           | 298 (2.45)             | 56 (22.8)           | 229 (1.88)           | 18 (16.5)            | 42 (3.53)            | 18 (16.5)            | 35 (2.94)            |
| Neutropenia                                       | 39 (12.2)          | 39 (12.2)          | 55 (10.5)          | 54 (10.3)          | 33 (13.4)           | 109 (0.90)             | 33 (13.4)           | 80 (0.66)            | 16 (14.7)            | 19 (1.60)            | 15 (13.8)            | 17 (1.43)            |
| Respiratory, thoracic and mediastinal disorders   | 208 (65.2)         | 61 (19.1)          | 336 (64.4)         | 110 (21.1)         | 163 (66.3)          | 491 (4.03)             | 46 (18.7)           | 68 (0.56)            | 38 (34.9)            | 70 (5.88)            | 12 (11.0)            | 16 (1.34)            |
| Cough                                             | 90 (28.2)          | 1 (0.3)            | 135 (25.9)         | 1 (0.2)            | 72 (29.3)           | 98 (0.81)              | 1 (0.4)             | 1 (0.01)             | 11 (10.1)            | 13 (1.09)            | 0                    | 0                    |
| Dyspnoea                                          | 77 (24.1)          | 14 (4.4)           | 123 (23.6)         | 25 (4.8)           | 58 (23.6)           | 77 (0.63)              | 10 (4.1)            | 10 (0.08)            | 7 (6.4)              | 10 (0.84)            | 3 (2.8)              | 3 (0.25)             |
| Epistaxis                                         | 58 (18.2)          | 3 (0.9)            | 98 (18.8)          | 5 (1.0)            | 42 (17.1)           | 51 (0.42)              | 2 (0.8)             | 2 (0.02)             | 8 (7.3)              | 8 (0.67)             | 1 (0.9)              | 1 (0.08)             |
| Metabolismand Nutrition Disorders                 | 203 (63.6)         | 101 (31.7)         | 320 (61.3)         | 158 (30.3)         | 165 (67.1)          | 900 (7.40)             | 85 (34.6)           | 192 (1.58)           | 58 (53.2)            | 164 (13.78)          | 35 (32.1)            | 50 (4.20)            |
| Hypokalaemia                                      | 82 (25.7)          | 33 (10.3)          | 122 (23.4)         | 43 (8.2)           | 71 (28.9)           | 183 (1.50)             | 32 (13.0)           | 42 (0.35)            | 34 (31.2)            | 49 (4.12)            | 12 (11.0)            | 14 (1.18)            |
| Hypocalcaemia                                     | 58 (18.2)          | 15 (4.7)           | 92 (17.6)          | 27 (5.2)           | 47 (19.1)           | 110 (0.90)             | 12 (4.9)            | 13 (0.11)            | 6 (5.5)              | 14 (1.18)            | 1 (0.9)              | 1 (0.08)             |
| Decreased appetite                                | 55 (17.2)          | 5 (1.6)            | 86 (16.5)          | 9 (1.7)            | 44 (17.9)           | 54 (0.44)              | 5 (2.0)             | 5 (0.04)             | 20 (18.3)            | 22 (1.85)            | 5 (4.6)              | 5 (0.42)             |
| Hypomagnesaemia                                   | 52 (16.3)          | 1 (0.3)            | 79 (15.1)          | 1 (0.2)            | 39 (15.9)           | 67 (0.55)              | 0                   | 0                    | 12 (11.0)            | 15 (1.26)            | 0                    | 0                    |
| Hypophosphataemia                                 | 47 (14.7)          | 25 (7.8)           | 64 (12.3)          | 39 (7.5)           | 41 (16.7)           | 70 (0.58)              | 20 (8.1)            | 30 (0.25)            | 5 (4.6)              | 5 (0.42)             | 4 (3.7)              | 4 (0.34)             |
| Hyperglycaemia                                    | 42 (13.2)          | 19 (6.0)           | 60 (11.5)          | 28 (5.4)           | 36 (14.6)           | 62 (0.51)              | 18 (17.3)           | 24 (0.20)            | 14 (12.8)            | 20 (1.68)            | 9 (8.3)              | 12 (1.01)            |
| Hyponatraemia                                     | 42 (13.2)          | 19 (6.0)           | 69 (13.2)          | 30 (5.7)           | 33 (13.4)           | 81 (0.67)              | 16 (16.5)           | 36 (0.30)            | 6 (5.5)              | 7 (0.59)             | 3 (2.8)              | 3 (0.25)             |
| Hypoalbuminaemia                                  | 39 (12.2)          | 5 (1.6)            | 67 (12.8)          | 10 (1.9)           | 32 (13.0)           | 64 (0.53)              | 3 (1.2)             | 5 (0.04)             | 7 (6.4)              | 11 (0.92)            | 2 (1.8)              | 2 (0.17)             |
| Nervous System Disorders                          | 175 (54.9)         | 37 (11.6)          | (54.4)             | 67 (12.8)          | 135 (54.9)          | 352 (2.89)             | 30 (12.2)           | 39 (0.32)            | 30 (27.5)            | 53 (4.45)            | 5 (4.6)              | 5 (0.42)             |
| Headache                                          | 75 (23.5)          | 4 (1.3)            | 101 (19.3)         | 5 (1.0)            | 64 (26.0)           | 92 (0.76)              | 3 (1.2)             | 3 (0.02)             | 16 (14.7)            | 18 (1.51)            | 0                    | 0                    |
| Dizziness                                         | 65 (20.4)          | 1 (0.3)            | 101 (19.3)         | 3 (0.6)            | 48 (19.5)           | 65 (0.53)              | 1 (0.4)             | 2 (0.02)             | 2 (1.8)              | (0.17)               | 0                    | 0                    |
| Dysgeusia                                         | 35 (11.0)          | 0                  | 56 (10.7)          | 0                  | 25 (10.2)           | 28 (0.23)              | 0                   | 0                    | 5 (4.6)              | 5 (0.42)             | 0                    | 0                    |
| Pain in extremity                                 | (53.9) 47          | 2 (0.6)            | 66 (12.6)          | 4 (0.8)            | 36                  | (2.57)                 | 2 (0.8)             | 2 (0.02)             | 8 (7.3)              | 12 (1.01)            | 1 (0.9)              | 1                    |
| MusculoskeletalandConnective Tissue Disorders     | 172 (14.7)         | 23 (7.2)           | 252 (48.3)         | 36 (6.9)           | 136 (55.3)          | 313                    | 17 (6.9)            | 22 (0.18)            | 35 (32.1)            | 62 (5.21)            | 5 (4.6)              | 6 (0.50)             |
| Arthralgia                                        | 40                 | 4                  | 65                 | 9                  | (14.6)              | 44 (0.36)              | 4                   | 5                    | 6                    | 8 (0.67)             | 1                    | (0.08)               |
|                                                   | (12.5)             | (1.3)              | (12.5)             | (1.1)              | 28 (11.4)           | 45 (0.37)              | (1.6)               | (0.04)               | (5.5)                |                      | (0.9)                | 1 (0.08)             |
| Myalgia                                           | 40 (12.5)          | 1 (0.3)            | 56 (10.7)          | 3 (0.6)            | 35 (14.2)           | 45 (0.37)              | 1 (0.4)             | 1 (0.01)             | 4 (3.7)              | + (0.34)             | 0                    | 0                    |
| Back pain                                         | 38 (11.9)          | 3 (0.9)            | 52 (10.0)          | 6                  | 29                  | 33                     | 2                   | 2                    | 13                   | 13                   | 1                    | 1                    |
|                                                   | 169 (53.0)         | 23 (7.2)           | 276 (52.9)         | (1.1)              | (11.8)              | (0.27)                 | (0.8)               | (0.02) 20            | (11.9)               | (1.09)               | (0.9)                | (0.08)               |
| Skin and Subcutaneous Tissue Disorders            |                    |                    |                    | 33 (6.3)           | 133 (54.1)          | 334 (2.74)             | 18                  | (0.16)               | 43 (39.4)            | 63 (5.29)            | 7 (6.4)              | 7 (0.59)             |
| Rash                                              | 48 (15.0)          | 2 (0.6)            | 65 (12.5)          | 2 (0.4)            | 36 (14.6)           | 48 (0.39)              | (7.3) 1 (0.4)       | 1 (0.01)             | 10 (9.2)             | 10 (0.84)            | 1 (0.9)              | 1 (0.08)             |

<div style=\"page-break-after: always\"></div>

| MedDRA (v19.1) System Organ Class Preferred Term                  | IntegratedData     | IntegratedData     | IntegratedData     | IntegratedData     | Study|2215-CL-0301   | Study|2215-CL-0301   | Study|2215-CL-0301   | Study|2215-CL-0301   | Study|2215-CL-0301   | Study|2215-CL-0301   | Study|2215-CL-0301   | Study|2215-CL-0301   |
|-------------------------------------------------------------------|--------------------|--------------------|--------------------|--------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| MedDRA (v19.1) System Organ Class Preferred Term                  | Gilteritinib 120mg | Gilteritinib 120mg | Gilteritinib Total | Gilteritinib Total | Gilteritinib 120mg   | Gilteritinib 120mg   | Gilteritinib 120mg   | Gilteritinib 120mg   | Chemo                | Chemo                | Chemo                | Chemo                |
| MedDRA (v19.1) System Organ Class Preferred Term                  | All â¥Grade 3       | All â¥Grade 3       | All                | â¥Grade3            | AlI                  | AlI                  | â¥Grade 3             | â¥Grade 3             | All                  | All                  | â¥Grade 3             | â¥Grade 3             |
| MedDRA (v19.1) System Organ Class Preferred Term                  | N =319             | N =319             | N=522              | N=522              | N=246                | PY = 121.7 E (E/PY)  | N =246               | PY = 121.7 E (E/PY)  | N=109                | PY = 11.9 E (E/PY)   | N = 109              | PY =11.9 E (E/PY)    |
| VascularDisorders                                                 | 132 (41.4)         | 54 (16.9)          | 206 (39.5)         | 79 (15.1)          | 106 (43.1)           | 174 (1.43)           | 46 (18.7)            | 55 (0.45)            | 25 (22.9)            | 35 (2.94)            | 7 (6.4)              | 8 (0.67)             |
| Hypotension                                                       | 55 (17.2)          | 23 (7.2)           | 92 (17.6)          | 37 (7.1)           | 43 (17.5)            | 50 (0.41)            | 19 (7.7)             | 21 (0.17)            | 8 (7.5)              | 9 (0.76)             | 3 (2.8)              | 3 (0.25)             |
| Hypertension                                                      | 41 (12.9)          | 22 (6.9)           | 67 (12.8)          | 29 (5.6)           | 34 (13.8)            | 57 (0.47)            | 20 (8.1)             | 24 (0.20)            | 10 (9.2)             | 11 (0.92)            | 4 (3.7)              | 5 (0.42)             |
| Eye Disorders                                                     | 125 (39.2)         | 8 (2.5)            | 170 (32.6)         | 11 (2.1)           | 97 (39.4)            | 180 (1.48)           | 5 (2.0)              | 5 (0.04)             | 12 (11.0)            | 19 (1.60)            | 0                    | 0                    |
| Dry eye                                                           | 33 (10.3)          | 1 (0.3)            | 41 (7.9)           | 1 (0.2)            | 24 (9.8)             | 25 (0.21)            | 1 (0.4)              | 1 (0.01)             | 3 (2.8)              | 3 (0.25)             | 0                    | 0                    |
| Injury, poisoning and Procedural Complications                    | 112 (35.1)         | 18 (5.6)           | 177 (33.9)         | 34 (6.5)           | 85 (34.6)            | 161 (1.32)           | 13 (5.3)             | 16 (0.13)            | 23 (21.1)            | 35 (2.94)            | 3 (2.8)              | 3 (0.25)             |
| Fall                                                              | 34 (10.7)          | 9 (2.8)            | 59 (11.3)          | 14 (2.7)           | 21 (8.5)             | 35 (0.29)            | 5 (2.0)              | 5 (0.04)             | 2 (1.8)              | 2 (0.17)             | 1 (0.9)              | 1 (0.08)             |
| PsychiatricDisorders                                              | 92 (28.8)          | 9 (2.8)            | 152 (29.1)         | 17 (3.3)           | 76 (30.9)            | 121 (0.99)           | 8 (3.3)              | 9 (0.07)             | 18 (16.5)            | 23 (1.93)            | 2 (1.8)              | 3 (0.25)             |
| Insomnia                                                          | 48 (15.0)          | 1 (0.3)            | 71 (13.6)          | 1 (0.2)            | 40 (16.3)            | 44 (0.36)            | 0                    | 0                    | 6 (5.5)              | 6 (0.50)             | 0                    | 0                    |
| RenalandUrinaryDisorder's                                         | 88 (27.6)          | 15 (4.7)           | 150 (28.7)         | 30 (5.7)           | 70 (28.5)            | 118 (0.97)           | 12 (4.9)             | 13 (0.11)            | 14 (12.8)            | 19 (1.60)            | 3 (2.8)              | 4 (0.34)             |
| CardiacDisorder's                                                 | 83 (26.0)          | 31 (9.7)           | 146 (28.0)         | 54 (10.3)          | 67 (27.2)            | 115 (0.94)           | 25 (10.2)            | 39 (0.32)            | 17 (15.6)            | 21 (1.76)            | 4 (3.7)              | 6 (0.50)             |
| Neoplasmsbenign,malignant and unspecified (incl cysts and polyps) | 73 (22.9)          | 56 (17.6)          | 120 (23.0)         | 99 (19.0)          | 57 (23.2)            | 72 (0.59)            | 44 (17.9)            | 54 (0.44)            | 11 (10.1)            | 17 (1.43)            | 5 (4.6)              | 10 (0.84)            |
| Acute myeloid leukaemia                                           | 43 (13.5)          | 43 (13.5)          | 82 (15.7)          | 82 (15.7)          | 33 (13.4)            | 38 (0.31)            | 33 (13.4)            | 38 (0.31)            | 4 (3.7)              | 6 (0.50)             | 4 (3.7)              | 6 (0.50)             |
| ImmuneSystemDisorders                                             | (13.8)             | 16 (5.0)           | 63 (12.1)          | 21 (4.0)           | 35 (14.2)            | 73 (0.60)            | 13 (5.3)             | 17 (0.14)            | 3 (2.8)              | 5 (0.42)             | 1 (0.9)              | 2 (0.17)             |
| HepatobiliaryDisorders                                            | 37 (11.6)          | 16 (5.0)           | 62 (11.9)          | 20 (3.8)           | 31 (12.6)            | 55 (0.45)            | 13 (5.3)             | 16 (0.13)            | 4 (3.7)              | 5 (0.42)             | 1 (0.9)              | 2 (0.17)             |
| ReproductiveSystemand BreastDisorders                             | 32 (10.0)          | 2 (0.0)            | 46 (8.8)           | 5 (1.0)            | 24 (9.8)             | 28 (0.23)            | 2 (0.8)              | 2 (0.02)             | 8 (7.3)              | 8 (0.67)             | 0                    | 0                    |

Sorting order:Descending order in the integrated gilteritinib120 mg group by system organ class and preferred term within system organ class.In the case of ties,alphabetical order was applied.

PatientswerecountedonceundermaximumNCI-CTCAEgrade.

âIntegrated data includes patients in Studies 2215-CL-0101, 2215-CL-0102 and 2215-CL-0301 who received at least 1 dose of gilteritinib 120 mg (gilteritinib 120 mg group) or any dose of gilteritinib(gilteritinib totalgroup:doses ranging fromgilteritinib20 to450mg).

## Â· Drug-related Treatment-emergent adverse events

Drugrelated  TEAEs  refer  to  events  that  were  assessed  by  the  Investigator  as  'possibly  related'  or 'probably related' to gilteritinib.

<div style=\"page-break-after: always\"></div>

Table 49 Drug-related Treatment-emergent Adverse Events ( â¥ 5% of Integrated Gilteritinib 120 mg Patients) by Preferred Term and Severity -Integrated R/R AML Safety Population

| MedDRA (v19.1) Preferred Term          | Integrated Datat    | Integrated Datat    | Integrated Datat   | Integrated Datat   | Studly 2215-CL-0301   | Studly 2215-CL-0301   | Studly 2215-CL-0301   | Studly 2215-CL-0301   | Studly 2215-CL-0301   | Studly 2215-CL-0301   | Studly 2215-CL-0301   | Studly 2215-CL-0301   |
|----------------------------------------|---------------------|---------------------|--------------------|--------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| MedDRA (v19.1) Preferred Term          | Gilteritinib 120 mg | Gilteritinib 120 mg | Gilteritinib Total | Gilteritinib Total | Gilteritinib 120 mg   | Gilteritinib 120 mg   | Gilteritinib 120 mg   | Gilteritinib 120 mg   | Chemo                 | Chemo                 | Chemo                 | Chemo                 |
| MedDRA (v19.1) Preferred Term          | AlI â¥Grade 3        | AlI â¥Grade 3        | All â¥Grade3 N=522  | All â¥Grade3 N=522  | AlI                   | AlI                   | â¥Grade3               | â¥Grade3               | All                   | All                   | â¥Grade 3              | â¥Grade 3              |
| MedDRA (v19.1) Preferred Term          | N=319               |                     |                    |                    | N=246                 | PY=121.7 E (E/PY)     | N=246                 | PY =121.7 E (E/PY)    | N=109                 | PY=11.9 E (E/PY)      | N=109                 | PY =11.9 E (E/PY)     |
| Overall, n (%)                         | 265 (83.1)          | 192 (60.2)          | 418 (80.1)         | 288 (55.2)         | 206 (83.7)            | 2011 (16.52)          | 153 (62.2)            | 638 (5.24)            | 71 (65.1)             | 562 (47.23)           | 57 (52.3)             | 227 (19.08)           |
| Alanine aminotransferase increased     | 81 (25.4)           | 20 (6.3)            | 107 (20.5)         | 27 (5.2)           | 73 (29.7)             | 153 (1.26)            | 19 (7.7)              | 23 (0.19)             | 4 (3.7)               | 9 (0.76)              | 2 (1.8)               | 2 (0.17)              |
| Aspartate aminotransferase increased   | 78 (24.5)           | 21 (6.6)            | 108 (20.7)         | 29 (5.6)           | 69 (28.0)             | 149 (1.22)            | 20 (8.1)              | 24 (0.20)             | 7 (6.4)               | 10 (0.84)             | 1 (0.9)               | 1 (0.08)              |
| Anaemia                                | 64 (20.1)           | 54 (16.9)           | 82 (15.7)          | 71 (13.6)          | 57 (23.2)             | 152 (1.25)            | 48 (19.5)             | 79 (0.65)             | 25 (22.9)             | 54 (4.54)             | 21 (19.3)             | 28 (2.35)             |
| Thrombocytopenia                       | 43 (13.5)           | 37 (11.6)           | 52 (10.0)          | 44 (8.4)           | 35 (14.2)             | 131 (1.08)            | 30 (12.2)             | 93 (0.76)             | 11 (10.1)             | 27 (2.27)             | 11 (10.1)             | 21 (1.76)             |
| Febrile neutropenia                    | 40 (12.5)           | 39 (12.2)           | 51 (9.8)           | 50 (9.6)           | 39 (15.9)             | 47 (0.39)             | 38 (15.4)             | 46 (0.38)             | 20 (18.3)             | 21 (1.76)             | 20 (18.3)             | 21 (1.76)             |
| Diarrhoea                              | 39 (12.2)           | 2 (0.6)             | 78 (14.9)          | 8 (1.5)            | 28 (11.4)             | 39 (0.32)             | 1 (0.4)               | 1 (0.01)              | 13 (11.9)             | 13 (1.09)             | 2 (1.8)               | 2 (0.17)              |
| Platelet count decreased               | 39 (12.2)           | 36 (11.3)           | 57 (10.9)          | 52 (10.0)          | 32 (13.0)             | 88 (0.72)             | 30 (12.2)             | 66 (0.54)             | 15 (13.8)             | 42 (3.53)             | 14 (12.8)             | 35 (2.94)             |
| Nausea                                 | 36 (11.3)           | 1 (0.3)             | 56 (10.7)          | 2 (0.4)            | 33 (13.4)             | 40 (0.33)             | 0                     | 0                     | 25 (22.9)             | 26 (2.18)             | 0                     | 0                     |
| Blood alkaline phosphatase increased   | 35 (11.0)           | 1 (0.3)             | 43 (8.2)           | 1 (0.2)            | 31 (12.6)             | 44 (0.36)             | 1 (0.4)               | 1 (0.01)              | 2 (1.8)               | 2 (0.17)              | 0                     | 0                     |
| Fatigue                                | 33 (10.3)           | 3 (0.9)             | 60 (11.5)          | 8 (1.5)            | 23 (9.3)              | 34 (0.28)             | 0                     | 0                     | 7 (6.4)               | 8 (0.67)              | 0                     | 0                     |
| Blood creatine phosphokinase increased | 32 (10.0)           | 8 (2.5)             | 58 (11.1)          | 19 (3.6)           | 26 (10.6)             | 54 (0.44)             | 6 (2.4)               | 6 (0.05)              | 0                     | 0                     | 0                     | 0                     |
| White bloodcell count decreased        | 32 (10.0)           | 29 (9.1)            | 39 (7.5)           | 36 (6.9)           | 29 (11.8)             | 101 (0.83)            | 26 (10.6)             | 72 (0.59)             | 14 (12.8)             | 20 (1.68)             | 14 (12.8)             | 19 (1.60)             |
| Neutrophil count decreased             | 30 (9.4)            | 28 (8.8)            | 39 (7.5)           | 36 (6.9)           | 25 (10.2)             | 66 (0.54)             | 24 (9.8)              | 54 (0.44)             | 9 (8.3)               | 17 (1.43)             | 9 (8.3)               | 12 (1.01)             |
| Constipation                           | 25 (7.8)            | 0                   | 42 (8.0)           | 0                  | 19 (7.7)              | 23 (0.19)             | 0                     | 0                     | 8 (7.3)               | 8 (0.67)              | 0                     | 0                     |
| Neutropenia                            | 25 (7.8)            | 25 (7.8)            | 34 (6.5)           | 33 (6.3)           | 21 (8.5)              | 38 (0.31)             | 21 (8.5)              | 31 (0.25)             | 9 (8.3)               | 10 (0.84)             | 8 (7.3)               | 6 (0.76)              |
| Dysgeusia                              | 21 (6.6)            | 0                   | 38 (7.3)           | 0                  | 16 (6.5)              | 16 (0.13)             | 0                     | 0                     | 2 (1.8)               | 2 (0.17)              | 0                     | 0                     |
| Pyrexia                                | 21 (6.6)            | 2 (0.6)             | 29 (5.6)           | 2 (0.4)            | 16 (6.5)              | 21 (0.17)             | 2 (0.8)               | 2 (0.02)              | 9 (8.3)               | 11 (0.92)             | 3 (2.8)               | 3 (0.25)              |
| ElectrocardiogramQT prolonged          | 20 (6.3)            | 3 (0.9)             | 29 (5.6)           | 6 (1.1)            | 12 (4.9)              | 15 (0.12)             | 1 (0.4)               | 1 (0.01)              | 0                     | 0                     | 0                     | 0                     |
| Headache                               | 20 (6.3)            | 0                   | 26 (5.0)           | 0                  | 18 (7.3)              | 25 (0.21)             | 0                     | 0                     | 5 (4.6)               | 7 (0.59)              | 0                     | 0                     |
| Vomiting                               | 20 (6.3)            | 1 (0.3)             | 32 (6.1)           | 3 (0.6)            | 14 (5.7)              | 17 (0.14)             | 0                     | 0                     | 10 (9.2)              | 10 (0.84)             | 0                     | 0                     |
| Decreased appetite                     | 19 (6.0)            | 0                   | 30 (5.7)           | 1 (0.2)            | 14 (5.7)              | 16 (0.13)             | 0                     | 0                     | 11 (10.1)             | 11 (0.92)             | 4 (3.7)               | 4 (0.34)              |
| Myalgia                                | 17 (5.3)            | 0                   | 26 (5.0)           | 2 (0.4)            | 15 (6.1)              | 18 (0.15)             | 0                     | 0                     | 0                     | 0                     | 0                     | 0                     |
| Oedema peripheral                      | 16 (5.0)            | 0                   | 31 (5.9)           | 1 (0.2)            | 7 (2.8)               | 8                     | 0                     | 0                     | 5 (4.6)               | 5 (0.42)              | 0                     | 0                     |
| Rash                                   | 16 (5.0)            | 0                   | 20 (3.8)           | 0                  | 11 (4.5)              | (0.07) 12 (0.10)      | 0                     | 0                     | 3 (2.8)               | 3 (0.25)              | 0                     | 0                     |

<div style=\"page-break-after: always\"></div>

- Adverse Drug Reactions Based on Preferred Term

Table 50 Adverse Reactions -Integrated R/R AML Safety Population

| MedDRA v19.1 System Organ Class                      | Integrated Gilteritinib 120 mg (N=319)   | Integrated Gilteritinib 120 mg (N=319)   | Integrated Gilteritinib 120 mg (N=319)   |
|------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Adverse Drug Reaction, n (%)                         | All Grades %                             | Grades 3/4 %                             | Frequency categoryt                      |
| Cardiac disorders                                    |                                          |                                          |                                          |
| Pericardial effusion                                 | 13 (4.1)                                 | 3 (0.9)                                  | Common                                   |
| Pericarditis                                         | 5 (1.6)                                  | 0                                        | Uncommon                                 |
| Cardiac failure                                      | 4 (1.3)                                  | 4 (1.3)                                  | Uncommon                                 |
| Gastrointestinal disorders                           |                                          |                                          |                                          |
| Diarrhoea                                            | 112 (35.1)                               | 13 (4.1)                                 | Very common                              |
| Nausea                                               | 95 (29.8)                                | 6 (1.9)                                  | Very common                              |
| Constipation                                         | 90 (28.2)                                | 2 (0.6)                                  | Very common                              |
| General disorders and administration site conditions |                                          |                                          |                                          |
| Fatigue                                              | 97 (30.4)                                | 10 (3.1)                                 | Very common                              |
| Oedema Peripheral                                    | 77 (24.1)                                | 1 (0.3)                                  | Very common                              |
| Asthenia                                             | 44 (13.8)                                | 8 (2.5)                                  | Very common                              |
| Malaise                                              | 14 (4.4)                                 | 0                                        | Common                                   |
| Immune system disorders                              |                                          |                                          |                                          |
| Anaphylactic reaction                                | 4 (1.3)                                  | 4 (1.3)                                  | Common                                   |
| Investigations                                       |                                          |                                          |                                          |
| Blood creatine phosphokinase increased               | 298 (93.4)                               | 10 (3.1)                                 | Very common                              |
| Alanine aminotransferase increased                   | 262 (82.1)                               | 41 (12.9)                                | Very common                              |
| Aspartate aminotransferase increased                 | 257 (80.6)                               | 33 (10.3)                                | Very common                              |
| Blood alkaline phosphatase increased                 | 219 (68.7)                               | 5 (1.6)                                  | Very common                              |
| Electrocardiogram QT prolonged                       | 28 (8.8)                                 | 8 (2.5)                                  | Common                                   |
| Musculoskeletal and connective tissue disorders      |                                          |                                          |                                          |
| Pain in extremity                                    | 47 (14.7)                                | 2 (0.6)                                  | Very common                              |
| Arthralgia                                           | 40 (12.5)                                | 4 (1.3)                                  | Very common                              |
| Myalgia                                              | 40 (12.5)                                | 1 (0.3)                                  | Very common                              |
| Musculoskeletal pain                                 | 13 (4.1)                                 | 1 (0.3)                                  | Common                                   |
| Nervous system disorders                             |                                          |                                          |                                          |
| Dizziness                                            | 65 (20.4)                                | 1 (0.3)                                  | Very common                              |
| Posterior reversible encephalopathy syndrome         | 2 (0.6)                                  | 2 (0.6)                                  | Uncommon                                 |
| Respiratory, thoracic and mediastinal disorder's     |                                          |                                          |                                          |
| Cough                                                | 90 (28.2)                                | 1 (0.3)                                  | Very common                              |
| Dyspnea                                              | 77 (24.1)                                | 14 (4.4)                                 | Very common                              |
| Vascular disorders                                   |                                          |                                          |                                          |
| Hypotension                                          | 55 (17.2)                                | 23 (7.2)                                 | Very common                              |

AML: acute myeloid leukemia; R/R: relapsed or reffractory.

âFrequency categories are defined as follows: very common (â¥1/10); common (â¥1/100 to &lt;1/10); uncommon (â¥1/1,000 to &lt;1/100); rare (â¥1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Frequency is based on central laboratory values, further described in [Module 5.3.5.3, ISS Table 40]

<div style=\"page-break-after: always\"></div>

## Adverse events of interest

- Posterior reversible encephalopathy syndrome (PRES)

Overall, 0.6% (3/522) of patients in the gilteritinib total group experienced the TEAE of PRES PT. In the integrated gilteritinib 120 mg group, 0.6% (2/319) of patients experienced the TEAE of PRES PT. These TEAEs were serious and grade â¥ 3; none resulted in death. In Study 2215-CL-0301, 0.4% (1/246) of gilteritinib  120  mg-treated  patients  experienced  the  TEAE  of  PRES,  compared  to  no  patients  in  the chemotherapy group (0/109).

In addition, 1 patient enrolled in the compassionate use program for gilteritinib (developed PRES 18 days after the last dose of gilteritinib.

- Differentiation syndrome

Of  319  patients  treated  with  Xospata  in  the  clinical  studies,  11  (3%)  experienced  differentiation syndrome. Differentiation syndrome occurred as early as two days and up to 75 days after  Xospata initiation  and  has  been  observed  with  or  without  concomitant  leukocytosis.  Of  the  11  patients  who experienced differentiation syndrome, 9 (82%) recovered after treatment or after dose interruption of Xospata (SmPC, section 4.8).

- QT prolongation

In the integrated gilteritinib 120 mg group, TEAEs within this category of arrhythmia of QT prolongation were  experienced  by  totally  15.7%  (50/319)  of  patients,  and  were  deemed  drug-related  in  7.2% (23/319)  of  patients  in  this  population.  The  most  frequent  TEAEs  were  ECG  QT  prolonged  (8.8% [28/319]; drug-related in 6.3% [20/319]) and syncope (5.0% [16/319]); drug-related in 0.6% [2/319]). One patient (0.3% [1/319]) experienced drug-related ventricular fibrillation.

Serious TEAEs were experienced by 5.3% (17/319) of patients and considered drug-related SAEs in 6 patients  (1.9%),  these  were  ECG  QT  prolonged  (3  patients),  syncope  (2  patients)  and  ventricular fibrillation (1 patient).

Of the 317 patients treated with gilteritinib at 120 mg with a post baseline QTC value in clinical studies, 4 patients (1%) experienced a QTcF &gt;500 msec. Additionally, across all doses, 12 patients (2.3%)  with relapsed/refractory AML had a maximum post baseline QTcF interval &gt;500 msec (SmPC, section 4.8).

- Serious gastrointestinal disorders

Overall, 11.3% (59/522) of patients in the gilteritinib total group experienced a TEAE of GI disorder. In the integrated gilteritinib 120 mg group, 10.3% (33/319) of patients experienced an event of GI disorder. These TEAEs were serious; 2 TEAE of GI disorder (in Study 2215-CL-0301) resulted in death. In Study 2215-CL-0301, 0.8% (2/246) of gilteritinib 120 mg-treated patients experienced a TEAE of GI disorder compared to 0.9% patients in the chemotherapy group (1/109).

- Eye disorders

Overall, 32.6% (170/522) of patients in the gilteritinib total group experienced a TEAE of eye disorders and 0.6% were serious non-fatal TEAEs (3/522). In the integrated gilteritinib 120 mg group, 39.2% (125/319) of patients experienced an event of eye disorders. These TEAEs were not serious; no TEAE of eye disorders (in Study 2215-CL-0301) resulted in death. In Study 2215-CL-0301, 39.4% (97/246) of gilteritinib 120 mg-treated patients experienced a TEAE of eye disorders compared to 11.0% patients in the chemotherapy group (12/109).

In the integrated gilteritinib 120 mg group, mean (SD) changes in mean visual acuity were 3.402 dB (8.486 dB) and 4.790 dB (10.666 dB) for patients ' left and right eyes, respectively, with median (min, max) changes of 1.180 dB (-5.62, 60.00) and 1.980 dB (-5.85, 62.52). Two patients in the integrated

<div style=\"page-break-after: always\"></div>

gilteritinib  120  mg  group  (both  in  Study  2215-CL-0301)  discontinued  treatment  due  to  a  TEAE  of retinopathy; no other TEAEs leading to discontinuation were reported in the system organ class (SOC) of Eye Disorders.

Four treatment-emergent SAEs in the SOC of Eye Disorders were reported for 3 patients in the integrated gilteritinib 120 mg group. Two of these events were experienced by 1 patient in Study 2215-CL-0301 who experienced a Grade 2 event of ocular hyperemia and a Grade 2 event of vision blurred; both events were considered not related to gilteritinib and were reported on the same day. The other 2 events were experienced by 1 patient each, both in Study 2215-CL-0101; 1 patient experienced a Grade 3 event of conjunctival edema, considered possibly related to gilteritinib, and 1 patient experienced a worsening of baseline papilledema considered not related to gilteritinib. No TEAE of eye disorders (in Study 2215-CL0301) resulted in death.

## Â· Pulmonary adverse events

Overall, 64.4% (336/522) of patients in the gilteritinib total group experienced a pulmonary TEAE. In the integrated gilteritinib 120 mg group, 65.2% (208/319) of patients experienced a pulmonary event; 15.4  %  (49/319)  of  patients  experienced  a  serious  pulmonary  event;  and  2.5%  (8/319)  patients experienced  a  pulmonary  event  that  resulted  in  death.  In  Study  2215-CL-0301,  7  (2.8%)  patients experienced a pulmonary event that resulted in death. In Study 2215-CL-0301, 66.3% (163/246) of gilteritinib 120 mg-treated patients experienced a pulmonary TEAE compared to 34.9% of patients in the chemotherapy group (38/109), however when adjusted for exposure of events per patient year, the pulmonary AE rate is 4.03% in the gilteritinib 120 mg treated patients compared to 5.88% of patients in the chemotherapy group.

## Â· Pancreatitis

In the integrated gilteritinib 120 mg group, TEAEs within this category were experienced by 0.9% (3/319) of patients. The only TEAE by preferred term (PT) within this category was pancreatitis (0.9% [3/319]). Drug-related  TEAEs  within  this  category  were  not  experienced  by  any  patients  in  the  integrated gilteritinib 120 mg group.  Grade 3 or higher TEAEs within this category were experienced by 0.3% (1/319) of patients in the integrated gilteritinib 120 mg group and none were considered drug-related. Serious TEAEs within this category were experienced by 0.9% (3/319) of patients in the integrated gilteritinib 120 mg group and none were considered drug-related.

## Â· Cardiac Failure

In  the  integrated  gilteritinib  120  mg  group,  TEAEs  within  this  category  were  experienced  by  6.6% (21/319) of patients. The most frequent TEAEs by PT within this category were pulmonary edema (3.4% [11/319]), ejection fraction decreased (1.6% [5/319]) and cardiac failure (1.3% [4/319]). Drug-related TEAEs within this category were experienced by 1.6% (5/319) of patients in the integrated gilteritinib 120 mg group. Grade 3 or higher TEAEs within this category were experienced by 3.8% (12/319) of patients in the integrated gilteritinib 120 mg group. Drug-related Grade 3 or higher TEAEs within this category were experienced by 4 patients (1.3%) in the integrated gilteritinib 120 mg group (PTs: cardiac failure [2 patients], cardiac failure congestive [1 patient] and ejection fraction decreased [2 patients])

Serious TEAEs within this category were experienced by 1.9% (6/319) of patients in the integrated gilteritinib 120 mg group. Drug-related SAEs within this category were experienced by 3 patients (0.9%) in the integrated gilteritinib 120 mg group (PTs: cardiac failure [2 patients] and cardiac failure congestive [1 patient]).

## Â· Hypersensitivity/Anaphylaxis

In the integrated gilteritinib 120 mg group, TEAEs within this category were experienced by 40.4% (129/319) of patients. The most frequent TEAEs by PT within this category were rash (15.0% [48/319])

<div style=\"page-break-after: always\"></div>

and face edema (5.3% [17/319]). Drug-related TEAEs within this category were experienced by 13.5% (43/319) of patients in the integrated gilteritinib 120 mg group.  Grade 3 or higher TEAEs within this category were experienced by 7.8% (25/319) of patients in the integrated gilteritinib 120 mg group, including 1.3% (4/319) of patients who experienced an anaphylactic reaction. Drug-related grade 3 or higher TEAEs within this category were experienced by 2.5% (8/319) in this population including 0.3% (1/319) of patients who experienced an anaphylactic reaction.

Serious TEAEs within this category were experienced by 4.4% (14/319) of patients in the integrated gilteritinib 120 mg group, including 1.3% (4/319) of patients who experienced an anaphylactic reaction. Drug-related SAEs within this category were experienced by 1.6% (5/319) in the integrated gilteritinib 120 mg group, including 0.3% (1/319) of patients who experienced an anaphylactic reaction.

## Serious adverse event/deaths/other significant events

## Serious adverse events

In the integrated gilteritinib 120 mg group, 33.9% (108/319) of patients experienced at least 1 drugrelated SAE. The most frequently reported drug-related SAEs by MedDRA PT were febrile neutropenia (7.5% [24/319]), ALT increased (3.4% [11/319]) and AST increased (3.1% [10/319]).

Table 51 Serious Treatment-emergent Adverse Events ( â¥ 2% of Integrated Gilteritinib 120 mg Patients) by Preferred Term and Relationship to Study Drug -Integrated R/R AML Safety Population

| MedDRA (V19.1) PreferredTerm         | Integrated Datat   | Integrated Datat   | Integrated Datat   | Integrated Datat   | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301   | Study2215-CL-0301   |
|--------------------------------------|--------------------|--------------------|--------------------|--------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| MedDRA (V19.1) PreferredTerm         | Gilteritinib 120mg | Gilteritinib 120mg | Gilteritinib Total | Gilteritinib Total | Gilteritinib 120mg  | Gilteritinib 120mg  | Gilteritinib 120mg  | Gilteritinib 120mg  | Chemo               | Chemo               | Chemo               | Chemo               |
| MedDRA (V19.1) PreferredTerm         | N=319              | N=319              | N=522              | N=522              | N=246               | PY=121.7 E(E/PY)    | N=246               | PY=121.7 E(E/PY)    | N=109               | PY=11.9 E(E/PY)     | N=109               | PY=11.9 E(E/PY)     |
| MedDRA (V19.1) PreferredTerm         | All                | Drug- Relatedt     | All                | Drug- Relatedt     | All                 | All                 | Drug-Relatedt       | Drug-Relatedt       | All                 | All                 | Drug-Related:       | Drug-Related:       |
| Overall, n (%)                       | 258 (80.9)         | 108 (33.9)         | 425 (81.4)         | 170 (32.6)         | 205 (83.3)          | 865 (7.11)          | 88 (35.8)           | 193 (1.59)          | 34 (31.2)           | 110 (9.24)          | 16 (14.7)           | 35 (2.94)           |
| Febrile neutropenia                  | 95 (29.8)          | 24 (7.5)           | 157 (30.1)         | 29 (5.6)           | 76 (30.9)           | 112 (0.92)          | 23 (9.3)            | 28 (0.23)           | 9 (8.3)             | 15 (1.26)           | 3 (2.8)             | 3 (0.25)            |
| Acute myeloid leukaemia              | 43 (13.5)          | 0                  | 82 (15.7)          | 0                  | 33 (13.4)           | 38 (0.31)           | 0                   | 0                   | 4 (3.7)             | 6 (0.50)            | 0                   | 0                   |
| Pyrexia                              | 42 (13.2)          | 3 (0.9)            | 54 (10.3)          | 6 (1.1)            | 32 (13.0)           | 43 (0.35)           | 2 (0.8)             | 2 (0.02)            | 1 (0.9)             | 2 (0.17)            | 0                   | 0                   |
| Pneumonia                            | 39 (12.2)          | 7 (2.2)            | 61 (11.7)          | 8 (1.5)            | 26 (10.6)           | 40 (0.33)           | 7 (2.8)             | 14 (0.12)           | 4 (3.7)             | 6 (0.50)            | 3 (2.8)             | 3 (0.25)            |
| Sepsis                               | 28 (8.8)           | 3 (0.9)            | 19 (11.7)          | 4 (0.8)            | 18 (7.3)            | 23 (0.19)           | 3 (1.2)             | 3 (0.02)            | 7 (6.4)             | 11 (0.92)           | 3 (2.8)             | 5 (0.42)            |
| Acutekidney injury                   | 21 (6.6)           | 5 (1.6)            | 44 (8.4)           | 8 (1.5)            | 16 (6.5)            | 20 (0.16)           | 3 (1.2)             | 3 (0.02)            | 4 (3.7)             | 5 (0.42)            | 2 (1.8)             | 2 (0.17)            |
| Lung infection                       | 16 (5.0)           | 0                  | 24 (4.6)           | 0                  | 14 (5.7)            | 17 (0.14)           | 0                   | 0                   | 5 (4.6)             | 6 (0.50)            | 2 (1.8)             | 3 (0.25)            |
| Diarrhoea                            | 15 (4.7)           | 2 (0.6)            | 24 (4.6)           | 6 (1.1)            | 10 (4.1)            | 13 (0.11)           | 1 (0.4)             | 3 (0.02)            | 0                   | 0                   | 0                   | 0                   |
| Alanine aminotransferase increased   | 13 (4.1)           | 11 (3.4)           | 15 (2.9)           | 13 (2.5)           | 13 (5.3)            | 17 (0.14)           | 11 (4.5)            | 15 (0.12)           | 0                   | 0                   | 0                   | 0                   |
| Bacteraemia                          | 12 (3.8)           | 1 (0.3)            | 24 (4.6)           | 2 (0.4)            | 10 (4.1)            | 11 (0.09)           | 1 (0.4)             | 1 (0.01)            | 1 (0.9)             | 1 (0.08)            | 1 (0.9)             | 1 (0.08)            |
| Dyspnoea                             | 11 (3.4)           | 0                  | 14 (2.7)           | 0                  | 10 (4.1)            | 10 (0.08)           | 0                   | 0                   | 2 (1.8)             | 2 (0.17)            | 1 (0.9)             | 1 (0.8)             |
| Aspartate aminotransferase increased | 10 (3.1)           | 10 (3.1)           | 14 (2.7)           | 14 (2.7)           | 10 (4.1)            | 14 (0.12)           | 10 (4.1)            | 14 (0.12)           | 0                   | 14 (0.10)           | 0                   | 0                   |

<div style=\"page-break-after: always\"></div>

| Cellulitis                      | 10 (3.1)   | 2 (0.6)   | 14 (2.7)   | 2 (0.4)   | 6 (2.4)   | 6 (0.05)   | 2 (0.8)   | 2 (0.02)   | 0       | 0        | 0       | 0      |
|---------------------------------|------------|-----------|------------|-----------|-----------|------------|-----------|------------|---------|----------|---------|--------|
| Fall                            | 10 (3.1)   | 1 (0.3)   | 12 (2.3)   | 1 (0.2)   | 8 (3.3)   | 8 (0.07)   | 1 (0.4)   | 1 (0.01)   | 1 (0.9) | 1 (0.08) | 0       | 0      |
| Hypotension                     | 9 (2.8)    | 2 (0.6)   | 16 (3.1)   | (0.8)     | 6 (2.4)   | 9 (0.5)    | 1 (0.4)   | 1 (0.01)   | 1 (0.9) | 1 (0.8)  | 0       | 0      |
| Septic shock                    | 9 (2.8)    | 2 (0.6)   | 16 (3.1)   | 3 (0.6)   | 9 (3.7)   | 15 (0.12)  | 2 (0.8)   | 3 (0.02)   | 1 (0.9) | 1 (0.08) | 0       | 0      |
| Anaemia                         | 8 (2.5)    | 5 (1.6)   | 15 (2.9)   | 6 (1.1)   | 8 (3.3)   | 10 (0.08)  | 5 (2.0)   | 5 (0.04)   | 0       | 0        | 0       | 0      |
| Respiratory failure             | 8 (2.5)    | 3 (0.9)   | 24 (4.6)   | (0.8)     | 7 (2.8)   | 8 (0.07)   | 3 (1.2)   | 3 (0.2)    | 3 (2.8) | 5 (0.42) | 2 (1.8) | (0.34) |
| Syncope                         | 8 (2.5)    | 2 (0.6)   | 13 (2.5)   | 3 (0.6)   | 7 (2.8)   | 8 (0.07)   | 2 (0.8)   | 2 (0.02)   | 0       | 0        | 0       | 0      |
| Acutemyeloidleukaemia recurrent | 7 (2.2)    | 0         | 8 (1.5)    | 0         | 7 (2.8)   | 6 (0.07)   | 0         | 0          | 0       | 0        | 0       | 0      |
| Pneumonia fungal                | 7 (2.2)    | 0         | 13 (2.5)   | 0         | 2 (0.8)   | 2 (0.02)   | 0         | 0          | 0       | (0.01)   | 0       | 0      |

## Deaths

In the integrated gilteritinib 120 mg group, 70.8% (226/319) of patients died due to any cause. In the integrated gilteritinib 120 mg group, 29.8% (95/319) of patients experienced TEAEs leading to death. AML was the most common TEAE leading to death (11.9% [38/319]), followed by septic shock (2.2% [7/319]), sepsis (1.9% [6/319]), pneumonia (1.6% [5/319]) and cardiac arrest and lung infection (1.3% [4/319], each); all other TEAEs leading to death were reported in &lt; 1.0% of patients in the integrated gilteritinib 120 mg group. TEAEs leading to death were considered drug-related by the Investigator for 3.8%  (12/319)  of  patients  in  the  integrated  gilteritinib  120  mg  group.  These  included  3  events  of pneumonia (0.9%), 2 events each of large intestine perforation and septic shock (0.6%) and 1 event each of cardiac failure  congestive,  cellulitis,  cerebral  hemorrhage,  depressed  level of  consciousness, intestinal ischemia, neutropenia, respiratory failure, sepsis and ventricular fibrillation (0.3%, each).

## Laboratory findings

## Haematology parameters

The table below shows haematology laboratory shifts from baseline to worst post baseline NCI-CTCAE (National Cancer Institute- Common Terminology Criteria for Adverse Events) (v4.03) Grade â¥ 3 for ANC, haemoglobin and platelets. Baseline was defined as the last available measurement prior to the first dose of gilteritinib. Worst post baseline was based on the worst case of all the post baseline visits including unscheduled visits of a patient.

<div style=\"page-break-after: always\"></div>

Table 52 Hematology Laboratory Results: Shift Table From Baseline to Worst Postbaseline by NCICTCAE (V4.03) Grade â¥ 3 Integrated R/R AML Safety Population

| Treatment Group            | Worst Postbaseline Grade           | Baseline Grade, n (%) Laboratory Test=Neutrophil Countfor Low   | Baseline Grade, n (%) Laboratory Test=Neutrophil Countfor Low   | Baseline Grade, n (%) Laboratory Test=Neutrophil Countfor Low   | Baseline Grade, n (%) Laboratory Test=Neutrophil Countfor Low   | Baseline Grade, n (%) Laboratory Test=Neutrophil Countfor Low   | Baseline Grade, n (%) Laboratory Test=Neutrophil Countfor Low   | Baseline Grade, n (%) Laboratory Test=Neutrophil Countfor Low   |
|----------------------------|------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Treatment Group            | Worst Postbaseline Grade           | GradeO                                                          | Grade 1                                                         | Grade 2                                                         | Grade 3                                                         | Grade 4                                                         | Total                                                           | No Data                                                         |
| Gilteritinib 120 mg        | Grade 3                            | 11 (12.4)                                                       | 0                                                               | 5 (16.1)                                                        | 1 (2.5)                                                         | 4 (2.8)                                                         | 21                                                              | 1                                                               |
| Gilteritinib 120 mg        | Grade 4                            | 65 (73.0)                                                       | 0                                                               | 25 (80.6)                                                       | 36 (90.0)                                                       | 138 (96.5)                                                      | 264                                                             | 4                                                               |
| Gilteritinib 120 mg        | Total                              | 89                                                              | 0                                                               | 31                                                              | 40                                                              | 143                                                             | 303                                                             | 7                                                               |
| Gilteritinib 120 mg        | No Data                            | 1                                                               | 0                                                               | 0                                                               | 0                                                               | 2                                                               | 3                                                               | 6                                                               |
| GilteritinibTotal          | Grade 3                            | 16 (12.9)                                                       | 0                                                               | 9 (20.9)                                                        | 4 (6.5)                                                         | 5 (2.0)                                                         | 34                                                              | 1                                                               |
| GilteritinibTotal          | Grade 4                            | 84 (67.7)                                                       | 0                                                               | 31 (72.1)                                                       | 54 (87.1)                                                       | 242 (96.8)                                                      | 411                                                             | 6                                                               |
| GilteritinibTotal          | Total                              | 124                                                             | 0                                                               | 43                                                              | 62                                                              | 250                                                             | 479                                                             | 9                                                               |
| GilteritinibTotal          | No Data                            | 4                                                               | 0                                                               | 0                                                               | 0                                                               | 3                                                               | 7                                                               | 27                                                              |
| CL-0301                    | Grade 3                            | 10 (13.2)                                                       | 0                                                               | 5 (20.0)                                                        | 1 (3.3)                                                         | 2 (1.9)                                                         | 18                                                              | 1                                                               |
| Gilteritinib 120 mg        | Grade 4                            | 56 (73.7)                                                       | 0                                                               | 19 (76.0)                                                       | 26 (86.7)                                                       | 102 (97.1)                                                      | 203                                                             | 3                                                               |
| Gilteritinib 120 mg        | Total                              | 76                                                              | 0                                                               | 25                                                              | 30                                                              | 105                                                             | 236                                                             | 6                                                               |
| Gilteritinib 120 mg        | No Data                            | 1                                                               | 0                                                               | 0                                                               | 0                                                               | 2                                                               | 3                                                               | 1                                                               |
| CL-0301                    | Grade 3                            | 4 (9.8)                                                         | 0                                                               | 0                                                               | 1 (9.1)                                                         | 2 (4.9)                                                         | 7                                                               | 0                                                               |
| Chemo                      | Grade 4                            | 29 (70.7)                                                       | 0                                                               | 8 (80.0)                                                        | 8 (72.7)                                                        | 33 (80.5)                                                       | 78                                                              | 0                                                               |
| Chemo                      | Total                              | 41                                                              | 0                                                               | 10                                                              | 11                                                              | 41                                                              | 103                                                             | 0                                                               |
| Chemo                      | No Data                            | 4                                                               | 0                                                               | 0                                                               | 0                                                               | 2                                                               | 6                                                               | 0                                                               |
|                            | LaboratoryTest =Hemoglobin for Low | LaboratoryTest =Hemoglobin for Low                              | LaboratoryTest =Hemoglobin for Low                              | LaboratoryTest =Hemoglobin for Low                              | LaboratoryTest =Hemoglobin for Low                              | LaboratoryTest =Hemoglobin for Low                              | LaboratoryTest =Hemoglobin for Low                              | LaboratoryTest =Hemoglobin for Low                              |
|                            |                                    | Grade O                                                         | Grade 1                                                         | Grade 2                                                         | Grade3                                                          | Grade4                                                          | Total                                                           | No Data                                                         |
| Gilteritinib 120 mg        | Grade 3                            | 6 (35.3)                                                        | 44 (46.8)                                                       | 112 (73.2)                                                      | 35 (83.3)                                                       | 0                                                               | 197                                                             | 5                                                               |
| Gilteritinib 120 mg        | Grade 4                            | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               |
| Gilteritinib 120 mg        | Total                              | 17                                                              | 94                                                              | 153                                                             | 42                                                              | 0                                                               | 306                                                             | 8                                                               |
| Gilteritinib 120 mg        | No Data                            | 0                                                               | 0                                                               | 2                                                               | 1                                                               | 0                                                               | 3                                                               | 2                                                               |
| GilteritinibTotal          | Grade 3                            | 7 (31.8)                                                        | 64 (44.8)                                                       | 168 (66.7)                                                      | 70 (82.4)                                                       | 0                                                               | 309                                                             | 6                                                               |
| GilteritinibTotal          | Grade 4                            | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               |
| GilteritinibTotal          | Total                              | 22                                                              | 143                                                             | 252                                                             | 85                                                              | 0                                                               | 502                                                             | 10                                                              |
| GilteritinibTotal          | No Data                            | 0                                                               | 1                                                               | 5                                                               | 1                                                               | 0                                                               | 7                                                               | 3                                                               |
| CL-0301 Gilteritinib 120mg | Grade3                             | 5(33.3)                                                         | 35 (44.3)                                                       | 82 (74.5)                                                       | 24 (77.4)                                                       | 0                                                               | 146                                                             | 4                                                               |
| CL-0301 Gilteritinib 120mg | Grade4                             |                                                                 | 0                                                               | 0                                                               |                                                                 | 0                                                               |                                                                 |                                                                 |
| CL-0301 Gilteritinib 120mg | Total                              | 15                                                              | 79                                                              | 110                                                             | 31                                                              | 0                                                               | 235                                                             | 7                                                               |
| CL-0301 Gilteritinib 120mg | NoData                             | 0                                                               | 0                                                               | 2                                                               | 1                                                               | 0                                                               | 3                                                               | 1                                                               |
| CL-0301 Chemo              | Grade3                             | 5 (50.0)                                                        | 12(36.4)                                                        | 22(42.3)                                                        | 6 (60.0)                                                        | 0                                                               | 45                                                              | 0                                                               |
|                            | Grade4                             | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               |
|                            | Total                              | 10                                                              | 33                                                              | 52                                                              | 10                                                              | 0                                                               | 105                                                             | 0                                                               |
|                            | NoData                             | 0                                                               | 3                                                               | 0                                                               | 1                                                               | 0                                                               | 4                                                               | 0                                                               |
|                            | Baseline Grade,n(%)                | Baseline Grade,n(%)                                             | Baseline Grade,n(%)                                             | Baseline Grade,n(%)                                             | Baseline Grade,n(%)                                             | Baseline Grade,n(%)                                             | Baseline Grade,n(%)                                             | Baseline Grade,n(%)                                             |
|                            | LaboratoryTest=PlateletsforLow     | LaboratoryTest=PlateletsforLow                                  | LaboratoryTest=PlateletsforLow                                  | LaboratoryTest=PlateletsforLow                                  | LaboratoryTest=PlateletsforLow                                  | LaboratoryTest=PlateletsforLow                                  | LaboratoryTest=PlateletsforLow                                  | LaboratoryTest=PlateletsforLow                                  |
|                            |                                    | Grade0Ã·                                                         | Grade1                                                          | Grade2                                                          | Grade3                                                          | Grade4                                                          | Total                                                           | NoData                                                          |
| Gilteritinib120mg          | Grade3                             | 5 (15.2)                                                        | 19(35.8)                                                        | 7(13.7)                                                         | 7 (8.3)                                                         | 2(2.4)                                                          | 40                                                              | 2                                                               |
| Gilteritinib120mg          | Grade4                             | 12(36.4)                                                        | 22 (41.5)                                                       | 39 (76.5)                                                       | 76 (90.5)                                                       | 83 (97.6)                                                       | 232                                                             | 5                                                               |
| Gilteritinib120mg          | Total                              | 33                                                              | 53                                                              | 51                                                              | 84                                                              | 85                                                              | 306 3                                                           | 8                                                               |
| GilteritinibTotal          | Grade3                             | 8(15.7)                                                         | 1 24 (30.8)                                                     | 0 12 (16.2)                                                     | 1                                                               | 5(3.3)                                                          | 67                                                              | 2 2                                                             |
| GilteritinibTotal          | NoData                             | 0                                                               | 39 (50.0)                                                       | 54 (73.0)                                                       | 18 (12.2)                                                       | 1                                                               | 383                                                             | 7                                                               |
| GilteritinibTotal          | Grade4 Total                       | 16(31.4) 51                                                     | 78                                                              | 74                                                              | 128(86.5) 148                                                   | 146 (96.7) 151                                                  | 502                                                             | 10                                                              |
| GilteritinibTotal          | NoData                             | 0                                                               | 1                                                               | 0                                                               | 4                                                               | 2                                                               | 7                                                               | 3                                                               |
| CL-0301                    | Grade3                             | 5(17.9)                                                         | 18 (39.1)                                                       | 4(10.0)                                                         | 5(8.6)                                                          | 1(1.6)                                                          | 33                                                              | 2                                                               |
| Gilteritinib120mg          | Grade4                             | 9 (32.1)                                                        | 18 (39.1)                                                       | 32 (80.0)                                                       | 52 (89.7)                                                       | 62(98.4)                                                        | 173                                                             | 4                                                               |
|                            | Total                              | 28                                                              | 46                                                              | 40                                                              | 58                                                              | 63                                                              | 235                                                             | 7                                                               |
|                            | NoData                             | 0                                                               | 1                                                               | 0                                                               | 1                                                               | 1                                                               | 3                                                               | 1                                                               |
| CL-0301                    | Grade3                             | 3 (20.0)                                                        | 3(11.1)                                                         | 5 (41.7)                                                        | 2(7.7)                                                          | 0                                                               | 13                                                              | 0                                                               |
| Chemo                      | Grade4                             | 9 (60.0)                                                        | 20 (74.1)                                                       | 7(58.3)                                                         | 24(92.3)                                                        | 24(96.0)                                                        | 84                                                              | 0                                                               |
| Chemo                      | Total                              | 15                                                              | 27                                                              | 12                                                              | 26                                                              | 25                                                              | 105                                                             | 0                                                               |
| Chemo                      | NoData                             | 0                                                               | 0                                                               | 2                                                               | 1                                                               | 1                                                               | 4                                                               | 0                                                               |

## Chemistry

In Table 53, a summary of central chemistry laboratory parameters with Grade 3 or 4 for the integrated R/R AML safety population is provided.

<div style=\"page-break-after: always\"></div>

Table 53 Summary of Central Chemistry Laboratory Parameters with Grade 3 or 4 NCI-CTCAE (V4.03) - Integrated R/R AML Safety Population

| Parameter Term (n,%)               |        | IntegratedDatat     | IntegratedDatat    | Study2215-CL-0301   | Study2215-CL-0301   |
|------------------------------------|--------|---------------------|--------------------|---------------------|---------------------|
|                                    |        | Gilteritinib 120 mg | Gilteritinib Total | Gilteritinib 120 mg | Chemo               |
|                                    | Grades | (N= 319)            | (N= 522)           | (N=246)             | (N=109)             |
| Creatinine,increased               | â¥1     | 298 (93.4)          | 491(94.1)          | 228 (92.7)          | 58 (53.2)           |
|                                    | 3/4    | 10 (3.1)            | 17(3.3)            | 6(2.4)              | 0                   |
| Aspartateaminotransferaseincreased | 21     | 257 (80.6)          | 420 (80.5)         | 200 (81.3)          | 42 (38.5)           |
|                                    | 3/4    | 33(10.3)            | 55 (10.5)          | 25 (10.2)           | 2 (1.8)             |
| Hyperglycemia                      | â¥1     | 281(88.1)           | 421 (80.7)         | 232 (94.3)          | 103 (94.5)          |
|                                    | 3/4    | 32(10.0)            | 55 (10.5)          | 29 (11.8)           | 13 (11.9)           |
| Alanine aminotransferase,increased | 21     | 262 (82.1)          | 412 (78.9)         | 205 (83.3)          | 52 (47.4)           |
|                                    | 3/4    | 41(12.9)            | 59 (11.3)          | 31 (12.6)           | 3 (2.8)             |
| Hypocalcemia                       | â¥1     | 207 (64.9)          | 354 (67.8)         | 151 (61.4)          | 55 (50.5)           |
|                                    | 3/4    | 19 (6.0)            | 37 (7.1)           | 16 (6.5)            | 4 (3.7)             |
| Hypoalbuminemia,albumin            | â¥1     | 191 (59.9)          | 345 (66.1)         | 133(54.1)           | 48 (44.0)           |
|                                    | 3/4    | 11 (3.4)            | 24 (4.6)           | 8 (3.3)             | 2 (1.8)             |
| Alkalinephosphatase,increased      | 21     | 219 (68.7)          | 357 (68.4)         | 168 (68.3)          | 46 (42.2)           |
|                                    | 3/4    | 5 (1.6)             | 5 (1.0)            | 4 (1.6)             | 0                   |
| Creatine kinaseincreased           | â¥1     | 172 (53.9)          | 276 (52.9)         | 126 (51.2)          | 1 (0.9)             |
|                                    | 3/4    | 20 (6.3)            | 40 (7.7)           | 16 (6.5)            | 0                   |
| Hypophosphatemia                   | â¥1     | 163 (51.1)          | 261 (50.0)         | 119 (48.4)          | 45 (41.3)           |
|                                    | 3/4    | 45 (14.1)           | 74 (14.2)          | 33 (13.4)           | 13 (11.9)           |
| Hypokalemia                        | 21     | 108 (33.9)          | 192 (36.8)         | 79 (32.1)           | 55 (50.5)           |
|                                    | 3/4    | 28 (8.8)            | 50 (9.6)           | 19 (7.7)            | 17 (15.6)           |
| Hyponatremia                       | â¥1     | 102 (32.0)          | 158 (30.3)         | 88 (35.8)           | 30 (27.5)           |
| Hyponatremia                       | 3/4    | 38 (11.9)           | 63 (12.1)          | 30 (12.2)           | 7 (6.4)             |
| Hypomagnesemia                     | â¥1     | 60 (18.8)           | 126 (24.1)         | 46 (18.7)           | 19 (17.4)           |
| Hypomagnesemia                     | 3/4    | 0                   | 2 (0.4)            | 0                   | 1(0.9)              |

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Age group

Table 54 Overview of treatment emergent adverse events by age group after treatment with gilteritinib 120 mg- safety analysis set-Integrated R/R AML safety population

| MedDRA Terms                                                                          | Age <65 (N = 183) n (%)   | Age 65-74 (N =96) n (%)   | Age 75-84 (N = 38) n (%)   | Age 85+ (N =2) n (%)   |
|---------------------------------------------------------------------------------------|---------------------------|---------------------------|----------------------------|------------------------|
| Total AEs                                                                             | 181 (98.9)                | 96 (100.0)                | 38 (100)                   | 2 (100.0)              |
| SAEs-Totalt                                                                           | 143 (78.1)                | 77 (80.2)                 | 37 (97.4)                  | 1 (50.0)               |
| - Fatal                                                                               | 42 (23.0)                 | 33 (34.4)                 | 19 (50.0)                  | 1 (50.0)               |
| - Hospitalization/prolong existing hospitalization                                    | 124 (67.8)                | 73 (76.0)                 | 36 (94.7)                  | 1 (50.0)               |
| - Life-threatening                                                                    | 23 (12.6)                 | 15 (15.6)                 | 5 (13.2)                   | 0                      |
| - Disability/incapacity                                                               | 3 (1.6)                   | 2 (2.1)                   | 1 (2.6)                    | 0                      |
| - Other (medically significant)                                                       | 37 (20.2)                 | 19 (19.8)                 | 9 (23.7)                   | 0                      |
| AE leading to drop-out                                                                | 38 (20.8)                 | 22 (22.9)                 | 10 (26.3)                  | 0                      |
| Psychiatrie disorders                                                                 | 50 (27.3)                 | 26 (27.1)                 | 15 (39.5)                  | 1 (50.0)               |
| Nervous system disorders                                                              | 108 (59.0)                | 46 (47.9)                 | 20 (52.6)                  | 1 (50.0)               |
| Accidents and injuriess                                                               | 37 (20.2)                 | 24 (25.0)                 | 12 (31.6)                  | 1 (50.0)               |
| Cardiac disorders                                                                     | 46 (25.1)                 | 20 (20.8)                 | 17 (44.7)                  | 0                      |
| Vascular disorders                                                                    | 77 (42.1)                 | 37 (38.5)                 | 17 (44.7)                  | 1 (50.0)               |
| Cerebrovascular disorderss                                                            | 9 (4.9)                   | 5 (5.2)                   | 4 (10.5)                   | 0                      |
| Infections and infestations                                                           | 132 (72.1)                | 76 (79.2)                 | 33 (86.8)                  | 2 (100.0)              |
| Anticholinergic syndromes                                                             | 113 (61.7)                | 60 (62.5)                 | 28 (73.7)                  | 2 (100.0)              |
| Quality of life decreased                                                             | 0                         | 0                         | 0                          | 0                      |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 56 (30.6)                 | 27 (28.1)                 | 12 (31.6)                  | 1 (50.0)               |

AE: adverse event; AML: acute myeloid leukemia; R/R: relapsed/refractory; SAE: serious adverse event. âIncludes SAEs upgraded by the sponsor based on review of the Sponsor's list of Always Serious terms, if any update was done.

Based on System Organ Class terms.

$Based on Standardized MedDRA Query terms.

IBased on Preferred Terms.

## Gender

A numerical higher incidence of all drug-related TEAEs and Grade 3 or higher TEAEs was reported in females. No meaningful differences were observed in frequencies of drug-related TEAEs or Grade 3 or higher drug-related TEAEs across subgroups of patients with different baseline BW measurements.  A numerical  higher  incidence  of  drug-related  ALT/AST  increased,  febrile  neutropenia,  platelet  count decreased and blood creatine phosphokinase (CK) increased in Asians compared to the white subgroup. Similar observations were made for Grade 3 or higher TEAEs.  All drug-related and Grade 3 or higher drug-related TEAEs were generally similar between subgroups with baseline ECOG status of 0 to 1 vs â¥ 2.  A  numerical  higher  incidence  of  drug  related  ALT  was  reported  in  Asian  patients  were  reported compared to subgroups living in Europe and North America (data not shown).

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No  specific  safety  issues  related  to  possible  DDI  were  identified  (see  also  discussion  on  clinical pharmacology).

## Discontinuation due to adverse events

In the integrated gilteritinib 120 mg group, 10.0% (32/319) of patients reported drug-related TEAEs leading to withdrawal of treatment as assessed by the Investigator. The most frequently reported drugrelated TEAEs leading to withdrawal of treatment as assessed by the Investigator were AST increased (1.3% [4/319]) and ALT increased and pneumonia (0.9% [3/319], each); all other TEAEs leading to withdrawal of treatment were reported in â¤ 2/319 (0.6%) of patients each.

## Post marketing experience

Not applicable

## 2.6.1. Discussion on clinical safety

Overall,  the  analysed  safety  population  is  considered  as  representative  in  terms  of  the  targeted population.

In the integrated gilteritinib 120 mg group, the median average daily dose was 120 mg/day (range 50 to 290 mg/day), and the median duration of exposure was 111 days (range 4 - 1320 days). The median number of dosing days was 106 days, ranging from 4 to 1313 days), and the median relative dose intensity was 100%, ranging from 39% to 227%. Increase in number and duration of the most frequent TEAEs by increasing of exposure time on 120 mg gilteritinib seems not to be related to worsening of the grade of TEAEs. The median duration of â¥ Grade 3 diarrhoea, neutropenia, and pyrexia was highest in the integrated total gilteritinib group. Although there was an increase in TEAEs after 60 days compared to the first 60 days, these events were most likely related to AML progression and worsening of the general condition of the patients, rather than gilteritinib treatment. Follow-up period was defined as 30 days or 28 days after the last dose. The 30- or 28-day follow-up was applied as a standard period required for reporting of all AEs that may occur after discontinuation of a study drug. Patients were followed-up after discontinuation until death or withdrawal of consent. The follow up was reported every 3 months. The presented long-term safety data did not reveal any new safety issues.

In the integrated gilteritinib 120 mg group, 99.4% (317/319) of patients experienced at least 1 TEAE, of which drug-related in 83.1% (265/319) of patients. TEAEs with a maximum NCICTCAE grade â¥3 were experienced by 93.4% (298/319) of patients, and considered drug-related in 60.2% (192/319) of the patients.

The most frequent adverse reactions with gilteritinib were blood CK increased (93.4%), ALT increased (82.1%), AST increased (80.6%), blood alkaline phosphatase increased (68.7%), diarrhoea (35.1%), fatigue (30.4%), nausea (29.8%), constipation (28.2%), cough (28.2%), peripheral oedema (24.1%), dyspnoea  (24.1%),    dizziness  (20.4%),  hypotension  (17.2%),  pain  in  extremity  (14.7%),  asthenia (13.8%), arthralgia (12.5%) and myalgia (12.5%) (SmPC, section 4.8).

The most frequent serious adverse reactions were diarrhoea (4.7%), ALT increased (4.1%), dyspnoea (3.4%),  AST  increased  (3.1%)  and  hypotension  (2.8%).  Other  clinically  significant  serious  adverse reactions included differentiation syndrome (2.2%), ECG QT prolonged (0.9%) and posterior reversible encephalopathy syndrome (0.6%) (SmPC, section 4.8).

<div style=\"page-break-after: always\"></div>

Posterior reversible encephalopathy syndrome (PRES): There have been reports of PRES in patients receiving Xospata (see section 4.8). Of the 319 patients treated with Xospata in the clinical studies, 0.6% experienced PRES. PRES is a rare, reversible, neurological disorder which can present with rapidly evolving symptoms including seizure, headache, confusion, visual and neurological disturbances, with or without associated hypertension and altered mental status. If PRES is suspected, it should be confirmed by  brain  imaging,  preferably  magnetic  resonance  imaging  (MRI).  Symptoms  have  resolved  after discontinuation of treatment. Discontinuation of Xospata in patients who develop PRES is recommended (SmPC sections 4.2 and 4.8). PRES has been categorized as an identified risk (see RMP).

Differentiation  syndrome: Gilteritinib  has  been  associated  with  differentiation  syndrome.  Following reassessment as requested, 11 cases was identified (including 1 fatal case). Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life threatening or fatal if not treated. Symptoms and clinical findings of differentiation syndrome include fever, dyspnoea, pleural effusion, pericardial effusion, pulmonary oedema, hypotension, rapid weight gain, peripheral oedema, rash, and renal dysfunction. If differentiation syndrome is suspected, corticosteroid therapy should be initiated along with hemodynamic monitoring until symptom resolution. If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, Xospata should be interrupted until signs and symptoms are no longer severe. Corticosteroids can be tapered after resolution of symptoms and should be administered for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid treatment (SmPC sections 4.2, 4.4 and 4.8). Differentiation syndrome has been categorized as an identified risk (see RMP).

QT prolongation: In the integrated gilteritinib 120 mg group, the majority of patients experienced an increase in QTcF value from baseline; although the mean value of QTc shows little change with use of gilteritinib,  more  patients  had  abnormally  high  values  while  taking  gilteritinib  than  at  baseline.  No exposure-safety  relationship  (with  respect  to  increased  AST,  ALT,  CK,  and  reduced  ALB)  was characterized. Similar to the exposure-efficacy analysis, there was also an exploratory analysis with limited ability to identify any relationships other than major trends. There is a tendency towards and increased  risk  of  increased  absolute  OTcF  value  in  patients  with  a  cardiac  history.  Regarding  comedication with QT prolonging agents; in the total gilteritinib group (across all doses), 11 out of 12 cases with absolute OTcF values &gt;500 msec were observed in patients receiving one or more QT prolonging agents. Three patients interrupted and re-initiated treatment without recurrence of QT prolongation. There were no reported cases of Torsade de Pointes. An increased risk of QTc prolongation at the 200 mg dose compared to 120 mg dose cannot be excluded. However, Torsade de Pointes is included as a safety concern in the RMP to gain more information about this risk. With the proposed ECG monitoring and dose adjustment guidance stated in the SmPC, this risk is considered acceptable. An additional pharmacovigilance (PhV) activity is also included in the PhV plan to characterise this risk further.

Additionally, concomitant use of CYP3A4 inhibitors (that could lead to increased gilteritinib exposure adding to the observed PK variability) as well as drugs with a known potential to prolong QTc is expected to be common in the target population. In study 0301 &gt;80% and &gt;90%, respectively, received such concomitant treatment.

Gilteritinib  has  been  associated  with  prolonged  cardiac  ventricular  repolarisation  (QT  Interval)  QT prolongation can be observed in the first two months of treatment with gilteritinib. Therefore, ECG should be performed prior to initiation of treatment, on day 15 and prior to the start of the next two subsequent months of treatment. Caution is warranted in patients with relevant cardiac history. Hypokalaemia or hypomagnesaemia may increase the QT prolongation risk. Hypokalaemia or hypomagnesaemia should therefore be corrected prior to and during Xospata treatment (SmPC, sections 4.4, 4.8 and 5.1).

<div style=\"page-break-after: always\"></div>

Xospata should be interrupted in patients who have a QTcF &gt;500 msec. If Xospata is re-introduced at a reduced dose, ECG should be performed on day 8 and 15 and prior to the start of the next two subsequent months of treatment (SmPC, sections 4.2, 4.4).

Serious gastrointestinal disorders: Among gilteritinib-treated patients in clinical trials, the events of GI haemorrhage SMQ, GI perforation SMQ and GI obstruction SMQ were generally grade 1 or 2 and nonserious. Estimated 5.7% (30/522) of patients experienced an AE of grade 3 or higher. In two patients, the  events  of  severe  GI  disorders  led  to  death  and  in  one  patient,  the  event  led  to  treatment discontinuation. Given the severity of the indication being treated, the occurrence of such events in the patient population due to pre-existing conditions and other risk factors, as well as few reports of serious events of GI disorders, the impact on the risk-benefit balance is considered low. An association of the events of GI disorder with gilteritinib therapy has not been confirmed. The overall benefits outweigh the risk in the treatment of AML. Serious GI disorders have been categorized as a potential risk in the RMP and will be followed by routine monitoring (see RMP).

Eye disorders: Ophthalmologic examinations have been performed in the studies to assess visual acuity. Two patients in the integrated gilteritinib 120 mg group (both in Study 2215-CL-0301) discontinued treatment due to a TEAE of retinopathy. Four SAEs in the SOC of Eye Disorders were reported for 3 patients in the integrated gilteritinib 120 mg group. It is unclear whether eye toxicity appears as a single toxicity symptom or always in relation to PRES. From the preclinical documentation, the eye is a target organ of toxicity. Ophthalmologic examinations have been performed in the studies to assess visual acuity, and there are few reports on eye toxicities, including treatment-related AEs. Due to these single reports, it is at present acceptable not to include these events in the product information (PI). However, since eye toxicity is a concern, eye disorders have been categorized a potential risk in the RMP and will be followed by routine monitoring (see RMP).

Pulmonary AEs: In non-clinical studies, lungs were one of the target organs with major findings in rats and dogs. In the integrated population 18.5% (59 patients) experienced pneumonia, of which gradeâ¥3 in 13.5% (43/319), not knowing how many cases are deemed drug-related. In the SOC Respiratory, thoracic and mediastinal disorders a total of 30 patients (9.4%) experienced SAEs, of which 5 patients (1.6%) were drug-related. These five were respiratory failure (3 patients), hypoxia and pleural effusion (1 patient each). In 3 patients (0.9%) experienced TEAE of pneumonia (all considered drug-related) leading to discontinuation of treatment. There were 3 fatal cases due to TEAE of pneumonia. Regarding the serious adverse events (SAEs), there is a clear increase in frequencies in the patients who have escalated to 200 mg dose, including serious events. Differences in SAEs between the patients before dose  escalation  (still  on  120  mg)  and  after  dose  escalation  to  200  mg  is  noted,  including  in  the SOCRespiratory,  thoracic  and  mediastinal  disorders  3.8%  vs.  11.5%  [3  vs  9  patients]).  Pulmonary toxicity may be symptomatically related to differentiation syndrome. Pulmonary AEs have been have been categorized a potential risk in the RMP (see RMP).

Pancreatitis: Within the category of pancreatitis, TEAEs were reported for 0.9% (3/319) patients, of which none were considered related to gilteritinib. Grade 3 or higher TEAEs and Serious TEAEs were reported for 0.3% (1/319) and 0.9% (3/319) respectively, none were considered related.

Patients who develop signs and symptoms suggestive of pancreatitis should be evaluated and monitored. Xospata should be interrupted and can be resumed at a reduced dose when the signs and symptoms of pancreatitis have resolved (SmpC, sections 4.2 and 4.8). Pancreatitis has been categorized a potential risk in the RMP (see RMP).

Hepatotoxicity :  Gilteritinib  is  associated  with  dose-  and  concentration-dependent  increases  in  liver function tests, most notably ALT and AST, and elevations in CK. In general, these increases were mostly Grade  1  or  2  in  severity,  were  reversible  upon  drug  interruption  and  seldom  resulted  in  patient discontinuation  from  treatment.  CK  elevations  were  not  consistently  associated  with  increases  in

<div style=\"page-break-after: always\"></div>

aldolase. Overall, liver enzyme elevations were frequently observed in patients the integrated gilteritinib 120 mg group, and included elevations of &gt;3, &gt;5, &gt;10 and &gt;20 x ULN of ALT and AST, as well elevated total bilirubin values &gt; 2 x ULN  alkaline phosphatase values &gt; 1.5 x ULN.

Renal toxicity: The kidney/urinary bladder are considered target organs of toxicity and clinical relevance of the findings in these organs cannot be excluded as per non-clinical assessment. There have been 44 SAEs of acute kidney injury (8.4%) in the total safety population of gilteritinib. Of these 8 (1.5%) were reported as drug-related serious events of acute kidney injury with gilteritinib. While drug-related acute kidney injury was comparable between gilteritinib and chemo in study 2215-CL-0301, the chemotherapy group included either the nephrotoxic agent cytarabine or azacitidine. The inherent potential of gilteritinib of causing acute kidney injury is still present and relevant for the single patient. That implies that since there seem to be a similar incidence of AKI in both gilteritinib and chemo, gilteritinib seem to have the same degree of nephrotoxicity / nephrotoxic potential as the comparators (cytarabine and azaticidine). The applicant committed to conduct a phase I study to investigate the effect of renal impairment on the pharmacokinetics, safety and tolerability of gilteritinib compared to subjects with normal renal function (see RMP).

Deaths: The percentage of patients in the phase 3 study 2215-CL-0301 with a TEAE leading to death that  was  considered  drug-related  was  similar  in  both  treatment  arms  (4.1%  in  the  gilteritinib  arm, compared with 4.6% of patients in the salvage chemotherapy arm).

SAEs: In the integrated gilteritinib 120 mg group, 80.9% (258/319) of patients experienced at least 1 serious TEAE of which were drug-related in 33.9% (108/319) of patients. The most frequently reported SAEs by MedDRA PT were febrile neutropenia (29.8% [95/319]), AML (13.5% [43/319]), pyrexia (13.2% [42/319])  and  pneumonia  (12.2%  [39/319]).  The  most  frequently  reported  drug-related  SAEs  by MedDRA  PT  were  febrile  neutropenia  (7.5%  [24/319]),  ALT  increased  (3.4%  [11/319])  and  AST increased (3.1% [10/319]).

Dose  modification: In  the  integrated  gilteritinib  120  mg  group,  dose  increases  to  200  mg  were experienced by 35.4% (113/319) of patients due to lack of efficacy. Dose decreases were experienced by 25.7% (82/319) of patients. In this population 12.9% (41/319) of patients experienced TEAEs leading to  dose  reduction,  the  majority  [11.0%  (35/319)]  of  which  were  considered  drug-related  by  the investigator.  Overall,  47.3%  (151/319)  of  patients  experienced  at  least  1  day  of  gilteritinib  dose interruption. TEAEs leading to drug interruption were experienced by 45.1% (144/319) of patients and considered drug-related in 30.4% (97/319) of patients.

Due to the limited long-term safety data available, long-term safety data is classified in the RMP as missing information (see RMP).

Although  a  limited  number  of  patients  escalated  to  200  mg,  these  results  suggest  that  the  dose  is tolerable.

Gilteritinib has minor influence on the ability to drive and use machines. Dizziness has been reported in patients taking Xospata and should be considered when assessing a patient's ability to drive or use machines (SmPC, section 4.7).

From the safety database all the adverse reactions reported in clinical trials have been included in the SmPC.

## 2.6.2. Conclusions on the clinical safety

The safety profile of gilteritinib at the proposed therapeutic dose of 120 mg was manageable in the R/R AML  patients.  The  most  commonly  occurring  AEs  were  generally  associated  with  the  known pathophysiology of AML, and known toxicity from other TKIs.

<div style=\"page-break-after: always\"></div>

## 2.7. Risk Management Plan

## Safety concerns

## Table 55 Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                   |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | â¢ Posterior reversible encephalopathy syndrome (PRES) â¢ Differentiation syndrome                                                                                             |
| Important potential risks    | â¢ Torsades de Pointes â¢ Serious GI disorders â¢ Eye disorders â¢ Pulmonary adverse events â¢ Pancreatitis â¢ Embryo-fetal lethality, suppressed fetal growth, and teratogenicity |
| Missing information          | â¢ Safety in patients with renal impairment â¢ Long term safety                                                                                                                |

## Pharmacovigilance plan

## Table 56 Ongoing and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                                                                                                                                          | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                                                                                     | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| Not applicable                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                                                                     | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Not applicable                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                  | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Gilteritinib Compared to Subjects with Normal Renal Function (planned)                                   | Primary: To evaluate the effect of severe renal impairment on the pharmacokinetics of gilteritinib relative to the pharmacokinetics in healthy subjects with normal renal function Secondary: To evaluate the safety and tolerability of gilteritinib in subjects with severe renal impairment and healthy subjects with normal renal function | Safety in patients with renal impairment                                                                                                                                                                                   | Protocol submission for review: Final study report submission:                                                                                                                                                             | Q2 2020 Q2 2022                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

## Table 56 Ongoing and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                                                    | Summary of objectives                                                                                 | Safety concerns addressed                                                                              | Milestones                                                     | Due dates       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|-----------------|
| Evaluation of the effectiveness of the Xospata Routine Risk Minimization Measures (RMMs) and an additional Risk Minimisation Measure (aRMM): A Cross-sectional study among Healthcare Professionals to assess awareness and knowledge (planned) | To evaluate awareness and clinical knowledge of healthcare professionals for selected safety concerns | â¢ Differentiation syndrome â¢ Posterior reversible encephalopathy syndrome (PRES) â¢ Torsades de Pointes | Protocol submission for review: Final study report submission: | Q2 2020 Q2 2022 |

## Risk minimisation measures

## Table 57 Summary table of pharmacovigilance activities and risk minimization activities by safety concern

| Safety concern                                      | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                                                                                                                          |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Posterior reversible encephalopathy syndrome (PRES) | Routine risk communication: â¢ SmPC sections 4.2,4.4,4.8 â¢ PL sections 2 and 4. Routine risk minimization activities recommending specific clinical measures to address the risk: â¢ Recommendation to discontinue gilteritinib in patients who develop PRES is provided in SmPC section 4.2 and 4.4.                                                                                                                                                                                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: â¢ None. Additional pharmacovigilance activities: â¢ Healthcare professional survey study                                                 |
| Differentiation Syndrome                            | Routine risk communication: â¢ SmPC sections 4.2; 4.4; 4.8 â¢ PL sections 2 and 4. Routine risk minimization activities recommending specific clinical measures to address the risk: â¢ Recommendation for monitoring is provided in SmPC section 4.4; â¢ Recommendation for treatment interruption of gilteritinib if severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids is provided in SmPC section 4.2 and 4.4. Additional risk minimisation measures: â¢ Healthcare Professional Information â¢ Patient alert card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: â¢ Follow-up questionnaire for Differentiation Syndrome. Additional pharmacovigilance activities: â¢ Healthcare professional survey study |

<div style=\"page-break-after: always\"></div>

## Conclusion

The CHMP and PRAC considered that the risk management plan version 0.5 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 21 September 2018. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. New Active Substance

The  applicant  compared  the  structure  of  gilteritinib  with  active  substances  contained  in  authorised medicinal products in the European Union and declared that it is not a salt, ester, ether, isomer, mixture of isomers, complex or derivative of any of them.

## 2.9.1. Additional monitoring

Pursuant  to  Article  23(1)  of  Regulation  No  (EU)  726/2004,  Xospata  (gilteritinib)  is  included  in  the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore the summary of product characteristics and the package leaflet include a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation (see sections 4.2 and 5.1).

## 3.1.2. Available therapies and unmet medical need

There is no universally accepted standard of care for patients with R/R AML; possible salvage regimens are IDAC with or without anthracycline, MEC or FLAG-IDA. Additionally, there are no definitive studies that showed superiority of any single regimen and patients should be enrolled in a clinical trial whenever possible.

In  view  of  the  inherent  poor  prognosis  of  R/R  FLT3-mutation  positive  AML  and  as  no  therapies  are approved in the EU, there is an unmet medical need.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The  clinical  package  of  gilteritinib  was  primarily  supported  by  data  from  a  phase  3  open-label, multicentre, randomized study of gilteritinib versus salvage chemotherapy in patients with R/R AML with FLT3 mutation (ADMIRAL Study/2215-CL-0301).

## 3.2. Favourable effects

ADMIRAL study has provided convincing evidence of clinical efficacy of gilteritinib in terms of the primary endpoint OS, compared to salvage chemotherapy in patients with R/R AML with FLT3 mutation. Results for the primary endpoint (OS) in the ITT population showed a median OS of 9.3 months in the gilteritinib arm and 5.6 months for salvage chemotherapy (HR= 0.637; 95% CI: 0.490 to 0.830; p=0.0004 onesided log rank test). Sensitivity analysis censoring at HSCT or time of new antileukaemia treatment showed consistent results with the primary analysis for OS.

Subgroup analyses were consistent with the primary efficacy analysis across several prognostic factors such as age, response category to first line therapy, AML risk score, and for patients eligible for low and high intensity treatment.

There was a numerical increase in EFS in the gilteritinib arm, compared to the salvage chemotherapy arm (median 2.8 months (95% CI: 1.4, 3.4) vs 0.7 months (95% CI; 0.2, NE)), but the EFS endpoint did  not  meet  the  pre-specified  criteria  for  statistical  significance  (HR=  0.93  95%:  CI  0.577,  1.089, p=0,0415 1-sided log rank test).

Responses were assessed using the sponsor modified 2003 IWG response criteria for AML. The CR rate was  higher  in  the  gilteritinib  arm,  21.1%  (95  %  CI:  16.1,  26.7),  compared  with  the  salvage chemotherapy arm, 10.5% (95% CI: 5.7, 17.3), with a treatment difference of 10.6% (95% CI: 2,7, 18).

Furthermore,  63  patients  (25.5%)  in  the  gilteritinib  arm  and  19  patients  (15.3%)  in  the  salvage chemotherapy arm underwent an allogenic HSCT post protocol treatment.In the supportive study, 2215CL-0101, the CR rate for FLT3 mutation positive patients receiving 120 mg gilteritinib was 12.5% and the median OS for dose groups â¥ 80 mg gilteritinib was 218.0 days.

## 3.3. Uncertainties and limitations about favourable effects

The key secondary endpoints (CR and EFS) were of limited value. The lack of long-term (beyond 2 months) systematic documentation of response and relapse status in the high intensity chemotherapy group, and the large proportion of patients with no evaluable post-baseline response assessments in the salvage chemotherapy arm preclude relevant comparisons of response rates and response related timeto  event  endpoints  between  the  treatment  arms.  However,  despite  the  lack  of  support  from  these endpoints, the robust and clinically relevant benefit on OS is considered sufficient to establish the benefit of gilteritinib.

The benefit-risk  of  increasing  the  gilteritinib  dose  from  120  mg  to  200  mg  in  patients  with  lack  of response  following  one  treatment  cycle  is  unclear.  No  exposure  response  relationship  has  been characterised to justify the dose escalation and it is not possible to differentiate whether the increase in response rates observed following dose-escalation is due to the increased dose or the longer treatment duration.  Nevertheless,  the  dose  escalation  was  part  of  the  treatment  strategy  in  the  pivotal  trial. Therefore, the option to dose escalate non-responding patients following one treatment cycle is included in the SmPC.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

In the integrated gilteritinib 120 mg group, almost all (99.4%) of patients experienced at least 1 TEAE, of  which  drug-related  in  83.1%.  TEAEs  with  grade â¥ 3  were  experienced  by  93.4%  of  patients,  and considered drug-related in 60.2%. The most frequently reported Grade 3 or higher drug related TEAEs in  the  integrated  gilteritinib  120  mg  group  included  anaemia  (16.9%  [54/319]),  febrile  neutropenia (12.2%  [39/319]),  thrombocytopenia  (11.6%  [37/319])  and  platelet  count  decreased  (11.3% [36/319]).

In the integrated gilteritinib 120 mg group, the majority of patients experienced an increase in QTcF value from baseline; although the mean value of QTc shows little change with use of gilteritinib, more patients had abnormally high values while taking gilteritinib than at baseline. The most frequent TEAEs were ECG QT prolonged (8.8% [28/319]; drug-related in 6.3% [20/319]) and syncope (5.0% [16/319]); drug-related  in  0.6%  [2/319]).  One  patient  (0.3%  [1/319])  experienced  drug-related  ventricular fibrillation. Serious TEAEs were experienced by 5.3% (17/319) of patients and considered drug-related SAEs in 6 patients (1.9%).

Differentiation syndrome was reported for 3% (11/319) of patients. Of the 11 patients who experienced differentiation syndrome, 9 (82%) recovered after treatment or after dose interruption of Xospata. No SAEs were reported, but 1 patient (0.3% [1/319]) experienced a drug-related Grade 3 or higher event.

The percentage of patients in the phase 3 study 2215-CL-0301 with a TEAE leading to death that was considered drug-related was similar in both treatment arms (4.1% in the gilteritinib arm, compared with 4.6% of patients in the salvage chemotherapy arm).

Serious TEAEs were experienced by 80.9% (258/319) of patients, of which were drug-related in 33.9% (108/319) of  patients.  The  most  frequently  reported  drug-related  SAEs  by  MedDRA  PT  were  febrile neutropenia (7.5% [24/319]), ALT increased (3.4% [11/319]) and AST increased (3.1% [10/319]).

TEAEs leading to discontinuation of gilteritinib were experienced by 21.9% (70/319) of patients, of which were considered drug-related in 10.0% (32/319) of patients. The most frequently reported drug-related TEAEs  leading  to  discontinuation  of  treatment  were  AST  increased  (1.3%)  and  ALT  increased  and pneumonia (0.9% each).

## 3.5. Uncertainties and limitations about unfavourable effects

Despite the higher frequencies of Grade â¥ 3 TEAEs and SAEs in the dose escalated gilteritinib group compared to the non-dose escalated group, the frequency rates of dose interruption and treatment discontinuation were similar across the groups. Although a limited number of patients escalated to 200 mg, these results suggest that the dose escalation is tolerable and no further data is required.

In the integrated gilteritinib 120 mg group, the majority of patients experienced an increase in QTcF value from baseline; although the mean value of QTc shows little change with use of gilteritinib, more patients had abnormally high values while taking gilteritinib than at baseline. There is uncertainty about the precise exposure-safety relationship (with respect to increased AST, ALT, CK, and reduced ALB) although there is a clear increase in frequencies of AEs, including serious events, in the patients who have escalated to the 200 mg dose, despite small number of events due to limited number of patients that was dose escalated. Thus, an increased risk of QTc prolongation at the 200 mg dose compared to 120 mg dose cannot be excluded. Therefore, torsade de pointes is included as a safety concern in the RMP to gain more information about this risk. Also, ECG monitoring and dose adjustment guidance are stated in the SmPC and the risk is considered acceptable.

In non-clinical studies, lungs were one of the target organs with major findings in rats and dogs. In the integrated population 18.5% (59 patients) experienced pneumonia, of which grade â¥ 3 in 13.5% (43/319)

<div style=\"page-break-after: always\"></div>

although it is uncertain how many cases are deemed drug-related. Three (3) patients (0.9%) experienced TEAE of pneumonia (all considered drug-related) leading to discontinuation of treatment. There were 3 fatal  cases  due  to  TEAE  of  pneumonia.  Pulmonary  toxicity  may  be  symptomatically  related  to differentiation syndrome. Pulmonary AEs have been have been categorized a potential risk in the RMP (see RMP).

## 3.6.

Effects Table

Table  58  Effects  Table  for  gilteritinib  in  adult  patients  who  have  R/R    AML  with  a  FLT3 mutation (Study/2215-CL-0301, cut-off date: 17 September 2018)

| Effect                       | Short Description                                        | Unit                     | Treatment Gilteritinib N=247   | Control chemothe rapy N=124   | Uncertainties/ Strength of evidence                                                                                                                                                                                                              | Reference s                          |
|------------------------------|----------------------------------------------------------|--------------------------|--------------------------------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| Favourable Effects           | Favourable Effects                                       | Favourable Effects       | Favourable Effects             | Favourable Effects            | Favourable Effects                                                                                                                                                                                                                               | Favourable Effects                   |
| OS                           | Median time from randomisatio n until death by any cause | Months                   | 9.3 (7.7, 10.7)                | 5.6 (4.7, 7.3)                | - HR= 0.637 95% CI: 0.490 to 0.830, p=0.0004 - Due to the lack of re- randomization following HSCT, the additional benefit conferred by post-HSCT gilteritinib cannot be determined - key secondary endpoints (CR and EFS) were of limited value | Study/221 5-CL-0301                  |
| Unfavourable Effects (1)     | Unfavourable Effects (1)                                 | Unfavourable Effects (1) | Unfavourable Effects (1)       | Unfavourable Effects (1)      | Unfavourable Effects (1)                                                                                                                                                                                                                         | Unfavourable Effects (1)             |
| Drug related TEAE            | - All grades - Grade â¥3                                  | %                        | 83.1 60.2                      | 65.1 52.3                     |                                                                                                                                                                                                                                                  | Integrated R/R AML safety population |
| ALT increased                | - All grades - Grade â¥3                                  | %                        | 82.1 12.9                      | 47.7 2.8                      |                                                                                                                                                                                                                                                  |                                      |
| Diarrhoea                    | - All grades - Grade â¥3                                  | %                        | 35.1 4.1                       | 29.4 2.8                      |                                                                                                                                                                                                                                                  |                                      |
| Nausea                       | - All grades - Grade â¥3                                  | %                        | 29.8 1.9                       | 33 0                          |                                                                                                                                                                                                                                                  |                                      |
| Fatigue                      | - All grades - Grade â¥3                                  | %                        | 30.4 3.1                       | 12.8 0                        |                                                                                                                                                                                                                                                  |                                      |
| Electrodiagr am QT prolonged | - All grades - Grade â¥3                                  | %                        | 8.8 2.5                        | 0 0                           |                                                                                                                                                                                                                                                  |                                      |
| Myalgia                      | - All grades - Grade â¥3                                  | %                        | 12.5 0.3                       | 0 0                           |                                                                                                                                                                                                                                                  |                                      |

Abbreviations: AML: acute myeloid leukemia; CI: Confidence interval; HR: Hazard ratio; OS: Overall survival; TEAE: treatment emergent adverse event; ALT: alanine aminotransferase

Notes (1): Integrated 120 mg gilteritinib population: n=319 and Chemotherapy: n=109

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The most important effect observed is the statistically significant and clinically relevant improvement in OS. This OS benefit appears robust across several sensitivity analyses with conservative assumptions.

Gilteritinib at the proposed therapeutic dose of 120 mg was manageable in the population of R/R AML patients  studied  considering  the  disease,  and  the  most  commonly  occurring  AEs  were  generally associated with the known pathophysiology of AML, and known toxicity from other TKIs.

## 3.7.2. Balance of benefits and risks

Given the poor prognosis of patients with AML, the treatment effect of gilteritinib is considered clinically relevant, and has been robustly demonstrated in the single pivotal study that was submitted. The safety profile of gilteritinib at the proposed therapeutic dose of 120 mg was manageable in the R/R AML patients and is acceptable in view of the therapeutic context.

Therefore, the benefit-risk balance for gilteritinib in the proposed indication is considered positive.

## 3.7.3. Additional considerations on the benefit-risk balance

The pivotal study included R/R AML patients previously treated with only 1 prior line of therapy. In order to support the broad indication claim, additional analyses of patients receiving &gt;1 prior treatment in the supportive, study (2215-0101) were conducted. These indicated that responses, i.e. CR and CRc are achieved also for patients in later treatment lines, and the reported median OS generally exceeds that observed  with  chemotherapy  both  in  the  clinical  pivotal  study  and  when  compared  to  a  published historical dataset. Furthermore, there is no clear indication from the PD data on potential resistance mechanisms, to suggest a reduced benefit of gilteritinib vs chemotherapy in later treatment lines. Also the safety data did not indicate any clinically meaningful differences with regards to number of prior treatment lines. Thus, taking into account the totality of the data, the B/R ratio of gilteritinib is considered positive also in patients with &gt; 1 prior treatments.

## 3.8. Conclusions

The overall Benefit-Risk balance of XOSPATA is positive.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Xospata is not similar to Rydapt, Vyxeos, Mylotarg and Dacogen within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1.

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of XOSPATA is favourable in the following indication:

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation (see sections 4.2 and 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the conditions

<div style=\"page-break-after: always\"></div>

described below.

## Conditions or restrictions regarding supply and use

Medicinal  product  subject  to  restricted  medical  prescription  (See  Annex  I:  Summary  of  Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Additional risk minimisation measures

Prior to the launch of Xospata in each Member State the MAH must agree about the content and format of the physician educational material, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority. The patient alert card will be integrated in the packaging and the content will be agreed as part of the labelling (Annex III of the SmPC).

The educational material is aimed at haematologists who treat patients with leukemias including AML, and patients with AML prescribed Xospata to further inform prescribers and patients regarding the important identified risk of differentiation syndrome.

The MAH shall ensure that in each Member State where Xospata is marketed, haematologists who are expected to prescribe Xospata, and patients who are expected to use Xospata are provided with the following educational materials:

- Physician educational material
- Patient Alert Card

Physician educational material:

<div style=\"page-break-after: always\"></div>

- The Summary of Product Characteristics
- Educational tool targeting prescribers:
- -Information on Xospata, including the approved indication according to the SmPC.
- -Description of the signs and symptoms of differentiation syndrome.
- -Management of differentiation syndrome.

## The patient information pack:

- Patient information leaflet
- Patient alert card
- o Patient alert card:
- -Information for patients that Xospata treatment may cause differentiation syndrome.
- -Description of signs or symptoms of the safety concern and when to seek medical care if differentiation syndrome is suspected
- -A warning message for healthcare professionals treating the patient at any time, including in conditions of emergency, that the patient is using Xospata.
- -Contact details of the treating physician who has prescribed Xospata.
- -Needs to be carried all the time and presented to any healthcare professional.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that gilteritinib is a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 5. References

1. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood. 2010;116(17):3147-56.
2. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 2019;20(7):984-97.
3. Jonker  DM,  Kenna  LA,  Leishman  D,  Wallis  R,  Milligan  PA,  Jonsson  EN.  A  pharmacokineticpharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther. 2005;77(6):572-82.
4. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular research. 2003;58(1):32-45.
5. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108(10):3477-83.
6. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition ed: IARC; 2008.
7. Cheson  BD,  Bennett  JM,  Kopecky  KJ,  Buchner  T,  Willman  CL,  Estey  EH,  et  al.  Revised recommendations  of  the  International  Working  Group  for  Diagnosis,  Standardization  of  Response Criteria,  Treatment  Outcomes,  and  Reporting  Standards  for  Therapeutic  Trials  in  Acute  Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
8. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-24.
9. Itzykson R, Thepot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leukemia research. 2015;39(2):124-30.
10. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294-301.
11. Parker  JE,  Pagliuca  A,  Mijovic  A,  Cullis  JO,  Czepulkowski  B,  Rassam  SM,  et  al.  Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. British journal of haematology. 1997;99(4):939-44.
12. Pallis M, Hills R, White P, Grundy M, Russell N, Burnett A. Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. Blood cancer journal. 2011;1(6):e23.
13. Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, et al. Profiling of somatic  mutations  in  acute  myeloid  leukemia  with  FLT3-ITD  at  diagnosis  and  relapse.  Blood. 2015;126(22):2491-501.
14. Zhao Y, Herring AH, Zhou H, Ali MW, Koch GG. A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring. J Biopharm Stat. 2014;24(2):22953.